{"PMC7127465": [["IntroductionEmerging, extremely contagious, infectious diseases caused by viruses such as severe acute respiratory syndrome (SARS), acquired immunodeficiency syndrome (AIDS), dengue fever and influenza have concerned public health organizations in recent years.", [["infectious diseases", "DISEASE", 44, 63], ["acute respiratory syndrome", "DISEASE", 97, 123], ["SARS", "DISEASE", 125, 129], ["acquired immunodeficiency syndrome", "DISEASE", 132, 166], ["AIDS", "DISEASE", 168, 172], ["dengue fever", "DISEASE", 175, 187], ["influenza", "DISEASE", 192, 201], ["dengue fever", "SPECIES", 175, 187], ["infectious diseases", "PROBLEM", 44, 63], ["viruses", "PROBLEM", 74, 81], ["severe acute respiratory syndrome", "PROBLEM", 90, 123], ["SARS", "PROBLEM", 125, 129], ["acquired immunodeficiency syndrome", "PROBLEM", 132, 166], ["AIDS", "PROBLEM", 168, 172], ["dengue fever", "PROBLEM", 175, 187], ["influenza", "PROBLEM", 192, 201], ["contagious", "OBSERVATION_MODIFIER", 32, 42], ["infectious", "OBSERVATION", 44, 54], ["viruses", "OBSERVATION", 74, 81], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome", "OBSERVATION", 103, 123], ["immunodeficiency syndrome", "OBSERVATION", 141, 166]]], ["Among them, influenza infection, which is induced by the influenza virus presented in the aerosols generated by sneezing and coughing, has been reported as a contagious disease of mainly the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 191, 214], ["influenza infection", "DISEASE", 12, 31], ["influenza virus", "DISEASE", 57, 72], ["sneezing and coughing", "DISEASE", 112, 133], ["influenza virus", "ORGANISM", 57, 72], ["upper respiratory", "ORGANISM_SUBDIVISION", 191, 208], ["tract", "ORGANISM_SUBDIVISION", 209, 214], ["influenza virus", "SPECIES", 57, 72], ["influenza infection", "PROBLEM", 12, 31], ["the influenza virus", "PROBLEM", 53, 72], ["sneezing", "PROBLEM", 112, 120], ["coughing", "PROBLEM", 125, 133], ["a contagious disease of mainly the upper respiratory tract", "PROBLEM", 156, 214], ["influenza", "OBSERVATION_MODIFIER", 12, 21], ["infection", "OBSERVATION", 22, 31], ["influenza virus", "OBSERVATION", 57, 72], ["sneezing", "OBSERVATION", 112, 120], ["contagious", "OBSERVATION_MODIFIER", 158, 168], ["disease", "OBSERVATION", 169, 176], ["upper", "ANATOMY_MODIFIER", 191, 196], ["respiratory tract", "ANATOMY", 197, 214]]], ["It may cause acute respiratory tract infection in humans and severe morbidity, especially in the elderly and children (Stockton et al., 1998).", [["respiratory tract", "ANATOMY", 19, 36], ["respiratory tract infection", "DISEASE", 19, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 19, 36], ["humans", "ORGANISM", 50, 56], ["children", "ORGANISM", 109, 117], ["humans", "SPECIES", 50, 56], ["children", "SPECIES", 109, 117], ["humans", "SPECIES", 50, 56], ["acute respiratory tract infection", "PROBLEM", 13, 46], ["severe morbidity", "PROBLEM", 61, 77], ["may cause", "UNCERTAINTY", 3, 12], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["respiratory tract", "ANATOMY", 19, 36], ["infection", "OBSERVATION", 37, 46], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["morbidity", "OBSERVATION", 68, 77]]], ["Human influenza virus is either type A or B; the influenza A virus is further classified into several subtypes such as A/H1N1, A/H1N3 based on the hemagglutinin (HA) and neuraminidase (NA) glycoproteins present in the viral envelope (Uyeki, 2003).", [["influenza virus", "DISEASE", 6, 21], ["influenza A virus", "DISEASE", 49, 66], ["Human influenza virus", "ORGANISM", 0, 21], ["B", "GENE_OR_GENE_PRODUCT", 42, 43], ["influenza A virus", "ORGANISM", 49, 66], ["A/H1N1", "ORGANISM", 119, 125], ["A/H1N3", "ORGANISM", 127, 133], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 147, 160], ["neuraminidase (NA) glycoproteins", "GENE_OR_GENE_PRODUCT", 170, 202], ["hemagglutinin (HA) and neuraminidase (NA) glycoproteins", "PROTEIN", 147, 202], ["Human", "SPECIES", 0, 5], ["influenza virus", "SPECIES", 6, 21], ["influenza A virus", "SPECIES", 49, 66], ["Human influenza virus", "SPECIES", 0, 21], ["influenza A virus", "SPECIES", 49, 66], ["A/H1N1", "SPECIES", 119, 125], ["A/H1N3", "SPECIES", 127, 133], ["Human influenza virus", "PROBLEM", 0, 21], ["type A", "PROBLEM", 32, 38], ["the influenza A virus", "PROBLEM", 45, 66], ["A/H1N1", "TREATMENT", 119, 125], ["A/H1N3", "TREATMENT", 127, 133], ["the hemagglutinin (HA)", "TREATMENT", 143, 165], ["neuraminidase (NA) glycoproteins", "TREATMENT", 170, 202]]], ["Particularly, influenza A viruses are among the most virulent pathogens that could cause devastating outbreaks and give rise to human influenza pandemics (Hay et al., 2001).", [["influenza A viruses", "DISEASE", 14, 33], ["influenza pandemics", "DISEASE", 134, 153], ["influenza A viruses", "ORGANISM", 14, 33], ["human", "ORGANISM", 128, 133], ["influenza A viruses", "SPECIES", 14, 33], ["human", "SPECIES", 128, 133], ["influenza A viruses", "SPECIES", 14, 33], ["human", "SPECIES", 128, 133], ["influenza A viruses", "PROBLEM", 14, 33], ["human influenza pandemics", "PROBLEM", 128, 153]]], ["For example, a novel influenza strain combined with the genes from humans and pigs, which was dubbed the \u201cswine flu\u201d and is also known as influenza A/H1N1, has emerged in Mexico, the United States and several other nations, causing fears of a severe worldwide pandemic (Chowell et al., 2009).", [["swine flu", "DISEASE", 106, 115], ["influenza A/H1N1", "DISEASE", 138, 154], ["humans", "ORGANISM", 67, 73], ["pigs", "ORGANISM", 78, 82], ["influenza A/H1N1", "ORGANISM", 138, 154], ["humans", "SPECIES", 67, 73], ["pigs", "SPECIES", 78, 82], ["swine", "SPECIES", 106, 111], ["humans", "SPECIES", 67, 73], ["pigs", "SPECIES", 78, 82], ["swine flu", "SPECIES", 106, 115], ["A/H1N1", "SPECIES", 148, 154], ["a novel influenza strain", "PROBLEM", 13, 37], ["influenza", "PROBLEM", 138, 147], ["H1N1", "PROBLEM", 150, 154], ["a severe worldwide pandemic", "PROBLEM", 241, 268], ["influenza", "OBSERVATION", 21, 30]]], ["In addition to effective vaccines, tools that enable fast, accurate, and sensitive diagnosis of influenza viruses are greatly needed during the early stage of infections, such that the epidemic spread of influenza infections can be quarantined and controlled.IntroductionAs a consequence, the ability to rapidly diagnosis for the presence of the influenza virus during the acute phase of the infection is essential in order to provide immediate and appropriate clinical treatment and to enact quarantine procedures.", [["influenza viruses", "DISEASE", 96, 113], ["infections", "DISEASE", 159, 169], ["influenza infections", "DISEASE", 204, 224], ["influenza", "DISEASE", 346, 355], ["infection", "DISEASE", 392, 401], ["influenza viruses", "ORGANISM", 96, 113], ["influenza", "ORGANISM", 204, 213], ["influenza virus", "ORGANISM", 346, 361], ["effective vaccines", "TREATMENT", 15, 33], ["influenza viruses", "PROBLEM", 96, 113], ["infections", "PROBLEM", 159, 169], ["influenza infections", "PROBLEM", 204, 224], ["the influenza virus", "PROBLEM", 342, 361], ["the infection", "PROBLEM", 388, 401], ["appropriate clinical treatment", "TREATMENT", 449, 479], ["quarantine procedures", "TREATMENT", 493, 514], ["influenza", "OBSERVATION", 96, 105], ["infections", "OBSERVATION", 159, 169], ["epidemic", "OBSERVATION_MODIFIER", 185, 193], ["spread", "OBSERVATION_MODIFIER", 194, 200], ["influenza infections", "OBSERVATION", 204, 224], ["influenza", "OBSERVATION", 346, 355], ["infection", "OBSERVATION", 392, 401]]], ["Recently, a number of diagnostic methods for the detection of the influenza virus, such as a culture, an immunofluorescence (IF) assay (Shibata et al., 2009), an enzyme-linked immunosorbent assay (ELISA) (Sala et al., 2003), a real-time polymerase chain reaction (PCR) assay (Boivin et al., 2004), a serological hemagglutination inhibition (HI) assay (Swayne et al., 2007) and a complement fixation test (CFT) (de Ory et al., 2004) have been developed.", [["influenza virus", "DISEASE", 66, 81], ["influenza virus", "ORGANISM", 66, 81], ["influenza virus", "SPECIES", 66, 81], ["diagnostic methods", "TEST", 22, 40], ["the influenza virus", "PROBLEM", 62, 81], ["a culture", "TEST", 91, 100], ["an immunofluorescence", "TEST", 102, 123], ["an enzyme", "TEST", 159, 168], ["immunosorbent assay", "TEST", 176, 195], ["a real-time polymerase chain reaction", "PROBLEM", 225, 262], ["PCR", "TEST", 264, 267], ["a serological hemagglutination inhibition", "TEST", 298, 339], ["a complement fixation test", "TEST", 377, 403], ["influenza virus", "OBSERVATION", 66, 81]]], ["Among them, the molecular diagnostic assays such as PCR and polymerase chain reaction reverse transcription (RT-PCR) for the detection of influenza infection provides a highly sensitive and selective diagnosis protocol.", [["influenza infection", "DISEASE", 138, 157], ["the molecular diagnostic assays", "TEST", 12, 43], ["PCR", "TEST", 52, 55], ["polymerase chain reaction", "TEST", 60, 85], ["RT-PCR", "TEST", 109, 115], ["influenza infection", "PROBLEM", 138, 157], ["influenza", "OBSERVATION", 138, 147]]], ["They also require a lengthy process and expensive apparatus to perform the entire process.", [["a lengthy process", "TREATMENT", 18, 35]]], ["Also, ELISA is an alternative, well-recognized, serological diagnostic method for the detection of influenza infection (Chomel et al., 1989, Zhang et al., 2006).", [["influenza infection", "DISEASE", 99, 118], ["influenza infection", "PROBLEM", 99, 118]]], ["The principle behind the immunological diagnosis is based on the detection of color change in or fluorescence of secondary antibodies, which are specific to the target pathogens.", [["secondary antibodies", "PROTEIN", 113, 133], ["color change", "PROBLEM", 78, 90], ["secondary antibodies", "PROBLEM", 113, 133], ["secondary antibodies", "OBSERVATION", 113, 133]]], ["However, a conventional ELISA is usually performed on two-dimensional (2D) 96-well plates, which involves a series of tedious processes such as incubation and washing steps.", [["a conventional ELISA", "TEST", 9, 29], ["tedious processes", "TREATMENT", 118, 135]]], ["This makes it a time-consuming (over 4 h) and labor-intensive process that requires well-trained personnel to precisely perform the protocol.", [["labor", "PROBLEM", 46, 51], ["the protocol", "TREATMENT", 128, 140]]], ["The sensitivity of the conventional ELISA is not satisfactory since the antibody is coated onto the 2D plate, which is the limiting factor for the binding capacity to the target antigens.", [["target antigens", "PROTEIN", 171, 186], ["the conventional ELISA", "TEST", 19, 41], ["the antibody", "TEST", 68, 80], ["the binding capacity", "PROBLEM", 143, 163]]], ["A more sensitive immunological detection technique is urgently needed.IntroductionThree-dimensional (3D) microsphere surfaces modified with functional groups for immunological diagnosis resulting in a high sensitivity has attracted considerable interest in recent years (Hendry and Herrmann, 1983, Leikina et al., 2004, Yan et al., 2005).", [["A more sensitive immunological detection technique", "PROBLEM", 0, 50], ["Three-dimensional (3D) microsphere surfaces", "TREATMENT", 82, 125], ["immunological diagnosis", "TEST", 162, 185], ["a high sensitivity", "PROBLEM", 199, 217]]], ["The binding capacity of a specific antibody can be increased using a 3D solid-phase immunoassay and, therefore, increase the detection sensitivity.", [["The binding capacity", "PROBLEM", 0, 20], ["a specific antibody", "TEST", 24, 43], ["a 3D solid-phase immunoassay", "TEST", 67, 95], ["the detection sensitivity", "TEST", 121, 146], ["capacity", "OBSERVATION_MODIFIER", 12, 20]]], ["For example, a microsphere-based, flow-cytometric immunoassay for the detection of influenza viruses was found to have a 10-fold lower detection limit than traditional ELISA (Yan et al., 2005).", [["influenza viruses", "DISEASE", 83, 100], ["flow-cytometric immunoassay", "TEST", 34, 61], ["influenza viruses", "PROBLEM", 83, 100], ["influenza viruses", "OBSERVATION", 83, 100]]], ["Another fluorophore-DNA-barcode-based immunoassay with the target avian influenza virus sandwiched between magnetic immunoprobes and barcode-carrying immunoprobes has also been demonstrated recently (Cao et al., 2010).", [["DNA", "CELLULAR_COMPONENT", 20, 23], ["avian influenza virus", "ORGANISM", 66, 87], ["avian influenza virus", "SPECIES", 66, 87], ["Another fluorophore", "TREATMENT", 0, 19], ["DNA-barcode", "TREATMENT", 20, 31], ["immunoassay", "TEST", 38, 49], ["the target avian influenza virus", "TREATMENT", 55, 87], ["magnetic immunoprobes", "TREATMENT", 107, 128], ["barcode-carrying immunoprobes", "TREATMENT", 133, 162]]], ["Its detection sensitivity was comparable to that of conventional RT-PCR.", [["Its detection sensitivity", "TEST", 0, 25], ["conventional RT-PCR", "TEST", 52, 71]]], ["More importantly, it is less time-consuming (<2 h for the entire detection protocol).", [["the entire detection protocol", "TEST", 54, 83]]], ["Nevertheless, it still presents a challenge for the rapid identification and accurate diagnosis of influenza infection using these state-of-the-art diagnostic techniques since several tedious purification processes and manual operation are always required, especially to prevent the spread of infection in resource-limited regions without the support of reference laboratories (Koh et al., 2008).", [["influenza infection", "DISEASE", 99, 118], ["infection", "DISEASE", 293, 302], ["the rapid identification", "TEST", 48, 72], ["influenza infection", "PROBLEM", 99, 118], ["several tedious purification processes", "TREATMENT", 176, 214], ["manual operation", "TREATMENT", 219, 235], ["infection", "PROBLEM", 293, 302], ["influenza", "OBSERVATION", 99, 108], ["infection", "OBSERVATION", 293, 302]]], ["Therefore, there is a great need to develop an easy-to-use, sample-to-answer platform for rapid and automatic detection of influenza infection with a high sensitivity and selectivity.IntroductionRecently, several bead-based assays incorporated with microfluidic systems have been demonstrated for biomedical applications (Szurdoki et al., 2001, Huang et al., 2002, Fuentes et al., 2004, Kartalov et al., 2006, Lien et al., 2007).", [["influenza infection", "DISEASE", 123, 142], ["sample", "TEST", 60, 66], ["influenza infection", "PROBLEM", 123, 142], ["several bead-based assays", "TEST", 205, 230], ["microfluidic systems", "TREATMENT", 249, 269], ["influenza", "OBSERVATION", 123, 132], ["bead", "OBSERVATION_MODIFIER", 213, 217]]], ["Consequently, various bead-based immunoassays implemented on microfluidic systems have been reported recently (Vignali, 2000, Fern\u00e1ndez-Lafuente and Guis\u00e1n, 2006, Yang et al., 2008).", [["various bead-based immunoassays", "TEST", 14, 45], ["microfluidic systems", "TEST", 61, 81], ["bead", "OBSERVATION_MODIFIER", 22, 26]]], ["In addition to their sample purification and concentration capabilities enabled by applying external magnetic fields, micro-beads have a 3D structure which increases the surface-to-volume ratio, thus providing more binding sites for target molecules or pathogens.", [["surface", "ANATOMY", 170, 177], ["target molecules", "PROTEIN", 233, 249], ["their sample purification", "TREATMENT", 15, 40], ["concentration capabilities", "TEST", 45, 71], ["external magnetic fields", "TREATMENT", 92, 116], ["micro-beads", "TREATMENT", 118, 129], ["the surface", "TEST", 166, 177], ["target molecules", "PROBLEM", 233, 249], ["pathogens", "PROBLEM", 253, 262], ["surface", "OBSERVATION_MODIFIER", 170, 177]]], ["Furthermore, surface modification of a microfluidic device has been reported to enhance the sensitivity and selectivity of an immunoassay (Vignali, 2000, Bai et al., 2006).", [["surface", "ANATOMY", 13, 20], ["a microfluidic device", "TREATMENT", 37, 58], ["an immunoassay", "TEST", 123, 137], ["surface", "OBSERVATION_MODIFIER", 13, 20], ["microfluidic device", "OBSERVATION", 39, 58]]], ["Still, several lengthy off-chip sample pre-treatment processes are necessary to purify the samples prior to use and bulky equipment is normally required, thus hindering the practical applications of the proposed assays for clinical diagnosis.", [["samples", "ANATOMY", 91, 98], ["-chip sample pre-treatment processes", "TREATMENT", 26, 62], ["bulky equipment", "TREATMENT", 116, 131], ["several", "OBSERVATION_MODIFIER", 7, 14], ["lengthy", "OBSERVATION_MODIFIER", 15, 22]]], ["In this study, a microfluidic diagnostic assay incorporated with a 3D magnetic-bead-based FIA and an optical detection module for influenza A virus purification, concentration, collection and detection is proposed.", [["influenza A virus", "ORGANISM", 130, 147], ["influenza A virus", "SPECIES", 130, 147], ["this study", "TEST", 3, 13], ["a microfluidic diagnostic assay", "TEST", 15, 46], ["an optical detection module", "TEST", 98, 125], ["influenza A virus purification", "TREATMENT", 130, 160]]], ["The entire diagnostic process can be completed within approximately 15 min with little human intervention.Working principle ::: Materials and methods", [["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["little human intervention", "TREATMENT", 80, 105]]]], "77e5433f7e21d8061040dc02c352267ef6755172": [["INTRODUCTIONSevere acute respiratory syndrome (SARS) is a new emerging disease that has affected many countries including Taiwan.", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["a new emerging disease", "PROBLEM", 56, 78], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["new", "OBSERVATION_MODIFIER", 58, 61]]], ["A novel virus, the SARS-associated coronavirus (SARS-CoV), has been identified as the causal agent [Ksiazek et al., 2003; Peiris et al., 2003a,b] .", [["SARS", "DISEASE", 19, 23], ["SARS-associated coronavirus", "ORGANISM", 19, 46], ["SARS-CoV", "ORGANISM", 48, 56], ["SARS-associated coronavirus", "SPECIES", 19, 46], ["SARS-CoV", "SPECIES", 48, 56], ["A novel virus", "PROBLEM", 0, 13], ["the SARS", "PROBLEM", 15, 23], ["coronavirus", "PROBLEM", 35, 46], ["virus", "OBSERVATION", 8, 13]]], ["High fever, myalgia, dry cough, and lymphopenia were the most characteristic symptoms seen in patients with this new illness.", [["fever", "DISEASE", 5, 10], ["myalgia", "DISEASE", 12, 19], ["dry cough", "DISEASE", 21, 30], ["lymphopenia", "DISEASE", 36, 47], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["High fever", "PROBLEM", 0, 10], ["myalgia", "PROBLEM", 12, 19], ["dry cough", "PROBLEM", 21, 30], ["lymphopenia", "PROBLEM", 36, 47], ["the most characteristic symptoms", "PROBLEM", 53, 85], ["this new illness", "PROBLEM", 108, 124], ["fever", "OBSERVATION", 5, 10], ["myalgia", "OBSERVATION", 12, 19], ["dry", "OBSERVATION_MODIFIER", 21, 24], ["cough", "OBSERVATION", 25, 30], ["lymphopenia", "OBSERVATION", 36, 47], ["most characteristic", "OBSERVATION_MODIFIER", 57, 76]]], ["In around 30% of the cases, patients also developed an atypical form of pneumonia, with acute respiratory distress as a result of acute lung damage, characterized by infiltrates on chest radio-graphy.", [["respiratory", "ANATOMY", 94, 105], ["lung", "ANATOMY", 136, 140], ["pneumonia", "DISEASE", 72, 81], ["respiratory distress", "DISEASE", 94, 114], ["acute lung damage", "DISEASE", 130, 147], ["patients", "ORGANISM", 28, 36], ["lung", "ORGAN", 136, 140], ["patients", "SPECIES", 28, 36], ["pneumonia", "PROBLEM", 72, 81], ["acute respiratory distress", "PROBLEM", 88, 114], ["acute lung damage", "PROBLEM", 130, 147], ["infiltrates", "PROBLEM", 166, 177], ["chest radio", "TEST", 181, 192], ["atypical", "OBSERVATION_MODIFIER", 55, 63], ["pneumonia", "OBSERVATION", 72, 81], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory distress", "OBSERVATION", 94, 114], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["lung", "ANATOMY", 136, 140], ["damage", "OBSERVATION", 141, 147], ["infiltrates", "OBSERVATION", 166, 177], ["chest", "ANATOMY", 181, 186]]], ["Amongst the changes observed in the lungs of SARS patients were epithelial cells proliferation and desquamation, hyaline membranes formation along alveolar walls and cells infiltration (lymphocytes, neutrophils, and monocytes) during the early stage of the disease, while increased fibrosis and multinucleated epithelial giant cells formation were seen at a later stage.", [["lungs", "ANATOMY", 36, 41], ["epithelial cells", "ANATOMY", 64, 80], ["hyaline membranes", "ANATOMY", 113, 130], ["alveolar walls", "ANATOMY", 147, 161], ["cells", "ANATOMY", 166, 171], ["lymphocytes", "ANATOMY", 186, 197], ["neutrophils", "ANATOMY", 199, 210], ["monocytes", "ANATOMY", 216, 225], ["multinucleated epithelial giant cells", "ANATOMY", 295, 332], ["SARS", "DISEASE", 45, 49], ["fibrosis", "DISEASE", 282, 290], ["lungs", "ORGAN", 36, 41], ["patients", "ORGANISM", 50, 58], ["epithelial cells", "CELL", 64, 80], ["hyaline membranes", "CELLULAR_COMPONENT", 113, 130], ["alveolar walls", "CELL", 147, 161], ["cells", "CELL", 166, 171], ["lymphocytes", "CELL", 186, 197], ["neutrophils", "CELL", 199, 210], ["monocytes", "CELL", 216, 225], ["multinucleated epithelial giant cells", "CELL", 295, 332], ["epithelial cells", "CELL_TYPE", 64, 80], ["lymphocytes", "CELL_TYPE", 186, 197], ["neutrophils", "CELL_TYPE", 199, 210], ["monocytes", "CELL_TYPE", 216, 225], ["multinucleated epithelial giant cells", "CELL_TYPE", 295, 332], ["patients", "SPECIES", 50, 58], ["SARS", "PROBLEM", 45, 49], ["epithelial cells proliferation", "PROBLEM", 64, 94], ["desquamation", "PROBLEM", 99, 111], ["hyaline membranes formation", "PROBLEM", 113, 140], ["cells infiltration", "PROBLEM", 166, 184], ["lymphocytes", "TEST", 186, 197], ["neutrophils", "TEST", 199, 210], ["monocytes", "TEST", 216, 225], ["the disease", "PROBLEM", 253, 264], ["increased fibrosis", "PROBLEM", 272, 290], ["multinucleated epithelial giant cells formation", "PROBLEM", 295, 342], ["lungs", "ANATOMY", 36, 41], ["epithelial cells proliferation", "OBSERVATION", 64, 94], ["desquamation", "OBSERVATION_MODIFIER", 99, 111], ["hyaline membranes", "OBSERVATION", 113, 130], ["alveolar", "ANATOMY_MODIFIER", 147, 155], ["walls", "ANATOMY_MODIFIER", 156, 161], ["cells infiltration", "OBSERVATION", 166, 184], ["lymphocytes", "ANATOMY", 186, 197], ["monocytes", "ANATOMY", 216, 225], ["early stage", "OBSERVATION_MODIFIER", 238, 249], ["disease", "OBSERVATION", 257, 264], ["increased", "OBSERVATION_MODIFIER", 272, 281], ["fibrosis", "OBSERVATION", 282, 290], ["multinucleated", "OBSERVATION_MODIFIER", 295, 309], ["epithelial giant cells formation", "OBSERVATION", 310, 342]]], ["These changes seem to indicate the existence of a two-phase development of the lung injury, acute phase diffuse alveolar damage followed by a more organized diffuse alveolar damage.", [["lung", "ANATOMY", 79, 83], ["alveolar", "ANATOMY", 112, 120], ["alveolar", "ANATOMY", 165, 173], ["lung injury", "DISEASE", 79, 90], ["alveolar damage", "DISEASE", 112, 127], ["alveolar damage", "DISEASE", 165, 180], ["lung", "ORGAN", 79, 83], ["alveolar", "MULTI-TISSUE_STRUCTURE", 112, 120], ["alveolar", "TISSUE", 165, 173], ["the lung injury", "PROBLEM", 75, 90], ["acute phase diffuse alveolar damage", "PROBLEM", 92, 127], ["a more organized diffuse alveolar damage", "PROBLEM", 140, 180], ["lung", "ANATOMY", 79, 83], ["injury", "OBSERVATION", 84, 90], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["phase", "OBSERVATION_MODIFIER", 98, 103], ["diffuse", "OBSERVATION_MODIFIER", 104, 111], ["alveolar damage", "OBSERVATION", 112, 127], ["more organized", "OBSERVATION_MODIFIER", 142, 156], ["diffuse", "OBSERVATION_MODIFIER", 157, 164], ["alveolar damage", "OBSERVATION", 165, 180]]], ["Based on such observations, the existence of an abnormally excessive inflammatory response in the lungs has been hypothesized to explain the development of an acute lung injury.", [["lungs", "ANATOMY", 98, 103], ["lung", "ANATOMY", 165, 169], ["acute lung injury", "DISEASE", 159, 176], ["lungs", "ORGAN", 98, 103], ["lung", "ORGAN", 165, 169], ["an abnormally excessive inflammatory response in the lungs", "PROBLEM", 45, 103], ["an acute lung injury", "PROBLEM", 156, 176], ["abnormally", "OBSERVATION_MODIFIER", 48, 58], ["excessive", "OBSERVATION_MODIFIER", 59, 68], ["inflammatory response", "OBSERVATION", 69, 90], ["lungs", "ANATOMY", 98, 103], ["acute", "OBSERVATION_MODIFIER", 159, 164], ["lung", "ANATOMY", 165, 169], ["injury", "OBSERVATION", 170, 176]]], ["Indeed, patients still manifested lung injury at a time when the viral load was falling, in support of the immune nature of the lung damage.INTRODUCTIONThe laboratory findings of SARS were lymphopenia, thrombocytopenia, and elevated lactate dehydrogenase and creatine kinase levels.", [["lung", "ANATOMY", 34, 38], ["lung", "ANATOMY", 128, 132], ["lung injury", "DISEASE", 34, 45], ["lung damage", "DISEASE", 128, 139], ["SARS", "DISEASE", 179, 183], ["lymphopenia", "DISEASE", 189, 200], ["thrombocytopenia", "DISEASE", 202, 218], ["lactate", "CHEMICAL", 233, 240], ["creatine", "CHEMICAL", 259, 267], ["lactate", "CHEMICAL", 233, 240], ["creatine", "CHEMICAL", 259, 267], ["patients", "ORGANISM", 8, 16], ["lung", "ORGAN", 34, 38], ["lung", "ORGAN", 128, 132], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 233, 254], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 259, 274], ["lactate dehydrogenase", "PROTEIN", 233, 254], ["creatine kinase", "PROTEIN", 259, 274], ["patients", "SPECIES", 8, 16], ["lung injury", "PROBLEM", 34, 45], ["the viral load", "TEST", 61, 75], ["the lung damage", "PROBLEM", 124, 139], ["SARS", "PROBLEM", 179, 183], ["lymphopenia", "PROBLEM", 189, 200], ["thrombocytopenia", "PROBLEM", 202, 218], ["elevated lactate dehydrogenase", "PROBLEM", 224, 254], ["creatine kinase levels", "TEST", 259, 281], ["lung", "ANATOMY", 34, 38], ["injury", "OBSERVATION", 39, 45], ["lung", "ANATOMY", 128, 132], ["damage", "OBSERVATION", 133, 139], ["lymphopenia", "OBSERVATION", 189, 200], ["thrombocytopenia", "OBSERVATION", 202, 218], ["elevated", "OBSERVATION_MODIFIER", 224, 232], ["lactate dehydrogenase", "OBSERVATION", 233, 254]]], ["Several factors including advanced age, male sex, a high peak lactate dehydrogenase level, a high peak creatine kinase level, and a high initial absolute neutrophil count were significant predictive factors for intense care unit admission and death.", [["neutrophil", "ANATOMY", 154, 164], ["lactate", "CHEMICAL", 62, 69], ["creatine", "CHEMICAL", 103, 111], ["death", "DISEASE", 243, 248], ["lactate", "CHEMICAL", 62, 69], ["creatine", "CHEMICAL", 103, 111], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 62, 83], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 103, 118], ["neutrophil", "CELL", 154, 164], ["lactate dehydrogenase", "PROTEIN", 62, 83], ["creatine kinase", "PROTEIN", 103, 118], ["a high peak lactate dehydrogenase level", "PROBLEM", 50, 89], ["a high peak creatine kinase level", "PROBLEM", 91, 124], ["a high initial absolute neutrophil count", "PROBLEM", 130, 170], ["death", "PROBLEM", 243, 248], ["absolute neutrophil count", "OBSERVATION", 145, 170]]], ["The mortality of SARS is reported to be around 10%-15%.", [["SARS", "DISEASE", 17, 21], ["SARS", "PROBLEM", 17, 21], ["SARS", "OBSERVATION", 17, 21]]], ["Acute viral infection might produce damage to host cells by direct cytopathy or by indirect immunopathological damage.", [["cells", "ANATOMY", 51, 56], ["viral infection", "DISEASE", 6, 21], ["host cells", "CELL", 46, 56], ["host cells", "CELL_TYPE", 46, 56], ["Acute viral infection", "PROBLEM", 0, 21], ["damage to host cells", "PROBLEM", 36, 56], ["direct cytopathy", "PROBLEM", 60, 76], ["indirect immunopathological damage", "PROBLEM", 83, 117], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["infection", "OBSERVATION", 12, 21], ["host cells", "OBSERVATION", 46, 56], ["immunopathological damage", "OBSERVATION", 92, 117]]], ["In the early stage, cytopathy is accompanied by viral amplification, such that antiviral drugs may be important for treatment.", [["cytopathy", "DISEASE", 20, 29], ["cytopathy", "PROBLEM", 20, 29], ["viral amplification", "PROBLEM", 48, 67], ["antiviral drugs", "TREATMENT", 79, 94], ["treatment", "TREATMENT", 116, 125], ["early stage", "OBSERVATION_MODIFIER", 7, 18], ["cytopathy", "OBSERVATION", 20, 29], ["accompanied by", "UNCERTAINTY", 33, 47], ["viral amplification", "OBSERVATION", 48, 67]]], ["In the later stage, when an adaptive immune response is mounted, viral clearance can be accompanied by severe inflammatory damage, especially with high viral burden.", [["viral clearance", "PROBLEM", 65, 80], ["severe inflammatory damage", "PROBLEM", 103, 129], ["high viral burden", "PROBLEM", 147, 164], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["inflammatory", "OBSERVATION", 110, 122]]], ["How the lung is damaged is not clearly understood.", [["lung", "ANATOMY", 8, 12], ["lung", "ORGAN", 8, 12], ["lung", "ANATOMY", 8, 12], ["damaged", "OBSERVATION", 16, 23]]], ["The intensive inflammation developed in the lung will generate cytokines to activate lung epithelial cells to undergo pathological changes [Nicholls et al., 2003] .", [["lung", "ANATOMY", 44, 48], ["lung epithelial cells", "ANATOMY", 85, 106], ["inflammation", "DISEASE", 14, 26], ["lung", "ORGAN", 44, 48], ["lung epithelial cells", "CELL", 85, 106], ["cytokines", "PROTEIN", 63, 72], ["lung epithelial cells", "CELL_TYPE", 85, 106], ["The intensive inflammation", "PROBLEM", 0, 26], ["cytokines", "TREATMENT", 63, 72], ["lung epithelial cells", "PROBLEM", 85, 106], ["pathological changes", "PROBLEM", 118, 138], ["intensive", "OBSERVATION_MODIFIER", 4, 13], ["inflammation", "OBSERVATION", 14, 26], ["lung", "ANATOMY", 44, 48], ["lung", "ANATOMY", 85, 89], ["epithelial cells", "OBSERVATION", 90, 106]]], ["Is there a cytokine storm involved in the pathological changes of the lung?", [["lung", "ANATOMY", 70, 74], ["lung", "ORGAN", 70, 74], ["cytokine", "PROTEIN", 11, 19], ["a cytokine storm", "PROBLEM", 9, 25], ["cytokine storm", "OBSERVATION", 11, 25], ["pathological", "OBSERVATION", 42, 54], ["lung", "ANATOMY", 70, 74]]], ["In this study, an IFN-g-related cytokine and chemokine storm was found to be indeed present in SARS patient and its level was associated with some clinical manifestations.", [["SARS", "DISEASE", 95, 99], ["IFN-g", "GENE_OR_GENE_PRODUCT", 18, 23], ["patient", "ORGANISM", 100, 107], ["IFN", "PROTEIN", 18, 21], ["cytokine", "PROTEIN", 32, 40], ["chemokine", "PROTEIN", 45, 54], ["patient", "SPECIES", 100, 107], ["this study", "TEST", 3, 13], ["an IFN", "TEST", 15, 21], ["some clinical manifestations", "PROBLEM", 142, 170]]], ["From March 14, 2003 to August 15, 2003 , a total of 346 cases were defined as probable SARS cases based on the medical records reviewed retrospectively plus laboratory data and epidemiological data by the SARS Advisory Committee in Center for Disease Control (CDC)-Taiwan and SARS expert committees in National Health Insurance Bureau-Taiwan.", [["SARS", "DISEASE", 87, 91], ["SARS", "DISEASE", 205, 209], ["SARS", "DISEASE", 276, 280], ["SARS cases", "PROBLEM", 87, 97], ["laboratory data", "TEST", 157, 172], ["epidemiological data", "TEST", 177, 197]]], ["Among these patients, 88 RT-PCR confirmed samples of acute phase sera and convalescent sera were analyzed for their serum cytokine levels.", [["samples", "ANATOMY", 42, 49], ["sera", "ANATOMY", 65, 69], ["sera", "ANATOMY", 87, 91], ["serum", "ANATOMY", 116, 121], ["patients", "ORGANISM", 12, 20], ["sera", "ORGANISM_SUBSTANCE", 65, 69], ["sera", "ORGANISM_SUBSTANCE", 87, 91], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["cytokine", "PROTEIN", 122, 130], ["patients", "SPECIES", 12, 20], ["RT-PCR", "TEST", 25, 31], ["acute phase sera", "TEST", 53, 69], ["convalescent sera", "TEST", 74, 91], ["their serum cytokine levels", "TEST", 110, 137], ["acute", "OBSERVATION_MODIFIER", 53, 58]]], ["The epidemiological characteristics of age and gender and clinical information such as symptoms, underlying diseases, outcomes including death and hospital length-of-stay, as well as laboratory findings of hematological, biochemical, and arterial blood gas data were collected from medical chart records, information of disease investigation, web-based data in our reporting system, and laboratories in CDC-Taiwan.Analysis of SARS-CoV InfectionSARS-CoV analysis was done primarily in the CDC-Taiwan Central Laboratory.", [["arterial blood", "ANATOMY", 238, 252], ["death", "DISEASE", 137, 142], ["arterial", "MULTI-TISSUE_STRUCTURE", 238, 246], ["blood", "ORGANISM_SUBSTANCE", 247, 252], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 426, 434], ["SARS-CoV InfectionSARS-CoV", "SPECIES", 426, 452], ["symptoms", "PROBLEM", 87, 95], ["underlying diseases", "PROBLEM", 97, 116], ["death", "PROBLEM", 137, 142], ["arterial blood gas data", "TEST", 238, 261], ["disease investigation", "TEST", 320, 341], ["Analysis", "TEST", 414, 422], ["SARS", "PROBLEM", 426, 430], ["CoV InfectionSARS", "TEST", 431, 448], ["CoV analysis", "TEST", 449, 461]]], ["SARS-CoV RT-PCR was used to define the infection.", [["infection", "DISEASE", 39, 48], ["SARS", "TEST", 0, 4], ["CoV RT-PCR", "TEST", 5, 15], ["the infection", "PROBLEM", 35, 48], ["infection", "OBSERVATION", 39, 48]]], ["The primers were used according to the CDC-US recommendation.", [["The primers", "TREATMENT", 0, 11]]], ["The ELISA, immunofluorescence assay, and neutralization test were done for serological identification of SARS-CoV infection [Wu et al., 2004b] .", [["SARS-CoV infection", "DISEASE", 105, 123], ["SARS-CoV", "ORGANISM", 105, 113], ["SARS-CoV", "SPECIES", 105, 113], ["The ELISA", "TEST", 0, 9], ["immunofluorescence assay", "TEST", 11, 35], ["neutralization test", "TEST", 41, 60], ["serological identification", "TEST", 75, 101], ["SARS", "PROBLEM", 105, 109], ["CoV infection", "PROBLEM", 110, 123]]], ["The acute and convalescent sera were tested in parallel for SARS-CoV.", [["sera", "ANATOMY", 27, 31], ["sera", "ORGANISM_SUBSTANCE", 27, 31], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["SARS-CoV", "SPECIES", 60, 68], ["The acute and convalescent sera", "PROBLEM", 0, 31], ["SARS", "PROBLEM", 60, 64], ["acute", "OBSERVATION_MODIFIER", 4, 9]]], ["The sensitivity and specificity of these assays were described previously, and our 88 samples were selected from these pool [Wu et al., 2004a] .", [["The sensitivity", "TEST", 0, 15], ["these assays", "TEST", 35, 47]]], ["A combination of ELISA, immunofluorescence, and neutralization test was used to define the antibody to SARS-CoV.", [["SARS", "DISEASE", 103, 107], ["SARS-CoV", "ORGANISM", 103, 111], ["SARS-CoV", "SPECIES", 103, 111], ["ELISA, immunofluorescence", "TEST", 17, 42], ["neutralization test", "TEST", 48, 67], ["CoV", "PROBLEM", 108, 111]]], ["The cases that had serum antibody against SARS-CoV were classified as Ab positive group while those who had no sera antibody were classified as Ab negative group.Quantitation of Cytokine LevelThe cytokines levels were determined by either BD Human Th1/Th2 Cytokine or Chemokine Bead Array (CBA) Kit.", [["serum", "ANATOMY", 19, 24], ["sera", "ANATOMY", 111, 115], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["SARS-CoV", "ORGANISM", 42, 50], ["Ab", "GENE_OR_GENE_PRODUCT", 70, 72], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["Ab", "GENE_OR_GENE_PRODUCT", 144, 146], ["Cytokine", "GENE_OR_GENE_PRODUCT", 178, 186], ["Human", "ORGANISM", 242, 247], ["serum antibody", "PROTEIN", 19, 33], ["sera antibody", "PROTEIN", 111, 124], ["Ab negative group", "PROTEIN", 144, 161], ["Cytokine", "PROTEIN", 178, 186], ["cytokines", "PROTEIN", 196, 205], ["BD Human Th1/Th2 Cytokine", "PROTEIN", 239, 264], ["Human", "SPECIES", 242, 247], ["SARS-CoV", "SPECIES", 42, 50], ["serum antibody", "TEST", 19, 33], ["SARS", "PROBLEM", 42, 46], ["CoV", "PROBLEM", 47, 50], ["sera antibody", "TEST", 111, 124], ["Quantitation", "TEST", 162, 174], ["Cytokine Level", "TEST", 178, 192], ["The cytokines levels", "TEST", 192, 212], ["Chemokine Bead Array (CBA)", "TREATMENT", 268, 294]]], ["The BD Human Th1/Th2 Cytokine CBA Kit (BD PharMingen, San Diego, CA) was used to measure IL-2, IL-4, IL-5, IL-10, TNF-a, and IFN-g protein levels by flow cytometry in a particle-based immunoassay.", [["Human", "ORGANISM", 7, 12], ["IL-2", "GENE_OR_GENE_PRODUCT", 89, 93], ["IL-4", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL-5", "GENE_OR_GENE_PRODUCT", 101, 105], ["IL-10", "GENE_OR_GENE_PRODUCT", 107, 112], ["TNF-a", "GENE_OR_GENE_PRODUCT", 114, 119], ["IFN-g", "GENE_OR_GENE_PRODUCT", 125, 130], ["BD Human Th1/Th2 Cytokine CBA Kit", "PROTEIN", 4, 37], ["BD PharMingen", "PROTEIN", 39, 52], ["TNF", "PROTEIN", 114, 117], ["IFN", "PROTEIN", 125, 128], ["Human", "SPECIES", 7, 12], ["The BD Human Th1", "TEST", 0, 16], ["BD PharMingen", "TEST", 39, 52], ["CA", "TEST", 65, 67], ["IL", "TEST", 89, 91], ["IL", "TEST", 95, 97], ["IL", "TEST", 101, 103], ["IL", "TEST", 107, 109], ["TNF", "TEST", 114, 117], ["IFN", "TEST", 125, 128], ["protein levels", "TEST", 131, 145], ["flow cytometry", "TEST", 149, 163]]], ["This kit allowed simultaneous measurement of six cytokines from 50 ml of sample.", [["sample", "ANATOMY", 73, 79], ["cytokines", "PROTEIN", 49, 58], ["This kit", "TEST", 0, 8], ["six cytokines", "TREATMENT", 45, 58]]], ["The use of 50 ml of sample is very critical for precious patient serum samples, and we have routinely used the CBA kit to quantitate the cytokines level on patients with various diseases Hung et al., 2004] .", [["sample", "ANATOMY", 20, 26], ["serum samples", "ANATOMY", 65, 78], ["patient", "ORGANISM", 57, 64], ["serum samples", "ORGANISM_SUBSTANCE", 65, 78], ["patients", "ORGANISM", 156, 164], ["cytokines", "PROTEIN", 137, 146], ["patient", "SPECIES", 57, 64], ["patients", "SPECIES", 156, 164], ["precious patient serum samples", "TEST", 48, 78], ["the CBA kit", "TREATMENT", 107, 118], ["the cytokines level", "TEST", 133, 152], ["various diseases", "PROBLEM", 170, 186]]], ["The assays were performed according to the instructions of the manufacturer.", [["The assays", "TEST", 0, 10]]], ["The limits of detection of these immunoassays were 2.6 pg/ml of IL-2, 2.6 pg/ml of IL-4, 2.4 pg/ml of IL-5, 2.8 pg/ml of IL-10, 2.8 pg/ml of TNF-a, and 7.1 pg/ml of IFN-g.", [["IL-2", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-4", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-5", "GENE_OR_GENE_PRODUCT", 102, 106], ["IL-10", "GENE_OR_GENE_PRODUCT", 121, 126], ["TNF", "GENE_OR_GENE_PRODUCT", 141, 144], ["IL", "PROTEIN", 64, 66], ["IL", "PROTEIN", 83, 85], ["IL", "PROTEIN", 102, 104], ["IL", "PROTEIN", 121, 123], ["TNF", "PROTEIN", 141, 144], ["IFN", "PROTEIN", 165, 168], ["these immunoassays", "TEST", 27, 45], ["IL", "TREATMENT", 64, 66], ["IL", "TREATMENT", 83, 85], ["IL", "TREATMENT", 102, 104], ["TNF", "TEST", 141, 144], ["IFN", "TREATMENT", 165, 168]]], ["The BD Human Chemokine CBA Kit was used to measure IP-10, MIG, MCP-1, RANTES, and IL-8 protein levels by flow cytometry in a particle-based immunoassay.", [["Human", "ORGANISM", 7, 12], ["IP-10", "GENE_OR_GENE_PRODUCT", 51, 56], ["MIG", "GENE_OR_GENE_PRODUCT", 58, 61], ["MCP-1", "GENE_OR_GENE_PRODUCT", 63, 68], ["RANTES", "GENE_OR_GENE_PRODUCT", 70, 76], ["IL-8", "GENE_OR_GENE_PRODUCT", 82, 86], ["BD", "PROTEIN", 4, 6], ["MIG", "PROTEIN", 58, 61], ["MCP", "PROTEIN", 63, 66], ["RANTES", "PROTEIN", 70, 76], ["Human", "SPECIES", 7, 12], ["Human", "SPECIES", 7, 12], ["The BD Human Chemokine CBA Kit", "TEST", 0, 30], ["IP", "TEST", 51, 53], ["MIG", "TEST", 58, 61], ["MCP", "TEST", 63, 66], ["RANTES", "TEST", 70, 76], ["IL", "TEST", 82, 84], ["protein levels", "TEST", 87, 101], ["flow cytometry", "TEST", 105, 119]]], ["This kit allowed simultaneous measurement of five chemokines from 50 ml of sample.", [["sample", "ANATOMY", 75, 81], ["chemokines", "PROTEIN", 50, 60], ["five chemokines", "TREATMENT", 45, 60]]], ["The limits of detection of these immunoassays were 0.2 pg/ml of IL-8, 1.0 pg/ml of RANTES, 2.5 pg/ml of MIG, 2.7 pg/ml of MCP-1, and 2.8 pg/ml of IP-10.", [["IL-8", "GENE_OR_GENE_PRODUCT", 64, 68], ["RANTES", "GENE_OR_GENE_PRODUCT", 83, 89], ["MIG", "GENE_OR_GENE_PRODUCT", 104, 107], ["MCP-1", "GENE_OR_GENE_PRODUCT", 122, 127], ["IP-10", "GENE_OR_GENE_PRODUCT", 146, 151], ["IL", "PROTEIN", 64, 66], ["RANTES", "PROTEIN", 83, 89], ["MIG", "PROTEIN", 104, 107], ["MCP", "PROTEIN", 122, 125], ["these immunoassays", "TEST", 27, 45], ["IL", "TREATMENT", 64, 66], ["RANTES", "TREATMENT", 83, 89], ["MIG", "TREATMENT", 104, 107], ["MCP", "TEST", 122, 125]]], ["TGF-b, sTNFRI, and TNF-a were detected with ELISA kits from Biosource (Camarillo, CA).", [["TGF-b", "GENE_OR_GENE_PRODUCT", 0, 5], ["sTNFRI", "GENE_OR_GENE_PRODUCT", 7, 13], ["TNF", "GENE_OR_GENE_PRODUCT", 19, 22], ["TGF", "PROTEIN", 0, 3], ["sTNFRI", "PROTEIN", 7, 13], ["TNF", "PROTEIN", 19, 22], ["TGF", "TEST", 0, 3], ["sTNFRI", "TEST", 7, 13], ["TNF", "TEST", 19, 22], ["ELISA kits", "TEST", 44, 54]]], ["The detection limits were 50 pg/ml of sTNFRI, 15.6 pg/ml of TGF-b, and 1.7 pg/ml of TNF-a.", [["TGF-b", "GENE_OR_GENE_PRODUCT", 60, 65], ["TNF-a.", "GENE_OR_GENE_PRODUCT", 84, 90], ["TGF", "PROTEIN", 60, 63], ["TNF", "PROTEIN", 84, 87], ["sTNFRI", "TEST", 38, 44], ["TGF", "TEST", 60, 63], ["TNF", "TEST", 84, 87]]], ["IL-18 and IL-13 were detected wit ELISA kits from MBL Medical & Biological Laboratories Co. (Nagoya, Japan) and R&D Systems, Inc. (Minneapolis, MN), respectively.", [["IL-18", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-13", "GENE_OR_GENE_PRODUCT", 10, 15], ["IL-18", "PROTEIN", 0, 5], ["IL", "PROTEIN", 10, 12], ["MBL", "PROTEIN", 50, 53], ["IL", "TEST", 0, 2], ["IL", "TEST", 10, 12]]], ["The detection limits were 12.5 pg/ml of IL-18 and 32 pg/ml of IL-13.Statistical AnalysisThe cytokine, clinical, and laboratory data between antibody positive and antibody negative group or death and survival group was compared by student's t-test with the SigmaPlot 8.0 software (SPSS, Inc., Chicago, IL).", [["death", "DISEASE", 189, 194], ["IL-18", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-13", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL", "PROTEIN", 40, 42], ["IL-13", "PROTEIN", 62, 67], ["cytokine", "PROTEIN", 92, 100], ["IL", "TEST", 40, 42], ["IL", "TEST", 62, 64], ["Statistical Analysis", "TEST", 68, 88], ["laboratory data", "TEST", 116, 131], ["antibody", "TEST", 140, 148], ["antibody", "TEST", 162, 170], ["death", "PROBLEM", 189, 194], ["student's t-test", "TEST", 230, 246], ["the SigmaPlot", "TEST", 252, 265], ["SPSS", "TEST", 280, 284]]], ["P < 0.05 was taken to be significant.Cytokines and Chemokines Levels Are Highly Elevated in SARS PatientsUsing the CBA Th1/Th2 cytokines, chemokines kits and ELISA, 14 cytokines or chemokines, including IFNg, TNF-a, IL-2, IL-4, IL-6, IL-10, IL-13, IL-18, TGF-b, IP-10, MCP-1, MIG, RANTES, and IL-8, as well as TNFRI, were analyzed.", [["Th2", "GENE_OR_GENE_PRODUCT", 123, 126], ["IFNg", "GENE_OR_GENE_PRODUCT", 203, 207], ["TNF-a", "GENE_OR_GENE_PRODUCT", 209, 214], ["IL-2", "GENE_OR_GENE_PRODUCT", 216, 220], ["IL-4", "GENE_OR_GENE_PRODUCT", 222, 226], ["IL-6", "GENE_OR_GENE_PRODUCT", 228, 232], ["IL-10", "GENE_OR_GENE_PRODUCT", 234, 239], ["IL-13", "GENE_OR_GENE_PRODUCT", 241, 246], ["IL-18", "GENE_OR_GENE_PRODUCT", 248, 253], ["TGF-b", "GENE_OR_GENE_PRODUCT", 255, 260], ["IP-10", "GENE_OR_GENE_PRODUCT", 262, 267], ["MCP-1", "GENE_OR_GENE_PRODUCT", 269, 274], ["MIG", "GENE_OR_GENE_PRODUCT", 276, 279], ["RANTES", "GENE_OR_GENE_PRODUCT", 281, 287], ["IL-8", "GENE_OR_GENE_PRODUCT", 293, 297], ["TNFRI", "GENE_OR_GENE_PRODUCT", 310, 315], ["Cytokines", "PROTEIN", 37, 46], ["Chemokines", "PROTEIN", 51, 61], ["CBA Th1/Th2 cytokines", "PROTEIN", 115, 136], ["chemokines", "PROTEIN", 138, 148], ["cytokines", "PROTEIN", 168, 177], ["chemokines", "PROTEIN", 181, 191], ["IFNg", "PROTEIN", 203, 207], ["TNF", "PROTEIN", 209, 212], ["MCP", "PROTEIN", 269, 272], ["MIG", "PROTEIN", 276, 279], ["RANTES", "PROTEIN", 281, 287], ["IL-8", "PROTEIN", 293, 297], ["TNFRI", "PROTEIN", 310, 315], ["Cytokines", "TEST", 37, 46], ["Chemokines Levels", "TEST", 51, 68], ["Highly Elevated", "PROBLEM", 73, 88], ["the CBA Th1/Th2 cytokines", "TEST", 111, 136], ["chemokines kits", "TEST", 138, 153], ["ELISA", "TEST", 158, 163], ["cytokines", "TEST", 168, 177], ["chemokines", "TEST", 181, 191], ["IFNg", "TEST", 203, 207], ["TNF", "TEST", 209, 212], ["IL", "TEST", 216, 218], ["IL", "TEST", 222, 224], ["IL", "TEST", 228, 230], ["IL", "TEST", 234, 236], ["IL", "TEST", 241, 243], ["IL", "TEST", 248, 250], ["TGF", "TEST", 255, 258], ["IP", "TEST", 262, 264], ["MCP", "TEST", 269, 272], ["MIG", "TEST", 276, 279], ["RANTES", "TEST", 281, 287], ["IL", "TEST", 293, 295], ["Elevated", "OBSERVATION_MODIFIER", 80, 88]]], ["As shown in Figure 1 , in a total 88 RT-PCR-confirmed SARS patients, high levels of IFN-g, IL-18, TGF-b, and IL-6 were found in the sera of SARS patients.", [["sera", "ANATOMY", 132, 136], ["SARS", "DISEASE", 54, 58], ["SARS", "DISEASE", 140, 144], ["patients", "ORGANISM", 59, 67], ["IFN-g", "GENE_OR_GENE_PRODUCT", 84, 89], ["IL-18", "GENE_OR_GENE_PRODUCT", 91, 96], ["TGF-b", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL-6", "GENE_OR_GENE_PRODUCT", 109, 113], ["sera", "ORGANISM_SUBSTANCE", 132, 136], ["patients", "ORGANISM", 145, 153], ["IFN", "PROTEIN", 84, 87], ["TGF", "PROTEIN", 98, 101], ["IL-6", "PROTEIN", 109, 113], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 145, 153], ["PCR", "TEST", 40, 43], ["SARS", "PROBLEM", 54, 58], ["IFN", "TEST", 84, 87], ["IL", "TEST", 91, 93], ["TGF", "TEST", 98, 101], ["IL", "TEST", 109, 111]]], ["The chemokines IP-10, MCP-1, MIG, and IL-8 were also elevated.", [["IP-10", "GENE_OR_GENE_PRODUCT", 15, 20], ["MCP-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["MIG", "GENE_OR_GENE_PRODUCT", 29, 32], ["IL-8", "GENE_OR_GENE_PRODUCT", 38, 42], ["chemokines", "PROTEIN", 4, 14], ["MCP", "PROTEIN", 22, 25], ["MIG", "PROTEIN", 29, 32], ["IL-8", "PROTEIN", 38, 42], ["The chemokines IP", "TEST", 0, 17], ["MCP", "TEST", 22, 25], ["MIG", "TEST", 29, 32], ["IL", "TEST", 38, 40]]], ["The mean values of IFN-g, IL-18, TGF-b, IL-6, IP-10, MCP-1, MIG, and IL-8 were 456.1, 638.6, 768.9, 245.7, 6775.3, 755.7, 1229.8, and 325 .6 pg/ml, respectively.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 19, 24], ["IL-18", "GENE_OR_GENE_PRODUCT", 26, 31], ["TGF-b", "GENE_OR_GENE_PRODUCT", 33, 38], ["IL-6", "GENE_OR_GENE_PRODUCT", 40, 44], ["IP-10", "GENE_OR_GENE_PRODUCT", 46, 51], ["MCP-1", "GENE_OR_GENE_PRODUCT", 53, 58], ["MIG", "GENE_OR_GENE_PRODUCT", 60, 63], ["IL-8", "GENE_OR_GENE_PRODUCT", 69, 73], ["IFN", "PROTEIN", 19, 22], ["MCP", "PROTEIN", 53, 56], ["MIG", "PROTEIN", 60, 63], ["IL", "PROTEIN", 69, 71], ["The mean values", "TEST", 0, 15], ["IFN", "TEST", 19, 22], ["IL", "TEST", 26, 28], ["TGF", "TEST", 33, 36], ["IL", "TEST", 40, 42], ["IP", "TEST", 46, 48], ["MCP", "TEST", 53, 56], ["MIG", "TEST", 60, 63], ["IL", "TEST", 69, 71]]], ["The serum levels of cytokines varied a great deal between different individuals, but they were highly elevated in the acute phase post SARS-CoV infection, and were significantly different from normal healthy controls.", [["serum", "ANATOMY", 4, 9], ["SARS-CoV infection", "DISEASE", 135, 153], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["SARS-CoV", "ORGANISM", 135, 143], ["cytokines", "PROTEIN", 20, 29], ["SARS-CoV", "SPECIES", 135, 143], ["The serum levels", "TEST", 0, 16], ["cytokines", "PROBLEM", 20, 29], ["SARS", "PROBLEM", 135, 139], ["CoV infection", "PROBLEM", 140, 153], ["elevated", "OBSERVATION_MODIFIER", 102, 110], ["acute phase", "OBSERVATION_MODIFIER", 118, 129], ["CoV", "OBSERVATION_MODIFIER", 140, 143], ["infection", "OBSERVATION", 144, 153], ["healthy controls", "OBSERVATION_MODIFIER", 200, 216]]], ["All of these cytokines had returned to normal levels at the convalescent phase (30 days or later post disease onset) (Table I ).", [["cytokines", "PROTEIN", 13, 22], ["these cytokines", "TEST", 7, 22], ["cytokines", "OBSERVATION", 13, 22], ["normal", "OBSERVATION", 39, 45]]], ["In contrast, cytokines TNF-a, IL-2, IL-4, IL-10, IL-13, or TNFRI were very low or undetectable.", [["TNF-a", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-2", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-4", "GENE_OR_GENE_PRODUCT", 36, 40], ["IL-10", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-13", "GENE_OR_GENE_PRODUCT", 49, 54], ["TNFRI", "GENE_OR_GENE_PRODUCT", 59, 64], ["cytokines", "PROTEIN", 13, 22], ["TNF", "PROTEIN", 23, 26], ["IL", "PROTEIN", 49, 51], ["TNFRI", "PROTEIN", 59, 64], ["cytokines TNF", "TEST", 13, 26], ["IL", "TEST", 30, 32], ["IL", "TEST", 36, 38], ["IL", "TEST", 42, 44], ["IL", "TEST", 49, 51], ["TNFRI", "TEST", 59, 64], ["low", "OBSERVATION", 75, 78]]], ["Among the detected cytokines, IFN-g and its related chemokines were especially prominent.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 30, 35], ["cytokines", "PROTEIN", 19, 28], ["IFN", "PROTEIN", 30, 33], ["chemokines", "PROTEIN", 52, 62], ["IFN", "TEST", 30, 33], ["cytokines", "OBSERVATION", 19, 28], ["chemokines", "OBSERVATION", 52, 62], ["prominent", "OBSERVATION_MODIFIER", 79, 88]]], ["Only 18% (16/88) of patients had no detectable IFN-g in the serum, while 50% of the patients had IFN-g level higher than 500 pg/ml, and 20% higher than 1,000 pg/ml.", [["serum", "ANATOMY", 60, 65], ["patients", "ORGANISM", 20, 28], ["IFN-g", "GENE_OR_GENE_PRODUCT", 47, 52], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["patients", "ORGANISM", 84, 92], ["IFN-g", "GENE_OR_GENE_PRODUCT", 97, 102], ["IFN", "PROTEIN", 47, 50], ["IFN", "PROTEIN", 97, 100], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 84, 92], ["the serum", "TEST", 56, 65], ["IFN", "TEST", 97, 100]]], ["The IFN-g-stimulated chemokines such as IP-10, MCP-1, and MIG were also highly elevated.Cytokines and Chemokines Levels Are Highly Elevated in SARS PatientsThe Th1/Th2 cytokines profile of SARS was then compared with that of other viral diseases, namely enterovirus 71 (EV71)-induced pulmonary edema and dengue virus-induced dengue hemorrhagic fever/dengue shock syndrome.", [["pulmonary", "ANATOMY", 284, 293], ["SARS", "DISEASE", 143, 147], ["SARS", "DISEASE", 189, 193], ["viral diseases", "DISEASE", 231, 245], ["enterovirus 71 (EV71)", "DISEASE", 254, 275], ["pulmonary edema", "DISEASE", 284, 299], ["dengue virus", "DISEASE", 304, 316], ["dengue hemorrhagic fever", "DISEASE", 325, 349], ["dengue shock syndrome", "DISEASE", 350, 371], ["IFN-g", "GENE_OR_GENE_PRODUCT", 4, 9], ["IP-10", "GENE_OR_GENE_PRODUCT", 40, 45], ["MCP-1", "GENE_OR_GENE_PRODUCT", 47, 52], ["MIG", "GENE_OR_GENE_PRODUCT", 58, 61], ["Patients", "ORGANISM", 148, 156], ["enterovirus 71", "ORGANISM", 254, 268], ["EV71", "ORGANISM", 270, 274], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 284, 299], ["IFN-g-stimulated chemokines", "PROTEIN", 4, 31], ["IP-10", "PROTEIN", 40, 45], ["MCP", "PROTEIN", 47, 50], ["MIG", "PROTEIN", 58, 61], ["Cytokines", "PROTEIN", 88, 97], ["Chemokines", "PROTEIN", 102, 112], ["cytokines", "PROTEIN", 168, 177], ["Patients", "SPECIES", 148, 156], ["dengue virus", "SPECIES", 304, 316], ["dengue hemorrhagic fever", "SPECIES", 325, 349], ["enterovirus 71", "SPECIES", 254, 268], ["EV71", "SPECIES", 270, 274], ["dengue virus", "SPECIES", 304, 316], ["dengue hemorrhagic fever/dengue", "SPECIES", 325, 356], ["The IFN", "TREATMENT", 0, 7], ["IP", "TEST", 40, 42], ["MCP", "TEST", 47, 50], ["MIG", "TEST", 58, 61], ["Cytokines", "TEST", 88, 97], ["Chemokines Levels", "TEST", 102, 119], ["Highly Elevated in SARS", "PROBLEM", 124, 147], ["The Th1/Th2 cytokines profile", "TEST", 156, 185], ["SARS", "PROBLEM", 189, 193], ["other viral diseases", "PROBLEM", 225, 245], ["enterovirus", "PROBLEM", 254, 265], ["EV71", "TEST", 270, 274], ["pulmonary edema", "PROBLEM", 284, 299], ["dengue virus", "PROBLEM", 304, 316], ["dengue hemorrhagic fever", "PROBLEM", 325, 349], ["dengue shock syndrome", "PROBLEM", 350, 371], ["elevated", "OBSERVATION", 79, 87], ["Elevated", "OBSERVATION_MODIFIER", 131, 139], ["viral diseases", "OBSERVATION", 231, 245], ["pulmonary", "ANATOMY", 284, 293], ["edema", "OBSERVATION", 294, 299], ["dengue virus", "OBSERVATION", 304, 316], ["dengue", "OBSERVATION_MODIFIER", 325, 331], ["hemorrhagic", "OBSERVATION_MODIFIER", 332, 343], ["dengue shock syndrome", "OBSERVATION", 350, 371]]], ["The amount of IFN-g observed in the SARS patients was four to sixfold higher than that of EV71-induced pulmonary edema (PE) or dengue virusinduced dengue hemorrhagic fever (DHF) Hung et al., 2004] .", [["pulmonary edema", "ANATOMY", 103, 118], ["SARS", "DISEASE", 36, 40], ["EV71", "DISEASE", 90, 94], ["pulmonary edema", "DISEASE", 103, 118], ["PE", "DISEASE", 120, 122], ["dengue", "DISEASE", 127, 133], ["dengue hemorrhagic fever", "DISEASE", 147, 171], ["DHF", "DISEASE", 173, 176], ["IFN-g", "GENE_OR_GENE_PRODUCT", 14, 19], ["patients", "ORGANISM", 41, 49], ["EV71", "ORGANISM", 90, 94], ["pulmonary", "ORGAN", 103, 112], ["IFN", "PROTEIN", 14, 17], ["patients", "SPECIES", 41, 49], ["dengue hemorrhagic fever", "SPECIES", 147, 171], ["dengue virusinduced dengue hemorrhagic fever (DHF)", "SPECIES", 127, 177], ["IFN-g", "TREATMENT", 14, 19], ["the SARS", "PROBLEM", 32, 40], ["EV71", "PROBLEM", 90, 94], ["pulmonary edema", "PROBLEM", 103, 118], ["PE", "PROBLEM", 120, 122], ["dengue virusinduced dengue hemorrhagic fever", "PROBLEM", 127, 171], ["DHF", "PROBLEM", 173, 176], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["IFN-g observed", "OBSERVATION_MODIFIER", 14, 28], ["EV71", "OBSERVATION", 90, 94], ["pulmonary", "ANATOMY", 103, 112], ["edema", "OBSERVATION", 113, 118], ["PE", "OBSERVATION", 120, 122], ["hemorrhagic", "OBSERVATION_MODIFIER", 154, 165]]], ["The mean values of IFN-g in pulmonary edema patients and dengue hemorrhagic fever patients were 68 and 111 pg/ml, respectively (Fig. 2a) .", [["pulmonary edema", "ANATOMY", 28, 43], ["pulmonary edema", "DISEASE", 28, 43], ["dengue hemorrhagic fever", "DISEASE", 57, 81], ["IFN-g", "GENE_OR_GENE_PRODUCT", 19, 24], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 28, 43], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 82, 90], ["IFN", "PROTEIN", 19, 22], ["patients", "SPECIES", 44, 52], ["dengue hemorrhagic fever", "SPECIES", 57, 81], ["patients", "SPECIES", 82, 90], ["The mean values", "TEST", 0, 15], ["IFN", "TEST", 19, 22], ["pulmonary edema", "PROBLEM", 28, 43], ["dengue hemorrhagic fever", "PROBLEM", 57, 81], ["mean values", "OBSERVATION_MODIFIER", 4, 15], ["pulmonary", "ANATOMY", 28, 37], ["edema", "OBSERVATION", 38, 43], ["dengue", "OBSERVATION_MODIFIER", 57, 63], ["hemorrhagic", "OBSERVATION_MODIFIER", 64, 75]]], ["Surprisingly, IL-10 level was very low as 82% (72/88) of patient had serum IL-10 level lower than 20 pg/ml.", [["serum", "ANATOMY", 69, 74], ["IL-10", "GENE_OR_GENE_PRODUCT", 14, 19], ["patient", "ORGANISM", 57, 64], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["IL-10", "GENE_OR_GENE_PRODUCT", 75, 80], ["IL", "PROTEIN", 14, 16], ["IL", "PROTEIN", 75, 77], ["patient", "SPECIES", 57, 64], ["IL", "TEST", 14, 16], ["serum IL", "TEST", 69, 77]]], ["This is in contrast to pulmonary edema and dengue hemorrhagic fever where the mean concentration of IL-10 in pulmonary edema and dengue hemorrhagic fever were 123.6 and 81.7 pg/ml, respectively.", [["pulmonary", "ANATOMY", 23, 32], ["pulmonary edema", "ANATOMY", 109, 124], ["pulmonary edema", "DISEASE", 23, 38], ["dengue hemorrhagic fever", "DISEASE", 43, 67], ["pulmonary edema", "DISEASE", 109, 124], ["dengue hemorrhagic fever", "DISEASE", 129, 153], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 23, 38], ["IL-10", "GENE_OR_GENE_PRODUCT", 100, 105], ["pulmonary", "ORGAN", 109, 118], ["IL", "PROTEIN", 100, 102], ["pulmonary edema", "PROBLEM", 23, 38], ["dengue hemorrhagic fever", "PROBLEM", 43, 67], ["the mean concentration of IL", "TEST", 74, 102], ["pulmonary edema", "PROBLEM", 109, 124], ["dengue hemorrhagic fever", "PROBLEM", 129, 153], ["pulmonary", "ANATOMY", 23, 32], ["edema", "OBSERVATION", 33, 38], ["dengue", "OBSERVATION_MODIFIER", 43, 49], ["hemorrhagic", "OBSERVATION_MODIFIER", 50, 61], ["fever", "OBSERVATION", 62, 67], ["mean", "OBSERVATION_MODIFIER", 78, 82], ["concentration", "OBSERVATION_MODIFIER", 83, 96], ["IL", "OBSERVATION_MODIFIER", 100, 102], ["pulmonary", "ANATOMY", 109, 118], ["edema", "OBSERVATION", 119, 124], ["dengue", "OBSERVATION_MODIFIER", 129, 135], ["hemorrhagic", "OBSERVATION_MODIFIER", 136, 147]]], ["The multiple cytokines were detected simultaneously by the CBA kit, therefore, the Th1-prone IFN-g of each individual was plotted to his/her Th2-prone IL-10.", [["Th1", "GENE_OR_GENE_PRODUCT", 83, 86], ["IL-10", "GENE_OR_GENE_PRODUCT", 151, 156], ["cytokines", "PROTEIN", 13, 22], ["IFN", "PROTEIN", 93, 96], ["The multiple cytokines", "TREATMENT", 0, 22], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["cytokines", "OBSERVATION", 13, 22]]], ["A reciprocal relationship between IFN-g and IL-10 was found for all individuals (Fig. 2f) .", [["IFN-g", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL-10", "GENE_OR_GENE_PRODUCT", 44, 49], ["IFN", "PROTEIN", 34, 37], ["IL", "PROTEIN", 44, 46], ["IFN-g and IL", "TREATMENT", 34, 46]]], ["The IL-10reciprocal relationship was also found for IL-18, MCP-1, IP-10, and MIG (data not shown).", [["IL-10reciprocal", "GENE_OR_GENE_PRODUCT", 4, 19], ["IL-18", "GENE_OR_GENE_PRODUCT", 52, 57], ["MCP-1", "GENE_OR_GENE_PRODUCT", 59, 64], ["IP-10", "GENE_OR_GENE_PRODUCT", 66, 71], ["MIG", "GENE_OR_GENE_PRODUCT", 77, 80], ["IL", "PROTEIN", 4, 6], ["IL-18", "PROTEIN", 52, 57], ["MCP", "PROTEIN", 59, 62], ["IP", "PROTEIN", 66, 68], ["MIG", "PROTEIN", 77, 80], ["IL", "TEST", 52, 54], ["MCP", "TEST", 59, 62], ["IP", "TEST", 66, 68], ["MIG (data", "TEST", 77, 86]]], ["This pattern was different from that of EV71-induced pulmonary edema or dengue virus-induced dengue hemorrhagic fever.", [["pulmonary", "ANATOMY", 53, 62], ["EV71", "DISEASE", 40, 44], ["pulmonary edema", "DISEASE", 53, 68], ["dengue", "DISEASE", 72, 78], ["dengue hemorrhagic fever", "DISEASE", 93, 117], ["EV71", "ORGANISM", 40, 44], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 53, 68], ["dengue virus", "ORGANISM", 72, 84], ["dengue virus", "SPECIES", 72, 84], ["dengue hemorrhagic fever", "SPECIES", 93, 117], ["dengue virus", "SPECIES", 72, 84], ["EV71", "PROBLEM", 40, 44], ["pulmonary edema", "PROBLEM", 53, 68], ["dengue virus", "PROBLEM", 72, 84], ["induced dengue hemorrhagic fever", "PROBLEM", 85, 117], ["different", "OBSERVATION_MODIFIER", 17, 26], ["pulmonary", "ANATOMY", 53, 62], ["edema", "OBSERVATION", 63, 68], ["dengue virus", "OBSERVATION", 72, 84], ["dengue", "OBSERVATION_MODIFIER", 93, 99], ["hemorrhagic", "OBSERVATION_MODIFIER", 100, 111], ["fever", "OBSERVATION", 112, 117]]], ["In these two diseases, a mix of IFN-g and IL-10 is present simultaneously.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 32, 37], ["IL-10", "GENE_OR_GENE_PRODUCT", 42, 47], ["IFN", "PROTEIN", 32, 35], ["IL", "PROTEIN", 42, 44], ["IFN-g and IL", "TREATMENT", 32, 44], ["two", "OBSERVATION_MODIFIER", 9, 12], ["diseases", "OBSERVATION", 13, 21]]], ["While, with regard to other cytokines such as IL-6, IL-18, and IL-8, there were all present in SARS, pulmonary edema, and dengue hemorrhagic fever (Fig. 2b,d,e) .", [["pulmonary", "ANATOMY", 101, 110], ["SARS", "DISEASE", 95, 99], ["pulmonary edema", "DISEASE", 101, 116], ["dengue hemorrhagic fever", "DISEASE", 122, 146], ["IL-6", "GENE_OR_GENE_PRODUCT", 46, 50], ["IL-18", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL-8", "GENE_OR_GENE_PRODUCT", 63, 67], ["pulmonary", "ORGAN", 101, 110], ["cytokines", "PROTEIN", 28, 37], ["IL-6", "PROTEIN", 46, 50], ["IL-18", "PROTEIN", 52, 57], ["IL", "PROTEIN", 63, 65], ["dengue hemorrhagic fever", "SPECIES", 122, 146], ["other cytokines", "TEST", 22, 37], ["IL", "TEST", 46, 48], ["IL", "TEST", 52, 54], ["IL", "TEST", 63, 65], ["SARS", "PROBLEM", 95, 99], ["pulmonary edema", "PROBLEM", 101, 116], ["dengue hemorrhagic fever", "PROBLEM", 122, 146], ["SARS", "OBSERVATION", 95, 99], ["pulmonary", "ANATOMY", 101, 110], ["edema", "OBSERVATION", 111, 116], ["dengue", "OBSERVATION_MODIFIER", 122, 128], ["hemorrhagic", "OBSERVATION_MODIFIER", 129, 140]]], ["But for IL-13, only 8 % (5/66) of SARS patients had detectable level higher than detection limit, 32 pg/ml (Fig. 2c) .", [["SARS", "DISEASE", 34, 38], ["IL-13", "GENE_OR_GENE_PRODUCT", 8, 13], ["patients", "ORGANISM", 39, 47], ["IL", "PROTEIN", 8, 10], ["patients", "SPECIES", 39, 47], ["IL", "TEST", 8, 10], ["SARS", "PROBLEM", 34, 38]]], ["On the contrary, IL-13 was markedly elevated in pulmonary edema patients, and it plays an important role in the pulmonary edema post EV71 infection.Comparison of Cytokines in Ab(\u00c0) and Ab(\u00fe) GroupsTo understand the cytokines profile in the developmental process of SARS post SARS-CoV infection, the 88 RT-PCR-confirmed cases were divided into two categories based on their antibody status.", [["pulmonary edema", "ANATOMY", 48, 63], ["pulmonary", "ANATOMY", 112, 121], ["pulmonary edema", "DISEASE", 48, 63], ["pulmonary edema", "DISEASE", 112, 127], ["EV71 infection", "DISEASE", 133, 147], ["SARS", "DISEASE", 265, 269], ["SARS-CoV infection", "DISEASE", 275, 293], ["IL-13", "GENE_OR_GENE_PRODUCT", 17, 22], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 48, 63], ["patients", "ORGANISM", 64, 72], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 112, 127], ["EV71", "ORGANISM", 133, 137], ["Cytokines", "GENE_OR_GENE_PRODUCT", 162, 171], ["Ab(\u00c0)", "GENE_OR_GENE_PRODUCT", 175, 180], ["SARS-CoV", "ORGANISM", 275, 283], ["IL-13", "PROTEIN", 17, 22], ["Cytokines", "PROTEIN", 162, 171], ["Ab(\u00c0)", "PROTEIN", 175, 180], ["cytokines", "PROTEIN", 215, 224], ["patients", "SPECIES", 64, 72], ["EV71", "SPECIES", 133, 137], ["SARS-CoV", "SPECIES", 275, 283], ["IL", "TEST", 17, 19], ["markedly elevated", "PROBLEM", 27, 44], ["pulmonary edema", "PROBLEM", 48, 63], ["the pulmonary edema", "PROBLEM", 108, 127], ["EV71 infection", "PROBLEM", 133, 147], ["Cytokines in Ab", "TEST", 162, 177], ["the cytokines profile", "PROBLEM", 211, 232], ["SARS", "PROBLEM", 265, 269], ["SARS", "PROBLEM", 275, 279], ["CoV infection", "PROBLEM", 280, 293], ["PCR", "TEST", 305, 308], ["elevated", "OBSERVATION_MODIFIER", 36, 44], ["pulmonary", "ANATOMY", 48, 57], ["edema", "OBSERVATION", 58, 63], ["pulmonary", "ANATOMY", 112, 121], ["edema", "OBSERVATION", 122, 127], ["EV71 infection", "OBSERVATION", 133, 147]]], ["As shown in Table II , the mean age of 51 patients in Ab(\u00c0) group was significantly higher than that of 37 patients in Ab(\u00fe) group.", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 107, 115]]], ["A larger percentage of males than of females were found in the Ab(\u00c0) group.", [["Ab(\u00c0)", "GENE_OR_GENE_PRODUCT", 63, 68], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["percentage", "OBSERVATION_MODIFIER", 9, 19], ["males", "OBSERVATION", 23, 28]]], ["On the other hand, a larger percentage of females than males were found in the Ab(\u00fe) group.", [["Ab(\u00fe)", "GENE_OR_GENE_PRODUCT", 79, 84], ["larger", "OBSERVATION_MODIFIER", 21, 27], ["percentage", "OBSERVATION_MODIFIER", 28, 38]]], ["The mortality was also significantly higher in the Ab(\u00c0) than in the Ab(\u00fe) group.", [["Ab(\u00c0)", "GENE_OR_GENE_PRODUCT", 51, 56], ["Ab(\u00fe)", "GENE_OR_GENE_PRODUCT", 69, 74], ["significantly", "OBSERVATION_MODIFIER", 23, 36], ["higher", "OBSERVATION_MODIFIER", 37, 43]]], ["Duration of stay in hospital reflects the mortality rate, therefore, it was lower in the Ab(\u00c0) than in the Ab(\u00fe) group.", [["Ab(\u00fe)", "GENE_OR_GENE_PRODUCT", 107, 112]]], ["Laboratory data on blood urine nitrogen, white blood count, and complete blood count were not different between these two groups.", [["blood urine", "ANATOMY", 19, 30], ["white blood", "ANATOMY", 41, 52], ["blood", "ANATOMY", 73, 78], ["urine nitrogen", "CHEMICAL", 25, 39], ["nitrogen", "CHEMICAL", 31, 39], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["urine", "ORGANISM_SUBSTANCE", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["Laboratory data", "TEST", 0, 15], ["blood urine nitrogen", "TEST", 19, 39], ["white blood count", "TEST", 41, 58], ["complete blood count", "TEST", 64, 84]]], ["IL-6, IL-18, IL-10, TGF-b, IP-10, MIG, MCP-1, and IL-8 were also not significantly different between these two groups: they were all highly elevated.", [["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-18", "GENE_OR_GENE_PRODUCT", 6, 11], ["IL-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["TGF-b", "GENE_OR_GENE_PRODUCT", 20, 25], ["IP-10", "GENE_OR_GENE_PRODUCT", 27, 32], ["MIG", "GENE_OR_GENE_PRODUCT", 34, 37], ["MCP-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-8", "GENE_OR_GENE_PRODUCT", 50, 54], ["MIG", "PROTEIN", 34, 37], ["MCP", "PROTEIN", 39, 42], ["IL", "PROTEIN", 50, 52], ["IL", "TEST", 0, 2], ["IL", "TEST", 6, 8], ["IL", "TEST", 13, 15], ["TGF", "TEST", 20, 23], ["IP", "TEST", 27, 29], ["MIG", "TEST", 34, 37], ["MCP", "TEST", 39, 42], ["IL", "TEST", 50, 52], ["elevated", "OBSERVATION", 140, 148]]], ["The only difference was the IFN-g level: the serum IFN-g level in the Ab(\u00fe) group was significantly higher than that in the Ab(\u00c0) group (Table II) .", [["serum", "ANATOMY", 45, 50], ["IFN-g", "GENE_OR_GENE_PRODUCT", 28, 33], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["IFN-g", "GENE_OR_GENE_PRODUCT", 51, 56], ["Ab", "GENE_OR_GENE_PRODUCT", 70, 72], ["IFN", "PROTEIN", 28, 31], ["IFN", "PROTEIN", 51, 54], ["the IFN", "TEST", 24, 31], ["the serum IFN", "TEST", 41, 54], ["g level", "TEST", 55, 62], ["the Ab", "TEST", 66, 72]]], ["To understand the kinetic changes of these cytokines in the early stage of acute infection, the levels of IFN-g, IP-10, MCP-1, MIG, IL-18, IL-8, IL-6, and TGF-b in Ab(\u00c0) group were plotted against the days post fever onset (Fig. 3) .", [["acute infection", "DISEASE", 75, 90], ["fever", "DISEASE", 211, 216], ["IFN-g", "GENE_OR_GENE_PRODUCT", 106, 111], ["IP-10", "GENE_OR_GENE_PRODUCT", 113, 118], ["MCP-1", "GENE_OR_GENE_PRODUCT", 120, 125], ["MIG", "GENE_OR_GENE_PRODUCT", 127, 130], ["IL-18", "GENE_OR_GENE_PRODUCT", 132, 137], ["IL-8", "GENE_OR_GENE_PRODUCT", 139, 143], ["IL-6", "GENE_OR_GENE_PRODUCT", 145, 149], ["TGF-b", "GENE_OR_GENE_PRODUCT", 155, 160], ["Ab(\u00c0)", "SIMPLE_CHEMICAL", 164, 169], ["cytokines", "PROTEIN", 43, 52], ["IFN", "PROTEIN", 106, 109], ["MCP", "PROTEIN", 120, 123], ["MIG", "PROTEIN", 127, 130], ["IL-6", "PROTEIN", 145, 149], ["TGF", "PROTEIN", 155, 158], ["the kinetic changes", "PROBLEM", 14, 33], ["these cytokines", "PROBLEM", 37, 52], ["acute infection", "PROBLEM", 75, 90], ["the levels", "TEST", 92, 102], ["IFN", "TEST", 106, 109], ["IP", "TEST", 113, 115], ["MCP", "TEST", 120, 123], ["MIG", "TEST", 127, 130], ["IL", "TEST", 132, 134], ["IL", "TEST", 139, 141], ["IL", "TEST", 145, 147], ["TGF", "TEST", 155, 158], ["fever onset", "PROBLEM", 211, 222], ["early stage", "OBSERVATION_MODIFIER", 60, 71], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["infection", "OBSERVATION", 81, 90]]], ["IFN-g and its related chemokines MCP-1, MIG, and IP-10 were already highly elevated at early days.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["MCP-1", "GENE_OR_GENE_PRODUCT", 33, 38], ["MIG", "GENE_OR_GENE_PRODUCT", 40, 43], ["IP-10", "GENE_OR_GENE_PRODUCT", 49, 54], ["IFN", "PROTEIN", 0, 3], ["chemokines", "PROTEIN", 22, 32], ["MCP", "PROTEIN", 33, 36], ["MIG", "PROTEIN", 40, 43], ["IFN", "TEST", 0, 3], ["chemokines MCP", "TEST", 22, 36], ["MIG", "TEST", 40, 43], ["IP", "TEST", 49, 51], ["elevated", "OBSERVATION", 75, 83]]], ["IFN-g, MIG, IP-10, and MCP-1 seemed to appear the earliest, and peaked at days 1-4 post fever onset.", [["fever", "DISEASE", 88, 93], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["MIG", "GENE_OR_GENE_PRODUCT", 7, 10], ["IP-10", "GENE_OR_GENE_PRODUCT", 12, 17], ["MCP-1", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN", "PROTEIN", 0, 3], ["MIG", "PROTEIN", 7, 10], ["MCP", "PROTEIN", 23, 26], ["IFN", "TEST", 0, 3], ["IP", "TEST", 12, 14], ["MCP", "TEST", 23, 26], ["fever onset", "PROBLEM", 88, 99]]], ["IL-8 and IL-18 increased later, and peaked at days 4-6 post fever onset.Comparison of Cytokines in Ab(\u00c0) and Ab(\u00fe) GroupsIL-6 and TGF-b also appeared later.", [["fever", "DISEASE", 60, 65], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-18", "GENE_OR_GENE_PRODUCT", 9, 14], ["Cytokines", "GENE_OR_GENE_PRODUCT", 86, 95], ["Ab(\u00c0)", "GENE_OR_GENE_PRODUCT", 99, 104], ["Ab(\u00fe) GroupsIL-6", "GENE_OR_GENE_PRODUCT", 109, 125], ["TGF-b", "GENE_OR_GENE_PRODUCT", 130, 135], ["IL-8", "PROTEIN", 0, 4], ["IL-18", "PROTEIN", 9, 14], ["Cytokines", "PROTEIN", 86, 95], ["Ab(\u00c0)", "PROTEIN", 99, 104], ["TGF-b", "PROTEIN", 130, 135], ["IL", "TEST", 0, 2], ["IL", "TEST", 9, 11], ["fever onset", "PROBLEM", 60, 71], ["Cytokines in Ab", "TEST", 86, 101], ["Ab", "TEST", 109, 111], ["GroupsIL", "TEST", 115, 123], ["TGF", "TEST", 130, 133]]], ["To further delineate the relationship between IFN-g and its related cytokines, the linear regressions between IFN-g or IL-18 and IP-10, MCP-1 or MIG were analyzed.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 46, 51], ["IFN-g", "GENE_OR_GENE_PRODUCT", 110, 115], ["IL-18", "GENE_OR_GENE_PRODUCT", 119, 124], ["IP-10", "GENE_OR_GENE_PRODUCT", 129, 134], ["MCP-1", "GENE_OR_GENE_PRODUCT", 136, 141], ["MIG", "GENE_OR_GENE_PRODUCT", 145, 148], ["IFN", "PROTEIN", 46, 49], ["cytokines", "PROTEIN", 68, 77], ["IFN", "PROTEIN", 110, 113], ["MCP", "PROTEIN", 136, 139], ["MIG", "PROTEIN", 145, 148], ["IFN-g", "TREATMENT", 46, 51], ["its related cytokines", "PROBLEM", 56, 77], ["the linear regressions", "PROBLEM", 79, 101], ["IFN", "TEST", 110, 113], ["IL", "TEST", 119, 121], ["IP", "TEST", 129, 131], ["MCP", "TEST", 136, 139], ["MIG", "TREATMENT", 145, 148], ["linear", "OBSERVATION_MODIFIER", 83, 89]]], ["A good association was found for IL-18 and IP-10, MCP-1, or MIG.", [["IL-18", "GENE_OR_GENE_PRODUCT", 33, 38], ["IP-10", "GENE_OR_GENE_PRODUCT", 43, 48], ["MCP-1", "GENE_OR_GENE_PRODUCT", 50, 55], ["MIG", "GENE_OR_GENE_PRODUCT", 60, 63], ["IL-18", "PROTEIN", 33, 38], ["MCP", "PROTEIN", 50, 53], ["MIG", "PROTEIN", 60, 63], ["IL", "TEST", 33, 35], ["IP", "TEST", 43, 45], ["MCP", "TEST", 50, 53]]], ["The correlation coefficient and r 2 for IL-18 and IP-10, MCP-1 or MIG were 0.568/0.344, 0.688/0.473, and 0.745/0.555, respectively (Fig. 4) .", [["IL-18", "GENE_OR_GENE_PRODUCT", 40, 45], ["IP-10", "GENE_OR_GENE_PRODUCT", 50, 55], ["MCP-1", "GENE_OR_GENE_PRODUCT", 57, 62], ["MIG", "GENE_OR_GENE_PRODUCT", 66, 69], ["IL", "PROTEIN", 40, 42], ["MCP", "PROTEIN", 57, 60], ["MIG", "PROTEIN", 66, 69], ["IL", "TEST", 40, 42], ["IP", "TEST", 50, 52], ["MCP", "TEST", 57, 60], ["MIG", "TEST", 66, 69]]], ["The association was better for IL-18 Fig. 2 .", [["IL-18", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL", "PROTEIN", 31, 33], ["IL", "TEST", 31, 33]]], ["Comparison of IFN-g, IL-18, IL-6, IL-8, and IL-13 between SARS, EV71-induced pulmonary edema, and dengue virus-induced dengue hemorrhagic fever.", [["pulmonary edema", "ANATOMY", 77, 92], ["SARS", "DISEASE", 58, 62], ["EV71", "DISEASE", 64, 68], ["pulmonary edema", "DISEASE", 77, 92], ["dengue virus", "DISEASE", 98, 110], ["dengue hemorrhagic fever", "DISEASE", 119, 143], ["IFN-g", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-18", "GENE_OR_GENE_PRODUCT", 21, 26], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["IL-8", "GENE_OR_GENE_PRODUCT", 34, 38], ["IL-13", "GENE_OR_GENE_PRODUCT", 44, 49], ["EV71", "ORGANISM", 64, 68], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 77, 92], ["dengue virus", "ORGANISM", 98, 110], ["IFN", "PROTEIN", 14, 17], ["dengue virus", "SPECIES", 98, 110], ["dengue hemorrhagic fever", "SPECIES", 119, 143], ["dengue virus", "SPECIES", 98, 110], ["IFN", "TEST", 14, 17], ["IL", "TEST", 21, 23], ["IL", "TEST", 28, 30], ["IL", "TEST", 34, 36], ["IL", "TEST", 44, 46], ["SARS", "PROBLEM", 58, 62], ["EV71", "PROBLEM", 64, 68], ["pulmonary edema", "PROBLEM", 77, 92], ["dengue virus", "PROBLEM", 98, 110], ["dengue hemorrhagic fever", "PROBLEM", 119, 143], ["pulmonary", "ANATOMY", 77, 86], ["edema", "OBSERVATION", 87, 92], ["dengue", "OBSERVATION_MODIFIER", 119, 125], ["hemorrhagic", "OBSERVATION_MODIFIER", 126, 137], ["fever", "OBSERVATION", 138, 143]]], ["The serum cytokines levels from SARS, pulmonary edema, and dengue hemorrhagic fever patients were compared for IFN-g (a), IL-6 (b), IL-13 (c), IL-8 (d), and IL-18 (e).", [["serum", "ANATOMY", 4, 9], ["pulmonary edema", "ANATOMY", 38, 53], ["SARS", "DISEASE", 32, 36], ["pulmonary edema", "DISEASE", 38, 53], ["dengue hemorrhagic fever", "DISEASE", 59, 83], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 38, 53], ["patients", "ORGANISM", 84, 92], ["IFN-g", "GENE_OR_GENE_PRODUCT", 111, 116], ["IL-6", "GENE_OR_GENE_PRODUCT", 122, 126], ["b", "GENE_OR_GENE_PRODUCT", 128, 129], ["IL-13", "GENE_OR_GENE_PRODUCT", 132, 137], ["c", "GENE_OR_GENE_PRODUCT", 139, 140], ["IL-8", "GENE_OR_GENE_PRODUCT", 143, 147], ["IL-18", "GENE_OR_GENE_PRODUCT", 157, 162], ["serum cytokines", "PROTEIN", 4, 19], ["IFN", "PROTEIN", 111, 114], ["IL-8", "PROTEIN", 143, 147], ["IL", "PROTEIN", 157, 159], ["dengue hemorrhagic fever", "SPECIES", 59, 83], ["patients", "SPECIES", 84, 92], ["The serum cytokines levels", "TEST", 0, 26], ["SARS", "PROBLEM", 32, 36], ["pulmonary edema", "PROBLEM", 38, 53], ["dengue hemorrhagic fever", "PROBLEM", 59, 83], ["IFN", "TEST", 111, 114], ["IL", "TEST", 122, 124], ["IL", "TEST", 132, 134], ["IL", "TEST", 143, 145], ["IL", "TEST", 157, 159], ["pulmonary", "ANATOMY", 38, 47], ["edema", "OBSERVATION", 48, 53], ["dengue", "OBSERVATION_MODIFIER", 59, 65], ["hemorrhagic", "OBSERVATION_MODIFIER", 66, 77]]], ["A reciprocal relationship of IFN-g and IL-10 was shown for SARS patients (f).", [["SARS", "DISEASE", 59, 63], ["IFN-g", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-10", "GENE_OR_GENE_PRODUCT", 39, 44], ["patients", "ORGANISM", 64, 72], ["IFN", "PROTEIN", 29, 32], ["IL", "PROTEIN", 39, 41], ["patients", "SPECIES", 64, 72], ["IFN-g and IL", "TREATMENT", 29, 41]]], ["The bar represents the mean value of each cytokine.", [["cytokine", "PROTEIN", 42, 50], ["bar", "OBSERVATION_MODIFIER", 4, 7]]], ["N is the patient serum samples determined. than for IFN-g.", [["serum samples", "ANATOMY", 17, 30], ["patient", "ORGANISM", 9, 16], ["serum samples", "ORGANISM_SUBSTANCE", 17, 30], ["IFN", "PROTEIN", 52, 55], ["patient", "SPECIES", 9, 16], ["the patient serum samples", "TEST", 5, 30], ["IFN", "TREATMENT", 52, 55]]], ["On the contrary, a reciprocal relationship existed between IL-10 and IFN-g and other related chemokines because no or low IL-10 was produced.", [["IL-10", "GENE_OR_GENE_PRODUCT", 59, 64], ["IFN-g", "GENE_OR_GENE_PRODUCT", 69, 74], ["IL-10", "GENE_OR_GENE_PRODUCT", 122, 127], ["IL-10", "PROTEIN", 59, 64], ["IFN", "PROTEIN", 69, 72], ["chemokines", "PROTEIN", 93, 103], ["IL", "PROTEIN", 122, 124], ["IL", "TEST", 59, 61], ["IFN-g", "TREATMENT", 69, 74], ["other related chemokines", "TREATMENT", 79, 103], ["low IL", "TREATMENT", 118, 124]]], ["These cytokine patterns on Ab(\u00fe) group were not so obvious as those on Ab(\u00c0) group (data not shown).", [["Ab(\u00fe)", "GENE_OR_GENE_PRODUCT", 27, 32], ["cytokine", "PROTEIN", 6, 14]]], ["It seems that IL-18, IFN-g, IP-10, MCP-1, and MIG are activated together during the early phase of SARS-CoV acute infection.", [["SARS-CoV acute infection", "DISEASE", 99, 123], ["IL-18", "GENE_OR_GENE_PRODUCT", 14, 19], ["IFN-g", "GENE_OR_GENE_PRODUCT", 21, 26], ["IP-10", "GENE_OR_GENE_PRODUCT", 28, 33], ["MCP-1", "GENE_OR_GENE_PRODUCT", 35, 40], ["MIG", "GENE_OR_GENE_PRODUCT", 46, 49], ["SARS-CoV", "ORGANISM", 99, 107], ["IL-18", "PROTEIN", 14, 19], ["IFN", "PROTEIN", 21, 24], ["MCP", "PROTEIN", 35, 38], ["MIG", "PROTEIN", 46, 49], ["SARS-CoV", "SPECIES", 99, 107], ["IL", "TEST", 14, 16], ["IFN", "TEST", 21, 24], ["IP", "TEST", 28, 30], ["MCP", "TEST", 35, 38], ["MIG", "TREATMENT", 46, 49], ["SARS", "PROBLEM", 99, 103], ["CoV acute infection", "PROBLEM", 104, 123], ["CoV", "OBSERVATION_MODIFIER", 104, 107], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["infection", "OBSERVATION", 114, 123]]], ["Since SARS-CoV infection can be fatal, and intensive inflammatory response is involved in the disease process, we compared the cytokines between death and survival cases of SARS patients.", [["SARS-CoV infection", "DISEASE", 6, 24], ["death", "DISEASE", 145, 150], ["SARS", "DISEASE", 173, 177], ["SARS-CoV", "ORGANISM", 6, 14], ["patients", "ORGANISM", 178, 186], ["cytokines", "PROTEIN", 127, 136], ["patients", "SPECIES", 178, 186], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "PROBLEM", 6, 10], ["CoV infection", "PROBLEM", 11, 24], ["intensive inflammatory response", "PROBLEM", 43, 74], ["the disease process", "PROBLEM", 90, 109], ["CoV", "OBSERVATION_MODIFIER", 11, 14], ["infection", "OBSERVATION", 15, 24], ["intensive", "OBSERVATION_MODIFIER", 43, 52], ["inflammatory", "OBSERVATION_MODIFIER", 53, 65]]], ["As shown in Table III , the mean age of the death group was older than that of survival group.", [["death", "DISEASE", 44, 49]]], ["The death group also had higher blood urine nitrogen or asparate aminotransferase value than the survival group.", [["blood", "ANATOMY", 32, 37], ["death", "DISEASE", 4, 9], ["urine nitrogen", "CHEMICAL", 38, 52], ["asparate", "CHEMICAL", 56, 64], ["nitrogen", "CHEMICAL", 44, 52], ["asparate", "CHEMICAL", 56, 64], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["urine", "ORGANISM_SUBSTANCE", 38, 43], ["nitrogen", "SIMPLE_CHEMICAL", 44, 52], ["asparate", "SIMPLE_CHEMICAL", 56, 64], ["aminotransferase", "SIMPLE_CHEMICAL", 65, 81], ["asparate aminotransferase", "PROTEIN", 56, 81], ["blood urine nitrogen", "TEST", 32, 52], ["asparate aminotransferase value", "PROBLEM", 56, 87]]], ["The SARS-CoV-infected patients with underlying diseases were more susceptible to death.", [["SARS-CoV-infected", "DISEASE", 4, 21], ["death", "DISEASE", 81, 86], ["SARS-CoV", "ORGANISM", 4, 12], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "PROBLEM", 0, 8], ["underlying diseases", "PROBLEM", 36, 55], ["death", "PROBLEM", 81, 86], ["infected", "OBSERVATION_MODIFIER", 13, 21], ["diseases", "OBSERVATION", 47, 55]]], ["Their cytokines IL-18, IP-10, MIG, and MCP-1 levels were significantly higher than in the survival group.", [["IL-18", "GENE_OR_GENE_PRODUCT", 16, 21], ["IP-10", "GENE_OR_GENE_PRODUCT", 23, 28], ["MIG", "GENE_OR_GENE_PRODUCT", 30, 33], ["MCP-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["cytokines", "PROTEIN", 6, 15], ["MIG", "PROTEIN", 30, 33], ["MCP", "PROTEIN", 39, 42], ["Their cytokines IL", "TEST", 0, 18], ["IP", "TEST", 23, 25], ["MIG", "TEST", 30, 33], ["MCP", "TEST", 39, 42]]], ["IL-8 seemed also higher in the death group than in the survival group, but the P value (0.091) was not statistically significant.", [["death", "DISEASE", 31, 36], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-8", "PROTEIN", 0, 4], ["IL", "TEST", 0, 2], ["the P value", "TEST", 75, 86], ["higher", "OBSERVATION_MODIFIER", 17, 23]]], ["IP-10, MIG, and MCP-1 are chemokines for activated T cells while IL-8 is a chemokine for neutrophils.", [["T cells", "ANATOMY", 51, 58], ["neutrophils", "ANATOMY", 89, 100], ["IP-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["MIG", "GENE_OR_GENE_PRODUCT", 7, 10], ["MCP-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["T cells", "CELL", 51, 58], ["IL-8", "GENE_OR_GENE_PRODUCT", 65, 69], ["neutrophils", "CELL", 89, 100], ["MIG", "PROTEIN", 7, 10], ["MCP-1", "PROTEIN", 16, 21], ["chemokines", "PROTEIN", 26, 36], ["activated T cells", "CELL_TYPE", 41, 58], ["IL-8", "PROTEIN", 65, 69], ["chemokine", "PROTEIN", 75, 84], ["neutrophils", "CELL_TYPE", 89, 100], ["IP", "TEST", 0, 2], ["MCP", "TEST", 16, 19], ["activated T cells", "PROBLEM", 41, 58], ["IL", "TEST", 65, 67], ["neutrophils", "TEST", 89, 100]]], ["This suggests that the extensive inflammation is probably responsible for the inflammatory response in the lung of SARS fatal cases.", [["lung", "ANATOMY", 107, 111], ["inflammation", "DISEASE", 33, 45], ["SARS", "DISEASE", 115, 119], ["lung", "ORGAN", 107, 111], ["the extensive inflammation", "PROBLEM", 19, 45], ["the inflammatory response in the lung of SARS fatal cases", "PROBLEM", 74, 131], ["extensive", "OBSERVATION_MODIFIER", 23, 32], ["inflammation", "OBSERVATION", 33, 45], ["probably responsible for", "UNCERTAINTY", 49, 73], ["inflammatory", "OBSERVATION", 78, 90], ["lung", "ANATOMY", 107, 111]]], ["For the survival group, when MCP-1 and IFN-g were plotted to the circulating lymphocytes count and monocytes count of the SARS patients, an inverse association was found.", [["lymphocytes", "ANATOMY", 77, 88], ["monocytes", "ANATOMY", 99, 108], ["SARS", "DISEASE", 122, 126], ["MCP-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["IFN-g", "GENE_OR_GENE_PRODUCT", 39, 44], ["lymphocytes", "CELL", 77, 88], ["monocytes", "CELL", 99, 108], ["patients", "ORGANISM", 127, 135], ["MCP", "PROTEIN", 29, 32], ["IFN", "PROTEIN", 39, 42], ["monocytes", "CELL_TYPE", 99, 108], ["patients", "SPECIES", 127, 135], ["MCP", "TEST", 29, 32], ["IFN", "TEST", 39, 42], ["the circulating lymphocytes count", "TEST", 61, 94], ["monocytes count", "TEST", 99, 114]]], ["For MCP-1 and lymphocyte and monocyte counts, the correlation coefficient and r 2 were \u00c00.438/ 0.192 and \u00c00.378/0.143, respectively (Fig. 5) .", [["lymphocyte", "ANATOMY", 14, 24], ["monocyte", "ANATOMY", 29, 37], ["MCP-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["lymphocyte", "CELL", 14, 24], ["monocyte", "CELL", 29, 37], ["MCP", "PROTEIN", 4, 7], ["MCP", "TEST", 4, 7], ["lymphocyte", "TEST", 14, 24], ["monocyte counts", "TEST", 29, 44], ["lymphocyte", "ANATOMY", 14, 24]]], ["The inverse association was also found for IFN-g and circulating lymphocyte counts (\u00c00.366/0.134).", [["lymphocyte", "ANATOMY", 65, 75], ["IFN-g", "GENE_OR_GENE_PRODUCT", 43, 48], ["lymphocyte", "CELL", 65, 75], ["IFN", "PROTEIN", 43, 46], ["IFN", "TEST", 43, 46], ["circulating lymphocyte counts", "TEST", 53, 82], ["lymphocyte counts", "OBSERVATION", 65, 82]]], ["However, the pattern was different for neutrophils, as a positive association occurred between MCP-1 and circulating neutrophils count (0.432/0.145).", [["neutrophils", "ANATOMY", 39, 50], ["neutrophils", "ANATOMY", 117, 128], ["neutrophils", "CELL", 39, 50], ["MCP-1", "GENE_OR_GENE_PRODUCT", 95, 100], ["neutrophils", "CELL", 117, 128], ["neutrophils", "CELL_TYPE", 39, 50], ["MCP", "PROTEIN", 95, 98], ["neutrophils", "TEST", 39, 50], ["MCP", "TEST", 95, 98], ["circulating neutrophils count", "TEST", 105, 134], ["neutrophils count", "OBSERVATION", 117, 134]]], ["As for other parameters, a positive association existed between TGF-b and the duration of stay in hospital in the survival group (Fig. 5e ).", [["TGF-b", "GENE_OR_GENE_PRODUCT", 64, 69], ["TGF", "PROTEIN", 64, 67]]], ["TGF-b was only detected in 48 % of the patients, and it appeared late post infection.", [["infection", "DISEASE", 75, 84], ["TGF-b", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 39, 47], ["TGF-b", "PROTEIN", 0, 5], ["patients", "SPECIES", 39, 47], ["TGF", "TEST", 0, 3], ["infection", "PROBLEM", 75, 84], ["late", "OBSERVATION_MODIFIER", 65, 69], ["post", "OBSERVATION_MODIFIER", 70, 74], ["infection", "OBSERVATION", 75, 84]]], ["But when generated, its serum level was positively associated with the duration of stay in hospital for the survival group (correlation coefficient, 0.539/r 2 , 0.291).", [["serum", "ANATOMY", 24, 29], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["its serum level", "TEST", 20, 35], ["correlation coefficient", "TEST", 124, 147]]], ["These cytokine patterns of death group were not so obvious as those of survival group (data not shown).", [["death", "DISEASE", 27, 32], ["cytokine", "PROTEIN", 6, 14]]], ["Based on these data, it is concluded that there is an interferon-g-related cytokine storm after SARS-CoV infection, and these cytokines are probably involved in the inflammatory response and damage of the host.DISCUSSIONDuring the SARS outbreak in Taiwan, all the sera from either suspected or probable cases were sent to CDC-Taiwan officially for final diagnosis of SARS-CoV infection.", [["sera", "ANATOMY", 264, 268], ["SARS-CoV infection", "DISEASE", 96, 114], ["SARS", "DISEASE", 231, 235], ["SARS-CoV infection", "DISEASE", 367, 385], ["SARS-CoV", "ORGANISM", 96, 104], ["sera", "ORGANISM_SUBSTANCE", 264, 268], ["SARS-CoV", "ORGANISM", 367, 375], ["interferon", "PROTEIN", 54, 64], ["cytokine", "PROTEIN", 75, 83], ["cytokines", "PROTEIN", 126, 135], ["SARS-CoV", "SPECIES", 96, 104], ["SARS-CoV", "SPECIES", 367, 375], ["these data", "TEST", 9, 19], ["an interferon", "TREATMENT", 51, 64], ["SARS", "PROBLEM", 96, 100], ["CoV infection", "PROBLEM", 101, 114], ["the inflammatory response", "PROBLEM", 161, 186], ["SARS", "PROBLEM", 367, 371], ["CoV infection", "PROBLEM", 372, 385], ["interferon", "OBSERVATION", 54, 64], ["infection", "OBSERVATION", 105, 114], ["inflammatory", "OBSERVATION_MODIFIER", 165, 177], ["SARS", "OBSERVATION", 367, 371], ["CoV", "OBSERVATION_MODIFIER", 372, 375], ["infection", "OBSERVATION", 376, 385]]], ["Therefore, in this study, the sera analyzed were the first-time point collected after hospitalization, no immunomodulators such as steroids, intravenous immunoglobulin, or ribavirin were given to patients before blood collection, and only the RT-PCR-confirmed cases were used.", [["sera", "ANATOMY", 30, 34], ["intravenous", "ANATOMY", 141, 152], ["blood", "ANATOMY", 212, 217], ["steroids", "CHEMICAL", 131, 139], ["ribavirin", "CHEMICAL", 172, 181], ["steroids", "CHEMICAL", 131, 139], ["ribavirin", "CHEMICAL", 172, 181], ["sera", "ORGANISM_SUBSTANCE", 30, 34], ["steroids", "SIMPLE_CHEMICAL", 131, 139], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 141, 167], ["ribavirin", "SIMPLE_CHEMICAL", 172, 181], ["patients", "ORGANISM", 196, 204], ["blood", "ORGANISM_SUBSTANCE", 212, 217], ["intravenous immunoglobulin", "PROTEIN", 141, 167], ["patients", "SPECIES", 196, 204], ["this study", "TEST", 14, 24], ["the sera", "TEST", 26, 34], ["immunomodulators", "TREATMENT", 106, 122], ["steroids", "TREATMENT", 131, 139], ["intravenous immunoglobulin", "TREATMENT", 141, 167], ["ribavirin", "TREATMENT", 172, 181], ["blood collection", "TEST", 212, 228], ["the RT-PCR", "TEST", 239, 249]]], ["This is a cross-section study, as only the first-time point before treatment in acute phase stage was analyzed.", [["a cross-section study", "TEST", 8, 29], ["treatment", "TREATMENT", 67, 76], ["acute phase stage", "PROBLEM", 80, 97], ["acute phase", "OBSERVATION_MODIFIER", 80, 91]]], ["The sera collected at the convalescent phase were also determined for their cytokine levels, but all of them had returned to basal levels.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["cytokine", "PROTEIN", 76, 84], ["The sera", "TEST", 0, 8], ["their cytokine levels", "TEST", 70, 91]]], ["Sequential serum samples were not available for examining the kinetic changes of cytokines in individual disease progression.", [["serum samples", "ANATOMY", 11, 24], ["serum samples", "ORGANISM_SUBSTANCE", 11, 24], ["cytokines", "PROTEIN", 81, 90], ["Sequential serum samples", "TEST", 0, 24], ["the kinetic changes of cytokines", "PROBLEM", 58, 90], ["individual disease progression", "PROBLEM", 94, 124], ["disease", "OBSERVATION_MODIFIER", 105, 112], ["progression", "OBSERVATION_MODIFIER", 113, 124]]], ["But when the patients were pooled and plotted against the day post fever onset, we found a high elevation of IFN-g and its related cytokine or chemokine.", [["fever", "DISEASE", 67, 72], ["patients", "ORGANISM", 13, 21], ["IFN-g", "GENE_OR_GENE_PRODUCT", 109, 114], ["IFN", "PROTEIN", 109, 112], ["cytokine", "PROTEIN", 131, 139], ["chemokine", "PROTEIN", 143, 152], ["patients", "SPECIES", 13, 21], ["fever onset", "PROBLEM", 67, 78], ["a high elevation of IFN-g", "PROBLEM", 89, 114], ["chemokine", "TREATMENT", 143, 152], ["high", "OBSERVATION_MODIFIER", 91, 95], ["elevation", "OBSERVATION", 96, 105]]], ["The serum levels of IL-18, IFN-g, IP-10, MCP-1, MIG, and IL-8 were already very high even at the day of fever onset.", [["serum", "ANATOMY", 4, 9], ["fever", "DISEASE", 104, 109], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["IL-18", "GENE_OR_GENE_PRODUCT", 20, 25], ["IFN-g", "GENE_OR_GENE_PRODUCT", 27, 32], ["IP-10", "GENE_OR_GENE_PRODUCT", 34, 39], ["MCP-1", "GENE_OR_GENE_PRODUCT", 41, 46], ["MIG", "GENE_OR_GENE_PRODUCT", 48, 51], ["IL-8", "GENE_OR_GENE_PRODUCT", 57, 61], ["IFN", "PROTEIN", 27, 30], ["MCP", "PROTEIN", 41, 44], ["MIG", "PROTEIN", 48, 51], ["IL", "PROTEIN", 57, 59], ["The serum levels", "TEST", 0, 16], ["IL", "TEST", 20, 22], ["IFN", "TEST", 27, 30], ["IP", "TEST", 34, 36], ["MCP", "TEST", 41, 44], ["MIG", "TEST", 48, 51], ["IL", "TEST", 57, 59], ["fever onset", "PROBLEM", 104, 115]]], ["The strong bias production toward IFN-g is different from EV71-induced pulmonary edema and dengue virus-induced dengue hemorrhagic fever: a reciprocal relationship existed for individual IFN-g and IL-10.", [["pulmonary", "ANATOMY", 71, 80], ["EV71", "DISEASE", 58, 62], ["pulmonary edema", "DISEASE", 71, 86], ["dengue", "DISEASE", 91, 97], ["dengue hemorrhagic fever", "DISEASE", 112, 136], ["IFN-g", "GENE_OR_GENE_PRODUCT", 34, 39], ["EV71", "ORGANISM", 58, 62], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 71, 86], ["dengue virus", "ORGANISM", 91, 103], ["IFN-g", "GENE_OR_GENE_PRODUCT", 187, 192], ["IL-10", "GENE_OR_GENE_PRODUCT", 197, 202], ["IFN", "PROTEIN", 34, 37], ["IFN", "PROTEIN", 187, 190], ["IL", "PROTEIN", 197, 199], ["dengue virus", "SPECIES", 91, 103], ["dengue hemorrhagic fever", "SPECIES", 112, 136], ["EV71", "SPECIES", 58, 62], ["dengue virus", "SPECIES", 91, 103], ["IFN", "TEST", 34, 37], ["EV71", "PROBLEM", 58, 62], ["pulmonary edema", "PROBLEM", 71, 86], ["dengue virus", "PROBLEM", 91, 103], ["induced dengue hemorrhagic fever", "PROBLEM", 104, 136], ["individual IFN", "TEST", 176, 190], ["IL", "TEST", 197, 199], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["bias", "OBSERVATION", 11, 15], ["pulmonary", "ANATOMY", 71, 80], ["edema", "OBSERVATION", 81, 86], ["dengue virus", "OBSERVATION", 91, 103], ["hemorrhagic", "OBSERVATION_MODIFIER", 119, 130]]], ["The over-production of inflammatory IFN-g and chemokines might be resulting from the lack of IL-10mediated down-regulation of the immune responses to SARS-CoV infection.DISCUSSIONIFN-g is an inflammatory cytokine, and possesses many biological activities [Barber, 2000; Liu et al., 2002] .", [["SARS-CoV infection", "DISEASE", 150, 168], ["IFN-g", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-10mediated", "GENE_OR_GENE_PRODUCT", 93, 106], ["SARS-CoV", "ORGANISM", 150, 158], ["inflammatory IFN-g", "PROTEIN", 23, 41], ["chemokines", "PROTEIN", 46, 56], ["IL", "PROTEIN", 93, 95], ["inflammatory cytokine", "PROTEIN", 191, 212], ["SARS-CoV", "SPECIES", 150, 158], ["inflammatory IFN-g", "TREATMENT", 23, 41], ["chemokines", "TREATMENT", 46, 56], ["IL", "TEST", 93, 95], ["SARS", "PROBLEM", 150, 154], ["CoV infection", "PROBLEM", 155, 168], ["an inflammatory cytokine", "PROBLEM", 188, 212], ["inflammatory", "OBSERVATION_MODIFIER", 23, 35], ["infection", "OBSERVATION", 159, 168], ["inflammatory", "OBSERVATION", 191, 203]]], ["It can enhance the major histocompatibility complex expression, activate macrophage function, stimulate chemokine production, induce apoptosis, arrest cell cycle, and enhance Fas expression.", [["macrophage", "ANATOMY", 73, 83], ["cell", "ANATOMY", 151, 155], ["macrophage", "CELL", 73, 83], ["cell", "CELL", 151, 155], ["Fas", "GENE_OR_GENE_PRODUCT", 175, 178], ["major histocompatibility complex", "PROTEIN", 19, 51], ["chemokine", "PROTEIN", 104, 113], ["Fas", "PROTEIN", 175, 178], ["chemokine production", "TEST", 104, 124], ["apoptosis", "PROBLEM", 133, 142], ["arrest cell cycle", "PROBLEM", 144, 161]]], ["IFN-g is primarily produced by NK cells, Th1 cells, and macrophages.", [["NK cells", "ANATOMY", 31, 39], ["Th1 cells", "ANATOMY", 41, 50], ["macrophages", "ANATOMY", 56, 67], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["NK cells", "CELL", 31, 39], ["Th1 cells", "CELL", 41, 50], ["macrophages", "CELL", 56, 67], ["IFN", "PROTEIN", 0, 3], ["NK cells", "CELL_TYPE", 31, 39], ["Th1 cells", "CELL_TYPE", 41, 50], ["macrophages", "CELL_TYPE", 56, 67], ["IFN", "TEST", 0, 3], ["Th1 cells", "TEST", 41, 50], ["NK cells", "OBSERVATION", 31, 39], ["Th1 cells", "OBSERVATION", 41, 50], ["macrophages", "ANATOMY", 56, 67]]], ["Its production can be up-regulated by IL-12 and/or IL-18.", [["IL-12", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL-18", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL", "PROTEIN", 38, 40], ["IL-18", "PROTEIN", 51, 56], ["IL", "TEST", 38, 40]]], ["The chemokines IP-10, MCP-1, and MIG were found to be markedly elevated in the acute stage of SARS patients.", [["SARS", "DISEASE", 94, 98], ["IP-10", "GENE_OR_GENE_PRODUCT", 15, 20], ["MCP-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["MIG", "GENE_OR_GENE_PRODUCT", 33, 36], ["patients", "ORGANISM", 99, 107], ["chemokines", "PROTEIN", 4, 14], ["MCP", "PROTEIN", 22, 25], ["MIG", "PROTEIN", 33, 36], ["patients", "SPECIES", 99, 107], ["The chemokines IP", "TEST", 0, 17], ["MCP", "TEST", 22, 25], ["MIG", "TEST", 33, 36], ["markedly elevated", "PROBLEM", 54, 71], ["markedly", "OBSERVATION_MODIFIER", 54, 62], ["elevated", "OBSERVATION", 63, 71], ["acute stage", "OBSERVATION_MODIFIER", 79, 90]]], ["The IP-10 levels are extremely high and it seems to be a more reliable marker for viral infection, which have been reported for respiratory syncytial virus [Miller et al., 2004] , influenza virus [Ishiguro et al., Fig. 4 .", [["viral infection", "DISEASE", 82, 97], ["respiratory syncytial virus", "DISEASE", 128, 155], ["influenza virus", "DISEASE", 180, 195], ["IP-10", "GENE_OR_GENE_PRODUCT", 4, 9], ["respiratory syncytial virus", "ORGANISM", 128, 155], ["influenza virus", "ORGANISM", 180, 195], ["influenza virus", "SPECIES", 180, 195], ["respiratory syncytial virus", "SPECIES", 128, 155], ["The IP-10 levels", "TEST", 0, 16], ["viral infection", "PROBLEM", 82, 97], ["respiratory syncytial virus", "PROBLEM", 128, 155], ["influenza virus", "PROBLEM", 180, 195], ["high", "OBSERVATION", 31, 35], ["infection", "OBSERVATION", 88, 97]]], ["Association between IFN-g/IL-18 and IP-10/MCP-1/MIG in Ab(\u00c0) SARS patients.", [["SARS", "DISEASE", 61, 65], ["IFN-g", "GENE_OR_GENE_PRODUCT", 20, 25], ["IL-18", "GENE_OR_GENE_PRODUCT", 26, 31], ["IP-10", "GENE_OR_GENE_PRODUCT", 36, 41], ["MCP-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["MIG", "GENE_OR_GENE_PRODUCT", 48, 51], ["Ab", "GENE_OR_GENE_PRODUCT", 55, 57], ["patients", "ORGANISM", 66, 74], ["IFN", "PROTEIN", 20, 23], ["MCP", "PROTEIN", 42, 45], ["MIG", "PROTEIN", 48, 51], ["patients", "SPECIES", 66, 74], ["IFN", "TEST", 20, 23], ["IL", "TEST", 26, 28], ["IP", "TEST", 36, 38]]], ["Serum chemokine (IP-10, MCP-1, and MIG) level from 51 Ab(\u00c0) group of SARS patients was plot against the IFN-g or IL-18 of that individual.", [["Serum", "ANATOMY", 0, 5], ["SARS", "DISEASE", 69, 73], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IP-10", "GENE_OR_GENE_PRODUCT", 17, 22], ["MCP-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["MIG", "GENE_OR_GENE_PRODUCT", 35, 38], ["patients", "ORGANISM", 74, 82], ["IFN-g", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL-18", "GENE_OR_GENE_PRODUCT", 113, 118], ["Serum chemokine", "PROTEIN", 0, 15], ["MCP", "PROTEIN", 24, 27], ["MIG", "PROTEIN", 35, 38], ["IFN", "PROTEIN", 104, 107], ["IL", "PROTEIN", 113, 115], ["patients", "SPECIES", 74, 82], ["Serum chemokine", "TEST", 0, 15], ["IP", "TEST", 17, 19], ["MCP", "TEST", 24, 27], ["MIG) level", "TEST", 35, 45], ["Ab", "TEST", 54, 56], ["SARS", "PROBLEM", 69, 73], ["the IFN", "TEST", 100, 107], ["IL", "TEST", 113, 115]]], ["Linear regression and association correlation were analyzed.", [["Linear regression", "PROBLEM", 0, 17]]], ["The IP-10 can be directly induced either by viral-infected epithelial cells or through the IFN-g stimulation.", [["epithelial cells", "ANATOMY", 59, 75], ["IP-10", "GENE_OR_GENE_PRODUCT", 4, 9], ["epithelial cells", "CELL", 59, 75], ["IFN-g", "GENE_OR_GENE_PRODUCT", 91, 96], ["viral-infected epithelial cells", "CELL_TYPE", 44, 75], ["IFN", "PROTEIN", 91, 94], ["The IP", "TREATMENT", 0, 6], ["viral-infected epithelial cells", "PROBLEM", 44, 75], ["the IFN-g stimulation", "TREATMENT", 87, 108], ["infected epithelial cells", "OBSERVATION", 50, 75]]], ["Therefore, the correlation between levels of IFN-g and IP-10 is not very strong.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 45, 50], ["IP-10", "GENE_OR_GENE_PRODUCT", 55, 60], ["IFN", "PROTEIN", 45, 48], ["IFN", "TEST", 45, 48], ["IP", "TEST", 55, 57]]], ["A stronger association existed for IL-18 and IP-10 and other chemokine MCP-1 and MIG.", [["IL-18", "GENE_OR_GENE_PRODUCT", 35, 40], ["IP-10", "GENE_OR_GENE_PRODUCT", 45, 50], ["MCP-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["MIG", "GENE_OR_GENE_PRODUCT", 81, 84], ["IL-18", "PROTEIN", 35, 40], ["chemokine", "PROTEIN", 61, 70], ["MCP", "PROTEIN", 71, 74], ["MIG", "PROTEIN", 81, 84], ["IL", "TEST", 35, 37], ["IP", "TREATMENT", 45, 47], ["other chemokine MCP", "TREATMENT", 55, 74]]], ["However, the SARS-CoV-induced chemokine production in the lung without the concomitant production of inflammatory cytokine probably would not cause lung pathological changes in SARS-CoV-infected mice [Glass et al., 2004] .", [["lung", "ANATOMY", 58, 62], ["lung", "ANATOMY", 148, 152], ["SARS", "DISEASE", 13, 17], ["SARS-CoV-infected", "DISEASE", 177, 194], ["SARS-CoV", "ORGANISM", 13, 21], ["lung", "ORGAN", 58, 62], ["lung", "ORGAN", 148, 152], ["SARS-CoV", "ORGANISM", 177, 185], ["mice", "ORGANISM", 195, 199], ["chemokine", "PROTEIN", 30, 39], ["inflammatory cytokine", "PROTEIN", 101, 122], ["mice", "SPECIES", 195, 199], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 177, 185], ["mice", "SPECIES", 195, 199], ["the SARS", "PROBLEM", 9, 17], ["chemokine production in the lung", "PROBLEM", 30, 62], ["inflammatory cytokine", "PROBLEM", 101, 122], ["lung pathological changes", "PROBLEM", 148, 173], ["SARS", "PROBLEM", 177, 181], ["chemokine production", "OBSERVATION", 30, 50], ["lung", "ANATOMY", 58, 62], ["inflammatory", "OBSERVATION", 101, 113], ["probably would not cause", "UNCERTAINTY", 123, 147], ["lung", "ANATOMY", 148, 152], ["pathological", "OBSERVATION", 153, 165]]], ["The detection of another chemokine, RANTES, was above the upper-limit of the CBA kit (>2,500 pg/ml) for both the normal healthy control and SARS patients.", [["SARS", "DISEASE", 140, 144], ["RANTES", "GENE_OR_GENE_PRODUCT", 36, 42], ["patients", "ORGANISM", 145, 153], ["chemokine", "PROTEIN", 25, 34], ["RANTES", "PROTEIN", 36, 42], ["patients", "SPECIES", 145, 153], ["another chemokine, RANTES", "TEST", 17, 42], ["normal", "OBSERVATION", 113, 119], ["healthy control", "OBSERVATION_MODIFIER", 120, 135]]], ["Unfortunately the sera were not diluted to determine the exact concentration because of the limited amount of the patient sera.", [["sera", "ANATOMY", 18, 22], ["sera", "ANATOMY", 122, 126], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["patient", "ORGANISM", 114, 121], ["sera", "ORGANISM_SUBSTANCE", 122, 126], ["patient", "SPECIES", 114, 121]]], ["But IFN-g can stimulate lung epithelial cell line to produce these chemokines including RANTES (unpublished observation).", [["lung epithelial cell line", "ANATOMY", 24, 49], ["IFN", "CHEMICAL", 4, 7], ["IFN-g", "GENE_OR_GENE_PRODUCT", 4, 9], ["lung epithelial cell line", "CELL", 24, 49], ["RANTES", "GENE_OR_GENE_PRODUCT", 88, 94], ["IFN", "PROTEIN", 4, 7], ["lung epithelial cell line", "CELL_LINE", 24, 49], ["chemokines", "PROTEIN", 67, 77], ["RANTES", "PROTEIN", 88, 94], ["IFN", "TREATMENT", 4, 7], ["lung epithelial cell line", "TREATMENT", 24, 49], ["lung", "ANATOMY", 24, 28], ["epithelial cell line", "OBSERVATION", 29, 49]]], ["Therefore, RANTES is supposed to be also elevated in SARS infection.", [["SARS infection", "DISEASE", 53, 67], ["RANTES", "GENE_OR_GENE_PRODUCT", 11, 17], ["RANTES", "PROTEIN", 11, 17], ["SARS infection", "PROBLEM", 53, 67], ["supposed to be", "UNCERTAINTY", 21, 35], ["elevated", "OBSERVATION_MODIFIER", 41, 49], ["SARS", "OBSERVATION_MODIFIER", 53, 57], ["infection", "OBSERVATION", 58, 67]]], ["These chemokines can recruit activated T cells into the lung.", [["T cells", "ANATOMY", 39, 46], ["lung", "ANATOMY", 56, 60], ["T cells", "CELL", 39, 46], ["lung", "ORGAN", 56, 60], ["chemokines", "PROTEIN", 6, 16], ["activated T cells", "CELL_TYPE", 29, 46], ["activated T cells into the lung", "PROBLEM", 29, 60], ["lung", "ANATOMY", 56, 60]]], ["There were several reports on the cytokine levels in SARS patients: proinflammatory cytokines TNF-a, IL-1, and IL-6 were increased in acute stage of SARS-CoV infection [Pang et al., 2003; Ng et al., 2004; Wong et al., 2004; Zhang et al., 2004] .", [["SARS", "DISEASE", 53, 57], ["SARS-CoV infection", "DISEASE", 149, 167], ["patients", "ORGANISM", 58, 66], ["TNF-a", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-1", "GENE_OR_GENE_PRODUCT", 101, 105], ["IL-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["SARS-CoV", "ORGANISM", 149, 157], ["cytokine", "PROTEIN", 34, 42], ["proinflammatory cytokines", "PROTEIN", 68, 93], ["TNF", "PROTEIN", 94, 97], ["IL", "PROTEIN", 101, 103], ["IL-6", "PROTEIN", 111, 115], ["patients", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 149, 157], ["the cytokine levels", "TEST", 30, 49], ["proinflammatory cytokines", "TEST", 68, 93], ["TNF", "TEST", 94, 97], ["a, IL", "TEST", 98, 103], ["IL", "TEST", 111, 113], ["SARS", "PROBLEM", 149, 153], ["CoV infection", "PROBLEM", 154, 167], ["acute stage", "OBSERVATION_MODIFIER", 134, 145]]], ["In our study, neither TNF-a nor TNFRI were detectable.", [["TNF-a", "GENE_OR_GENE_PRODUCT", 22, 27], ["TNFRI", "GENE_OR_GENE_PRODUCT", 32, 37], ["TNF", "PROTEIN", 22, 25], ["TNFRI", "PROTEIN", 32, 37], ["our study", "TEST", 3, 12], ["TNF", "TEST", 22, 25]]], ["This might be related to the timing of the samples collected and the use of corticosteroid, intravenous immunoglobulin, or ribavirin in treated SARS patients, which would modulate the cytokine production.", [["samples", "ANATOMY", 43, 50], ["intravenous", "ANATOMY", 92, 103], ["ribavirin", "CHEMICAL", 123, 132], ["SARS", "DISEASE", 144, 148], ["ribavirin", "CHEMICAL", 123, 132], ["corticosteroid", "SIMPLE_CHEMICAL", 76, 90], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 103], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 104, 118], ["ribavirin", "SIMPLE_CHEMICAL", 123, 132], ["patients", "ORGANISM", 149, 157], ["intravenous immunoglobulin", "PROTEIN", 92, 118], ["cytokine", "PROTEIN", 184, 192], ["patients", "SPECIES", 149, 157], ["the samples", "TEST", 39, 50], ["corticosteroid", "TREATMENT", 76, 90], ["intravenous immunoglobulin", "TREATMENT", 92, 118], ["ribavirin", "TREATMENT", 123, 132], ["cytokine production", "OBSERVATION", 184, 203]]], ["All the sera tested are from the first-time point collection after hospitalization, patients have not been treated with these immunomodulators.", [["sera", "ANATOMY", 8, 12], ["sera", "ORGANISM_SUBSTANCE", 8, 12], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["All the sera", "TEST", 0, 12], ["these immunomodulators", "TREATMENT", 120, 142]]], ["Lung pathological study has shown intense lymphocytic infiltration in SARS patients.", [["Lung", "ANATOMY", 0, 4], ["lymphocytic", "ANATOMY", 42, 53], ["SARS", "DISEASE", 70, 74], ["Lung", "ORGAN", 0, 4], ["lymphocytic", "PATHOLOGICAL_FORMATION", 42, 53], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Lung pathological study", "TEST", 0, 23], ["intense lymphocytic infiltration in SARS patients", "PROBLEM", 34, 83], ["pathological", "OBSERVATION", 5, 17], ["intense", "OBSERVATION_MODIFIER", 34, 41], ["lymphocytic infiltration", "OBSERVATION", 42, 66]]], ["IFN-g is already highly induced at the early Ab(\u00c0) stage, and it was even higher in the late Ab(\u00fe) stage.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "PROTEIN", 0, 3], ["higher", "OBSERVATION_MODIFIER", 74, 80]]], ["Although IFN-a or b were reported to inhibit in vitro replication of SARS-CoV or protect type I pneumocytes against SARS-CoV infection in macaques [Haagmans et al., 2004; Tan et al., 2004] , interferons, especially IFN-g, is a double-edged sword.", [["type I pneumocytes", "ANATOMY", 89, 107], ["SARS-CoV infection", "DISEASE", 116, 134], ["IFN-a", "GENE_OR_GENE_PRODUCT", 9, 14], ["b", "GENE_OR_GENE_PRODUCT", 18, 19], ["SARS-CoV", "ORGANISM", 69, 77], ["type I pneumocytes", "GENE_OR_GENE_PRODUCT", 89, 107], ["SARS-CoV", "ORGANISM", 116, 124], ["macaques", "ORGANISM", 138, 146], ["IFN-g", "GENE_OR_GENE_PRODUCT", 215, 220], ["IFN", "PROTEIN", 9, 12], ["type I pneumocytes", "CELL_TYPE", 89, 107], ["interferons", "PROTEIN", 191, 202], ["IFN", "PROTEIN", 215, 218], ["macaques", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 116, 124], ["SARS", "PROBLEM", 69, 73], ["CoV", "PROBLEM", 74, 77], ["type I pneumocytes", "PROBLEM", 89, 107], ["SARS", "PROBLEM", 116, 120], ["CoV infection", "PROBLEM", 121, 134], ["interferons", "TREATMENT", 191, 202]]], ["The bias IFN-g and its related chemokine production might be responsible for the abnormal inflammatory response in SARS patients.", [["SARS", "DISEASE", 115, 119], ["IFN-g", "GENE_OR_GENE_PRODUCT", 9, 14], ["patients", "ORGANISM", 120, 128], ["IFN", "PROTEIN", 9, 12], ["chemokine", "PROTEIN", 31, 40], ["patients", "SPECIES", 120, 128], ["The bias IFN-g", "TREATMENT", 0, 14], ["its related chemokine production", "PROBLEM", 19, 51], ["the abnormal inflammatory response in SARS patients", "PROBLEM", 77, 128], ["abnormal", "OBSERVATION_MODIFIER", 81, 89], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102]]], ["An IFN-g-related cytokine storm was induced post SARS-CoV infection.2004] as well as SARS-CoVThe antibody response to SARS-CoV antigen was delayed after SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 49, 67], ["SARS", "DISEASE", 85, 89], ["SARS", "DISEASE", 118, 122], ["SARS-CoV infection", "DISEASE", 153, 171], ["IFN-g", "GENE_OR_GENE_PRODUCT", 3, 8], ["SARS-CoV", "ORGANISM", 49, 57], ["SARS-CoV antigen", "GENE_OR_GENE_PRODUCT", 118, 134], ["SARS-CoV", "ORGANISM", 153, 161], ["IFN", "PROTEIN", 3, 6], ["cytokine", "PROTEIN", 17, 25], ["SARS-CoV antigen", "PROTEIN", 118, 134], ["SARS-CoV", "SPECIES", 49, 57], ["SARS-CoV", "SPECIES", 118, 126], ["SARS-CoV", "SPECIES", 153, 161], ["An IFN", "TREATMENT", 0, 6], ["cytokine storm", "PROBLEM", 17, 31], ["SARS", "PROBLEM", 49, 53], ["CoV infection", "PROBLEM", 54, 67], ["SARS-CoVThe antibody response", "TEST", 85, 114], ["SARS", "TEST", 118, 122], ["CoV antigen", "TEST", 123, 134], ["SARS", "PROBLEM", 153, 157], ["CoV infection", "PROBLEM", 158, 171], ["cytokine storm", "OBSERVATION", 17, 31], ["CoV", "OBSERVATION_MODIFIER", 54, 57], ["infection", "OBSERVATION", 58, 67], ["CoV", "OBSERVATION_MODIFIER", 158, 161], ["infection", "OBSERVATION", 162, 171]]], ["It is not detectable until 2-3 weeks later [Peiris et al., 2003b] .", [["not", "UNCERTAINTY", 6, 9], ["detectable", "OBSERVATION_MODIFIER", 10, 20]]], ["The Ab(\u00c0) group represents the early stage of acute SARS-CoV infection as shown by early timing of sera collected after fever onset in Figure 3 .", [["sera", "ANATOMY", 99, 103], ["SARS-CoV infection", "DISEASE", 52, 70], ["fever", "DISEASE", 120, 125], ["Ab(\u00c0)", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS-CoV", "ORGANISM", 52, 60], ["sera", "ORGANISM_SUBSTANCE", 99, 103], ["Ab(\u00c0) group", "PROTEIN", 4, 15], ["SARS-CoV", "SPECIES", 52, 60], ["acute SARS", "PROBLEM", 46, 56], ["CoV infection", "PROBLEM", 57, 70], ["sera", "TEST", 99, 103], ["fever", "PROBLEM", 120, 125], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["SARS", "OBSERVATION", 52, 56], ["CoV infection", "OBSERVATION", 57, 70]]], ["The elders with weak immune response were also included in this category.", [["weak immune response", "PROBLEM", 16, 36]]], ["Older males had high mortality while young females seemed to have a strong immune response and higher IFN-g production.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 102, 107], ["IFN", "PROTEIN", 102, 105], ["a strong immune response", "PROBLEM", 66, 90], ["high mortality", "OBSERVATION_MODIFIER", 16, 30]]], ["This is consistent with the risk factor analysis between survival and death groups.", [["death", "DISEASE", 70, 75], ["the risk factor analysis", "PROBLEM", 24, 48], ["consistent with", "UNCERTAINTY", 8, 23]]], ["The IP-10, MIG, and MCP-1 levels were higher in death than in survival groups.", [["death", "DISEASE", 48, 53], ["IP-10", "GENE_OR_GENE_PRODUCT", 4, 9], ["MIG", "GENE_OR_GENE_PRODUCT", 11, 14], ["MCP-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["MIG", "PROTEIN", 11, 14], ["MCP", "PROTEIN", 20, 23], ["The IP", "TEST", 0, 6], ["MIG", "TEST", 11, 14], ["MCP-1 levels", "TEST", 20, 32], ["higher", "OBSERVATION_MODIFIER", 38, 44]]], ["It seems that male, older patients who have higher chemokine production or with underlying diseases were more susceptible to death post SARS-CoV infection.", [["death", "DISEASE", 125, 130], ["SARS-CoV infection", "DISEASE", 136, 154], ["patients", "ORGANISM", 26, 34], ["SARS-CoV", "ORGANISM", 136, 144], ["chemokine", "PROTEIN", 51, 60], ["patients", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 136, 144], ["higher chemokine production", "PROBLEM", 44, 71], ["underlying diseases", "PROBLEM", 80, 99], ["SARS", "PROBLEM", 136, 140], ["CoV infection", "PROBLEM", 141, 154], ["CoV", "OBSERVATION_MODIFIER", 141, 144], ["infection", "OBSERVATION", 145, 154]]], ["A SARS in the lung was caused by intense chemokineinduced activated T cell-mediated inflammation and might be fatal.", [["lung", "ANATOMY", 14, 18], ["T cell", "ANATOMY", 68, 74], ["SARS", "DISEASE", 2, 6], ["inflammation", "DISEASE", 84, 96], ["lung", "ORGAN", 14, 18], ["T cell", "CELL", 68, 74], ["A SARS in the lung", "PROBLEM", 0, 18], ["intense chemokineinduced activated T cell-mediated inflammation", "PROBLEM", 33, 96], ["SARS", "OBSERVATION", 2, 6], ["lung", "ANATOMY", 14, 18], ["intense", "OBSERVATION_MODIFIER", 33, 40], ["T cell", "OBSERVATION", 68, 74], ["inflammation", "OBSERVATION", 84, 96], ["might be", "UNCERTAINTY", 101, 109], ["fatal", "OBSERVATION_MODIFIER", 110, 115]]], ["IL-8-mediated neutrophil inflammation is probably also involved.2004] as well as SARS-CoVFor the surviving SARS patients, the inversed relationship between MCP-1 or IFN-g and lymphocyte and monocyte count is interesting.", [["neutrophil", "ANATOMY", 14, 24], ["lymphocyte", "ANATOMY", 175, 185], ["monocyte", "ANATOMY", 190, 198], ["inflammation", "DISEASE", 25, 37], ["SARS", "DISEASE", 81, 85], ["SARS", "DISEASE", 107, 111], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["neutrophil", "CELL", 14, 24], ["patients", "ORGANISM", 112, 120], ["MCP-1", "GENE_OR_GENE_PRODUCT", 156, 161], ["IFN-g", "GENE_OR_GENE_PRODUCT", 165, 170], ["lymphocyte", "CELL", 175, 185], ["monocyte", "CELL", 190, 198], ["IL-8", "PROTEIN", 0, 4], ["MCP", "PROTEIN", 156, 159], ["IFN", "PROTEIN", 165, 168], ["patients", "SPECIES", 112, 120], ["IL", "TEST", 0, 2], ["neutrophil inflammation", "PROBLEM", 14, 37], ["MCP", "TEST", 156, 159], ["IFN", "TEST", 165, 168], ["lymphocyte", "TEST", 175, 185], ["monocyte count", "TEST", 190, 204], ["neutrophil inflammation", "OBSERVATION", 14, 37], ["probably also", "UNCERTAINTY", 41, 54], ["lymphocyte", "ANATOMY", 175, 185], ["monocyte count", "OBSERVATION", 190, 204]]], ["Lymphopenia is common in SARS patients.", [["Lymphopenia", "DISEASE", 0, 11], ["SARS", "DISEASE", 25, 29], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["Lymphopenia", "PROBLEM", 0, 11]]], ["How lymphopenia occur is not clearly understood.", [["lymphopenia", "DISEASE", 4, 15], ["lymphopenia", "PROBLEM", 4, 15], ["lymphopenia", "OBSERVATION", 4, 15]]], ["IFN-g was reported to induce apoptosis of activated T cells [Bernabei et al., 2001; Sobek et al., 2002] .", [["T cells", "ANATOMY", 52, 59], ["IFN", "CHEMICAL", 0, 3], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["T cells", "CELL", 52, 59], ["IFN", "PROTEIN", 0, 3], ["activated T cells", "CELL_TYPE", 42, 59]]], ["Two possibilities are reasoned: sequestration into the lung of b-chemokine-recruited lymphocytes and IFN-g-induced apoptosis.", [["lung", "ANATOMY", 55, 59], ["lymphocytes", "ANATOMY", 85, 96], ["lung", "ORGAN", 55, 59], ["lymphocytes", "CELL", 85, 96], ["IFN-g", "GENE_OR_GENE_PRODUCT", 101, 106], ["b-chemokine", "PROTEIN", 63, 74], ["lymphocytes", "CELL_TYPE", 85, 96], ["IFN", "PROTEIN", 101, 104], ["b-chemokine", "TEST", 63, 74], ["lymphocytes", "PROBLEM", 85, 96], ["IFN", "TEST", 101, 104], ["apoptosis", "PROBLEM", 115, 124], ["sequestration", "OBSERVATION", 32, 45], ["lung", "ANATOMY", 55, 59], ["b-chemokine", "OBSERVATION", 63, 74], ["lymphocytes", "ANATOMY", 85, 96], ["apoptosis", "OBSERVATION", 115, 124]]], ["But for neutrophils, a positive association was found for MCP-1 and neutrophils count.", [["neutrophils", "ANATOMY", 8, 19], ["neutrophils", "ANATOMY", 68, 79], ["neutrophils", "CELL", 8, 19], ["MCP-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["neutrophils", "CELL", 68, 79], ["neutrophils", "CELL_TYPE", 8, 19], ["MCP", "PROTEIN", 58, 61], ["neutrophils", "TEST", 8, 19], ["MCP", "TEST", 58, 61], ["neutrophils count", "TEST", 68, 85]]], ["The neutrophils a-chemokine IL-8 was also elevated, and once the neutrophils are recruited into the lung, they will enhance more lung damage.", [["neutrophils", "ANATOMY", 4, 15], ["neutrophils", "ANATOMY", 65, 76], ["lung", "ANATOMY", 100, 104], ["lung", "ANATOMY", 129, 133], ["lung damage", "DISEASE", 129, 140], ["neutrophils", "CELL", 4, 15], ["IL-8", "GENE_OR_GENE_PRODUCT", 28, 32], ["neutrophils", "CELL", 65, 76], ["lung", "ORGAN", 100, 104], ["lung", "ORGAN", 129, 133], ["neutrophils a-chemokine IL-8", "PROTEIN", 4, 32], ["neutrophils", "CELL_TYPE", 65, 76], ["The neutrophils a-chemokine IL", "TEST", 0, 30], ["more lung damage", "PROBLEM", 124, 140], ["elevated", "OBSERVATION_MODIFIER", 42, 50], ["lung", "ANATOMY", 100, 104], ["lung", "ANATOMY", 129, 133], ["damage", "OBSERVATION", 134, 140]]], ["TGF-b is found to be increased after SARS-CoV infection, 48% (32/66) of patients having detectable serum TGF-b at the late stage.", [["serum", "ANATOMY", 99, 104], ["SARS-CoV infection", "DISEASE", 37, 55], ["TGF-b", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV", "ORGANISM", 37, 45], ["patients", "ORGANISM", 72, 80], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["TGF-b", "GENE_OR_GENE_PRODUCT", 105, 110], ["TGF-b", "PROTEIN", 0, 5], ["serum TGF-b", "PROTEIN", 99, 110], ["patients", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 37, 45], ["TGF", "TEST", 0, 3], ["SARS", "PROBLEM", 37, 41], ["CoV infection", "PROBLEM", 42, 55], ["serum TGF", "TEST", 99, 108], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["CoV", "OBSERVATION_MODIFIER", 42, 45], ["infection", "OBSERVATION", 46, 55], ["late stage", "OBSERVATION_MODIFIER", 118, 128]]], ["The TGF-b level is not significantly different between death and survival group.", [["death", "DISEASE", 55, 60], ["TGF-b", "GENE_OR_GENE_PRODUCT", 4, 9], ["TGF", "PROTEIN", 4, 7], ["The TGF-b level", "TEST", 0, 15], ["not", "UNCERTAINTY", 19, 22], ["significantly different", "OBSERVATION_MODIFIER", 23, 46]]], ["But when this TGF-b level was plotted to the clinical data of the patient, it was interesting to find a positive association between TGF-b amount and his or her duration of stay-in-hospital for the individuals who survived.", [["TGF-b", "GENE_OR_GENE_PRODUCT", 14, 19], ["patient", "ORGANISM", 66, 73], ["TGF-b", "GENE_OR_GENE_PRODUCT", 133, 138], ["TGF", "PROTEIN", 14, 17], ["TGF", "PROTEIN", 133, 136], ["patient", "SPECIES", 66, 73], ["this TGF-b level", "TEST", 9, 25]]], ["Fibrosis is a sequelae post SARS-CoV infection in some individual.", [["Fibrosis", "DISEASE", 0, 8], ["SARS-CoV infection", "DISEASE", 28, 46], ["SARS-CoV", "SPECIES", 28, 36], ["Fibrosis", "PROBLEM", 0, 8], ["a sequelae", "PROBLEM", 12, 22], ["SARS", "PROBLEM", 28, 32], ["CoV infection", "PROBLEM", 33, 46], ["sequelae", "OBSERVATION_MODIFIER", 14, 22], ["CoV", "OBSERVATION_MODIFIER", 33, 36], ["infection", "OBSERVATION", 37, 46]]], ["TGF-b can induce proliferation of fibroblasts [Krein and Winston, 2002; Dhainaut et al., 2003] , therefore, high production of TGF-b might be involved in the development of fibrosis.2004] as well as SARS-CoVDexamethasone and intravenous immunoglobulin were used to treat SARS patients with some beneficial Fig. 5 .", [["fibroblasts", "ANATOMY", 34, 45], ["intravenous", "ANATOMY", 225, 236], ["fibrosis", "DISEASE", 173, 181], ["SARS-CoVDexamethasone", "CHEMICAL", 199, 220], ["SARS", "DISEASE", 271, 275], ["CoVDexamethasone", "CHEMICAL", 204, 220], ["TGF-b", "GENE_OR_GENE_PRODUCT", 0, 5], ["fibroblasts", "CELL", 34, 45], ["TGF-b", "GENE_OR_GENE_PRODUCT", 127, 132], ["SARS-CoVDexamethasone", "SIMPLE_CHEMICAL", 199, 220], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 225, 251], ["patients", "ORGANISM", 276, 284], ["TGF-b", "PROTEIN", 0, 5], ["fibroblasts", "CELL_TYPE", 34, 45], ["TGF-b", "PROTEIN", 127, 132], ["intravenous immunoglobulin", "PROTEIN", 225, 251], ["patients", "SPECIES", 276, 284], ["TGF", "TEST", 0, 3], ["proliferation of fibroblasts", "PROBLEM", 17, 45], ["fibrosis", "PROBLEM", 173, 181], ["CoVDexamethasone", "TREATMENT", 204, 220], ["intravenous immunoglobulin", "TREATMENT", 225, 251], ["SARS", "PROBLEM", 271, 275], ["proliferation", "OBSERVATION_MODIFIER", 17, 30], ["fibrosis", "OBSERVATION", 173, 181]]], ["Association between MCP-1, IFN-g, or TGF-b and clinical manifestations of the SARS surviving patients.", [["SARS", "DISEASE", 78, 82], ["MCP-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["IFN-g", "GENE_OR_GENE_PRODUCT", 27, 32], ["TGF-b", "GENE_OR_GENE_PRODUCT", 37, 42], ["patients", "ORGANISM", 93, 101], ["MCP", "PROTEIN", 20, 23], ["IFN", "PROTEIN", 27, 30], ["TGF", "PROTEIN", 37, 40], ["patients", "SPECIES", 93, 101], ["MCP", "TEST", 20, 23], ["IFN", "TEST", 27, 30]]], ["Serum chemokine MCP-1 or IFN-g level from 56 surviving SARS patients was plot against the circulating lymphocyte counts, monocyte counts, or neutrophil counts of that individual.", [["Serum", "ANATOMY", 0, 5], ["lymphocyte", "ANATOMY", 102, 112], ["monocyte", "ANATOMY", 121, 129], ["neutrophil", "ANATOMY", 141, 151], ["SARS", "DISEASE", 55, 59], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["MCP-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["IFN-g", "GENE_OR_GENE_PRODUCT", 25, 30], ["patients", "ORGANISM", 60, 68], ["lymphocyte", "CELL", 102, 112], ["monocyte", "CELL", 121, 129], ["neutrophil", "CELL", 141, 151], ["chemokine", "PROTEIN", 6, 15], ["IFN", "PROTEIN", 25, 28], ["neutrophil", "CELL_TYPE", 141, 151], ["patients", "SPECIES", 60, 68], ["Serum chemokine MCP", "TEST", 0, 19], ["IFN-g level", "TEST", 25, 36], ["the circulating lymphocyte counts", "TEST", 86, 119], ["monocyte counts", "TEST", 121, 136], ["neutrophil counts", "TEST", 141, 158], ["neutrophil counts", "OBSERVATION", 141, 158]]], ["In the analysis of TGF-b with duration of stay-in-hospital, only patients (n \u00bc 18) that have detectable TGF-b were determined.", [["TGF-b", "GENE_OR_GENE_PRODUCT", 19, 24], ["patients", "ORGANISM", 65, 73], ["TGF-b", "GENE_OR_GENE_PRODUCT", 104, 109], ["TGF", "PROTEIN", 19, 22], ["TGF-b", "PROTEIN", 104, 109], ["patients", "SPECIES", 65, 73]]], ["Linear regression and association correlation were analyzed.", [["Linear regression", "PROBLEM", 0, 17]]], ["Dexamethasone is known to inhibit the cytokine production and delayed chemokinerecruited inflammation while the immunoglobulin can modulate the cytokine over-action and inhibit the lymphocyte or macrophage activation.", [["lymphocyte", "ANATOMY", 181, 191], ["macrophage", "ANATOMY", 195, 205], ["Dexamethasone", "CHEMICAL", 0, 13], ["inflammation", "DISEASE", 89, 101], ["Dexamethasone", "CHEMICAL", 0, 13], ["Dexamethasone", "SIMPLE_CHEMICAL", 0, 13], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 112, 126], ["lymphocyte", "CELL", 181, 191], ["macrophage", "CELL", 195, 205], ["cytokine", "PROTEIN", 38, 46], ["immunoglobulin", "PROTEIN", 112, 126], ["cytokine", "PROTEIN", 144, 152], ["Dexamethasone", "TREATMENT", 0, 13], ["the cytokine production", "PROBLEM", 34, 57], ["delayed chemokinerecruited inflammation", "PROBLEM", 62, 101], ["the immunoglobulin", "TREATMENT", 108, 126], ["macrophage activation", "PROBLEM", 195, 216], ["lymphocyte", "ANATOMY", 181, 191], ["macrophage activation", "OBSERVATION", 195, 216]]], ["If the IFN-g cytokine storm is induced and is responsible for the immunological damage of the host, it is reasoned that their beneficial effects were probably due to the interference with the IFN-g cytokine storm.", [["IFN", "PROTEIN", 7, 10], ["cytokine", "PROTEIN", 13, 21], ["IFN", "PROTEIN", 192, 195], ["cytokine", "PROTEIN", 198, 206], ["the IFN-g cytokine storm", "TREATMENT", 188, 212]]], ["It was reported that IFN-g alone and in combination with activation of the Fas pathway induced apoptosis in A549 lung epithelial cells, and this IFN-g and IFN-g plus anti-Fasinduced apoptosis could be blocked by dexamethasone [Wen et al., 1997] .", [["A549 lung epithelial cells", "ANATOMY", 108, 134], ["IFN", "CHEMICAL", 21, 24], ["dexamethasone", "CHEMICAL", 212, 225], ["dexamethasone", "CHEMICAL", 212, 225], ["IFN-g", "GENE_OR_GENE_PRODUCT", 21, 26], ["Fas", "GENE_OR_GENE_PRODUCT", 75, 78], ["A549 lung epithelial cells", "CELL", 108, 134], ["IFN-g", "GENE_OR_GENE_PRODUCT", 145, 150], ["IFN-g", "GENE_OR_GENE_PRODUCT", 155, 160], ["anti-Fasinduced", "SIMPLE_CHEMICAL", 166, 181], ["dexamethasone", "SIMPLE_CHEMICAL", 212, 225], ["IFN", "PROTEIN", 21, 24], ["Fas", "PROTEIN", 75, 78], ["A549 lung epithelial cells", "CELL_LINE", 108, 134], ["IFN", "PROTEIN", 145, 148], ["IFN-g", "TREATMENT", 21, 26], ["the Fas pathway", "TREATMENT", 71, 86], ["apoptosis in A549 lung epithelial cells", "PROBLEM", 95, 134], ["this IFN", "TREATMENT", 140, 148], ["IFN", "TREATMENT", 155, 158], ["anti-Fasinduced apoptosis", "TREATMENT", 166, 191], ["dexamethasone", "TREATMENT", 212, 225], ["lung", "ANATOMY", 113, 117], ["epithelial cells", "OBSERVATION", 118, 134]]]], "ac35457b704e8b8a8802ab8bea3188f26cab265f": [["Introduction2019 novel coronavirus disease (COVID-19) is a zoonotic illness caused by a new viral pathogen named as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus(2019-nCoV) [1] .The rapid spread of COVID-19 has created a global health crisis.", [["coronavirus disease", "DISEASE", 23, 42], ["zoonotic illness", "DISEASE", 59, 75], ["viral pathogen", "DISEASE", 92, 106], ["acute respiratory syndrome coronavirus", "DISEASE", 127, 165], ["COVID-19", "CHEMICAL", 261, 269], ["coronavirus", "ORGANISM", 23, 34], ["COVID-19", "ORGANISM", 44, 52], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 120, 167], ["SARS-CoV-2", "ORGANISM", 169, 179], ["coronavirus", "SPECIES", 213, 224], ["severe acute respiratory syndrome coronavirus", "SPECIES", 120, 165], ["SARS-CoV-2", "SPECIES", 169, 179], ["novel coronavirus disease", "PROBLEM", 17, 42], ["COVID", "TEST", 44, 49], ["a zoonotic illness", "PROBLEM", 57, 75], ["a new viral pathogen", "PROBLEM", 86, 106], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 116, 165], ["SARS-CoV", "TEST", 169, 177], ["novel coronavirus", "PROBLEM", 207, 224], ["COVID", "TEST", 261, 266], ["a global health crisis", "PROBLEM", 282, 304], ["coronavirus disease", "OBSERVATION", 23, 42], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["respiratory syndrome", "OBSERVATION", 133, 153], ["rapid", "OBSERVATION_MODIFIER", 245, 250], ["spread", "OBSERVATION_MODIFIER", 251, 257], ["global", "OBSERVATION_MODIFIER", 284, 290], ["health crisis", "OBSERVATION", 291, 304]]], ["Lung is considered as a major organ attacked by SARS-CoV-2.", [["Lung", "ANATOMY", 0, 4], ["organ", "ANATOMY", 30, 35], ["SARS", "DISEASE", 48, 52], ["Lung", "ORGAN", 0, 4], ["organ", "ORGAN", 30, 35], ["SARS-CoV-2", "ORGANISM", 48, 58], ["SARS-CoV", "SPECIES", 48, 56]]], ["Besides the respiratory system, the infection of SARS-CoV-2 leads to various degrees of damage to other organs such as the liver, heart, kidney and gastrointestinal tract [2] [3] [4] [5] .", [["respiratory system", "ANATOMY", 12, 30], ["organs", "ANATOMY", 104, 110], ["liver", "ANATOMY", 123, 128], ["heart", "ANATOMY", 130, 135], ["kidney", "ANATOMY", 137, 143], ["gastrointestinal tract", "ANATOMY", 148, 170], ["infection", "DISEASE", 36, 45], ["SARS", "DISEASE", 49, 53], ["SARS-CoV-2", "ORGANISM", 49, 59], ["organs", "ORGAN", 104, 110], ["liver", "ORGAN", 123, 128], ["heart", "ORGAN", 130, 135], ["kidney", "ORGAN", 137, 143], ["gastrointestinal", "ORGAN", 148, 164], ["2] [3] [4] [5]", "SIMPLE_CHEMICAL", 172, 186], ["SARS-CoV", "SPECIES", 49, 57], ["the respiratory system", "PROBLEM", 8, 30], ["the infection of SARS", "PROBLEM", 32, 53], ["damage to other organs such as the liver, heart, kidney and gastrointestinal tract", "PROBLEM", 88, 170], ["respiratory system", "ANATOMY", 12, 30], ["infection", "OBSERVATION", 36, 45], ["damage", "OBSERVATION", 88, 94], ["liver", "ANATOMY", 123, 128], ["heart", "ANATOMY", 130, 135], ["kidney", "ANATOMY", 137, 143], ["gastrointestinal tract", "ANATOMY", 148, 170]]], ["The majority of COVID-19 patients only suffered mild symptoms; while some COVID-19 patients progressed rapidly with acute respiratory distress syndrome (ARDS), and eventually resulted in multiple organ failure (MOF) [1, 6] .IntroductionPrevious studies showed that some of patients infected by SARS-CoV-2 had gastrointestinal symptoms, such as diarrhea, abdominal pain, inappetence, nausea and vomiting [7] [8] [9] .", [["respiratory", "ANATOMY", 122, 133], ["organ", "ANATOMY", 196, 201], ["gastrointestinal", "ANATOMY", 309, 325], ["abdominal", "ANATOMY", 354, 363], ["acute respiratory distress syndrome", "DISEASE", 116, 151], ["ARDS", "DISEASE", 153, 157], ["multiple organ failure", "DISEASE", 187, 209], ["MOF", "DISEASE", 211, 214], ["SARS", "DISEASE", 294, 298], ["gastrointestinal symptoms", "DISEASE", 309, 334], ["diarrhea", "DISEASE", 344, 352], ["abdominal pain", "DISEASE", 354, 368], ["inappetence", "DISEASE", 370, 381], ["nausea", "DISEASE", 383, 389], ["vomiting", "DISEASE", 394, 402], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 83, 91], ["organ", "ORGAN", 196, 201], ["patients", "ORGANISM", 273, 281], ["SARS-CoV-2", "ORGANISM", 294, 304], ["gastrointestinal", "ORGAN", 309, 325], ["abdominal", "ORGANISM_SUBDIVISION", 354, 363], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 273, 281], ["SARS-CoV", "SPECIES", 294, 302], ["COVID", "TEST", 16, 21], ["mild symptoms", "PROBLEM", 48, 61], ["acute respiratory distress syndrome", "PROBLEM", 116, 151], ["ARDS", "PROBLEM", 153, 157], ["multiple organ failure", "PROBLEM", 187, 209], ["IntroductionPrevious studies", "TEST", 224, 252], ["SARS", "PROBLEM", 294, 298], ["CoV", "TEST", 299, 302], ["gastrointestinal symptoms", "PROBLEM", 309, 334], ["diarrhea", "PROBLEM", 344, 352], ["abdominal pain", "PROBLEM", 354, 368], ["inappetence", "PROBLEM", 370, 381], ["nausea", "PROBLEM", 383, 389], ["vomiting", "PROBLEM", 394, 402], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["symptoms", "OBSERVATION", 53, 61], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["respiratory distress", "OBSERVATION", 122, 142], ["multiple", "OBSERVATION_MODIFIER", 187, 195], ["organ", "ANATOMY", 196, 201], ["failure", "OBSERVATION", 202, 209], ["infected", "OBSERVATION", 282, 290], ["gastrointestinal", "ANATOMY", 309, 325], ["abdominal", "ANATOMY", 354, 363]]], ["In addition, liver injury occurred in patients with COVID-19 [8] [9] [10] .The abnormality of liver function tests was observed in some of COVID-19 patients at admission [11] .", [["liver", "ANATOMY", 13, 18], ["liver", "ANATOMY", 94, 99], ["liver injury", "DISEASE", 13, 25], ["COVID-19 [8] [9", "CHEMICAL", 52, 67], ["COVID-19", "CHEMICAL", 52, 60], ["liver", "ORGAN", 13, 18], ["patients", "ORGANISM", 38, 46], ["liver", "ORGAN", 94, 99], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 148, 156], ["liver injury", "PROBLEM", 13, 25], ["COVID", "TEST", 52, 57], ["The abnormality of liver function tests", "PROBLEM", 75, 114], ["COVID", "TEST", 139, 144], ["liver", "ANATOMY", 13, 18], ["injury", "OBSERVATION", 19, 25], ["liver", "ANATOMY", 94, 99]]], ["Pathological examination of COVID-19 patient showed hepatocyte degeneration accompanied by focal necrosis, moderate steatosis, infiltration of leukocytes into lobular and portal area, and sinusoidal congestion [12] .", [["hepatocyte", "ANATOMY", 52, 62], ["leukocytes", "ANATOMY", 143, 153], ["lobular", "ANATOMY", 159, 166], ["portal area", "ANATOMY", 171, 182], ["sinusoidal", "ANATOMY", 188, 198], ["hepatocyte degeneration", "DISEASE", 52, 75], ["necrosis", "DISEASE", 97, 105], ["steatosis", "DISEASE", 116, 125], ["patient", "ORGANISM", 37, 44], ["hepatocyte", "CELL", 52, 62], ["leukocytes", "CELL", 143, 153], ["lobular", "TISSUE", 159, 166], ["portal area", "MULTI-TISSUE_STRUCTURE", 171, 182], ["leukocytes", "CELL_TYPE", 143, 153], ["patient", "SPECIES", 37, 44], ["Pathological examination", "TEST", 0, 24], ["COVID", "TEST", 28, 33], ["hepatocyte degeneration", "PROBLEM", 52, 75], ["focal necrosis", "PROBLEM", 91, 105], ["moderate steatosis", "PROBLEM", 107, 125], ["infiltration of leukocytes into lobular and portal area", "PROBLEM", 127, 182], ["sinusoidal congestion", "PROBLEM", 188, 209], ["hepatocyte", "ANATOMY", 52, 62], ["degeneration", "OBSERVATION", 63, 75], ["focal", "OBSERVATION_MODIFIER", 91, 96], ["necrosis", "OBSERVATION", 97, 105], ["moderate", "OBSERVATION_MODIFIER", 107, 115], ["steatosis", "OBSERVATION", 116, 125], ["infiltration", "OBSERVATION", 127, 139], ["leukocytes", "OBSERVATION", 143, 153], ["lobular", "ANATOMY_MODIFIER", 159, 166], ["portal area", "ANATOMY", 171, 182], ["sinusoidal congestion", "OBSERVATION", 188, 209]]], ["Thus, all these indicated liver involvement in patients infected by SARS-CoV-2.", [["liver", "ANATOMY", 26, 31], ["SARS", "DISEASE", 68, 72], ["liver", "ORGAN", 26, 31], ["patients", "ORGANISM", 47, 55], ["SARS-CoV-2", "ORGANISM", 68, 78], ["patients", "SPECIES", 47, 55], ["SARS-CoV", "SPECIES", 68, 76], ["liver", "ANATOMY", 26, 31], ["involvement", "OBSERVATION", 32, 43]]], ["While previous studies collected the data from the whole cohort of patients and some of them probably had chronic liver diseases.IntroductionChest CT, a routine imaging tool for pneumonia diagnosis, plays a central role in the diagnosis and classification of COVID-19 pneumonia [13] [14] [15] .", [["liver", "ANATOMY", 114, 119], ["chronic liver diseases", "DISEASE", 106, 128], ["pneumonia", "DISEASE", 178, 187], ["pneumonia", "DISEASE", 268, 277], ["COVID-19", "CHEMICAL", 259, 267], ["patients", "ORGANISM", 67, 75], ["liver", "ORGAN", 114, 119], ["COVID-19 pneumonia [13] [14] [15]", "SIMPLE_CHEMICAL", 259, 292], ["patients", "SPECIES", 67, 75], ["previous studies", "TEST", 6, 22], ["chronic liver diseases", "PROBLEM", 106, 128], ["IntroductionChest CT", "TEST", 129, 149], ["a routine imaging tool", "TEST", 151, 173], ["pneumonia", "PROBLEM", 178, 187], ["COVID", "TEST", 259, 264], ["pneumonia", "PROBLEM", 268, 277], ["chronic", "OBSERVATION_MODIFIER", 106, 113], ["liver", "ANATOMY", 114, 119], ["diseases", "OBSERVATION", 120, 128], ["pneumonia", "OBSERVATION", 178, 187], ["pneumonia", "OBSERVATION", 268, 277]]], ["Moreover, radiological signs of chest CT varied with the course of diseases, and the change of radiological signs might be associated with the outcomes of diseases [15, 16] .", [["chest", "ANATOMY", 32, 37], ["radiological signs", "TEST", 10, 28], ["chest CT", "TEST", 32, 40], ["diseases", "PROBLEM", 67, 75], ["radiological signs", "TEST", 95, 113], ["diseases", "PROBLEM", 155, 163], ["chest", "ANATOMY", 32, 37], ["diseases", "OBSERVATION", 67, 75]]], ["Liver injury in patients infected by SARS-CoV-2 might result in radiological change in liver.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 87, 92], ["Liver injury", "DISEASE", 0, 12], ["SARS", "DISEASE", 37, 41], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 16, 24], ["SARS-CoV-2", "ORGANISM", 37, 47], ["liver", "ORGAN", 87, 92], ["patients", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 37, 45], ["Liver injury", "PROBLEM", 0, 12], ["SARS", "PROBLEM", 37, 41], ["radiological change in liver", "PROBLEM", 64, 92], ["injury", "OBSERVATION", 6, 12], ["infected", "OBSERVATION_MODIFIER", 25, 33], ["liver", "ANATOMY", 87, 92]]], ["However, radiological findings of abdominal CT scan have not been explored so far.", [["abdominal", "ANATOMY", 34, 43], ["abdominal", "ORGAN", 34, 43], ["abdominal CT scan", "TEST", 34, 51], ["abdominal", "ANATOMY", 34, 43]]], ["Thus, the aim of our study is to determine clinical profiles of the COVID-19 patients based on severity grading, describe abdominal radiological signs, and investigate the correlations of the severity with clinical profiles and radiological signs.Study populationOur retrospective study was performed at Cancer Center of Union Hospital and main campus of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from Jan 24, 2020 to Feb 17, 2020.", [["abdominal", "ANATOMY", 122, 131], ["Cancer", "DISEASE", 304, 310], ["patients", "ORGANISM", 77, 85], ["abdominal", "ORGANISM_SUBDIVISION", 122, 131], ["patients", "SPECIES", 77, 85], ["our study", "TEST", 17, 26], ["the COVID", "TEST", 64, 73], ["severity grading", "TEST", 95, 111], ["abdominal radiological signs", "TEST", 122, 150], ["clinical profiles", "TEST", 206, 223], ["radiological signs", "TEST", 228, 246], ["Study populationOur retrospective study", "TEST", 247, 286], ["abdominal", "ANATOMY", 122, 131]]], ["178 consecutive patients with COVID 19 pneumonia were enrolled.", [["COVID", "DISEASE", 30, 35], ["pneumonia", "DISEASE", 39, 48], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["COVID 19 pneumonia", "PROBLEM", 30, 48], ["pneumonia", "OBSERVATION", 39, 48]]], ["The diagnosis of COVID 19 patients are: (1) fever and/or respiratory symptoms; (2) positive nucleic acid of the virus (RT-PCR analysis of throat swab specimens).", [["respiratory", "ANATOMY", 57, 68], ["throat swab specimens", "ANATOMY", 138, 159], ["COVID", "DISEASE", 17, 22], ["fever", "DISEASE", 44, 49], ["nucleic acid", "CHEMICAL", 92, 104], ["patients", "ORGANISM", 26, 34], ["throat swab specimens", "CANCER", 138, 159], ["patients", "SPECIES", 26, 34], ["COVID", "TEST", 17, 22], ["fever", "PROBLEM", 44, 49], ["respiratory symptoms", "PROBLEM", 57, 77], ["positive nucleic acid of the virus", "PROBLEM", 83, 117], ["RT-PCR analysis", "TEST", 119, 134], ["throat swab specimens", "TEST", 138, 159], ["respiratory", "ANATOMY", 57, 68]]], ["A severity-grading system for patients with COVID 19 was issued by National Health Commission of the People's Republic of China and National Administration of Traditional Chinese Medicine of the People's Republic of China.", [["COVID", "DISEASE", 44, 49], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["Traditional Chinese Medicine", "TREATMENT", 159, 187]]], ["The severity of COVID 19 patients is classified into four grades: mild, ordinary, severe and critical [13] .", [["COVID", "DISEASE", 16, 21], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["COVID", "TEST", 16, 21], ["mild, ordinary", "PROBLEM", 66, 80], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["severe", "OBSERVATION_MODIFIER", 82, 88]]], ["Mild cases: symptomatic infection includes fever, cough, sore throat, fatigue, headache or myalgia, but there were no pneumonia signs on chest imaging.", [["chest", "ANATOMY", 137, 142], ["infection", "DISEASE", 24, 33], ["fever", "DISEASE", 43, 48], ["cough", "DISEASE", 50, 55], ["sore throat", "DISEASE", 57, 68], ["fatigue", "DISEASE", 70, 77], ["headache", "DISEASE", 79, 87], ["myalgia", "DISEASE", 91, 98], ["pneumonia", "DISEASE", 118, 127], ["chest", "ORGANISM_SUBDIVISION", 137, 142], ["symptomatic infection", "PROBLEM", 12, 33], ["fever", "PROBLEM", 43, 48], ["cough", "PROBLEM", 50, 55], ["sore throat", "PROBLEM", 57, 68], ["fatigue", "PROBLEM", 70, 77], ["headache", "PROBLEM", 79, 87], ["myalgia", "PROBLEM", 91, 98], ["pneumonia signs", "PROBLEM", 118, 133], ["chest imaging", "TEST", 137, 150], ["symptomatic", "OBSERVATION_MODIFIER", 12, 23], ["infection", "OBSERVATION", 24, 33], ["sore throat", "ANATOMY", 57, 68], ["myalgia", "OBSERVATION", 91, 98], ["no", "UNCERTAINTY", 115, 117], ["pneumonia", "OBSERVATION", 118, 127], ["chest", "ANATOMY", 137, 142]]], ["Ordinary cases: symptomatic infection includes fever, cough, sore throat, fatigue, headache or myalgia, and pneumonia signs showed on chest imaging, meanwhile, these patients do not have any of the severe or critical symptoms and complications described below.", [["chest", "ANATOMY", 134, 139], ["infection", "DISEASE", 28, 37], ["fever", "DISEASE", 47, 52], ["cough", "DISEASE", 54, 59], ["sore throat", "DISEASE", 61, 72], ["fatigue", "DISEASE", 74, 81], ["headache", "DISEASE", 83, 91], ["myalgia", "DISEASE", 95, 102], ["pneumonia", "DISEASE", 108, 117], ["chest", "ORGANISM_SUBDIVISION", 134, 139], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["symptomatic infection", "PROBLEM", 16, 37], ["fever", "PROBLEM", 47, 52], ["cough", "PROBLEM", 54, 59], ["sore throat", "PROBLEM", 61, 72], ["fatigue", "PROBLEM", 74, 81], ["headache", "PROBLEM", 83, 91], ["myalgia", "PROBLEM", 95, 102], ["pneumonia signs", "PROBLEM", 108, 123], ["chest imaging", "TEST", 134, 147], ["the severe or critical symptoms", "PROBLEM", 194, 225], ["complications", "PROBLEM", 230, 243], ["symptomatic", "OBSERVATION_MODIFIER", 16, 27], ["infection", "OBSERVATION", 28, 37], ["sore throat", "ANATOMY", 61, 72], ["myalgia", "OBSERVATION", 95, 102], ["pneumonia", "OBSERVATION", 108, 117], ["chest", "ANATOMY", 134, 139]]], ["Severe cases: the disease progresses to meet any of the following conditions: \u2460 significantly increased respiration rate: RR \u2265 30/min; \u2461 SpO 2 \u2264 93% from a finger oximeter; \u2462 PaO 2 /FiO 2 \u2264 300 mmHg; \u2463 patients with > 50% lesions progression within 24-48 h in pulmonary imaging.", [["finger", "ANATOMY", 156, 162], ["lesions", "ANATOMY", 222, 229], ["pulmonary", "ANATOMY", 260, 269], ["patients", "ORGANISM", 202, 210], ["lesions", "PATHOLOGICAL_FORMATION", 222, 229], ["pulmonary", "ORGAN", 260, 269], ["patients", "SPECIES", 202, 210], ["the disease", "PROBLEM", 14, 25], ["significantly increased respiration rate", "PROBLEM", 80, 120], ["RR", "TEST", 122, 124], ["SpO", "TEST", 137, 140], ["a finger oximeter", "TEST", 154, 171], ["PaO", "TEST", 175, 178], ["FiO", "TEST", 182, 185], ["> 50% lesions progression", "PROBLEM", 216, 241], ["pulmonary imaging", "TEST", 260, 277], ["lesions", "OBSERVATION", 222, 229], ["pulmonary", "ANATOMY", 260, 269]]], ["Critical cases: with any of the following conditions: \u2460 respiratory failure which requires mechanical ventilation; \u2461 shock; \u2462 accompanied by other organ failure that needs ICU monitoring and treatment.", [["respiratory", "ANATOMY", 56, 67], ["organ", "ANATOMY", 147, 152], ["respiratory failure", "DISEASE", 56, 75], ["shock", "DISEASE", 117, 122], ["organ failure", "DISEASE", 147, 160], ["organ", "ORGAN", 147, 152], ["respiratory failure", "PROBLEM", 56, 75], ["mechanical ventilation", "TREATMENT", 91, 113], ["shock", "PROBLEM", 117, 122], ["other organ failure", "PROBLEM", 141, 160], ["ICU monitoring", "TEST", 172, 186], ["treatment", "TREATMENT", 191, 200], ["respiratory failure", "OBSERVATION", 56, 75], ["mechanical ventilation", "OBSERVATION", 91, 113], ["shock", "OBSERVATION", 117, 122], ["organ", "ANATOMY", 147, 152], ["failure", "OBSERVATION", 153, 160]]], ["Inclusion criteria were as follows: \u2460 confirmed cases with COVID-19; \u2461 pneumonia manifestation on chest CT scan; \u2462 CT scan and laboratory examinations were performed within 2 days after admission.", [["pneumonia", "DISEASE", 71, 80], ["COVID", "TEST", 59, 64], ["\u2461 pneumonia manifestation", "PROBLEM", 69, 94], ["chest CT scan", "TEST", 98, 111], ["CT scan", "TEST", 115, 122], ["laboratory examinations", "TEST", 127, 150], ["pneumonia", "OBSERVATION", 71, 80], ["chest", "ANATOMY", 98, 103]]], ["Exclusion criteria included: \u2460 patients who received antiviral treatment for more than 3 days before admission, such as interferon, chloroquine phosphate, arbidol, lopinavir/ritonavir, which may result in the alleviation of COVID-19 and side effects including GI symptoms and drug-induced liver injury, etc., (n = 30). \u2461 CT images of upper abdomen were not obtained (n = 19); \u2462 patients with hematological malignancy who were receiving chemotherapy (n = 6); \u2463 patients with severe underlying pulmonary diseases (n = 4); \u2464 patients with chronic liver diseases and liver cancer (n = 4) (Fig. 1 ).Data collectionThe pertinent data of the patients were collected from medical records and tabulated in a database.", [["GI", "ANATOMY", 260, 262], ["liver", "ANATOMY", 289, 294], ["upper abdomen", "ANATOMY", 334, 347], ["hematological malignancy", "ANATOMY", 392, 416], ["pulmonary", "ANATOMY", 492, 501], ["liver", "ANATOMY", 544, 549], ["liver cancer", "ANATOMY", 563, 575], ["chloroquine phosphate", "CHEMICAL", 132, 153], ["arbidol", "CHEMICAL", 155, 162], ["lopinavir/ritonavir", "CHEMICAL", 164, 183], ["GI symptoms", "DISEASE", 260, 271], ["liver injury", "DISEASE", 289, 301], ["hematological malignancy", "DISEASE", 392, 416], ["pulmonary diseases", "DISEASE", 492, 510], ["chronic liver diseases", "DISEASE", 536, 558], ["liver cancer", "DISEASE", 563, 575], ["chloroquine phosphate", "CHEMICAL", 132, 153], ["arbidol", "CHEMICAL", 155, 162], ["lopinavir", "CHEMICAL", 164, 173], ["ritonavir", "CHEMICAL", 174, 183], ["patients", "ORGANISM", 31, 39], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 132, 153], ["arbidol", "SIMPLE_CHEMICAL", 155, 162], ["lopinavir", "SIMPLE_CHEMICAL", 164, 173], ["ritonavir", "SIMPLE_CHEMICAL", 174, 183], ["liver", "ORGAN", 289, 294], ["upper abdomen", "ORGAN", 334, 347], ["patients", "ORGANISM", 378, 386], ["patients", "ORGANISM", 460, 468], ["pulmonary", "ORGAN", 492, 501], ["patients", "ORGANISM", 522, 530], ["liver", "ORGAN", 544, 549], ["liver cancer", "CANCER", 563, 575], ["patients", "ORGANISM", 635, 643], ["interferon", "PROTEIN", 120, 130], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 378, 386], ["patients", "SPECIES", 460, 468], ["patients", "SPECIES", 522, 530], ["patients", "SPECIES", 635, 643], ["antiviral treatment", "TREATMENT", 53, 72], ["interferon", "TREATMENT", 120, 130], ["chloroquine phosphate", "TREATMENT", 132, 153], ["arbidol", "TREATMENT", 155, 162], ["lopinavir", "TREATMENT", 164, 173], ["ritonavir", "TREATMENT", 174, 183], ["COVID", "TEST", 224, 229], ["side effects", "PROBLEM", 237, 249], ["GI symptoms", "PROBLEM", 260, 271], ["drug-induced liver injury", "PROBLEM", 276, 301], ["CT images of upper abdomen", "TEST", 321, 347], ["hematological malignancy", "PROBLEM", 392, 416], ["chemotherapy (n", "TREATMENT", 436, 451], ["severe underlying pulmonary diseases", "PROBLEM", 474, 510], ["chronic liver diseases", "PROBLEM", 536, 558], ["liver cancer", "PROBLEM", 563, 575], ["Data collection", "TEST", 594, 609], ["liver", "ANATOMY", 289, 294], ["injury", "OBSERVATION", 295, 301], ["upper", "ANATOMY_MODIFIER", 334, 339], ["abdomen", "ANATOMY", 340, 347], ["hematological", "ANATOMY", 392, 405], ["malignancy", "OBSERVATION", 406, 416], ["severe", "OBSERVATION_MODIFIER", 474, 480], ["pulmonary", "ANATOMY", 492, 501], ["diseases", "OBSERVATION", 502, 510], ["chronic", "OBSERVATION_MODIFIER", 536, 543], ["liver", "ANATOMY", 544, 549], ["diseases", "OBSERVATION", 550, 558], ["liver", "ANATOMY", 563, 568], ["cancer", "OBSERVATION", 569, 575]]], ["The pertinent data of the patients included demographic data; presenting symptoms and signs; medical history; laboratory tests; imaging findings; therapeutic process.Imaging technique and imaging analysisAll CT examinations were performed with one of the following three scanners: 64-detector spiral CT scanner (Somatom Definition AS, Siemens, Germany), gemstone spectral CT scanner (Discovery CT750 HD, GE, USA), 16-detector spiral CT scanner (Activion 16, Toshiba, Japan).", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["demographic data", "TEST", 44, 60], ["presenting symptoms", "PROBLEM", 62, 81], ["laboratory tests", "TEST", 110, 126], ["imaging findings", "TEST", 128, 144], ["therapeutic process", "PROBLEM", 146, 165], ["Imaging technique", "TEST", 166, 183], ["imaging analysis", "TEST", 188, 204], ["All CT examinations", "TEST", 204, 223], ["detector spiral CT scanner", "TEST", 284, 310], ["gemstone spectral CT scanner", "TEST", 354, 382]]], ["Images were reconstructed into lung window and soft tissue mediastinal window with a slice thickness of 1.5 mm, 2 mm or 5 mm and an interval of 1.5 mm, 2 mm or 5 mm, respectively.", [["lung", "ANATOMY", 31, 35], ["soft tissue mediastinal window", "ANATOMY", 47, 77], ["slice", "ANATOMY", 85, 90], ["lung", "ORGAN", 31, 35], ["soft tissue", "TISSUE", 47, 58], ["Images", "TEST", 0, 6], ["a slice thickness", "TEST", 83, 100], ["lung", "ANATOMY", 31, 35], ["window", "ANATOMY_MODIFIER", 36, 42], ["soft tissue", "ANATOMY", 47, 58], ["mediastinal", "ANATOMY", 59, 70], ["window", "OBSERVATION", 71, 77], ["1.5 mm", "OBSERVATION_MODIFIER", 104, 110], ["1.5 mm", "OBSERVATION_MODIFIER", 144, 150]]], ["The radiological evaluation included pulmonary involvement and abnormal signs of upper abdomen.", [["pulmonary", "ANATOMY", 37, 46], ["upper abdomen", "ANATOMY", 81, 94], ["pulmonary", "ORGAN", 37, 46], ["upper abdomen", "ORGANISM_SUBDIVISION", 81, 94], ["The radiological evaluation", "TEST", 0, 27], ["pulmonary involvement", "PROBLEM", 37, 58], ["abnormal signs of upper abdomen", "PROBLEM", 63, 94], ["pulmonary", "ANATOMY", 37, 46], ["upper", "ANATOMY_MODIFIER", 81, 86], ["abdomen", "ANATOMY", 87, 94]]], ["All CT images were independently reviewed and the findings were recorded by two experienced radiologists who were unaware of clinical data.", [["All CT images", "TEST", 0, 13]]], ["For semi-quantitative and qualitative imaging evaluation, discrepant evaluation was jointly re-evaluated to reach a final consensus [17] [18] [19] ; whereas, intraclass correlation coefficient (ICC) was introduced to assess interobserver consistency for quantitative imaging evaluation.", [["qualitative imaging evaluation", "TEST", 26, 56], ["discrepant evaluation", "TEST", 58, 79], ["quantitative imaging evaluation", "TEST", 254, 285]]], ["The severity of pneumonia was evaluated by a semi-quantitative scoring system, i.e., each of the 5 lung lobes was visually scored from 0 to 5 as: 0, no involvement; 1, < 5% involvement; 2, 5-25% involvement; 3, 26-49% involvement; 4, 50-75% involvement; 5, > 75% involvement.", [["lung lobes", "ANATOMY", 99, 109], ["pneumonia", "DISEASE", 16, 25], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 99, 109], ["pneumonia", "PROBLEM", 16, 25], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["pneumonia", "OBSERVATION", 16, 25], ["lung", "ANATOMY", 99, 103], ["lobes", "ANATOMY_MODIFIER", 104, 109], ["no", "UNCERTAINTY", 149, 151]]], ["The total CT score was the sum of individual lobar scores and ranged from 0 (no involvement) to 25 (maximum involvement) [20, 21] .", [["lobar", "ANATOMY", 45, 50], ["The total CT score", "TEST", 0, 18], ["individual lobar scores", "TEST", 34, 57], ["lobar", "ANATOMY_MODIFIER", 45, 50]]], ["Radiologic signs reviewed in upper abdominal CT scan include: hepatomegaly, the density of liver, periportal edema, pericholecystic fat stranding, portal lymphadenopathy, biliary ductal dilatation, ascites.", [["liver", "ANATOMY", 91, 96], ["periportal edema", "ANATOMY", 98, 114], ["pericholecystic fat", "ANATOMY", 116, 135], ["portal lymphadenopathy", "ANATOMY", 147, 169], ["biliary ductal", "ANATOMY", 171, 185], ["ascites", "ANATOMY", 198, 205], ["hepatomegaly", "DISEASE", 62, 74], ["periportal edema", "DISEASE", 98, 114], ["fat stranding", "DISEASE", 132, 145], ["portal lymphadenopathy", "DISEASE", 147, 169], ["biliary ductal dilatation", "DISEASE", 171, 196], ["ascites", "DISEASE", 198, 205], ["upper abdominal", "ORGANISM_SUBDIVISION", 29, 44], ["liver", "ORGAN", 91, 96], ["periportal edema", "PATHOLOGICAL_FORMATION", 98, 114], ["fat", "TISSUE", 132, 135], ["portal lymphadenopathy", "PATHOLOGICAL_FORMATION", 147, 169], ["biliary ductal", "MULTI-TISSUE_STRUCTURE", 171, 185], ["Radiologic signs", "TEST", 0, 16], ["upper abdominal CT scan", "TEST", 29, 52], ["hepatomegaly", "PROBLEM", 62, 74], ["the density of liver", "PROBLEM", 76, 96], ["periportal edema", "PROBLEM", 98, 114], ["pericholecystic fat stranding", "PROBLEM", 116, 145], ["portal lymphadenopathy", "PROBLEM", 147, 169], ["biliary ductal dilatation", "PROBLEM", 171, 196], ["ascites", "PROBLEM", 198, 205], ["upper", "ANATOMY_MODIFIER", 29, 34], ["abdominal", "ANATOMY", 35, 44], ["hepatomegaly", "OBSERVATION", 62, 74], ["density", "OBSERVATION", 80, 87], ["liver", "ANATOMY", 91, 96], ["periportal", "ANATOMY", 98, 108], ["edema", "OBSERVATION", 109, 114], ["pericholecystic", "ANATOMY_MODIFIER", 116, 131], ["fat", "ANATOMY", 132, 135], ["stranding", "OBSERVATION", 136, 145], ["portal", "ANATOMY", 147, 153], ["lymphadenopathy", "OBSERVATION", 154, 169], ["biliary ductal", "ANATOMY", 171, 185], ["dilatation", "OBSERVATION", 186, 196], ["ascites", "OBSERVATION", 198, 205]]], ["Liver hypodensity was defined when the density of liver is homogeneous or heterogeneous lower than or nearly equal to that of spleen.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 50, 55], ["spleen", "ANATOMY", 126, 132], ["Liver", "ORGAN", 0, 5], ["liver", "ORGAN", 50, 55], ["spleen", "ORGAN", 126, 132], ["Liver hypodensity", "PROBLEM", 0, 17], ["hypodensity", "OBSERVATION", 6, 17], ["density", "OBSERVATION", 39, 46], ["liver", "ANATOMY", 50, 55], ["homogeneous", "OBSERVATION_MODIFIER", 59, 70], ["heterogeneous", "OBSERVATION_MODIFIER", 74, 87], ["lower", "OBSERVATION_MODIFIER", 88, 93], ["spleen", "ANATOMY", 126, 132]]], ["CT-quantified hepatic density was measured by liver-to-spleen (L/S) attenuation ratio.", [["hepatic", "ANATOMY", 14, 21], ["liver", "ANATOMY", 46, 51], ["spleen", "ANATOMY", 55, 61], ["hepatic", "MULTI-TISSUE_STRUCTURE", 14, 21], ["liver", "ORGAN", 46, 51], ["spleen", "ORGAN", 55, 61], ["CT", "TEST", 0, 2], ["quantified hepatic density", "PROBLEM", 3, 29], ["attenuation ratio", "TEST", 68, 85], ["hepatic", "ANATOMY", 14, 21], ["density", "OBSERVATION", 22, 29], ["liver", "ANATOMY", 46, 51], ["spleen", "ANATOMY", 55, 61], ["attenuation", "OBSERVATION_MODIFIER", 68, 79], ["ratio", "OBSERVATION", 80, 85]]], ["Hepatic and splenic CT attenuation values were measured using regions of interest (ROI) > 100 mm 2 in area [22] on the PACS (CARESTRAM 3.1.S12.1, Canada).", [["Hepatic", "ANATOMY", 0, 7], ["splenic", "ANATOMY", 12, 19], ["Hepatic", "MULTI-TISSUE_STRUCTURE", 0, 7], ["splenic CT", "MULTI-TISSUE_STRUCTURE", 12, 22], ["Hepatic and splenic CT attenuation values", "TEST", 0, 41], ["ROI", "TEST", 83, 86], ["the PACS", "TEST", 115, 123], ["CARESTRAM", "TEST", 125, 134], ["splenic", "ANATOMY", 12, 19], ["attenuation", "OBSERVATION_MODIFIER", 23, 34]]], ["Two ROIs were in the right liver lobe, one ROI in the left liver lobe and three ROIs in the spleen.", [["right liver lobe", "ANATOMY", 21, 37], ["left liver lobe", "ANATOMY", 54, 69], ["spleen", "ANATOMY", 92, 98], ["liver lobe", "MULTI-TISSUE_STRUCTURE", 27, 37], ["liver lobe", "MULTI-TISSUE_STRUCTURE", 59, 69], ["spleen", "ORGAN", 92, 98], ["Two ROIs", "TEST", 0, 8], ["ROIs", "OBSERVATION", 4, 8], ["right", "ANATOMY_MODIFIER", 21, 26], ["liver", "ANATOMY", 27, 32], ["lobe", "ANATOMY_MODIFIER", 33, 37], ["one", "OBSERVATION_MODIFIER", 39, 42], ["ROI", "OBSERVATION_MODIFIER", 43, 46], ["left", "ANATOMY_MODIFIER", 54, 58], ["liver", "ANATOMY", 59, 64], ["lobe", "ANATOMY_MODIFIER", 65, 69], ["three", "OBSERVATION_MODIFIER", 74, 79], ["ROIs", "OBSERVATION_MODIFIER", 80, 84], ["spleen", "ANATOMY", 92, 98]]], ["ROI should include a greater area of the liver and spleen whenever possible, Fig. 1 Flowchart of the patients' selection, inclusion, and exclusion meanwhile ROI selection should exclude regions of hepatic vessels and bile ducts (Fig. S1 ).", [["liver", "ANATOMY", 41, 46], ["spleen", "ANATOMY", 51, 57], ["hepatic vessels", "ANATOMY", 197, 212], ["bile ducts", "ANATOMY", 217, 227], ["liver", "ORGAN", 41, 46], ["spleen", "ORGAN", 51, 57], ["patients", "ORGANISM", 101, 109], ["hepatic vessels", "MULTI-TISSUE_STRUCTURE", 197, 212], ["bile ducts", "MULTI-TISSUE_STRUCTURE", 217, 227], ["patients", "SPECIES", 101, 109], ["ROI", "TEST", 0, 3], ["ROI selection", "TEST", 157, 170], ["greater", "OBSERVATION_MODIFIER", 21, 28], ["liver", "ANATOMY", 41, 46], ["spleen", "ANATOMY", 51, 57], ["whenever possible", "UNCERTAINTY", 58, 75], ["hepatic vessels", "ANATOMY", 197, 212], ["bile ducts", "ANATOMY", 217, 227]]], ["Then L/S ratio was calculated by taking mean HU measurement of liver lobe ROIs and dividing it by the mean splenic HU measurement of its ROIs (Fig.S1 ).Statistical analysisContinuous variables were expressed as mean and standard deviation for normal distribution data and median (25th-75th percentiles) if the distribution was skewed.", [["liver lobe", "ANATOMY", 63, 73], ["splenic", "ANATOMY", 107, 114], ["liver lobe", "MULTI-TISSUE_STRUCTURE", 63, 73], ["L/S ratio", "TEST", 5, 14], ["liver lobe ROIs", "PROBLEM", 63, 78], ["Statistical analysisContinuous variables", "TEST", 152, 192], ["liver", "ANATOMY", 63, 68], ["lobe", "ANATOMY_MODIFIER", 69, 73], ["splenic", "ANATOMY", 107, 114], ["HU", "OBSERVATION_MODIFIER", 115, 117]]], ["Categorical variables were presented as count (percentage).", [["Categorical variables", "TEST", 0, 21]]], ["The interobserver agreement for measurement of CT-quantified hepatic density was determined using the intraclass correlation efficient (ICC).", [["hepatic", "ANATOMY", 61, 68], ["hepatic", "MULTI-TISSUE_STRUCTURE", 61, 68], ["CT", "TEST", 47, 49], ["hepatic", "ANATOMY", 61, 68], ["density", "OBSERVATION", 69, 76]]], ["The level of agreement was generally recognized as follows: poor, ICC < 0.20; fair, 0.2 < ICC \u2264 0.40; moderate, 0.4 < ICC \u2264 0.60; good, 0.6 < ICC \u2264 0.80; and very good, 0.8 < ICC \u2264 1.0.", [["ICC", "TEST", 66, 69], ["ICC", "TEST", 90, 93], ["ICC", "TEST", 118, 121], ["ICC", "TEST", 142, 145], ["ICC", "TEST", 175, 178], ["moderate", "OBSERVATION_MODIFIER", 102, 110]]], ["The differences of categorical variables among groups were analyzed by Chi-square test (the Fisher exact test was used when the data were limited) and continuous variables by Kruskal-Wallis H test.", [["Chi-square test", "TEST", 71, 86], ["the Fisher exact test", "TEST", 88, 109], ["the data", "TEST", 124, 132], ["Kruskal-Wallis H test", "TEST", 175, 196]]], ["The correlation of categorical variables was analyzed by Spearman correlation test and continuous variables by Pearson correlation test.", [["Spearman correlation test", "TEST", 57, 82], ["Pearson correlation test", "TEST", 111, 135]]], ["All statistical tests were two-sided. p value less than 0.05 was considered to indicate statistical significance.", [["All statistical tests", "TEST", 0, 21], ["p value", "TEST", 38, 45]]], ["Statistical analyses were performed using SPSS version 22.0 (SPSS Inc., Chicago, Illinois, USA).Clinical presentation115 patients with COVID-19 pneumonia were consecutively enrolled in our study.", [["pneumonia", "DISEASE", 144, 153], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["Statistical analyses", "TEST", 0, 20], ["SPSS version", "TEST", 42, 54], ["COVID", "TEST", 135, 140], ["pneumonia", "PROBLEM", 144, 153], ["our study", "TEST", 185, 194], ["pneumonia", "OBSERVATION", 144, 153]]], ["The patients were classified into mild group, ordinary group, severe group and critical group according to the severity [13] .", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["severe", "OBSERVATION_MODIFIER", 62, 68]]], ["Mild cases without pneumonia manifestation did not receive inpatient hospital care in Wuhan, China, so mild cases were not included in our study.", [["pneumonia", "DISEASE", 19, 28], ["Mild cases", "PROBLEM", 0, 10], ["pneumonia", "PROBLEM", 19, 28], ["mild cases", "PROBLEM", 103, 113], ["our study", "TEST", 135, 144], ["without", "UNCERTAINTY", 11, 18], ["pneumonia", "OBSERVATION", 19, 28]]], ["Thus, the enrolled patients included ordinary cases (50 patients), severe cases (48 patients) and critical cases (17 patients) (Fig. 1) .", [["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 117, 125]]], ["The median age of enrolled patients were 66 years (IQR: 60-70), there was 58 males and 57 females, with a male-to-female ratio of 1.02:1 (Supplementary Table 1 ).", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["IQR", "TEST", 51, 54]]], ["Significant difference in patients' age existed among different groups, which revealed that older patients were at higher risk for severe illness.", [["illness", "DISEASE", 138, 145], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 98, 106], ["severe illness", "PROBLEM", 131, 145], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["illness", "OBSERVATION", 138, 145]]], ["Then, the clinical manifestations of the patients were analyzed, and the results showed fever in 68.70% (79/115) of the patients, cough in 56.52% (65/115), fatigue in 31.30% (36/115), and shortness of breath in 13.91% (16/115) of the patients (Supplementary Table 1 ).", [["fever", "DISEASE", 88, 93], ["cough", "DISEASE", 130, 135], ["fatigue", "DISEASE", 156, 163], ["shortness of breath", "DISEASE", 188, 207], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 234, 242], ["fever", "PROBLEM", 88, 93], ["cough", "TEST", 130, 135], ["fatigue", "PROBLEM", 156, 163], ["shortness of breath", "PROBLEM", 188, 207]]], ["Thirdly, gastrointestinal symptoms were determined in the patients, and we found that 12.17% (14/115) of the cases had diarrhea, 7.83% (9/115) of the cases with nausea or vomiting, 7.83% (9/115) of the cases with inappetence (Supplementary Table 1 ).", [["gastrointestinal", "ANATOMY", 9, 25], ["gastrointestinal symptoms", "DISEASE", 9, 34], ["diarrhea", "DISEASE", 119, 127], ["nausea", "DISEASE", 161, 167], ["vomiting", "DISEASE", 171, 179], ["inappetence", "DISEASE", 213, 224], ["gastrointestinal", "ORGAN", 9, 25], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["gastrointestinal symptoms", "PROBLEM", 9, 34], ["diarrhea", "PROBLEM", 119, 127], ["nausea", "PROBLEM", 161, 167], ["vomiting", "PROBLEM", 171, 179], ["inappetence", "PROBLEM", 213, 224], ["gastrointestinal", "ANATOMY", 9, 25]]], ["In addition, no significant differences in clinical manifestions were evident among different groups.Laboratory tests (peripheral blood routine examination and clinical biochemistry)Laboratory results of the patients containing peripheral blood routine examination and clinical biochemistry were summarized in Table 1 at the time of baseline evaluation.", [["peripheral blood", "ANATOMY", 119, 135], ["peripheral blood", "ANATOMY", 228, 244], ["peripheral blood", "MULTI-TISSUE_STRUCTURE", 119, 135], ["patients", "ORGANISM", 208, 216], ["peripheral blood", "ORGANISM_SUBSTANCE", 228, 244], ["patients", "SPECIES", 208, 216], ["significant differences in clinical manifestions", "PROBLEM", 16, 64], ["Laboratory tests", "TEST", 101, 117], ["peripheral blood routine examination", "TEST", 119, 155], ["clinical biochemistry", "TEST", 160, 181], ["peripheral blood routine examination", "TEST", 228, 264], ["clinical biochemistry", "TEST", 269, 290], ["baseline evaluation", "TEST", 333, 352], ["no", "UNCERTAINTY", 13, 15], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["differences", "OBSERVATION_MODIFIER", 28, 39]]], ["Firstly, blood routine examination of the patients was determined.", [["blood", "ANATOMY", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["blood routine examination", "TEST", 9, 34]]], ["Generally, the values of erythrocyte, leukocyte and platelet were within normal limit in most of COVID-19 patients (Table 1) .", [["erythrocyte", "ANATOMY", 25, 36], ["leukocyte", "ANATOMY", 38, 47], ["platelet", "ANATOMY", 52, 60], ["erythrocyte", "CELL", 25, 36], ["leukocyte", "CELL", 38, 47], ["platelet", "CELL", 52, 60], ["patients", "ORGANISM", 106, 114], ["leukocyte", "CELL_TYPE", 38, 47], ["platelet", "CELL_TYPE", 52, 60], ["patients", "SPECIES", 106, 114], ["erythrocyte", "TEST", 25, 36], ["leukocyte", "TEST", 38, 47], ["platelet", "TEST", 52, 60], ["COVID", "TEST", 97, 102], ["erythrocyte", "ANATOMY", 25, 36], ["leukocyte", "ANATOMY", 38, 47]]], ["Lymphocytopenia was observed in 54.78% of the COVID-19 patients and lymphocytopenia occurred in 100% of critical cases.", [["Lymphocytopenia", "DISEASE", 0, 15], ["COVID", "DISEASE", 46, 51], ["lymphocytopenia", "DISEASE", 68, 83], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["Lymphocytopenia", "PROBLEM", 0, 15], ["the COVID", "TEST", 42, 51], ["lymphocytopenia", "PROBLEM", 68, 83], ["lymphocytopenia", "OBSERVATION", 68, 83]]], ["T cell subsets were also analyzed and the results showed that CD3+ , CD4+ and CD8+ T lymphocyte subsets were decreased in some of the COVID-19 patients.", [["T cell", "ANATOMY", 0, 6], ["CD3+ , CD4+ and CD8+", "ANATOMY", 62, 82], ["T lymphocyte", "ANATOMY", 83, 95], ["T cell", "CELL", 0, 6], ["CD3", "GENE_OR_GENE_PRODUCT", 62, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["T lymphocyte", "CELL", 83, 95], ["patients", "ORGANISM", 143, 151], ["T cell subsets", "CELL_TYPE", 0, 14], ["CD3", "PROTEIN", 62, 65], ["CD4", "PROTEIN", 69, 72], ["CD8", "PROTEIN", 78, 81], ["T lymphocyte subsets", "CELL_TYPE", 83, 103], ["patients", "SPECIES", 143, 151], ["T cell subsets", "TEST", 0, 14], ["CD3", "TEST", 62, 65], ["CD4", "TEST", 69, 72], ["CD8", "TEST", 78, 81], ["T lymphocyte subsets", "TEST", 83, 103], ["the COVID", "TEST", 130, 139], ["cell subsets", "OBSERVATION", 2, 14], ["lymphocyte subsets", "OBSERVATION", 85, 103], ["decreased", "OBSERVATION_MODIFIER", 109, 118]]], ["Compared with the ordinary group and the severe group, the proportion of CD3+ , CD4+ and CD8+ T cells decreased significantly in the critical group (Table 1) .", [["CD3+ , CD4+", "ANATOMY", 73, 84], ["T cells", "ANATOMY", 94, 101], ["CD3", "GENE_OR_GENE_PRODUCT", 73, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["T cells", "CELL", 94, 101], ["CD3", "PROTEIN", 73, 76], ["CD4", "PROTEIN", 80, 83], ["CD8", "PROTEIN", 89, 92], ["T cells", "CELL_TYPE", 94, 101], ["CD3", "TEST", 73, 76], ["CD4", "TEST", 80, 83], ["CD8", "TEST", 89, 92], ["T cells", "PROBLEM", 94, 101], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["CD3", "OBSERVATION", 73, 76], ["decreased", "OBSERVATION_MODIFIER", 102, 111]]], ["Secondly, the parameters of liver functional tests were analyzed.", [["liver", "ANATOMY", 28, 33], ["liver", "ORGAN", 28, 33], ["liver functional tests", "TEST", 28, 50], ["liver", "ANATOMY", 28, 33]]], ["Most of the patients had normal levels of AST, ALT, ALP, \u03b3GT and total bilirubin.", [["bilirubin", "CHEMICAL", 71, 80], ["bilirubin", "CHEMICAL", 71, 80], ["patients", "ORGANISM", 12, 20], ["AST", "SIMPLE_CHEMICAL", 42, 45], ["ALT", "SIMPLE_CHEMICAL", 47, 50], ["ALP", "GENE_OR_GENE_PRODUCT", 52, 55], ["\u03b3GT", "SIMPLE_CHEMICAL", 57, 60], ["bilirubin", "GENE_OR_GENE_PRODUCT", 71, 80], ["AST", "PROTEIN", 42, 45], ["ALT", "PROTEIN", 47, 50], ["ALP", "PROTEIN", 52, 55], ["\u03b3GT", "PROTEIN", 57, 60], ["patients", "SPECIES", 12, 20], ["AST", "TEST", 42, 45], ["ALT", "TEST", 47, 50], ["ALP", "TEST", 52, 55], ["GT", "TEST", 58, 60], ["total bilirubin", "TEST", 65, 80]]], ["Significant difference in AST level was observed among different groups.", [["AST", "SIMPLE_CHEMICAL", 26, 29], ["AST", "PROTEIN", 26, 29], ["Significant difference in AST level", "PROBLEM", 0, 35], ["difference", "OBSERVATION_MODIFIER", 12, 22]]], ["Liver synthetic function was also assessed by the detection of albumin and PT, and we found that 60.00% (69/115) of the cases had hypoalbuminemia, 3.88% of the cases had increased prothrombin time.", [["Liver", "ANATOMY", 0, 5], ["hypoalbuminemia", "DISEASE", 130, 145], ["Liver", "ORGAN", 0, 5], ["albumin", "GENE_OR_GENE_PRODUCT", 63, 70], ["PT", "GENE_OR_GENE_PRODUCT", 75, 77], ["prothrombin", "GENE_OR_GENE_PRODUCT", 180, 191], ["albumin", "PROTEIN", 63, 70], ["prothrombin", "PROTEIN", 180, 191], ["Liver synthetic function", "TEST", 0, 24], ["albumin", "TEST", 63, 70], ["PT", "TEST", 75, 77], ["hypoalbuminemia", "PROBLEM", 130, 145], ["increased prothrombin time", "PROBLEM", 170, 196], ["hypoalbuminemia", "OBSERVATION", 130, 145], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["prothrombin time", "OBSERVATION", 180, 196]]], ["Thirdly, biomarkers of renal function indicated by serum urea and creatinine showed that most of the patients had normal renal function (Table 1) .", [["renal", "ANATOMY", 23, 28], ["serum", "ANATOMY", 51, 56], ["renal", "ANATOMY", 121, 126], ["urea", "CHEMICAL", 57, 61], ["creatinine", "CHEMICAL", 66, 76], ["urea", "CHEMICAL", 57, 61], ["creatinine", "CHEMICAL", 66, 76], ["renal", "ORGAN", 23, 28], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["urea", "SIMPLE_CHEMICAL", 57, 61], ["creatinine", "SIMPLE_CHEMICAL", 66, 76], ["patients", "ORGANISM", 101, 109], ["renal", "ORGAN", 121, 126], ["patients", "SPECIES", 101, 109], ["renal function", "TEST", 23, 37], ["serum urea", "TEST", 51, 61], ["creatinine", "TEST", 66, 76], ["renal", "ANATOMY", 23, 28], ["normal", "OBSERVATION", 114, 120], ["renal", "ANATOMY", 121, 126]]], ["Fourthly, some biomarkers of metabolic syndrome were collected and the results showed that no significant differences in the levels of cholesterol (CHOL) and triglyceride (TG) were observed among different groups.", [["metabolic syndrome", "DISEASE", 29, 47], ["cholesterol", "CHEMICAL", 135, 146], ["CHOL", "CHEMICAL", 148, 152], ["triglyceride", "CHEMICAL", 158, 170], ["TG", "DISEASE", 172, 174], ["cholesterol", "CHEMICAL", 135, 146], ["CHOL", "CHEMICAL", 148, 152], ["triglyceride", "CHEMICAL", 158, 170], ["cholesterol", "SIMPLE_CHEMICAL", 135, 146], ["CHOL", "SIMPLE_CHEMICAL", 148, 152], ["triglyceride", "SIMPLE_CHEMICAL", 158, 170], ["TG", "SIMPLE_CHEMICAL", 172, 174], ["metabolic syndrome", "PROBLEM", 29, 47], ["cholesterol", "TEST", 135, 146], ["triglyceride (TG", "TEST", 158, 174], ["metabolic syndrome", "OBSERVATION", 29, 47], ["no", "UNCERTAINTY", 91, 93], ["significant", "OBSERVATION_MODIFIER", 94, 105], ["differences", "OBSERVATION_MODIFIER", 106, 117]]], ["Most of the patients had normal uric acid level; surprisingly, critical cases with the lowest level of uric acid (Table 1 ).", [["uric acid", "CHEMICAL", 32, 41], ["uric acid", "CHEMICAL", 103, 112], ["uric acid", "CHEMICAL", 32, 41], ["uric acid", "CHEMICAL", 103, 112], ["patients", "ORGANISM", 12, 20], ["uric acid", "SIMPLE_CHEMICAL", 32, 41], ["uric acid", "SIMPLE_CHEMICAL", 103, 112], ["patients", "SPECIES", 12, 20], ["uric acid", "TEST", 103, 112]]], ["Finally, abnormal CRP level was detected in 64.42% of the patients.", [["CRP", "GENE_OR_GENE_PRODUCT", 18, 21], ["patients", "ORGANISM", 58, 66], ["CRP", "PROTEIN", 18, 21], ["patients", "SPECIES", 58, 66], ["abnormal CRP level", "PROBLEM", 9, 27], ["abnormal", "OBSERVATION_MODIFIER", 9, 17], ["CRP", "OBSERVATION_MODIFIER", 18, 21]]], ["Elevated AST level, hypoalbuminemia and increased CRP level were frequently found in critical cases.Imaging findings of chest and upper abdominal CT in COVID-19 patientsPneumonia in COVID-19 patients was commonly manifested as ground-glass opacity, smooth or irregular interlobular septal thickening, consolidation with air bronchogram, crazy-paving pattern, and pleura effusion (Figs.", [["chest", "ANATOMY", 120, 125], ["abdominal", "ANATOMY", 136, 145], ["interlobular septal", "ANATOMY", 269, 288], ["pleura effusion", "ANATOMY", 363, 378], ["hypoalbuminemia", "DISEASE", 20, 35], ["Pneumonia", "DISEASE", 169, 178], ["pleura effusion", "DISEASE", 363, 378], ["AST", "GENE_OR_GENE_PRODUCT", 9, 12], ["CRP", "GENE_OR_GENE_PRODUCT", 50, 53], ["chest", "ORGANISM_SUBDIVISION", 120, 125], ["upper abdominal", "ORGANISM_SUBDIVISION", 130, 145], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 191, 199], ["interlobular septal", "MULTI-TISSUE_STRUCTURE", 269, 288], ["pleura", "ORGAN", 363, 369], ["AST", "PROTEIN", 9, 12], ["CRP", "PROTEIN", 50, 53], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 191, 199], ["Elevated AST level", "PROBLEM", 0, 18], ["hypoalbuminemia", "PROBLEM", 20, 35], ["increased CRP level", "PROBLEM", 40, 59], ["Imaging findings", "TEST", 100, 116], ["chest and upper abdominal CT", "TEST", 120, 148], ["Pneumonia", "PROBLEM", 169, 178], ["COVID", "TEST", 182, 187], ["ground-glass opacity", "PROBLEM", 227, 247], ["irregular interlobular septal thickening", "PROBLEM", 259, 299], ["consolidation", "PROBLEM", 301, 314], ["air bronchogram", "PROBLEM", 320, 335], ["pleura effusion", "PROBLEM", 363, 378], ["hypoalbuminemia", "OBSERVATION", 20, 35], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["CRP", "OBSERVATION_MODIFIER", 50, 53], ["chest", "ANATOMY", 120, 125], ["upper", "ANATOMY_MODIFIER", 130, 135], ["abdominal", "ANATOMY", 136, 145], ["ground", "OBSERVATION_MODIFIER", 227, 233], ["glass opacity", "OBSERVATION", 234, 247], ["smooth", "OBSERVATION_MODIFIER", 249, 255], ["irregular", "OBSERVATION_MODIFIER", 259, 268], ["interlobular", "ANATOMY_MODIFIER", 269, 281], ["septal", "ANATOMY_MODIFIER", 282, 288], ["thickening", "OBSERVATION", 289, 299], ["consolidation", "OBSERVATION", 301, 314], ["air bronchogram", "OBSERVATION", 320, 335], ["crazy", "OBSERVATION_MODIFIER", 337, 342], ["pleura", "ANATOMY", 363, 369], ["effusion", "OBSERVATION", 370, 378]]], ["Most of the patients suffered pneumonia in multiple lobes.", [["lobes", "ANATOMY", 52, 57], ["pneumonia", "DISEASE", 30, 39], ["patients", "ORGANISM", 12, 20], ["lobes", "ORGAN", 52, 57], ["patients", "SPECIES", 12, 20], ["pneumonia in multiple lobes", "PROBLEM", 30, 57], ["pneumonia", "OBSERVATION", 30, 39], ["multiple lobes", "ANATOMY", 43, 57]]], ["The severity of pneumonia was evaluated by a semi-quantitative scoring system and the median score (Table 2) .", [["pneumonia", "DISEASE", 16, 25], ["pneumonia", "PROBLEM", 16, 25], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["pneumonia", "OBSERVATION", 16, 25]]], ["Hepatomegaly, splenomegaly, periportal edema, edema of the gallbladder walls, periportal lymphadenopathy, biliary dilatation and ascites were not observed.", [["periportal edema", "ANATOMY", 28, 44], ["edema", "ANATOMY", 46, 51], ["gallbladder walls", "ANATOMY", 59, 76], ["periportal lymphadenopathy", "ANATOMY", 78, 104], ["biliary", "ANATOMY", 106, 113], ["ascites", "ANATOMY", 129, 136], ["Hepatomegaly", "DISEASE", 0, 12], ["splenomegaly", "DISEASE", 14, 26], ["periportal edema", "DISEASE", 28, 44], ["edema", "DISEASE", 46, 51], ["lymphadenopathy", "DISEASE", 89, 104], ["biliary dilatation", "DISEASE", 106, 124], ["ascites", "DISEASE", 129, 136], ["splenomegaly", "PATHOLOGICAL_FORMATION", 14, 26], ["periportal edema", "PATHOLOGICAL_FORMATION", 28, 44], ["edema", "PATHOLOGICAL_FORMATION", 46, 51], ["gallbladder walls", "PATHOLOGICAL_FORMATION", 59, 76], ["periportal lymphadenopathy", "PATHOLOGICAL_FORMATION", 78, 104], ["biliary", "MULTI-TISSUE_STRUCTURE", 106, 113], ["Hepatomegaly", "PROBLEM", 0, 12], ["splenomegaly", "PROBLEM", 14, 26], ["periportal edema", "PROBLEM", 28, 44], ["edema of the gallbladder walls", "PROBLEM", 46, 76], ["periportal lymphadenopathy", "PROBLEM", 78, 104], ["biliary dilatation", "PROBLEM", 106, 124], ["ascites", "PROBLEM", 129, 136], ["splenomegaly", "OBSERVATION", 14, 26], ["periportal", "ANATOMY", 28, 38], ["edema", "OBSERVATION", 39, 44], ["edema", "OBSERVATION", 46, 51], ["gallbladder", "ANATOMY", 59, 70], ["walls", "ANATOMY_MODIFIER", 71, 76], ["periportal", "ANATOMY", 78, 88], ["lymphadenopathy", "OBSERVATION", 89, 104], ["biliary", "ANATOMY", 106, 113], ["dilatation", "OBSERVATION", 114, 124], ["ascites", "OBSERVATION", 129, 136]]], ["Homogeneous or heterogeneous hepatic hypodensity was the most common CT finding (Figs.", [["hepatic", "ANATOMY", 29, 36], ["hepatic hypodensity", "DISEASE", 29, 48], ["hepatic", "ORGAN", 29, 36], ["Homogeneous or heterogeneous hepatic hypodensity", "PROBLEM", 0, 48], ["heterogeneous", "OBSERVATION_MODIFIER", 15, 28], ["hepatic", "ANATOMY", 29, 36], ["hypodensity", "OBSERVATION", 37, 48], ["most common", "OBSERVATION_MODIFIER", 57, 68]]], ["Liver hypodensity was observed in 26.09% (30/115) of the patients and statistical analysis revealed significant difference among different groups (Table2).", [["Liver", "ANATOMY", 0, 5], ["Liver hypodensity", "DISEASE", 0, 17], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["Liver hypodensity", "PROBLEM", 0, 17], ["statistical analysis", "TEST", 70, 90], ["significant difference", "PROBLEM", 100, 122], ["hypodensity", "OBSERVATION", 6, 17], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["difference", "OBSERVATION_MODIFIER", 112, 122]]], ["Moreover, the liver-to-spleen (L/S) attenuation ratio was measured and the interobserver agreement for assessment of L/S attenuation ratios was very good (ICC = 0.98).", [["liver", "ANATOMY", 14, 19], ["spleen", "ANATOMY", 23, 29], ["liver", "ORGAN", 14, 19], ["spleen", "ORGAN", 23, 29], ["L/S) attenuation ratio", "TEST", 31, 53], ["assessment", "TEST", 103, 113], ["L/S attenuation ratios", "TEST", 117, 139], ["ICC", "TEST", 155, 158], ["liver", "ANATOMY", 14, 19], ["spleen", "ANATOMY", 23, 29]]], ["A decrease in the L/S attenuation ratio (< 1) was detected in 16.52% of the whole cohort, up to 47.06% of critical cases.", [["A decrease", "PROBLEM", 0, 10], ["the L/S attenuation ratio", "TEST", 14, 39], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["L", "OBSERVATION_MODIFIER", 18, 19], ["attenuation", "OBSERVATION_MODIFIER", 22, 33], ["ratio", "OBSERVATION_MODIFIER", 34, 39]]], ["Meanwhile, significant difference in the L/S attenuation ratio was observed among different groups (Table2).", [["significant difference", "PROBLEM", 11, 33], ["the L/S attenuation ratio", "TEST", 37, 62], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["difference", "OBSERVATION_MODIFIER", 23, 33]]], ["Finally, pericholecystic fat stranding was evaluated.", [["pericholecystic fat", "ANATOMY", 9, 28], ["pericholecystic fat", "TISSUE", 9, 28], ["pericholecystic fat stranding", "PROBLEM", 9, 38], ["pericholecystic", "ANATOMY_MODIFIER", 9, 24], ["fat", "ANATOMY", 25, 28], ["stranding", "OBSERVATION", 29, 38]]], ["Unfortunately, 21 cases were excluded due to the patients with cholecystolithiasis or cholecystectomy.", [["cholecystolithiasis", "DISEASE", 63, 82], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["cholecystolithiasis", "PROBLEM", 63, 82], ["cholecystectomy", "TREATMENT", 86, 101], ["cholecystolithiasis", "OBSERVATION", 63, 82], ["cholecystectomy", "OBSERVATION", 86, 101]]], ["Pericholecystic fat stranding was observed in 21.27% (21/94) of the patients (Fig. 3) , but no significant difference was evident among different groups.Correlation of severity grading with clinical manifestations, radiologic features and liver function testsTo evaluate the value of radiological features and liver function tests, the correlations of severity grading with clinical manifestations, CT features and liver function tests were determined.", [["Pericholecystic fat", "ANATOMY", 0, 19], ["liver", "ANATOMY", 239, 244], ["liver", "ANATOMY", 310, 315], ["liver", "ANATOMY", 415, 420], ["fat stranding", "DISEASE", 16, 29], ["Pericholecystic fat", "TISSUE", 0, 19], ["patients", "ORGANISM", 68, 76], ["liver", "ORGAN", 239, 244], ["liver", "ORGAN", 310, 315], ["liver", "ORGAN", 415, 420], ["patients", "SPECIES", 68, 76], ["Pericholecystic fat stranding", "PROBLEM", 0, 29], ["significant difference", "PROBLEM", 95, 117], ["severity grading", "TEST", 168, 184], ["clinical manifestations", "PROBLEM", 190, 213], ["radiologic features", "TEST", 215, 234], ["liver function tests", "TEST", 239, 259], ["radiological features", "TEST", 284, 305], ["liver function tests", "TEST", 310, 330], ["severity grading", "TEST", 352, 368], ["clinical manifestations", "PROBLEM", 374, 397], ["CT features", "TEST", 399, 410], ["liver function tests", "TEST", 415, 435], ["fat", "ANATOMY", 16, 19], ["stranding", "OBSERVATION", 20, 29], ["no", "UNCERTAINTY", 92, 94], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["difference", "OBSERVATION", 107, 117], ["liver", "ANATOMY", 239, 244], ["liver", "ANATOMY", 310, 315], ["liver", "ANATOMY", 415, 420]]], ["Firstly, the correlations of clinical manifestation with a panel of liver function tests and severity grading were investigated in patients with COVID-19 and the results showed no correlation of clinical manifestations with pulmonary lesions, severity grading and liver functional tests (Table S2) ; secondly, the correlations of semi-quantitative scoring of pulmonary lesions with a panel of liver function tests and severity grading were investigated in patients with COVID-19, and the correlation tests demonstrated that the score of pulmonary lesions was associated with liver function tests, severity grading and CRP (Table3).", [["liver", "ANATOMY", 68, 73], ["pulmonary lesions", "ANATOMY", 224, 241], ["liver", "ANATOMY", 264, 269], ["pulmonary lesions", "ANATOMY", 359, 376], ["liver", "ANATOMY", 393, 398], ["pulmonary lesions", "ANATOMY", 537, 554], ["liver", "ANATOMY", 575, 580], ["pulmonary lesions", "DISEASE", 224, 241], ["pulmonary lesions", "DISEASE", 537, 554], ["liver", "ORGAN", 68, 73], ["patients", "ORGANISM", 131, 139], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 224, 241], ["liver", "ORGAN", 264, 269], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 359, 376], ["liver", "ORGAN", 393, 398], ["patients", "ORGANISM", 456, 464], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 537, 554], ["liver", "ORGAN", 575, 580], ["CRP", "GENE_OR_GENE_PRODUCT", 618, 621], ["CRP", "PROTEIN", 618, 621], ["Table3", "PROTEIN", 623, 629], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 456, 464], ["a panel", "TEST", 57, 64], ["liver function tests", "TEST", 68, 88], ["severity grading", "TEST", 93, 109], ["COVID", "TEST", 145, 150], ["clinical manifestations", "PROBLEM", 195, 218], ["pulmonary lesions", "PROBLEM", 224, 241], ["severity grading", "TEST", 243, 259], ["liver functional tests", "TEST", 264, 286], ["pulmonary lesions", "PROBLEM", 359, 376], ["liver function tests", "TEST", 393, 413], ["severity grading", "TEST", 418, 434], ["COVID", "TEST", 470, 475], ["the correlation tests", "TEST", 484, 505], ["pulmonary lesions", "PROBLEM", 537, 554], ["liver function tests", "TEST", 575, 595], ["severity grading", "TEST", 597, 613], ["CRP", "TEST", 618, 621], ["liver", "ANATOMY", 68, 73], ["pulmonary", "ANATOMY", 224, 233], ["lesions", "OBSERVATION", 234, 241], ["liver", "ANATOMY", 264, 269], ["pulmonary", "ANATOMY", 359, 368], ["lesions", "OBSERVATION", 369, 376], ["liver", "ANATOMY", 393, 398], ["pulmonary", "ANATOMY", 537, 546], ["lesions", "OBSERVATION", 547, 554], ["liver", "ANATOMY", 575, 580]]], ["Thirdly, the correlations of severity grading with a panel of liver function tests, CRP and pulmonary lesions were determined.", [["liver", "ANATOMY", 62, 67], ["pulmonary lesions", "ANATOMY", 92, 109], ["liver", "ORGAN", 62, 67], ["CRP", "GENE_OR_GENE_PRODUCT", 84, 87], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 92, 109], ["CRP", "PROTEIN", 84, 87], ["severity grading", "TEST", 29, 45], ["a panel", "TEST", 51, 58], ["liver function tests", "TEST", 62, 82], ["CRP", "TEST", 84, 87], ["pulmonary lesions", "PROBLEM", 92, 109], ["liver", "ANATOMY", 62, 67], ["pulmonary", "ANATOMY", 92, 101], ["lesions", "OBSERVATION", 102, 109]]], ["The results demonstrated the severity correlated with AST, albumin, CRP, semi-quantitative CT-scoring of pulmonary lesions and CT-quantified liver/spleen attenuation ratio (Table3).COVID-19 has turned into a global pandemic disease.", [["pulmonary lesions", "ANATOMY", 105, 122], ["liver", "ANATOMY", 141, 146], ["spleen", "ANATOMY", 147, 153], ["COVID-19", "CHEMICAL", 181, 189], ["AST", "SIMPLE_CHEMICAL", 54, 57], ["albumin", "GENE_OR_GENE_PRODUCT", 59, 66], ["CRP", "GENE_OR_GENE_PRODUCT", 68, 71], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 105, 122], ["liver", "ORGAN", 141, 146], ["spleen", "ORGAN", 147, 153], ["AST", "PROTEIN", 54, 57], ["albumin", "PROTEIN", 59, 66], ["CRP", "PROTEIN", 68, 71], ["COVID-19", "DNA", 181, 189], ["AST", "TEST", 54, 57], ["albumin", "TEST", 59, 66], ["CRP", "TEST", 68, 71], ["semi-quantitative CT", "TEST", 73, 93], ["pulmonary lesions", "PROBLEM", 105, 122], ["CT", "TEST", 127, 129], ["COVID", "TEST", 181, 186], ["a global pandemic disease", "PROBLEM", 206, 231], ["pulmonary", "ANATOMY", 105, 114], ["lesions", "OBSERVATION", 115, 122], ["liver", "ANATOMY", 141, 146], ["spleen", "ANATOMY", 147, 153], ["attenuation", "OBSERVATION_MODIFIER", 154, 165], ["global", "OBSERVATION_MODIFIER", 208, 214], ["pandemic disease", "OBSERVATION", 215, 231]]], ["Previous studies demonstrated coronavirus COVID-19 (SARS-CoV-2) resulted in liver injury in the whole cohort [8] [9] [10] , we described clinical profiles and abdominal radiological features of COVID-19 patients according to severity grading, and then determined the correlation of radiological features with clinical profiles.", [["liver", "ANATOMY", 76, 81], ["abdominal", "ANATOMY", 159, 168], ["liver injury", "DISEASE", 76, 88], ["coronavirus COVID-19", "ORGANISM", 30, 50], ["SARS-CoV-2", "ORGANISM", 52, 62], ["liver", "ORGAN", 76, 81], ["abdominal", "ORGANISM_SUBDIVISION", 159, 168], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["coronavirus COVID-19", "SPECIES", 30, 50], ["Previous studies", "TEST", 0, 16], ["coronavirus COVID", "TEST", 30, 47], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["liver injury", "PROBLEM", 76, 88], ["COVID", "TEST", 194, 199], ["severity grading", "TEST", 225, 241], ["coronavirus", "OBSERVATION", 30, 41], ["liver", "ANATOMY", 76, 81], ["injury", "OBSERVATION", 82, 88], ["abdominal", "ANATOMY", 159, 168]]], ["Abnormal liver function tests were observed in some of COVID-19 patients, radiological signs of liver in non-contrast CT scan included liver hypodensity and pericholecystic fat stranding.", [["liver", "ANATOMY", 9, 14], ["liver", "ANATOMY", 96, 101], ["liver", "ANATOMY", 135, 140], ["pericholecystic fat", "ANATOMY", 157, 176], ["liver hypodensity", "DISEASE", 135, 152], ["liver", "ORGAN", 9, 14], ["patients", "ORGANISM", 64, 72], ["liver", "ORGAN", 96, 101], ["liver", "ORGAN", 135, 140], ["fat", "TISSUE", 173, 176], ["patients", "SPECIES", 64, 72], ["Abnormal liver function tests", "PROBLEM", 0, 29], ["COVID", "TEST", 55, 60], ["radiological signs", "TEST", 74, 92], ["liver in non-contrast CT scan", "TEST", 96, 125], ["liver hypodensity", "PROBLEM", 135, 152], ["pericholecystic fat stranding", "PROBLEM", 157, 186], ["liver", "ANATOMY", 9, 14], ["liver", "ANATOMY", 96, 101], ["liver", "ANATOMY", 135, 140], ["hypodensity", "OBSERVATION", 141, 152], ["pericholecystic", "ANATOMY_MODIFIER", 157, 172], ["fat", "ANATOMY", 173, 176], ["stranding", "OBSERVATION", 177, 186]]], ["The correlation tests demonstrated that disease severity correlated with AST, albumin, CRP, the score of pulmonary lesions, the L/S attenuation ratio.", [["pulmonary lesions", "ANATOMY", 105, 122], ["AST", "SIMPLE_CHEMICAL", 73, 76], ["albumin", "GENE_OR_GENE_PRODUCT", 78, 85], ["CRP", "GENE_OR_GENE_PRODUCT", 87, 90], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 105, 122], ["AST", "PROTEIN", 73, 76], ["albumin", "PROTEIN", 78, 85], ["CRP", "PROTEIN", 87, 90], ["The correlation tests", "TEST", 0, 21], ["disease severity", "PROBLEM", 40, 56], ["AST", "TEST", 73, 76], ["albumin", "TEST", 78, 85], ["CRP", "TEST", 87, 90], ["pulmonary lesions", "PROBLEM", 105, 122], ["the L/S attenuation ratio", "TEST", 124, 149], ["disease", "OBSERVATION", 40, 47], ["pulmonary", "ANATOMY", 105, 114], ["lesions", "OBSERVATION", 115, 122], ["L", "ANATOMY_MODIFIER", 128, 129]]], ["Thus, it will allow an earlier identification of high-risk patients for immediate effective intervention in future.COVID-19 has turned into a global pandemic disease.", [["COVID-19", "CHEMICAL", 115, 123], ["patients", "ORGANISM", 59, 67], ["COVID-19", "DNA", 115, 123], ["patients", "SPECIES", 59, 67], ["immediate effective intervention", "TREATMENT", 72, 104], ["COVID", "TEST", 115, 120], ["a global pandemic disease", "PROBLEM", 140, 165], ["global", "OBSERVATION_MODIFIER", 142, 148], ["pandemic disease", "OBSERVATION", 149, 165]]], ["Previous studies demonstrated coronavirus COVID-19 (SARS-Gastrointestinal symptoms of patients with COVID-19 were analyzed, and common GI symptoms included diarrhea, nausea, vomiting, and inappetence.", [["GI", "ANATOMY", 135, 137], ["SARS-Gastrointestinal symptoms", "DISEASE", 52, 82], ["diarrhea", "DISEASE", 156, 164], ["nausea", "DISEASE", 166, 172], ["vomiting", "DISEASE", 174, 182], ["inappetence", "DISEASE", 188, 199], ["coronavirus", "ORGANISM", 30, 41], ["patients", "ORGANISM", 86, 94], ["GI", "ORGANISM_SUBDIVISION", 135, 137], ["coronavirus", "SPECIES", 30, 41], ["patients", "SPECIES", 86, 94], ["Previous studies", "TEST", 0, 16], ["coronavirus COVID", "TEST", 30, 47], ["SARS", "PROBLEM", 52, 56], ["Gastrointestinal symptoms", "PROBLEM", 57, 82], ["COVID", "TEST", 100, 105], ["common GI symptoms", "PROBLEM", 128, 146], ["diarrhea", "PROBLEM", 156, 164], ["nausea", "PROBLEM", 166, 172], ["vomiting", "PROBLEM", 174, 182], ["inappetence", "PROBLEM", 188, 199], ["coronavirus", "OBSERVATION", 30, 41], ["Gastrointestinal", "ANATOMY", 57, 73]]], ["The proportion of COVID-19 patients with GI symptoms in our study was similar to that of previous research [7] .", [["GI", "ANATOMY", 41, 43], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["COVID", "TEST", 18, 23], ["GI symptoms", "PROBLEM", 41, 52], ["our study", "TEST", 56, 65]]], ["GI symptoms in patients with COVID-19 may result from the infection of COVID-19 in intestinal tissues [7] .", [["intestinal tissues", "ANATOMY", 83, 101], ["GI symptoms", "DISEASE", 0, 11], ["COVID-19", "CHEMICAL", 29, 37], ["infection", "DISEASE", 58, 67], ["COVID-19", "CHEMICAL", 71, 79], ["COVID-19", "CHEMICAL", 29, 37], ["patients", "ORGANISM", 15, 23], ["COVID-19", "GENE_OR_GENE_PRODUCT", 71, 79], ["intestinal tissues", "TISSUE", 83, 101], ["patients", "SPECIES", 15, 23], ["GI symptoms", "PROBLEM", 0, 11], ["COVID", "TEST", 29, 34], ["the infection of COVID", "PROBLEM", 54, 76], ["infection", "OBSERVATION", 58, 67], ["intestinal tissues", "ANATOMY", 83, 101]]], ["In addition, the interaction between brain and gut might cause discomfort to the gastrointestinal tract.", [["brain", "ANATOMY", 37, 42], ["gut", "ANATOMY", 47, 50], ["gastrointestinal tract", "ANATOMY", 81, 103], ["discomfort to the gastrointestinal tract", "DISEASE", 63, 103], ["brain", "ORGAN", 37, 42], ["gut", "ORGANISM_SUBDIVISION", 47, 50], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 81, 103], ["discomfort to the gastrointestinal tract", "PROBLEM", 63, 103], ["brain", "ANATOMY", 37, 42], ["gastrointestinal tract", "ANATOMY", 81, 103]]], ["The results of peripheral routine blood examination showed the values of erythrocyte, leukocyte and platelet were within normal limit in most of the patients.", [["blood", "ANATOMY", 34, 39], ["erythrocyte", "ANATOMY", 73, 84], ["leukocyte", "ANATOMY", 86, 95], ["platelet", "ANATOMY", 100, 108], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["erythrocyte", "CELL", 73, 84], ["leukocyte", "CELL", 86, 95], ["platelet", "CELL", 100, 108], ["patients", "ORGANISM", 149, 157], ["leukocyte", "CELL_TYPE", 86, 95], ["platelet", "CELL_TYPE", 100, 108], ["patients", "SPECIES", 149, 157], ["peripheral routine blood examination", "TEST", 15, 51], ["erythrocyte", "TEST", 73, 84], ["leukocyte", "TEST", 86, 95], ["platelet", "TEST", 100, 108], ["peripheral", "ANATOMY_MODIFIER", 15, 25], ["leukocyte", "ANATOMY", 86, 95], ["normal limit", "OBSERVATION", 121, 133]]], ["Some of the patients had lymphocytopenia, especially CD3+ T cells.", [["CD3+ T cells", "ANATOMY", 53, 65], ["lymphocytopenia", "DISEASE", 25, 40], ["patients", "ORGANISM", 12, 20], ["CD3", "GENE_OR_GENE_PRODUCT", 53, 56], ["CD3", "PROTEIN", 53, 56], ["T cells", "CELL_TYPE", 58, 65], ["patients", "SPECIES", 12, 20], ["lymphocytopenia", "PROBLEM", 25, 40], ["CD3+ T cells", "PROBLEM", 53, 65], ["lymphocytopenia", "OBSERVATION", 25, 40]]], ["CD3+ T cells are mainly composed of CD4+ T and CD8+ T cells, CD4+ T and CD8+ T cells are critical for mediating clearance following many acute viral infections in the lung, which leads to a decrease in CD4+ T and CD8+ T cells [23, 24] .", [["CD3+ T cells", "ANATOMY", 0, 12], ["CD4+ T", "ANATOMY", 36, 42], ["CD8+ T cells", "ANATOMY", 47, 59], ["CD4+ T", "ANATOMY", 61, 67], ["CD8+ T cells", "ANATOMY", 72, 84], ["lung", "ANATOMY", 167, 171], ["CD4+ T", "ANATOMY", 202, 208], ["CD8+ T cells", "ANATOMY", 213, 225], ["infections", "DISEASE", 149, 159], ["CD3", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "GENE_OR_GENE_PRODUCT", 36, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 47, 50], ["CD4", "GENE_OR_GENE_PRODUCT", 61, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 72, 75], ["lung", "ORGAN", 167, 171], ["CD4", "GENE_OR_GENE_PRODUCT", 202, 205], ["CD8", "GENE_OR_GENE_PRODUCT", 213, 216], ["CD3", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["CD4+ T and CD8+ T cells", "CELL_TYPE", 36, 59], ["CD4+ T and CD8+ T cells", "CELL_TYPE", 61, 84], ["CD4", "PROTEIN", 202, 205], ["T and CD8+ T cells", "CELL_TYPE", 207, 225], ["CD3", "TEST", 0, 3], ["T cells", "TEST", 5, 12], ["CD4", "TEST", 36, 39], ["T", "TEST", 41, 42], ["CD8", "TEST", 47, 50], ["CD4", "TEST", 61, 64], ["T", "TEST", 66, 67], ["CD8", "TEST", 72, 75], ["T cells", "PROBLEM", 77, 84], ["mediating clearance", "PROBLEM", 102, 121], ["many acute viral infections in the lung", "PROBLEM", 132, 171], ["a decrease in CD4", "PROBLEM", 188, 205], ["T cells", "OBSERVATION", 5, 12], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["viral", "OBSERVATION_MODIFIER", 143, 148], ["infections", "OBSERVATION", 149, 159], ["lung", "ANATOMY", 167, 171], ["decrease", "OBSERVATION_MODIFIER", 190, 198]]], ["A panel of liver functional tests was determined, and the result showed that some of the patients had abnormal liver function, and clinically significant liver injury was uncommon even in critical cases.", [["liver", "ANATOMY", 11, 16], ["liver", "ANATOMY", 111, 116], ["liver", "ANATOMY", 154, 159], ["abnormal liver function", "DISEASE", 102, 125], ["liver injury", "DISEASE", 154, 166], ["liver", "ORGAN", 11, 16], ["patients", "ORGANISM", 89, 97], ["liver", "ORGAN", 111, 116], ["liver", "ORGAN", 154, 159], ["patients", "SPECIES", 89, 97], ["A panel", "TEST", 0, 7], ["liver functional tests", "TEST", 11, 33], ["abnormal liver function", "PROBLEM", 102, 125], ["clinically significant liver injury", "PROBLEM", 131, 166], ["liver", "ANATOMY", 11, 16], ["liver", "ANATOMY", 111, 116], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["liver", "ANATOMY", 154, 159], ["injury", "OBSERVATION", 160, 166]]], ["The mechanism underlying liver damage has not been explored until now.", [["liver", "ANATOMY", 25, 30], ["liver damage", "DISEASE", 25, 37], ["liver", "ORGAN", 25, 30], ["liver damage", "PROBLEM", 25, 37], ["liver", "ANATOMY", 25, 30], ["damage", "OBSERVATION", 31, 37]]], ["Liver damage in the COVID-19 patients might be caused by viral infection of liver cells, adverse drug reactions, systemic inflammation, underlying liver diseases, hypoxic hepatitis, etc. [3] [4] [5] .", [["Liver", "ANATOMY", 0, 5], ["liver cells", "ANATOMY", 76, 87], ["liver", "ANATOMY", 147, 152], ["Liver damage", "DISEASE", 0, 12], ["viral infection", "DISEASE", 57, 72], ["adverse drug reactions", "DISEASE", 89, 111], ["inflammation", "DISEASE", 122, 134], ["liver diseases", "DISEASE", 147, 161], ["hypoxic hepatitis", "DISEASE", 163, 180], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 29, 37], ["liver cells", "CELL", 76, 87], ["liver", "ORGAN", 147, 152], ["[3] [4] [5]", "SIMPLE_CHEMICAL", 187, 198], ["liver cells", "CELL_TYPE", 76, 87], ["patients", "SPECIES", 29, 37], ["Liver damage", "PROBLEM", 0, 12], ["viral infection of liver cells", "PROBLEM", 57, 87], ["adverse drug reactions", "PROBLEM", 89, 111], ["systemic inflammation", "PROBLEM", 113, 134], ["underlying liver diseases", "PROBLEM", 136, 161], ["hypoxic hepatitis", "PROBLEM", 163, 180], ["damage", "OBSERVATION", 6, 12], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72], ["liver", "ANATOMY", 76, 81], ["drug reactions", "OBSERVATION", 97, 111], ["systemic", "OBSERVATION_MODIFIER", 113, 121], ["inflammation", "OBSERVATION", 122, 134], ["liver", "ANATOMY", 147, 152], ["diseases", "OBSERVATION", 153, 161], ["hypoxic hepatitis", "OBSERVATION", 163, 180]]], ["Xu et al. reported the drugs used for COVID-19 patients probably induced liver damage, such as antibiotics, antiviral agents, etc. [5] .", [["liver", "ANATOMY", 73, 78], ["liver damage", "DISEASE", 73, 85], ["patients", "ORGANISM", 47, 55], ["liver", "ORGAN", 73, 78], ["patients", "SPECIES", 47, 55], ["the drugs", "TREATMENT", 19, 28], ["COVID", "TREATMENT", 38, 43], ["liver damage", "PROBLEM", 73, 85], ["antibiotics", "TREATMENT", 95, 106], ["antiviral agents", "TREATMENT", 108, 124], ["liver", "ANATOMY", 73, 78], ["damage", "OBSERVATION", 79, 85]]], ["Thus, to exclude drug-induced liver injury (DILI), liver functional tests were collected within 2 days after admission.", [["liver", "ANATOMY", 30, 35], ["liver", "ANATOMY", 51, 56], ["liver injury", "DISEASE", 30, 42], ["DILI", "DISEASE", 44, 48], ["liver", "ORGAN", 30, 35], ["liver", "ORGAN", 51, 56], ["drug-induced liver injury", "PROBLEM", 17, 42], ["liver functional tests", "TEST", 51, 73], ["liver", "ANATOMY", 30, 35], ["injury", "OBSERVATION", 36, 42], ["liver", "ANATOMY", 51, 56]]], ["In addition, liver dysfunction occurred in patients with chronic liver diseases, so the patients with chronic liver diseases were excluded in our study.", [["liver", "ANATOMY", 13, 18], ["liver", "ANATOMY", 65, 70], ["liver", "ANATOMY", 110, 115], ["liver dysfunction", "DISEASE", 13, 30], ["chronic liver diseases", "DISEASE", 57, 79], ["chronic liver diseases", "DISEASE", 102, 124], ["liver", "ORGAN", 13, 18], ["patients", "ORGANISM", 43, 51], ["liver", "ORGAN", 65, 70], ["patients", "ORGANISM", 88, 96], ["liver", "ORGAN", 110, 115], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 88, 96], ["liver dysfunction", "PROBLEM", 13, 30], ["chronic liver diseases", "PROBLEM", 57, 79], ["chronic liver diseases", "PROBLEM", 102, 124], ["our study", "TEST", 142, 151], ["liver", "ANATOMY", 13, 18], ["dysfunction", "OBSERVATION", 19, 30], ["chronic", "OBSERVATION_MODIFIER", 57, 64], ["liver", "ANATOMY", 65, 70], ["diseases", "OBSERVATION", 71, 79], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["liver", "ANATOMY", 110, 115], ["diseases", "OBSERVATION", 116, 124]]], ["Thus, we speculate liver injury in COVID-19 patients might result from viral infection of liver cells, inflammatory responses, and hypoxic hepatitis in our study.", [["liver", "ANATOMY", 19, 24], ["liver cells", "ANATOMY", 90, 101], ["liver injury", "DISEASE", 19, 31], ["viral infection", "DISEASE", 71, 86], ["hypoxic hepatitis", "DISEASE", 131, 148], ["liver", "ORGAN", 19, 24], ["patients", "ORGANISM", 44, 52], ["liver cells", "CELL", 90, 101], ["liver cells", "CELL_TYPE", 90, 101], ["patients", "SPECIES", 44, 52], ["liver injury", "PROBLEM", 19, 31], ["COVID", "TEST", 35, 40], ["viral infection of liver cells", "PROBLEM", 71, 101], ["inflammatory responses", "PROBLEM", 103, 125], ["hypoxic hepatitis", "PROBLEM", 131, 148], ["our study", "TEST", 152, 161], ["liver", "ANATOMY", 19, 24], ["injury", "OBSERVATION", 25, 31], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["infection", "OBSERVATION", 77, 86], ["liver", "ANATOMY", 90, 95], ["inflammatory", "OBSERVATION_MODIFIER", 103, 115], ["hypoxic", "OBSERVATION_MODIFIER", 131, 138], ["hepatitis", "OBSERVATION", 139, 148]]], ["Preliminary studies showed that angiotensin-converting enzyme 2 (ACE2) receptor expression is enriched in cholangiocytes [25] and SARS-CoV-2 enters the target cell through ACE2 receptor [25] , which results in abnormality of serum \u03b3GT, a diagnostic biomarker for cholangiocyte injury.", [["cholangiocytes", "ANATOMY", 106, 120], ["cell", "ANATOMY", 159, 163], ["serum", "ANATOMY", 225, 230], ["cholangiocyte", "ANATOMY", 263, 276], ["angiotensin", "CHEMICAL", 32, 43], ["cholangiocyte injury", "DISEASE", 263, 283], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 32, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["cholangiocytes", "CELL", 106, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 140], ["cell", "CELL", 159, 163], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 172, 185], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["\u03b3GT", "GENE_OR_GENE_PRODUCT", 231, 234], ["cholangiocyte", "CANCER", 263, 276], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 32, 79], ["ACE2 receptor", "PROTEIN", 172, 185], ["serum \u03b3GT", "PROTEIN", 225, 234], ["Preliminary studies", "TEST", 0, 19], ["angiotensin", "TEST", 32, 43], ["converting enzyme", "TEST", 44, 61], ["ACE2", "TEST", 65, 69], ["receptor expression", "TEST", 71, 90], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138], ["ACE2 receptor", "TEST", 172, 185], ["abnormality of serum \u03b3GT", "PROBLEM", 210, 234], ["a diagnostic biomarker", "TEST", 236, 258], ["cholangiocyte injury", "PROBLEM", 263, 283], ["cholangiocytes", "ANATOMY", 106, 120], ["cholangiocyte", "ANATOMY", 263, 276], ["injury", "OBSERVATION", 277, 283]]], ["Abnormal PT and hypoalbuminemia were found in some of COVID-19 patients.", [["hypoalbuminemia", "DISEASE", 16, 31], ["PT", "GENE_OR_GENE_PRODUCT", 9, 11], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Abnormal PT and hypoalbuminemia", "PROBLEM", 0, 31], ["COVID", "TEST", 54, 59], ["hypoalbuminemia", "OBSERVATION", 16, 31]]], ["Severe COVID-19 frequently induces hypercoagulability with both microangiopathy and local thrombus formation; abnormality in prothrombin time is relatively uncommon in initial presentations [26, 27] .", [["thrombus", "ANATOMY", 90, 98], ["COVID-19", "CHEMICAL", 7, 15], ["hypercoagulability", "DISEASE", 35, 53], ["microangiopathy", "DISEASE", 64, 79], ["thrombus", "DISEASE", 90, 98], ["COVID-19", "CHEMICAL", 7, 15], ["thrombus", "PATHOLOGICAL_FORMATION", 90, 98], ["prothrombin", "GENE_OR_GENE_PRODUCT", 125, 136], ["prothrombin", "PROTEIN", 125, 136], ["Severe COVID", "PROBLEM", 0, 12], ["hypercoagulability", "PROBLEM", 35, 53], ["both microangiopathy", "PROBLEM", 59, 79], ["local thrombus formation", "PROBLEM", 84, 108], ["abnormality in prothrombin time", "PROBLEM", 110, 141], ["19 frequently", "OBSERVATION_MODIFIER", 13, 26], ["hypercoagulability", "OBSERVATION", 35, 53], ["both", "OBSERVATION_MODIFIER", 59, 63], ["microangiopathy", "OBSERVATION", 64, 79], ["local", "OBSERVATION_MODIFIER", 84, 89], ["thrombus", "OBSERVATION", 90, 98], ["prothrombin time", "OBSERVATION_MODIFIER", 125, 141], ["relatively", "OBSERVATION_MODIFIER", 145, 155], ["uncommon", "OBSERVATION_MODIFIER", 156, 164]]], ["Abnormal PT might result from liver injury or coagulopathy.", [["liver", "ANATOMY", 30, 35], ["liver injury", "DISEASE", 30, 42], ["coagulopathy", "DISEASE", 46, 58], ["PT", "GENE_OR_GENE_PRODUCT", 9, 11], ["liver", "ORGAN", 30, 35], ["Abnormal PT", "PROBLEM", 0, 11], ["liver injury", "PROBLEM", 30, 42], ["coagulopathy", "PROBLEM", 46, 58], ["liver", "ANATOMY", 30, 35], ["injury", "OBSERVATION", 36, 42], ["coagulopathy", "OBSERVATION", 46, 58]]], ["Hypoalbuminemia is caused by liver dysfunction, heart failure, kidney damage, protein-losing enteropathy, and malnutrition.", [["liver", "ANATOMY", 29, 34], ["heart", "ANATOMY", 48, 53], ["kidney", "ANATOMY", 63, 69], ["Hypoalbuminemia", "DISEASE", 0, 15], ["liver dysfunction", "DISEASE", 29, 46], ["heart failure", "DISEASE", 48, 61], ["kidney damage", "DISEASE", 63, 76], ["protein-losing enteropathy", "DISEASE", 78, 104], ["malnutrition", "DISEASE", 110, 122], ["liver", "ORGAN", 29, 34], ["heart", "ORGAN", 48, 53], ["kidney", "ORGAN", 63, 69], ["Hypoalbuminemia", "PROBLEM", 0, 15], ["liver dysfunction", "PROBLEM", 29, 46], ["heart failure", "PROBLEM", 48, 61], ["kidney damage", "PROBLEM", 63, 76], ["protein-losing enteropathy", "PROBLEM", 78, 104], ["malnutrition", "PROBLEM", 110, 122], ["liver", "ANATOMY", 29, 34], ["dysfunction", "OBSERVATION", 35, 46], ["heart", "ANATOMY", 48, 53], ["failure", "OBSERVATION", 54, 61], ["kidney", "ANATOMY", 63, 69], ["damage", "OBSERVATION", 70, 76], ["losing enteropathy", "OBSERVATION", 86, 104], ["malnutrition", "OBSERVATION", 110, 122]]], ["In our study, heart failure, kidney damage, protein-losing enteropathy were not observed in our study.", [["heart", "ANATOMY", 14, 19], ["kidney", "ANATOMY", 29, 35], ["heart failure", "DISEASE", 14, 27], ["kidney damage", "DISEASE", 29, 42], ["enteropathy", "DISEASE", 59, 70], ["heart", "ORGAN", 14, 19], ["kidney", "ORGAN", 29, 35], ["our study", "TEST", 3, 12], ["heart failure", "PROBLEM", 14, 27], ["kidney damage", "PROBLEM", 29, 42], ["protein-losing enteropathy", "PROBLEM", 44, 70], ["our study", "TEST", 92, 101], ["heart", "ANATOMY", 14, 19], ["failure", "OBSERVATION", 20, 27], ["kidney", "ANATOMY", 29, 35], ["damage", "OBSERVATION", 36, 42], ["losing enteropathy", "OBSERVATION", 52, 70]]], ["Thus, hypoalbuminemia would be caused by malnutrition or liver dysfunction.", [["liver", "ANATOMY", 57, 62], ["hypoalbuminemia", "DISEASE", 6, 21], ["malnutrition", "DISEASE", 41, 53], ["liver dysfunction", "DISEASE", 57, 74], ["liver", "ORGAN", 57, 62], ["hypoalbuminemia", "PROBLEM", 6, 21], ["malnutrition", "PROBLEM", 41, 53], ["liver dysfunction", "PROBLEM", 57, 74], ["hypoalbuminemia", "OBSERVATION", 6, 21], ["malnutrition", "OBSERVATION", 41, 53], ["liver", "ANATOMY", 57, 62], ["dysfunction", "OBSERVATION", 63, 74]]], ["Interestingly, hypoalbuminemia and increased AST level were frequently found in critical cases, and correlation analysis revealed the correlations of albumin and AST level with severity grading.", [["hypoalbuminemia", "DISEASE", 15, 30], ["AST", "SIMPLE_CHEMICAL", 45, 48], ["albumin", "GENE_OR_GENE_PRODUCT", 150, 157], ["AST", "SIMPLE_CHEMICAL", 162, 165], ["AST", "PROTEIN", 45, 48], ["albumin", "PROTEIN", 150, 157], ["AST", "PROTEIN", 162, 165], ["hypoalbuminemia", "PROBLEM", 15, 30], ["increased AST level", "PROBLEM", 35, 54], ["correlation analysis", "TEST", 100, 120], ["albumin", "TEST", 150, 157], ["AST level", "TEST", 162, 171], ["severity grading", "PROBLEM", 177, 193], ["hypoalbuminemia", "OBSERVATION", 15, 30], ["increased", "OBSERVATION_MODIFIER", 35, 44]]], ["Thus, biomarkers of liver function containing AST and albumin should be detected in patients with COVID-19.", [["liver", "ANATOMY", 20, 25], ["COVID-19", "CHEMICAL", 98, 106], ["liver", "ORGAN", 20, 25], ["AST", "SIMPLE_CHEMICAL", 46, 49], ["albumin", "GENE_OR_GENE_PRODUCT", 54, 61], ["patients", "ORGANISM", 84, 92], ["AST", "PROTEIN", 46, 49], ["albumin", "PROTEIN", 54, 61], ["patients", "SPECIES", 84, 92], ["liver function", "TEST", 20, 34], ["AST", "TEST", 46, 49], ["albumin", "TEST", 54, 61], ["COVID", "TEST", 98, 103], ["liver", "ANATOMY", 20, 25]]], ["Common findings of upper abdominal CT scan in the patients with COVID-19 were mainly manifested as homogeneous or heterogeneous liver hypodensity and pericholecystic fat stranding.", [["liver", "ANATOMY", 128, 133], ["pericholecystic fat", "ANATOMY", 150, 169], ["liver hypodensity", "DISEASE", 128, 145], ["upper abdominal", "ORGANISM_SUBDIVISION", 19, 34], ["patients", "ORGANISM", 50, 58], ["liver", "ORGAN", 128, 133], ["fat", "TISSUE", 166, 169], ["patients", "SPECIES", 50, 58], ["upper abdominal CT scan", "TEST", 19, 42], ["COVID", "TEST", 64, 69], ["homogeneous or heterogeneous liver hypodensity", "PROBLEM", 99, 145], ["pericholecystic fat stranding", "PROBLEM", 150, 179], ["upper", "ANATOMY_MODIFIER", 19, 24], ["abdominal", "ANATOMY", 25, 34], ["homogeneous", "OBSERVATION_MODIFIER", 99, 110], ["heterogeneous", "OBSERVATION_MODIFIER", 114, 127], ["liver", "ANATOMY", 128, 133], ["hypodensity", "OBSERVATION", 134, 145], ["pericholecystic", "ANATOMY_MODIFIER", 150, 165], ["fat", "ANATOMY", 166, 169], ["stranding", "OBSERVATION", 170, 179]]], ["Further study revealed the L/S attenuation ratio and pulmonary lesions correlated positively with the severity of the disease.", [["pulmonary lesions", "ANATOMY", 53, 70], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 53, 70], ["Further study", "TEST", 0, 13], ["the L/S attenuation ratio", "TEST", 23, 48], ["pulmonary lesions", "PROBLEM", 53, 70], ["the disease", "PROBLEM", 114, 125], ["attenuation", "OBSERVATION_MODIFIER", 31, 42], ["ratio", "OBSERVATION_MODIFIER", 43, 48], ["pulmonary", "ANATOMY", 53, 62], ["lesions", "OBSERVATION", 63, 70], ["disease", "OBSERVATION", 118, 125]]], ["These indicated that the infection of SARS-CoV-2 may result in multiple organ dysfunction syndrome (MODS) containing liver injury.", [["organ", "ANATOMY", 72, 77], ["liver", "ANATOMY", 117, 122], ["infection", "DISEASE", 25, 34], ["SARS", "DISEASE", 38, 42], ["multiple organ dysfunction syndrome", "DISEASE", 63, 98], ["MODS", "DISEASE", 100, 104], ["liver injury", "DISEASE", 117, 129], ["SARS-CoV-2", "ORGANISM", 38, 48], ["organ", "ORGAN", 72, 77], ["liver", "ORGAN", 117, 122], ["SARS-CoV", "SPECIES", 38, 46], ["the infection of SARS", "PROBLEM", 21, 42], ["CoV", "TEST", 43, 46], ["multiple organ dysfunction syndrome", "PROBLEM", 63, 98], ["MODS", "PROBLEM", 100, 104], ["liver injury", "PROBLEM", 117, 129], ["infection", "OBSERVATION", 25, 34], ["multiple", "OBSERVATION_MODIFIER", 63, 71], ["organ", "ANATOMY", 72, 77], ["dysfunction", "OBSERVATION", 78, 89], ["MODS", "OBSERVATION", 100, 104], ["liver", "ANATOMY", 117, 122], ["injury", "OBSERVATION", 123, 129]]], ["Pathological examination of liver showed moderate steatosis and mild lobular and portal activity in a patient with COVID-19 [12] .", [["liver", "ANATOMY", 28, 33], ["lobular", "ANATOMY", 69, 76], ["portal", "ANATOMY", 81, 87], ["steatosis", "DISEASE", 50, 59], ["liver", "ORGAN", 28, 33], ["lobular", "CANCER", 69, 76], ["portal", "MULTI-TISSUE_STRUCTURE", 81, 87], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["Pathological examination of liver", "TEST", 0, 33], ["moderate steatosis", "PROBLEM", 41, 59], ["mild lobular and portal activity", "PROBLEM", 64, 96], ["COVID", "TEST", 115, 120], ["liver", "ANATOMY", 28, 33], ["moderate", "OBSERVATION_MODIFIER", 41, 49], ["steatosis", "OBSERVATION", 50, 59], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["lobular", "OBSERVATION", 69, 76], ["portal", "ANATOMY", 81, 87], ["activity", "OBSERVATION_MODIFIER", 88, 96]]], ["Liver hypodensity was a common sign of liver steatosis or acute hepatitis, while other imaging signs of acute hepatitis, such as hepatomegaly, periportal edema, edema of the gallbladder wall, and periportal lymphadenopathy were not observed in patients with COVID-19.", [["Liver", "ANATOMY", 0, 5], ["liver", "ANATOMY", 39, 44], ["periportal edema", "ANATOMY", 143, 159], ["edema", "ANATOMY", 161, 166], ["gallbladder wall", "ANATOMY", 174, 190], ["periportal lymphadenopathy", "ANATOMY", 196, 222], ["Liver hypodensity", "DISEASE", 0, 17], ["liver steatosis", "DISEASE", 39, 54], ["hepatitis", "DISEASE", 64, 73], ["hepatitis", "DISEASE", 110, 119], ["hepatomegaly", "DISEASE", 129, 141], ["periportal edema", "DISEASE", 143, 159], ["edema", "DISEASE", 161, 166], ["lymphadenopathy", "DISEASE", 207, 222], ["Liver", "ORGAN", 0, 5], ["liver", "ORGAN", 39, 44], ["periportal edema", "PATHOLOGICAL_FORMATION", 143, 159], ["edema", "PATHOLOGICAL_FORMATION", 161, 166], ["gallbladder wall", "MULTI-TISSUE_STRUCTURE", 174, 190], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 244, 252], ["Liver hypodensity", "PROBLEM", 0, 17], ["liver steatosis", "PROBLEM", 39, 54], ["acute hepatitis", "PROBLEM", 58, 73], ["other imaging signs", "TEST", 81, 100], ["acute hepatitis", "PROBLEM", 104, 119], ["hepatomegaly", "PROBLEM", 129, 141], ["periportal edema", "PROBLEM", 143, 159], ["edema of the gallbladder wall", "PROBLEM", 161, 190], ["periportal lymphadenopathy", "PROBLEM", 196, 222], ["COVID", "TEST", 258, 263], ["hypodensity", "OBSERVATION", 6, 17], ["liver", "ANATOMY", 39, 44], ["steatosis", "OBSERVATION", 45, 54], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["hepatitis", "OBSERVATION", 64, 73], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["hepatitis", "OBSERVATION", 110, 119], ["hepatomegaly", "OBSERVATION", 129, 141], ["periportal", "ANATOMY", 143, 153], ["edema", "OBSERVATION", 154, 159], ["edema", "OBSERVATION", 161, 166], ["gallbladder", "ANATOMY", 174, 185], ["wall", "ANATOMY_MODIFIER", 186, 190], ["periportal", "ANATOMY", 196, 206], ["lymphadenopathy", "OBSERVATION", 207, 222]]], ["Thus, liver hypodensity and a decrease in the L/S attenuation ratio might be attributed to liver steatosis.", [["liver", "ANATOMY", 6, 11], ["liver", "ANATOMY", 91, 96], ["liver hypodensity", "DISEASE", 6, 23], ["liver steatosis", "DISEASE", 91, 106], ["liver", "ORGAN", 6, 11], ["liver", "ORGAN", 91, 96], ["liver hypodensity", "PROBLEM", 6, 23], ["a decrease", "PROBLEM", 28, 38], ["the L/S attenuation ratio", "TEST", 42, 67], ["liver steatosis", "PROBLEM", 91, 106], ["liver", "ANATOMY", 6, 11], ["hypodensity", "OBSERVATION", 12, 23], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["L/S attenuation", "OBSERVATION_MODIFIER", 46, 61], ["might be attributed to", "UNCERTAINTY", 68, 90], ["liver", "ANATOMY", 91, 96], ["steatosis", "OBSERVATION", 97, 106]]], ["Obviously, transient elastography (FibroScan) with controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis; however, most of the patients did not receive Fibroscan due to mild liver injury and uncovered medical procedures.", [["liver", "ANATOMY", 150, 155], ["liver", "ANATOMY", 235, 240], ["liver steatosis", "DISEASE", 150, 165], ["liver injury", "DISEASE", 235, 247], ["liver", "ORGAN", 150, 155], ["patients", "ORGANISM", 188, 196], ["liver", "ORGAN", 235, 240], ["patients", "SPECIES", 188, 196], ["transient elastography", "TEST", 11, 33], ["FibroScan", "TEST", 35, 44], ["liver steatosis", "PROBLEM", 150, 165], ["Fibroscan", "TEST", 213, 222], ["mild liver injury", "PROBLEM", 230, 247], ["medical procedures", "TREATMENT", 262, 280], ["attenuation", "OBSERVATION_MODIFIER", 62, 73], ["good", "OBSERVATION_MODIFIER", 107, 111], ["liver", "ANATOMY", 150, 155], ["steatosis", "OBSERVATION", 156, 165], ["mild", "OBSERVATION_MODIFIER", 230, 234], ["liver", "ANATOMY", 235, 240], ["injury", "OBSERVATION", 241, 247]]], ["The etiologies of hepatic steatosis Table 3 The include NAFLD, alcoholism, hepatitis C infection, some drugs, autoimmune disease, malnutrition, etc. Liver steatosis resulting from NAFLD should be excluded.", [["hepatic", "ANATOMY", 18, 25], ["Liver", "ANATOMY", 149, 154], ["hepatic steatosis", "DISEASE", 18, 35], ["NAFLD", "DISEASE", 56, 61], ["alcoholism", "DISEASE", 63, 73], ["hepatitis C infection", "DISEASE", 75, 96], ["autoimmune disease", "DISEASE", 110, 128], ["malnutrition", "DISEASE", 130, 142], ["steatosis", "DISEASE", 155, 164], ["NAFLD", "DISEASE", 180, 185], ["Liver", "ORGAN", 149, 154], ["hepatic steatosis Table", "PROBLEM", 18, 41], ["NAFLD", "PROBLEM", 56, 61], ["alcoholism", "PROBLEM", 63, 73], ["hepatitis C infection", "PROBLEM", 75, 96], ["autoimmune disease", "PROBLEM", 110, 128], ["malnutrition", "PROBLEM", 130, 142], ["Liver steatosis", "PROBLEM", 149, 164], ["NAFLD", "PROBLEM", 180, 185], ["hepatic", "ANATOMY", 18, 25], ["steatosis", "OBSERVATION", 26, 35], ["NAFLD", "OBSERVATION", 56, 61], ["alcoholism", "OBSERVATION", 63, 73], ["hepatitis", "OBSERVATION", 75, 84], ["infection", "OBSERVATION", 87, 96], ["autoimmune disease", "OBSERVATION", 110, 128], ["malnutrition", "OBSERVATION", 130, 142], ["steatosis", "OBSERVATION", 155, 164], ["NAFLD", "OBSERVATION", 180, 185], ["should be excluded", "UNCERTAINTY", 186, 204]]], ["Some of clinical profiles in the COVID-19 patients were different from those of NAFLD patients.", [["NAFLD", "DISEASE", 80, 85], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 86, 94], ["the COVID", "TEST", 29, 38]]], ["Firstly, the enrolled patients had normal value for ALT and AST before hospital admission.", [["patients", "ORGANISM", 22, 30], ["ALT", "SIMPLE_CHEMICAL", 52, 55], ["AST", "SIMPLE_CHEMICAL", 60, 63], ["patients", "SPECIES", 22, 30], ["ALT", "TEST", 52, 55], ["AST", "TEST", 60, 63]]], ["Thus, liver damage was not caused by chronic liver diseases, such as NAFLD.", [["liver", "ANATOMY", 6, 11], ["liver", "ANATOMY", 45, 50], ["liver damage", "DISEASE", 6, 18], ["chronic liver diseases", "DISEASE", 37, 59], ["NAFLD", "DISEASE", 69, 74], ["liver", "ORGAN", 6, 11], ["liver", "ORGAN", 45, 50], ["liver damage", "PROBLEM", 6, 18], ["chronic liver diseases", "PROBLEM", 37, 59], ["NAFLD", "PROBLEM", 69, 74], ["liver", "ANATOMY", 6, 11], ["damage", "OBSERVATION", 12, 18], ["not caused", "UNCERTAINTY", 23, 33], ["chronic", "OBSERVATION_MODIFIER", 37, 44], ["liver", "ANATOMY", 45, 50], ["diseases", "OBSERVATION", 51, 59]]], ["Secondly, elevated levels of liver enzymes are often seen in NAFLD, hypoalbuminemia is often observed in COVD-19 patients.", [["liver", "ANATOMY", 29, 34], ["NAFLD", "DISEASE", 61, 66], ["hypoalbuminemia", "DISEASE", 68, 83], ["liver", "ORGAN", 29, 34], ["patients", "ORGANISM", 113, 121], ["liver enzymes", "PROTEIN", 29, 42], ["patients", "SPECIES", 113, 121], ["elevated levels of liver enzymes", "PROBLEM", 10, 42], ["NAFLD", "PROBLEM", 61, 66], ["hypoalbuminemia", "PROBLEM", 68, 83], ["elevated", "OBSERVATION", 10, 18], ["liver", "ANATOMY", 29, 34], ["NAFLD", "OBSERVATION", 61, 66], ["hypoalbuminemia", "OBSERVATION", 68, 83]]], ["Thirdly, liver hypodensity on CT scans was improved within a short time in some COVID-19 patients (Fig. S2) ; however, the improvement of CT sign needs a long period of time in NAFLD.", [["liver", "ANATOMY", 9, 14], ["liver hypodensity", "DISEASE", 9, 26], ["NAFLD", "DISEASE", 177, 182], ["liver", "ORGAN", 9, 14], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["liver hypodensity", "PROBLEM", 9, 26], ["CT scans", "TEST", 30, 38], ["some COVID", "TEST", 75, 85], ["CT sign", "TEST", 138, 145], ["NAFLD", "PROBLEM", 177, 182], ["liver", "ANATOMY", 9, 14], ["hypodensity", "OBSERVATION", 15, 26], ["improved", "OBSERVATION_MODIFIER", 43, 51]]], ["Fourthly, no significant differences in plasma lipid levels were observed among different groups of the COVID-19 patients divided by the severity.", [["plasma", "ANATOMY", 40, 46], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["lipid", "SIMPLE_CHEMICAL", 47, 52], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["plasma lipid levels", "TEST", 40, 59], ["the COVID", "TEST", 100, 109], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["differences", "OBSERVATION_MODIFIER", 25, 36]]], ["Thus, the hypothesis is supported by indirect evidences and it should be confirmed by a large sample of pathological examinations in future.", [["pathological examinations", "TEST", 104, 129]]], ["More importantly, the mechanism underlying liver steatosis should be explored in the patients infected with SARS-CoV-2.", [["liver", "ANATOMY", 43, 48], ["liver steatosis", "DISEASE", 43, 58], ["SARS", "DISEASE", 108, 112], ["liver", "ORGAN", 43, 48], ["patients", "ORGANISM", 85, 93], ["SARS-CoV-2", "ORGANISM", 108, 118], ["patients", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 108, 116], ["liver steatosis", "PROBLEM", 43, 58], ["liver", "ANATOMY", 43, 48], ["steatosis", "OBSERVATION", 49, 58]]], ["In addition, pericholecystic fat stranding, a common sign of abdominal CT scan, might be associated with inflammation.", [["pericholecystic fat", "ANATOMY", 13, 32], ["abdominal", "ANATOMY", 61, 70], ["fat stranding", "DISEASE", 29, 42], ["inflammation", "DISEASE", 105, 117], ["pericholecystic fat", "TISSUE", 13, 32], ["abdominal", "ORGANISM_SUBDIVISION", 61, 70], ["pericholecystic fat stranding", "PROBLEM", 13, 42], ["abdominal CT scan", "TEST", 61, 78], ["inflammation", "PROBLEM", 105, 117], ["pericholecystic", "ANATOMY_MODIFIER", 13, 28], ["fat", "ANATOMY", 29, 32], ["stranding", "OBSERVATION", 33, 42], ["abdominal", "ANATOMY", 61, 70], ["might be associated with", "UNCERTAINTY", 80, 104], ["inflammation", "OBSERVATION", 105, 117]]], ["Interestingly, enlargement of hilar lymph nodes and spleen were not found.", [["hilar lymph nodes", "ANATOMY", 30, 47], ["spleen", "ANATOMY", 52, 58], ["hilar lymph nodes", "MULTI-TISSUE_STRUCTURE", 30, 47], ["spleen", "ORGAN", 52, 58], ["enlargement of hilar lymph nodes and spleen", "PROBLEM", 15, 58], ["enlargement", "OBSERVATION_MODIFIER", 15, 26], ["hilar", "ANATOMY", 30, 35], ["lymph nodes", "OBSERVATION", 36, 47], ["spleen", "ANATOMY", 52, 58]]], ["The correlations of clinical profiles and radiological signs with severity grading were investigated, and the results showed severity grading correlated with AST, albumin, CRP, semi-quantitative scoring of pulmonary lesions, the liver-to-spleen (L/S) attenuation ratio.", [["pulmonary lesions", "ANATOMY", 206, 223], ["liver", "ANATOMY", 229, 234], ["spleen", "ANATOMY", 238, 244], ["AST", "SIMPLE_CHEMICAL", 158, 161], ["albumin", "GENE_OR_GENE_PRODUCT", 163, 170], ["CRP", "GENE_OR_GENE_PRODUCT", 172, 175], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 206, 223], ["liver", "ORGAN", 229, 234], ["spleen", "ORGAN", 238, 244], ["AST", "PROTEIN", 158, 161], ["albumin", "PROTEIN", 163, 170], ["CRP", "PROTEIN", 172, 175], ["clinical profiles", "TEST", 20, 37], ["radiological signs", "TEST", 42, 60], ["severity grading", "TEST", 66, 82], ["severity grading", "TEST", 125, 141], ["AST", "TEST", 158, 161], ["albumin", "TEST", 163, 170], ["CRP", "TEST", 172, 175], ["pulmonary lesions", "PROBLEM", 206, 223], ["attenuation ratio", "TEST", 251, 268], ["pulmonary", "ANATOMY", 206, 215], ["lesions", "OBSERVATION", 216, 223], ["liver", "ANATOMY", 229, 234], ["spleen", "ANATOMY", 238, 244]]], ["These indicated elevated AST level, hypoalbuminemia, a high CRP, a low L/S attenuation ratio, a high score of pulmonary lesions might be indicators of severe or critical cases.", [["pulmonary lesions", "ANATOMY", 110, 127], ["hypoalbuminemia", "DISEASE", 36, 51], ["pulmonary lesions", "DISEASE", 110, 127], ["AST", "SIMPLE_CHEMICAL", 25, 28], ["CRP", "GENE_OR_GENE_PRODUCT", 60, 63], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 110, 127], ["AST", "PROTEIN", 25, 28], ["CRP", "PROTEIN", 60, 63], ["elevated AST level", "PROBLEM", 16, 34], ["hypoalbuminemia", "PROBLEM", 36, 51], ["a high CRP", "PROBLEM", 53, 63], ["a low L/S attenuation ratio", "PROBLEM", 65, 92], ["a high score of pulmonary lesions", "PROBLEM", 94, 127], ["severe or critical cases", "PROBLEM", 151, 175], ["elevated", "OBSERVATION_MODIFIER", 16, 24], ["AST level", "OBSERVATION_MODIFIER", 25, 34], ["hypoalbuminemia", "OBSERVATION", 36, 51], ["high CRP", "OBSERVATION_MODIFIER", 55, 63], ["pulmonary", "ANATOMY", 110, 119], ["lesions", "OBSERVATION", 120, 127]]], ["Our study demonstrated the severity of SARS-CoV-2 infection correlated with CRP and pulmonary lesions, which was similar to previous studies.", [["pulmonary lesions", "ANATOMY", 84, 101], ["SARS", "DISEASE", 39, 43], ["infection", "DISEASE", 50, 59], ["pulmonary lesions", "DISEASE", 84, 101], ["SARS-CoV-2", "ORGANISM", 39, 49], ["CRP", "GENE_OR_GENE_PRODUCT", 76, 79], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 84, 101], ["CRP", "PROTEIN", 76, 79], ["SARS-CoV-2", "SPECIES", 39, 49], ["Our study", "TEST", 0, 9], ["SARS", "PROBLEM", 39, 43], ["CoV-2 infection", "PROBLEM", 44, 59], ["CRP", "TEST", 76, 79], ["pulmonary lesions", "PROBLEM", 84, 101], ["previous studies", "TEST", 124, 140], ["SARS", "OBSERVATION", 39, 43], ["infection", "OBSERVATION", 50, 59], ["pulmonary", "ANATOMY", 84, 93], ["lesions", "OBSERVATION", 94, 101]]], ["Interestingly, the severity correlates with AST, CT-quantified liver/spleen attenuation ratio in patients with COVID-19.", [["liver", "ANATOMY", 63, 68], ["spleen", "ANATOMY", 69, 75], ["AST", "SIMPLE_CHEMICAL", 44, 47], ["liver", "ORGAN", 63, 68], ["spleen", "ORGAN", 69, 75], ["patients", "ORGANISM", 97, 105], ["AST", "PROTEIN", 44, 47], ["patients", "SPECIES", 97, 105], ["AST", "TEST", 44, 47], ["CT", "TEST", 49, 51], ["COVID", "TEST", 111, 116], ["liver", "ANATOMY", 63, 68], ["spleen", "ANATOMY", 69, 75], ["attenuation ratio", "OBSERVATION", 76, 93]]], ["Elevated AST can be caused by liver injury, cardiovascular disease, kidney diseases, muscle disorders, etc. Elevated AST might result from multiple organ dysfunction, which is associated with the severity of SARS-CoV-2 infection.", [["liver", "ANATOMY", 30, 35], ["cardiovascular", "ANATOMY", 44, 58], ["kidney", "ANATOMY", 68, 74], ["muscle", "ANATOMY", 85, 91], ["organ", "ANATOMY", 148, 153], ["liver injury", "DISEASE", 30, 42], ["cardiovascular disease", "DISEASE", 44, 66], ["kidney diseases", "DISEASE", 68, 83], ["muscle disorders", "DISEASE", 85, 101], ["organ dysfunction", "DISEASE", 148, 165], ["SARS-CoV-2 infection", "DISEASE", 208, 228], ["AST", "SIMPLE_CHEMICAL", 9, 12], ["liver", "ORGAN", 30, 35], ["cardiovascular", "ANATOMICAL_SYSTEM", 44, 58], ["kidney", "ORGAN", 68, 74], ["muscle", "ORGAN", 85, 91], ["AST", "SIMPLE_CHEMICAL", 117, 120], ["organ", "ORGAN", 148, 153], ["SARS-CoV-2", "ORGANISM", 208, 218], ["AST", "PROTEIN", 9, 12], ["AST", "PROTEIN", 117, 120], ["SARS-CoV-2", "SPECIES", 208, 218], ["Elevated AST", "PROBLEM", 0, 12], ["liver injury", "PROBLEM", 30, 42], ["cardiovascular disease", "PROBLEM", 44, 66], ["kidney diseases", "PROBLEM", 68, 83], ["muscle disorders", "PROBLEM", 85, 101], ["Elevated AST", "PROBLEM", 108, 120], ["multiple organ dysfunction", "PROBLEM", 139, 165], ["SARS", "PROBLEM", 208, 212], ["CoV", "PROBLEM", 213, 216], ["2 infection", "PROBLEM", 217, 228], ["liver", "ANATOMY", 30, 35], ["injury", "OBSERVATION", 36, 42], ["cardiovascular disease", "OBSERVATION", 44, 66], ["kidney", "ANATOMY", 68, 74], ["diseases", "OBSERVATION", 75, 83], ["muscle", "ANATOMY", 85, 91], ["disorders", "OBSERVATION", 92, 101], ["multiple", "OBSERVATION_MODIFIER", 139, 147], ["organ", "ANATOMY", 148, 153], ["dysfunction", "OBSERVATION", 154, 165], ["SARS", "OBSERVATION", 208, 212], ["CoV", "OBSERVATION_MODIFIER", 213, 216], ["infection", "OBSERVATION", 219, 228]]], ["CT-quantified liver/spleen attenuation ratio revealed the severity of liver damage, which was related to multiple organ dysfunction syndrome.COVID-19 has turned into a global pandemic disease.", [["liver", "ANATOMY", 14, 19], ["spleen", "ANATOMY", 20, 26], ["liver", "ANATOMY", 70, 75], ["organ", "ANATOMY", 114, 119], ["liver damage", "DISEASE", 70, 82], ["organ dysfunction syndrome", "DISEASE", 114, 140], ["COVID-19", "CHEMICAL", 141, 149], ["liver", "ORGAN", 14, 19], ["spleen", "ORGAN", 20, 26], ["liver", "ORGAN", 70, 75], ["organ", "ORGAN", 114, 119], ["COVID-19", "DNA", 141, 149], ["CT-quantified liver/spleen attenuation ratio", "TEST", 0, 44], ["liver damage", "PROBLEM", 70, 82], ["multiple organ dysfunction syndrome", "PROBLEM", 105, 140], ["COVID", "TEST", 141, 146], ["a global pandemic disease", "PROBLEM", 166, 191], ["liver", "ANATOMY", 14, 19], ["spleen", "ANATOMY", 20, 26], ["severity", "OBSERVATION_MODIFIER", 58, 66], ["liver", "ANATOMY", 70, 75], ["damage", "OBSERVATION", 76, 82], ["multiple", "OBSERVATION_MODIFIER", 105, 113], ["organ", "OBSERVATION", 114, 119], ["dysfunction syndrome", "OBSERVATION", 120, 140], ["global", "OBSERVATION_MODIFIER", 168, 174], ["pandemic disease", "OBSERVATION", 175, 191]]], ["Previous studies demonstrated coronavirus COVID-19 (SARS-Obviously, our study had several limitations.", [["SARS", "DISEASE", 52, 56], ["coronavirus", "ORGANISM", 30, 41], ["Previous studies", "TEST", 0, 16], ["coronavirus COVID", "TEST", 30, 47], ["SARS", "TEST", 52, 56], ["our study", "TEST", 68, 77], ["coronavirus", "OBSERVATION", 30, 41]]], ["Firstly, it was a single-center retrospective study.", [["retrospective study", "TEST", 32, 51]]], ["Selection bias occurred in retrospective cohort studies, the patients with mild system and normal lung manifestation were excluded in our study.", [["lung", "ANATOMY", 98, 102], ["patients", "ORGANISM", 61, 69], ["lung", "ORGAN", 98, 102], ["patients", "SPECIES", 61, 69], ["Selection bias", "TEST", 0, 14], ["retrospective cohort studies", "TEST", 27, 55], ["mild system and normal lung manifestation", "PROBLEM", 75, 116], ["our study", "TEST", 134, 143], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["normal", "OBSERVATION", 91, 97], ["lung", "ANATOMY", 98, 102], ["manifestation", "OBSERVATION", 103, 116]]], ["In addition, most of the enrolled patients were middle-aged and aged people.", [["patients", "ORGANISM", 34, 42], ["people", "ORGANISM", 69, 75], ["patients", "SPECIES", 34, 42], ["people", "SPECIES", 69, 75]]], ["Secondly, the patients did not receive contrast-enhanced CT scan.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["contrast-enhanced CT scan", "TEST", 39, 64]]], ["Finally, follow-up data of the patients were not provided.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["At the end of the 2-month follow-up, 106 patients survived, nine patients died.", [["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 65, 73]]], ["We analyzed the prognosis of COVID-19 patients; unfortunately, we did not get useful data due to small sample size and relatively few deaths.", [["deaths", "DISEASE", 134, 140], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["small sample size", "PROBLEM", 97, 114], ["size", "OBSERVATION_MODIFIER", 110, 114], ["few", "OBSERVATION_MODIFIER", 130, 133], ["deaths", "OBSERVATION", 134, 140]]], ["In conclusion: COVID-19 patients display abdominal and pulmonary CT imaging abnormalities and some of the patients have abnormal liver function.", [["abdominal", "ANATOMY", 41, 50], ["pulmonary", "ANATOMY", 55, 64], ["liver", "ANATOMY", 129, 134], ["abnormal liver function", "DISEASE", 120, 143], ["patients", "ORGANISM", 24, 32], ["abdominal", "ORGAN", 41, 50], ["pulmonary", "ORGAN", 55, 64], ["patients", "ORGANISM", 106, 114], ["liver", "ORGAN", 129, 134], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 106, 114], ["COVID", "TEST", 15, 20], ["abdominal and pulmonary CT imaging abnormalities", "TEST", 41, 89], ["abnormal liver function", "PROBLEM", 120, 143], ["abdominal", "ANATOMY", 41, 50], ["pulmonary", "ANATOMY", 55, 64], ["liver", "ANATOMY", 129, 134]]], ["Furthermore, some of CT signs and CRP are positively correlated with severity grading; thus, it will allow an earlier identification of high-risk patients.", [["CRP", "GENE_OR_GENE_PRODUCT", 34, 37], ["patients", "ORGANISM", 146, 154], ["CRP", "PROTEIN", 34, 37], ["patients", "SPECIES", 146, 154], ["CT signs", "TEST", 21, 29], ["CRP", "TEST", 34, 37], ["severity grading", "TEST", 69, 85]]], ["Further studies should be performed to confirm our conclusion and develop suitable therapeutic strategies, and investigate the prognosis in future.", [["Further studies", "TEST", 0, 15]]]], "8436d7d8d421c0922475e4b665b1be36f1395de1": [["BackgroundThe 2015 Middle East respiratory syndrome (MERS) outbreak in the Republic of Korea (ROK) was initiated by the arrival of a single infected international traveler who visited the Middle East [1] .", [["Middle East respiratory syndrome", "DISEASE", 19, 51], ["MERS", "DISEASE", 53, 57], ["Middle East respiratory syndrome", "PROBLEM", 19, 51], ["Middle", "OBSERVATION_MODIFIER", 19, 25], ["respiratory syndrome", "OBSERVATION", 31, 51]]], ["The first case was confirmed on May 20, 2015 , and the outbreak resulted in 186 cases and 38 deaths before the government of the ROK and the World Health Organization (WHO) officially announced the end of the outbreak on December 23, 2015 [2] .BackgroundDuring the 2015 MERS outbreak, the ROK government conducted entry screening and active monitoring of all travelers from the Middle East region to avoid additional importations of MERS cases [2] .", [["deaths", "DISEASE", 93, 99], ["MERS", "DISEASE", 433, 437], ["entry screening", "TEST", 314, 329], ["active monitoring", "TEST", 334, 351], ["Middle", "ANATOMY_MODIFIER", 378, 384]]], ["In addition, the ROK government restricted international departures by confirmed or suspected MERS patients or their contacts to prevent the global spread of MERS [2] .", [["MERS", "DISEASE", 94, 98], ["MERS", "DISEASE", 158, 162], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107]]], ["Although WHO did not recommend any travel restrictions or entry screening for MERS coronavirus (MERS-CoV) [3] , the numbers of international travelers visiting the ROK decreased significantly during the 2015 MERS outbreak [4, 5] .BackgroundFear-induced behavioral changes during novel infectious disease outbreaks have been reported to depend on an individual's perception of risk rather than the actual risk [6] .", [["MERS coronavirus", "DISEASE", 78, 94], ["infectious disease", "DISEASE", 285, 303], ["MERS coronavirus", "ORGANISM", 78, 94], ["MERS-CoV", "ORGANISM", 96, 104], ["MERS coronavirus", "SPECIES", 78, 94], ["MERS-CoV", "SPECIES", 96, 104], ["entry screening", "TEST", 58, 73], ["MERS coronavirus", "PROBLEM", 78, 94], ["BackgroundFear", "PROBLEM", 230, 244], ["behavioral changes", "PROBLEM", 253, 271], ["novel infectious disease outbreaks", "PROBLEM", 279, 313]]], ["One factor that could affect an individual's perception of the risk of an infectious disease outbreak is the individual's previous experience of a similar infectious disease outbreak.", [["an infectious disease outbreak", "PROBLEM", 71, 101], ["a similar infectious disease outbreak", "PROBLEM", 145, 182], ["infectious", "OBSERVATION", 74, 84], ["similar", "OBSERVATION_MODIFIER", 147, 154], ["infectious", "OBSERVATION", 155, 165]]], ["Governments of countries that had a similar sizable outbreak, as well as individuals from those countries, may have responded differently to the ROK MERS outbreak than governments or individuals who had less exposure to a similar sizable outbreak.BackgroundThis evaluation estimates the changes in numbers of non-citizen short-term visitor arrivals from selected areas to the ROK during the 2015 MERS outbreak and examines the correlation between travel volume declines and previous experience of the most similar sizable outbreak, the 2003 severe acute respiratory syndrome (SARS) outbreak.", [["acute respiratory syndrome", "DISEASE", 548, 574], ["SARS", "DISEASE", 576, 580], ["a similar sizable outbreak", "PROBLEM", 220, 246], ["This evaluation", "TEST", 257, 272], ["travel volume declines", "PROBLEM", 447, 469], ["severe acute respiratory syndrome", "PROBLEM", 541, 574], ["SARS) outbreak", "PROBLEM", 576, 590], ["sizable", "OBSERVATION_MODIFIER", 44, 51], ["outbreak", "OBSERVATION", 52, 60], ["sizable", "OBSERVATION_MODIFIER", 230, 237], ["outbreak", "OBSERVATION", 238, 246], ["sizable", "OBSERVATION_MODIFIER", 514, 521], ["outbreak", "OBSERVATION", 522, 530], ["severe", "OBSERVATION_MODIFIER", 541, 547], ["acute", "OBSERVATION_MODIFIER", 548, 553], ["respiratory syndrome", "OBSERVATION", 554, 574]]], ["We also examined the correlation between decrease in travel volume and proximity to the ROK.BackgroundOrganization [7] .", [["ROK", "GENE_OR_GENE_PRODUCT", 88, 91], ["ROK", "PROTEIN", 88, 91], ["decrease", "OBSERVATION_MODIFIER", 41, 49]]], ["Note that area information in the data set is based on travelers' passports rather than the areas from which travelers departed.", [["travelers' passports", "TREATMENT", 55, 75]]], ["First, we selected areas comprising more than 0.5% of total non-citizen visitor arrivals, i.e. more than 70 000 visitors to the ROK during 2014.", [["ROK", "PROTEIN", 128, 131]]], ["Selected areas in descending order of numbers of arrivals to the ROK during 2014 are China (mainland China excluding Hong Kong Special Administrative Region (SAR), Macau, and Taiwan), Japan, United States (USA), Taiwan-China, Hong Kong SAR-China, Thailand, Philippines, Malaysia, Russia, Indonesia, Singapore, India, Canada, Vietnam, Australia, United Kingdom (UK), Germany, and France.", [["descending", "ANATOMY_MODIFIER", 18, 28]]], ["They combined to contribute 94% of the total number of arrivals to the ROK during 2014.", [["ROK", "PROTEIN", 71, 74]]], ["Monthly actual numbers of arrivals in 2015 by area from TOURGO are shown in Appendix Table 1 . where \"i\" stands for each area, while \"j\" stands for each month during the ROK MERS outbreak from June 2015 to December 2015.", [["Appendix", "ANATOMY", 76, 84]]], ["If the actual value is smaller than the projected value in a given area-month, i.e. decreasing arrivals associated with the MERS outbreak, the negative value y ij corresponds to the estimated percentage decrease in visitor arrivals.", [["the actual value", "TEST", 3, 19], ["the MERS outbreak", "PROBLEM", 120, 137], ["smaller", "OBSERVATION_MODIFIER", 23, 30], ["percentage", "OBSERVATION_MODIFIER", 192, 202], ["decrease", "OBSERVATION_MODIFIER", 203, 211]]], ["The number of travelers for each area in each month were treated as a single observation.", [["travelers", "TREATMENT", 14, 23]]], ["The first variable was whether an area had a sizable outbreak of limited duration of a novel viral respiratory disease before the 2015 MERS outbreak.", [["respiratory", "ANATOMY", 99, 110], ["viral respiratory disease", "DISEASE", 93, 118], ["a novel viral respiratory disease", "PROBLEM", 85, 118], ["sizable", "OBSERVATION_MODIFIER", 45, 52], ["outbreak", "OBSERVATION_MODIFIER", 53, 61], ["viral", "OBSERVATION_MODIFIER", 93, 98], ["respiratory disease", "OBSERVATION", 99, 118]]], ["The 2003 SARS outbreak was chosen because it was sizable including local transmission and its duration was limited [8] .", [["SARS", "DISEASE", 9, 13]]], ["During the 2003 SARS outbreak, more than 8000 individuals were infected worldwide with a 9.6% average case fatality rate [9] .", [["SARS", "DISEASE", 16, 20], ["individuals", "ORGANISM", 46, 57]]], ["In addition, SARS and MERS are both viral respiratory infections caused by coronaviruses, although the case fatality rates reported for SARS were lower than for MERS [10] .", [["SARS", "DISEASE", 13, 17], ["viral respiratory infections", "DISEASE", 36, 64], ["SARS", "DISEASE", 136, 140], ["SARS", "PROBLEM", 13, 17], ["both viral respiratory infections", "PROBLEM", 31, 64], ["coronaviruses", "PROBLEM", 75, 88], ["SARS", "PROBLEM", 136, 140], ["SARS", "OBSERVATION", 13, 17], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["respiratory infections", "OBSERVATION", 42, 64]]], ["Community transmission of SARS was more commonly reported, while MERS transmission in the ROK occurred primarily in healthcare settings or through close contact, e.g. caring for or living with an infected person [10, 11] .", [["SARS", "DISEASE", 26, 30], ["person", "SPECIES", 205, 211], ["SARS", "PROBLEM", 26, 30]]], ["The 2009 H1N1 influenza pandemic was also caused by viral respiratory infection; however, country-specific H1N1 attack rates were orders of magnitude higher and its case fatality rate was much lower compared to the limited-duration outbreaks of SARS and MERS [10, 12, 13] .BackgroundUsing WHO data for reported numbers of probable SARS cases by area during the 2003 outbreak [9] , we hypothesized that individuals from areas with \u2265100 SARS cases during the 2003 outbreak may have been significantly more or less likely to visit the ROK during the 2015 MERS outbreak.", [["influenza pandemic", "DISEASE", 14, 32], ["viral respiratory infection", "DISEASE", 52, 79], ["SARS", "DISEASE", 245, 249], ["MERS", "DISEASE", 254, 258], ["SARS", "DISEASE", 331, 335], ["SARS", "DISEASE", 435, 439], ["H1N1", "ORGANISM", 107, 111], ["H1N1 influenza pandemic", "SPECIES", 9, 32], ["H1N1 influenza pandemic", "PROBLEM", 9, 32], ["viral respiratory infection", "PROBLEM", 52, 79], ["its case fatality rate", "TEST", 161, 183], ["SARS", "PROBLEM", 245, 249], ["SARS cases", "PROBLEM", 331, 341], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["respiratory infection", "OBSERVATION", 58, 79]]], ["China, Taiwan-China, Singapore, Canada, and Hong Kong SAR-China each had \u2265100 SARS cases during the 2003 outbreak, and all of those areas were included in the current analyses.", [["SARS", "DISEASE", 78, 82]]], ["Although the threshold was set at 100 probable SARS cases, each of the five areas experienced at least 238 probable SARS cases, while the country/area with next highest number of probable SARS cases, Vietnam, had 64 cases (Appendix Figure 3 ) [9] .", [["SARS", "DISEASE", 47, 51], ["SARS", "DISEASE", 116, 120], ["SARS", "DISEASE", 188, 192], ["SARS cases", "PROBLEM", 47, 57], ["SARS cases", "PROBLEM", 116, 126]]], ["Thus, our results would be consistent with any threshold set between 65 cases and 237 WHO-reported probable cases.BackgroundThe second variable we considered was travel distance to the ROK from each area.", [["ROK", "PROTEIN", 185, 188]]], ["Since travel time cost is likely to be correlated to travel distance between two areas, the opportunity cost to change travel plans from a more distant place to the ROK would be expected to be higher.", [["ROK", "PROTEIN", 165, 168]]], ["Thus, individuals from more distant areas might be less likely to cancel trips to the ROK during the outbreak period.", [["ROK", "PROTEIN", 86, 89]]], ["More details about how we defined distance categories for analyses are shown in Appendix Tables 2 and 3 For both variables, we performed Welch's t-tests for two samples with unequal variances [14] to examine whether the monthly average percentage decreases in numbers of arrivals from each category differed significantly.", [["analyses", "TEST", 58, 66], ["Welch's t-tests", "TEST", 137, 152], ["two samples", "TEST", 157, 168], ["Appendix", "ANATOMY", 80, 88], ["decreases", "OBSERVATION_MODIFIER", 247, 256]]], ["For the SARS variable, the null hypothesis is that the simple average percentage change of arrivals from areas with < 100 SARS cases (reference) was the same as the percentage change of arrivals for areas with \u2265100 SARS cases.", [["SARS", "DISEASE", 122, 126], ["SARS", "DISEASE", 215, 219], ["the SARS", "PROBLEM", 4, 12], ["the null hypothesis", "PROBLEM", 23, 42], ["simple", "OBSERVATION_MODIFIER", 55, 61], ["average", "OBSERVATION_MODIFIER", 62, 69], ["percentage", "OBSERVATION_MODIFIER", 70, 80], ["change", "OBSERVATION_MODIFIER", 81, 87]]], ["The alternative hypothesis is that the percentage decreases for arrivals from areas with \u2265100 SARS cases were larger than for areas with < 100 SARS cases.", [["SARS", "DISEASE", 94, 98], ["SARS", "DISEASE", 143, 147], ["percentage", "OBSERVATION_MODIFIER", 39, 49], ["decreases", "OBSERVATION_MODIFIER", 50, 59], ["larger", "OBSERVATION_MODIFIER", 110, 116]]], ["For the distance categories, the null hypothesis is that the simple average percentage change of arrivals from the far category (reference) was the same as the percentage change of arrivals from the intermediate or the close category.", [["simple", "OBSERVATION_MODIFIER", 61, 67], ["average", "OBSERVATION_MODIFIER", 68, 75], ["percentage", "OBSERVATION_MODIFIER", 76, 86]]], ["The alternative hypothesis is that the percentage decreases for arrivals from areas in the far category were smaller than for arrivals from the areas in the intermediate or the close categories.", [["percentage", "OBSERVATION_MODIFIER", 39, 49], ["decreases", "OBSERVATION_MODIFIER", 50, 59], ["smaller", "OBSERVATION_MODIFIER", 109, 116]]], ["When p-values from Welch's t-tests are < 0.05, we reject the null hypotheses in favor of the alternative hypotheses.BackgroundWe used ordinary least squares (OLS) regression models to examine the impact of each factor on percentage changes in numbers of visitor arrivals for each month during the ROK MERS outbreak (June-December 2015).", [["p-values", "TEST", 5, 13], ["Welch's t-tests", "TEST", 19, 34], ["the null hypotheses", "PROBLEM", 57, 76]]], ["The following equation was used in an OLS regression model.Backgroundis a dependent variable that shows percentage changes in numbers of arrivals by area-month.", [["percentage changes", "PROBLEM", 104, 122], ["dependent", "OBSERVATION", 74, 83], ["percentage", "OBSERVATION_MODIFIER", 104, 114]]], ["\"SARS i \" is a dummy variable, which is one an area \"i\" reported \u2265100 SARS cases during the 2003 outbreak, otherwise zero.", [["SARS", "DISEASE", 1, 5], ["SARS", "DISEASE", 70, 74], ["a dummy variable", "PROBLEM", 13, 29]]], ["In summary, the OLS model included two independent variables: 1) a binary variable to identify areas with \u2265100 SARS cases during the 2003 outbreak (reference category: < 100 SARS cases during the 2003 outbreak), and 2) a categorical variable summarizing the distance between an area and the ROK that was transformed into two binary variables (reference category: \"far\").", [["SARS", "DISEASE", 111, 115], ["SARS", "DISEASE", 174, 178], ["ROK", "PROTEIN", 291, 294]]], ["We conducted sensitivity analyses using alternative projected values.", [["sensitivity analyses", "TEST", 13, 33]]], ["The baseline model used the average numbers of arrivals in 2013 and 2014 by area to project the expected numbers of arrivals to the ROK in the absence of the outbreak.", [["ROK", "PROTEIN", 132, 135]]], ["The baseline model, however, may not account for year-to-year increasing or decreasing trends in the numbers of arrivals to the ROK.", [["ROK", "PROTEIN", 128, 131], ["decreasing", "OBSERVATION_MODIFIER", 76, 86]]], ["That omission could result in underestimated or overestimated projected values in the absence of the MERS outbreak, causing biased estimates from regression models.", [["the MERS outbreak", "PROBLEM", 97, 114]]], ["Alternative 2 used the same method that was used to compare projected and actual numbers of arrivals in Mexico during the 2009 H1N1 pandemic [15] .BackgroundTo avoid bias, we conducted additional sensitivity analyses by excluding outliers.", [["H1N1", "DISEASE", 127, 131], ["additional sensitivity analyses", "TEST", 185, 216]]], ["We excluded the observation for India in August 2015, when an exceptional increase in the number of crewmembers arriving at seaports [16] resulted in an increase of 106.4% relative to the average of arrivals for India in August 2013 and 2014.ResultsDecreases in numbers of arrivals to the ROK were observed during June and July 2015 across all examined areas compared to the average numbers of arrivals in 2013 and 2014 (Table 1 ).", [["ROK", "PROTEIN", 289, 292], ["exceptional", "OBSERVATION_MODIFIER", 62, 73], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["increase", "OBSERVATION_MODIFIER", 153, 161], ["Decreases", "OBSERVATION_MODIFIER", 249, 258]]], ["In June, the number of arrivals decreased by 7.5% from the least affected area and 74.2% from the most affected area.", [["number", "OBSERVATION_MODIFIER", 13, 19], ["decreased", "OBSERVATION_MODIFIER", 32, 41]]], ["The simple average decrease across 17 areas was 31.4%.", [["simple", "OBSERVATION_MODIFIER", 4, 10], ["average", "OBSERVATION_MODIFIER", 11, 18], ["decrease", "OBSERVATION_MODIFIER", 19, 27]]], ["In July, the simple average decrease in numbers of arrivals was 39.3% (range 4.8%-82.0% across areas).", [["range", "TEST", 71, 76], ["simple", "OBSERVATION_MODIFIER", 13, 19], ["average", "OBSERVATION_MODIFIER", 20, 27], ["decrease", "OBSERVATION_MODIFIER", 28, 36]]], ["Although travel volumes declined across all areas during June and July, actual traveler volumes for some areas exceeded projected values starting in August and continuing through December 2015 (Appendix Figures 1 and 2) .", [["travel volumes", "TEST", 9, 23], ["actual traveler volumes", "TREATMENT", 72, 95], ["some areas", "PROBLEM", 100, 110], ["Appendix Figures", "TEST", 194, 210]]], ["Table 2 shows that the percentage decrease in numbers of arrivals from areas with \u2265100 SARS cases during the 2003 SARS outbreak was significantly greater than the decrease from areas with < 100 SARS cases in June (52.4% vs. 23.3%), July (60.0% vs. 31.4%), and August 2015 (28.5% vs. 3.8%).", [["SARS", "DISEASE", 87, 91], ["SARS", "DISEASE", 114, 118], ["SARS", "DISEASE", 194, 198], ["SARS outbreak", "PROBLEM", 114, 127], ["percentage", "OBSERVATION_MODIFIER", 23, 33], ["decrease", "OBSERVATION_MODIFIER", 34, 42], ["numbers", "OBSERVATION_MODIFIER", 46, 53], ["decrease", "OBSERVATION_MODIFIER", 163, 171]]], ["In comparison, during the pre-outbreak January to May period, the simple averages from both groups showed higher numbers of arrivals than the averages for 2013 and 2014 ( Fig. 1 ).", [["higher", "OBSERVATION_MODIFIER", 106, 112], ["numbers", "OBSERVATION_MODIFIER", 113, 120]]], ["The numbers of arrivals from areas with a previous SARS outbreak with \u2265100 cases were 21.7%-38.5% higher in January-May 2015 than in January-May averages for 2013 and 2014, while the simple averages from areas with < 100 SARS cases were only 1.7%-15.4% higher in January-May 2015 ( Table 2) .ResultsThe percentage changes in arrivals from areas in the close category decreased more than the percentage changes in arrivals in the far category in June (56.1% vs. 19.5%), July (69.9% vs. 17.1%), and August Table 1 Percentage changes between 2015 actual and projected (average of 2013 and 2014) monthly non-citizen arrivals to the Republic of Korea (ROK) by area (%). .", [["SARS", "DISEASE", 51, 55], ["SARS", "DISEASE", 221, 225], ["a previous SARS outbreak", "PROBLEM", 40, 64], ["SARS cases", "TEST", 221, 231], ["The percentage changes", "PROBLEM", 299, 321], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["percentage", "OBSERVATION_MODIFIER", 303, 313], ["areas", "OBSERVATION_MODIFIER", 339, 344], ["decreased", "OBSERVATION_MODIFIER", 367, 376]]], ["In addition, the percentage changes in arrivals in the intermediate category decreased more than the percentage changes in arrivals in the far category in July (44.0% vs. 17.1%).", [["the percentage changes", "PROBLEM", 13, 35], ["percentage", "OBSERVATION_MODIFIER", 17, 27], ["intermediate", "OBSERVATION_MODIFIER", 55, 67], ["category", "OBSERVATION_MODIFIER", 68, 76], ["decreased", "OBSERVATION_MODIFIER", 77, 86], ["percentage", "OBSERVATION_MODIFIER", 101, 111]]], ["The results from baseline OLS regression models also identified statistically significant correlations between the percentage decrease of numbers of arrivals and previous SARS outbreak of \u2265100 cases (Table 4) .", [["SARS", "DISEASE", 171, 175], ["baseline OLS regression models", "PROBLEM", 17, 47], ["percentage", "OBSERVATION_MODIFIER", 115, 125], ["decrease", "OBSERVATION_MODIFIER", 126, 134]]], ["Areas with a previous SARS outbreak of \u2265100 cases showed significant correlations in June (p-value = 0.032).", [["SARS", "DISEASE", 22, 26], ["a previous SARS outbreak", "TEST", 11, 35], ["p-value", "TEST", 91, 98]]], ["Also, the correlation between the percentage decrease of numbers of arrivals and distance from the ROK was statistically significant.", [["ROK", "PROTEIN", 99, 102], ["percentage", "OBSERVATION_MODIFIER", 34, 44], ["decrease", "OBSERVATION_MODIFIER", 45, 53], ["numbers", "OBSERVATION_MODIFIER", 57, 64], ["significant", "OBSERVATION_MODIFIER", 121, 132]]], ["The significant percentage decreases in numbers of visitor arrivals occurred in areas in the close category in June (p-value = 0.012) and July (p-value\u2264 0.001), and in the intermediate category in July (p-value\u2264 0.001) .ResultsResults from sensitivity analyses were consistent with the baseline analysis.", [["The significant percentage decreases", "PROBLEM", 0, 36], ["sensitivity analyses", "TEST", 240, 260], ["the baseline analysis", "TEST", 282, 303], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["percentage", "OBSERVATION_MODIFIER", 16, 26], ["decreases", "OBSERVATION_MODIFIER", 27, 36], ["numbers", "OBSERVATION_MODIFIER", 40, 47], ["consistent with", "UNCERTAINTY", 266, 281]]], ["For Baseline and Alternatives 1, the percentage changes of arrivals from areas with a previous SARS outbreak of \u2265100 cases showed greater decreases than the percentage changes in arrivals from their counterparts in June, July, and August 2015 (Appendix Table 4 ).", [["SARS", "DISEASE", 95, 99], ["a previous SARS outbreak", "TEST", 84, 108], ["greater", "OBSERVATION_MODIFIER", 130, 137], ["decreases", "OBSERVATION_MODIFIER", 138, 147], ["percentage", "OBSERVATION_MODIFIER", 157, 167]]], ["For Alternative 2, the differences between areas with and without a SARS outbreak of \u2265100 cases were significant in every month from June through December 2015, except for September.ResultsFor both Alternatives, declines in numbers of arrivals from areas in the close category were larger than for areas in the far category from June to August 2015 (Appendix Table 5 ).", [["SARS", "DISEASE", 68, 72], ["a SARS outbreak", "PROBLEM", 66, 81], ["larger", "OBSERVATION_MODIFIER", 282, 288]]], ["For Alternative 1, the declines in arrivals in the intermediate category were significantly larger than the declines in arrivals from the far category from April through December 2015, except for August.", [["larger", "OBSERVATION_MODIFIER", 92, 98]]], ["However, if we instead used Alternative 2, the decline in numbers of arrivals from the intermediate distance category was statistically significantly greater than the far category only in April, June, and July 2015.ResultsThe results from sensitivity analyses of regression models were also consistent with the results from baseline models.", [["sensitivity analyses", "TEST", 239, 259], ["regression models", "TEST", 263, 280]]], ["Using all three projected values, the percentage decrease of arrivals in June and July showed some significant correlations with proximity and previous SARS outbreaks of \u2265100 cases (Appendix Table 6 ).", [["SARS", "DISEASE", 152, 156], ["previous SARS outbreaks", "PROBLEM", 143, 166]]], ["When excluding outliers, the observation for India in August 2015, the difference in the percentage changes in arrivals between the intermediate and far categories was significant; however, when the India, August 2015 observation was included in the analysis (i.e. not excluded), the difference between the intermediate and far categories was no longer significant (Appendix Table 7 ).DiscussionResults from the baseline and sensitivity analyses found that the 2015 MERS outbreak in the ROK appeared to have a greater effect on travel volumes from areas with \u2265100 SARS cases in 2003, especially in June and July 2015.", [["SARS", "DISEASE", 564, 568], ["the percentage changes", "PROBLEM", 85, 107], ["the analysis", "TEST", 246, 258], ["sensitivity analyses", "TEST", 425, 445], ["no longer", "UNCERTAINTY", 343, 352], ["greater", "OBSERVATION_MODIFIER", 510, 517], ["effect", "OBSERVATION_MODIFIER", 518, 524]]], ["Most of the ROK MERS cases were confirmed during those 2 months, and the ROK government declared a de facto end to the outbreak on July 28, 2015 by which time no individuals were quarantined because of MERS, nor were there any newly confirmed cases [2] .", [["ROK", "GENE_OR_GENE_PRODUCT", 12, 15]]], ["The decrease of arrivals during the 2015 MERS outbreak is underscored when we compare the trends of numbers of arrivals before and during the 2015 MERS outbreak.", [["decrease", "OBSERVATION_MODIFIER", 4, 12]]], ["Positive values in Tables 1-3 (i.e. increases in arrivals) before the 2015 MERS outbreak reflect the general trend that the number of arrivals to the ROK would be increasing without the outbreak.DiscussionVisitors from areas with a previous SARS outbreak of \u2265100 cases may have been more likely to change their travel plans because of similarities between SARS and MERS, which are both caused by coronaviruses and capable of causing serious respiratory impairment.", [["respiratory", "ANATOMY", 441, 452], ["SARS", "DISEASE", 241, 245], ["SARS", "DISEASE", 356, 360], ["MERS", "DISEASE", 365, 369], ["respiratory impairment", "DISEASE", 441, 463], ["ROK", "PROTEIN", 150, 153], ["SARS", "PROBLEM", 356, 360], ["MERS", "PROBLEM", 365, 369], ["coronaviruses", "PROBLEM", 396, 409], ["serious respiratory impairment", "PROBLEM", 433, 463], ["values", "OBSERVATION_MODIFIER", 9, 15], ["serious", "OBSERVATION_MODIFIER", 433, 440], ["respiratory impairment", "OBSERVATION", 441, 463]]], ["In addition, the governments in areas that experienced previous SARS outbreaks may have had stronger restrictions or recommendations about travel to the ROK during the MERS outbreak period.", [["SARS", "DISEASE", 64, 68], ["previous SARS outbreaks", "PROBLEM", 55, 78]]], ["Although WHO did not recommend any travel restrictions to the ROK during the 2015 MERS outbreak [17] , WHO noted that raising awareness about Table 4 Monthly marginal percentage change between actual (2015) and baseline projected (average of 2013 and 2014) non-citizen arrivals to the Republic of Korea (ROK) associated with areas that experienced \u2265100 probable severe acute respiratory syndrome (SARS) cases and distance to the Republic of Korea.", [["acute respiratory syndrome", "DISEASE", 369, 395], ["SARS", "DISEASE", 397, 401], ["severe acute respiratory syndrome", "PROBLEM", 362, 395], ["probable", "UNCERTAINTY", 353, 361], ["severe", "OBSERVATION_MODIFIER", 362, 368], ["acute", "OBSERVATION_MODIFIER", 369, 374], ["respiratory syndrome", "OBSERVATION", 375, 395]]], ["The results were from baseline ordinary least squares (OLS) regression models using percentage changes between 2015 actual and the average of 2013 and 2014 monthly arrivals as dependent variables.", [["percentage changes", "PROBLEM", 84, 102]]], ["The reference category for the 2003 SARS outbreak areas with < 100 probable SARS cases, and the reference for distance is the far category.DiscussionMERS among those traveling to affected areas was good public health practice [18] .", [["SARS", "DISEASE", 36, 40], ["SARS", "DISEASE", 76, 80], ["SARS cases", "PROBLEM", 76, 86]]], ["Some areas issued travel notices to inform travelers about the potential risks and risk mitigation strategies.", [["risk mitigation strategies", "TREATMENT", 83, 109]]], ["For instance, Hong Kong SAR, which showed the biggest percentage difference between projected and actual arrivals to the ROK, had experienced a sizable SARS outbreak in 2003 with 1755 cases [9] .", [["SARS", "DISEASE", 152, 156], ["Hong Kong SAR", "TEST", 14, 27], ["a sizable SARS outbreak", "PROBLEM", 142, 165], ["sizable", "OBSERVATION_MODIFIER", 144, 151], ["SARS", "OBSERVATION", 152, 156]]], ["Since only about 2% of travelers from Hong Kong SAR to the ROK arrive via cruise [7] , most tourists from Hong Kong SAR were affected by the cancellation.", [["travelers", "ORGANISM", 23, 32]]], ["In addition, some local governments in mainland China (Sichuan and Shandong provinces, and Guangzhou, the capital of Guangdong province) issued travel notices to the ROK because of the 2015 MERS outbreak [23] .", [["some", "OBSERVATION_MODIFIER", 13, 17], ["local", "OBSERVATION_MODIFIER", 18, 23], ["governments", "OBSERVATION", 24, 35]]], ["Also, some flights between China and Jeju international airport in the ROK were cancelled [24] .DiscussionTaiwan also experienced a sizable SARS outbreak in 2003, and the Taiwan Centers for Disease Control (CDC) issued a level 2 travel notice (Alert) for Seoul and a level 1 travel notice (Watch) for all other areas in the ROK on June 2, 2015 [25] .", [["SARS", "DISEASE", 140, 144], ["Jeju", "ANATOMY", 37, 41], ["sizable", "OBSERVATION_MODIFIER", 132, 139], ["SARS", "OBSERVATION", 140, 144]]], ["The level 2 travel notice was extended to the entire ROK on June 9, 2015 [26] .", [["ROK", "DNA", 53, 56]]], ["The Taiwan Ministry of Foreign Affairs also issued a travel alert for MERS to the ROK [29] .DiscussionThe experience with SARS outbreaks in 2003 is only one potential reason that governments with previous SARS outbreak experiences may have issued stronger restrictions or recommendations about travel to the ROK during the MERS outbreak than governments without previous SARS outbreak experiences.", [["SARS", "DISEASE", 122, 126], ["SARS", "DISEASE", 205, 209], ["SARS", "DISEASE", 371, 375], ["Foreign Affairs", "OBSERVATION", 23, 38]]], ["For example, a Korean traveler who was experiencing symptoms consistent with MERS pushed ahead with his plan to travel to Guangdong, China with a layover in Hong Kong SAR [17] .", [["symptoms", "PROBLEM", 52, 60]]], ["When this traveler was diagnosed with MERS after arrival in China, a public health response was required in China [2] .", [["traveler", "ORGANISM", 10, 18]]], ["Although there was no further MERS transmission in China or Hong Kong SAR, public awareness of this imported case may have exacerbated fear among individuals in Hong Kong SAR and Guangdong as well as their local governments.", [["no", "UNCERTAINTY", 19, 21]]], ["In Taiwan, a patient with suspected MERS was reported on May 30, 2015, although this patient was later confirmed to have influenza B virus infection [30] .", [["MERS", "DISEASE", 36, 40], ["influenza B virus infection", "DISEASE", 121, 148], ["patient", "ORGANISM", 13, 20], ["patient", "ORGANISM", 85, 92], ["influenza B virus", "ORGANISM", 121, 138], ["patient", "SPECIES", 13, 20], ["patient", "SPECIES", 85, 92], ["influenza B virus", "SPECIES", 121, 138], ["influenza B virus", "SPECIES", 121, 138], ["influenza B virus infection", "PROBLEM", 121, 148]]], ["The 17th suspected case was in a person who was neither a ROK citizen nor had visited the ROK [30] .", [["person", "SPECIES", 33, 39]]], ["However, the patient could have increased public awareness of MERS in Taiwan.", [["MERS", "DISEASE", 62, 66], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["increased", "OBSERVATION_MODIFIER", 32, 41]]], ["Although countries issued varied levels of travel notices, no countries enforced travel bans or strict quarantine requirements for travelers from the ROK as some did for travelers from countries with Ebola during the West African epidemic [31] .DiscussionSince the 2015 MERS outbreak ended, the ROK government has continuously made efforts to prevent future MERS outbreaks in the ROK.", [["Ebola", "DISEASE", 200, 205], ["Ebola", "ORGANISM", 200, 205], ["ROK", "PROTEIN", 380, 383]]], ["The Korea Centers for Disease Control & Prevention updated its national prevention and control guidelines for MERS in April 2016 [32] .", [["Disease Control", "TREATMENT", 22, 37]]], ["These guidelines include response plans at airports, hospitals, and local health departments to expedite the identification of individuals suspected of MERS-CoV infection after arriving from MERS-affected areas [32] .", [["MERS-CoV infection", "DISEASE", 152, 170], ["individuals", "ORGANISM", 127, 138], ["MERS-CoV", "ORGANISM", 152, 160], ["MERS-CoV", "SPECIES", 152, 160], ["MERS", "PROBLEM", 152, 156], ["CoV infection", "PROBLEM", 157, 170], ["infection", "OBSERVATION", 161, 170]]], ["Following the guidelines, virological testing for MERS-CoV and other respiratory viruses has been implemented to confirm whether individuals with recent travel to MERS-affected areas and symptoms consistent with MERS are infected with MERS-CoV or not [32, 33] .", [["respiratory viruses", "DISEASE", 69, 88], ["MERS-CoV", "ORGANISM", 50, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 235, 243], ["MERS-CoV", "SPECIES", 50, 58], ["MERS-CoV", "SPECIES", 235, 243], ["the guidelines", "TEST", 10, 24], ["virological testing", "TEST", 26, 45], ["MERS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 55, 58], ["other respiratory viruses", "PROBLEM", 63, 88], ["affected areas", "PROBLEM", 168, 182], ["symptoms", "PROBLEM", 187, 195], ["MERS", "PROBLEM", 212, 216], ["consistent with", "UNCERTAINTY", 196, 211]]], ["Also, the ROK's amended quarantine act specifies MERS as a quarantinable infectious disease [34] .", [["infectious disease", "DISEASE", 73, 91], ["ROK", "PROTEIN", 10, 13]]], ["These efforts may decrease the risk of future MERS outbreaks in the ROK.", [["ROK", "PROTEIN", 68, 71]]], ["This analysis has some limitations.", [["This analysis", "TEST", 0, 13]]], ["For instance, a Japanese national may live in the United States before visiting the ROK but would be counted as if traveling from Japan (close category) for our analysis.", [["our analysis", "TEST", 157, 169]]], ["Such discrepancies between citizenship and residency might cause some bias in examining the effect of distance on travel volumes to the ROK during the MERS outbreak.DiscussionNext, we were limited in our ability to assess the mechanism by which a previous sizable outbreak experience would affect travel to the ROK.", [["ROK", "PROTEIN", 136, 139], ["ROK", "PROTEIN", 311, 314], ["some bias", "PROBLEM", 65, 74]]], ["In addition, stronger travel notices in some countries may have correlated with greater decreases in travel volumes during the MERS outbreak in the ROK.", [["ROK", "PROTEIN", 148, 151], ["greater", "OBSERVATION_MODIFIER", 80, 87], ["decreases", "OBSERVATION_MODIFIER", 88, 97]]], ["Also, there could be other country-or area-specific factors, which could affect travel volumes during a disease outbreak, but were not considered in the current analyses.DiscussionLast, we chose only one previous outbreak, the 2003 SARS outbreak as an indicator for previous outbreak experiences.", [["SARS", "DISEASE", 232, 236], ["area-specific factors", "PROBLEM", 38, 59], ["a disease outbreak", "PROBLEM", 102, 120]]], ["While SARS was also caused by a novel coronavirus resulting in respiratory disease similar to MERS, exposure to other sizable outbreaks, such as the 2009 H1N1 pandemic or the 2013-2015 Ebola epidemic, may also have affected governments' and individuals' perceptions of risk from the 2015 MERS outbreak.", [["respiratory", "ANATOMY", 63, 74], ["SARS", "DISEASE", 6, 10], ["coronavirus", "DISEASE", 38, 49], ["respiratory disease", "DISEASE", 63, 82], ["MERS", "DISEASE", 94, 98], ["H1N1 pandemic", "DISEASE", 154, 167], ["Ebola", "DISEASE", 185, 190], ["coronavirus", "ORGANISM", 38, 49], ["SARS", "PROBLEM", 6, 10], ["a novel coronavirus", "PROBLEM", 30, 49], ["respiratory disease", "PROBLEM", 63, 82], ["other sizable outbreaks", "PROBLEM", 112, 135], ["respiratory disease", "OBSERVATION", 63, 82], ["sizable", "OBSERVATION_MODIFIER", 118, 125], ["outbreaks", "OBSERVATION", 126, 135]]], ["Although there was a large difference between the top five areas with at least 238 probable SARS cases for each and the next highest country with 63 probable SARS cases during the 2013 outbreak (Appendix Figure 3) , a single threshold of \u2265100 SARS cases were used.", [["SARS", "DISEASE", 92, 96], ["SARS", "DISEASE", 158, 162], ["SARS", "DISEASE", 243, 247], ["a large difference between the top five areas", "PROBLEM", 19, 64], ["SARS cases", "TEST", 92, 102], ["SARS cases", "PROBLEM", 158, 168], ["large", "OBSERVATION_MODIFIER", 21, 26], ["difference", "OBSERVATION_MODIFIER", 27, 37]]], ["Also, a threshold of \u2265100 SARS cases was used without considering other potentially critical factors, such as population size, the extent of geographic area, the time duration of the SARS outbreak, or extent of unlinked community transmission.", [["SARS", "DISEASE", 26, 30], ["SARS", "DISEASE", 183, 187], ["the SARS outbreak", "PROBLEM", 179, 196], ["size", "OBSERVATION_MODIFIER", 121, 125], ["extent", "OBSERVATION_MODIFIER", 131, 137], ["geographic", "OBSERVATION_MODIFIER", 141, 151], ["area", "OBSERVATION_MODIFIER", 152, 156], ["community", "OBSERVATION_MODIFIER", 220, 229]]], ["For instance, both Canada and Singapore had \u2265100 SARS cases in 2003.", [["SARS", "DISEASE", 49, 53]]], ["However, more than 95% of probable SARS cases in Canada (n = 247) were observed in the greater Toronto area [35] , a small part of Canada, while the SARS outbreak in Singapore (n = 238) was over the entire country [9] .", [["SARS", "DISEASE", 35, 39], ["SARS", "DISEASE", 149, 153], ["SARS cases", "PROBLEM", 35, 45], ["probable", "UNCERTAINTY", 26, 34], ["SARS", "OBSERVATION", 35, 39], ["small", "OBSERVATION_MODIFIER", 117, 122]]], ["Thus, Canadian governments' and individuals' perceptions of risk from the 2015 MERS outbreak associated with their SARS outbreak experience could be different from the perception of risk from the 2015 MERS outbreak in Singapore.ConclusionsDuring the 2015 MERS outbreak, the numbers of arrivals to the ROK from around the world decreased.", [["SARS", "DISEASE", 115, 119], ["ROK", "PROTEIN", 301, 304]]], ["Countries with a previous sizable SARS outbreak and countries closer to the ROK had the greatest percentage decreases in travel volumes to the ROK.", [["SARS", "DISEASE", 34, 38], ["ROK", "PROTEIN", 76, 79], ["ROK", "PROTEIN", 143, 146], ["a previous sizable SARS outbreak", "PROBLEM", 15, 47], ["greatest", "OBSERVATION_MODIFIER", 88, 96], ["percentage", "OBSERVATION_MODIFIER", 97, 107], ["decreases", "OBSERVATION_MODIFIER", 108, 117]]], ["This is the first analysis that has examined area-specific impacts on travel volume to an outbreak area as we know.", [["the first analysis", "TEST", 8, 26], ["travel volume", "TREATMENT", 70, 83]]], ["Appendix Table 6 Monthly marginal percentage change of non-citizen arrivals to the Republic of Korea (ROK) during 2015 from areas associated with \u2265100 probable severe acute respiratory syndrome (SARS) cases and by distance to the ROK based on projected values from regression models-sensitivity analyses using different models to project values.", [["acute respiratory syndrome", "DISEASE", 167, 193], ["SARS", "DISEASE", 195, 199], ["ROK", "DNA", 230, 233], ["severe acute respiratory syndrome", "PROBLEM", 160, 193], ["SARS) cases", "PROBLEM", 195, 206], ["regression models", "TEST", 265, 282], ["sensitivity analyses", "TEST", 283, 303], ["marginal", "OBSERVATION_MODIFIER", 25, 33], ["percentage", "OBSERVATION_MODIFIER", 34, 44], ["change", "OBSERVATION", 45, 51], ["probable", "UNCERTAINTY", 151, 159], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["respiratory syndrome", "OBSERVATION", 173, 193]]], ["Boldface indicates statistical significance (p-value < 0.05).", [["p-value", "TEST", 45, 52]]]], "55d5a4930204e858d6a980e0f268b7d3b60ff3a3": [["In many respects, the GMC's standards constitute a social contract or compact with society on medical practice.", [["medical practice", "TREATMENT", 94, 110]]], ["8 Arguments for a new compact that gives primacy to patients' interests allied to effective accountability have already been made, 9, 10 and the findings of the inquiry reinforce the case.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["12 The collective failure of these institutions to provide effective leadership on a fundamental principle of medical practice raises doubts about their ability to take up the challenge, and consequently creates concern about how they are currently constituted.", [["medical practice", "TREATMENT", 110, 126], ["collective", "OBSERVATION_MODIFIER", 7, 17], ["failure", "OBSERVATION", 18, 25]]]], "b4673cf125af9990a6e8dc146eaec13b3d25b015": [["IntroductionGroup A rotaviruses (RV-A) are the main etiological agent of acute viral gastroenteritis in infants and young children worldwide (Aoki et al., 2009; CDC, 2008) .", [["viral gastroenteritis", "DISEASE", 79, 100], ["IntroductionGroup A rotaviruses", "ORGANISM", 0, 31], ["RV-A", "CANCER", 33, 37], ["infants", "ORGANISM", 104, 111], ["children", "ORGANISM", 122, 130], ["infants", "SPECIES", 104, 111], ["children", "SPECIES", 122, 130], ["A rotaviruses (RV-A", "SPECIES", 18, 37], ["acute viral gastroenteritis", "PROBLEM", 73, 100], ["rotaviruses", "OBSERVATION", 20, 31], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["viral gastroenteritis", "OBSERVATION", 79, 100]]], ["The Rotavirus genus belongs to the family Reoviridae and its genome consist of 11 double-stranded RNA (dsRNA) gene segments encoding six structural (VP) and six non-structural proteins (NSP) (Estes and Kapikian, 2007) .", [["Rotavirus genus", "ORGANISM", 4, 19], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 42, 52], ["Reoviridae", "DNA", 42, 52], ["double-stranded RNA (dsRNA) gene segments", "DNA", 82, 123], ["VP", "PROTEIN", 149, 151], ["non-structural proteins", "PROTEIN", 161, 184], ["NSP", "PROTEIN", 186, 189], ["the family Reoviridae", "TREATMENT", 31, 52], ["double-stranded RNA (dsRNA) gene segments", "TREATMENT", 82, 123]]], ["Based on the two genes that codify the outer neutralizing capsid proteins, VP4 and VP7, a widely used binary classification system was established for RV-A that defined G (from VP7, glycoprotein) and P (from VP4, protease-cleaved protein) genotypes (Estes and Kapikian, 2007) .", [["VP4", "GENE_OR_GENE_PRODUCT", 75, 78], ["VP7", "GENE_OR_GENE_PRODUCT", 83, 86], ["RV-A", "CANCER", 151, 155], ["G", "GENE_OR_GENE_PRODUCT", 169, 170], ["VP7", "GENE_OR_GENE_PRODUCT", 177, 180], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 182, 194], ["VP4", "GENE_OR_GENE_PRODUCT", 208, 211], ["protease-cleaved protein", "GENE_OR_GENE_PRODUCT", 213, 237], ["outer neutralizing capsid proteins", "PROTEIN", 39, 73], ["VP4", "PROTEIN", 75, 78], ["VP7", "PROTEIN", 83, 86], ["VP7", "PROTEIN", 177, 180], ["glycoprotein", "PROTEIN", 182, 194], ["P", "PROTEIN", 200, 201], ["VP4", "PROTEIN", 208, 211], ["protease", "PROTEIN", 213, 221], ["cleaved protein", "PROTEIN", 222, 237], ["the outer neutralizing capsid proteins", "TEST", 35, 73], ["VP4", "TEST", 75, 78], ["VP7", "TEST", 83, 86], ["RV", "TEST", 151, 153], ["G", "TEST", 169, 170], ["VP7", "TEST", 177, 180], ["glycoprotein", "TEST", 182, 194], ["P", "TEST", 200, 201], ["VP4", "TEST", 208, 211], ["protease", "TEST", 213, 221]]], ["Five RV-A G genotypes (G1-G4 and G9) and two P genotypes (P[8] and P[4]) are prevalent worldwide (Santos and Hoshino, 2005; Leite et al., 2008; Iturriza-G\u00f3 mara et al., 2009) .", [["RV-A G", "GENE_OR_GENE_PRODUCT", 5, 11], ["RV", "TEST", 5, 7], ["A G genotypes", "TEST", 8, 21], ["G1", "TEST", 23, 25], ["two P genotypes", "TEST", 41, 56], ["RV", "ANATOMY", 5, 7]]], ["Different surveillance studies with RV-A-positive samples have shown that genotype P[4]G2 reemerges in Brazil in 2005, and since then has become predominant in this country (Carvalho-Costa et al., 2006; Gurgel et al., 2007; de Oliveira et al., 2008; Leite et al., 2008; Nakagomi et al., 2008; Mascarenhas et al., 2010) .IntroductionDue to the degeneracy of the genetic code, most amino acids are coded by more than one codon.", [["amino acids", "CHEMICAL", 380, 391], ["amino acids", "CHEMICAL", 380, 391], ["amino acids", "AMINO_ACID", 380, 391], ["Different surveillance studies", "TEST", 0, 30], ["RV", "TEST", 36, 38], ["most amino acids", "TREATMENT", 375, 391], ["RV", "ANATOMY", 36, 38], ["predominant", "OBSERVATION_MODIFIER", 145, 156]]], ["Synonymous codons are not used randomly, and in several organisms natural selection seems to bias codon usage toward a certain subset of optimal codons, mainly in highly expressed genes (Stoletzki and Eyre-Walker, 2007) .IntroductionTwo major models have been proposed to explain codon usage, the translation related model and the mutational model (Wong et al., 2010) .", [["Synonymous codons", "TREATMENT", 0, 17], ["codon usage", "TREATMENT", 280, 291], ["codons", "OBSERVATION", 11, 17]]], ["Translational efficiency or translational accuracy bias may be due to the relationship between local tRNA abundance and A B S T R A C T The Rotavirus genus belongs to the family Reoviridae and its genome consist of 11 segments of doublestranded RNA.", [["Reoviridae", "GENE_OR_GENE_PRODUCT", 178, 188], ["Reoviridae", "DNA", 178, 188], ["doublestranded RNA", "RNA", 230, 248], ["Translational efficiency", "PROBLEM", 0, 24], ["translational accuracy bias", "PROBLEM", 28, 55], ["The Rotavirus genus", "TREATMENT", 136, 155], ["Reoviridae", "TREATMENT", 178, 188], ["doublestranded RNA", "PROBLEM", 230, 248], ["doublestranded RNA", "OBSERVATION", 230, 248]]], ["Group A rotaviruses (RV-A) are the main etiological agent of acute viral gastroenteritis in infants and young children worldwide.", [["viral gastroenteritis", "DISEASE", 67, 88], ["Group A rotaviruses", "ORGANISM", 0, 19], ["RV-A", "CANCER", 21, 25], ["infants", "ORGANISM", 92, 99], ["children", "ORGANISM", 110, 118], ["infants", "SPECIES", 92, 99], ["children", "SPECIES", 110, 118], ["Group A rotaviruses (RV-A", "SPECIES", 0, 25], ["acute viral gastroenteritis", "PROBLEM", 61, 88], ["rotaviruses", "OBSERVATION", 8, 19], ["RV", "ANATOMY", 21, 23], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["viral gastroenteritis", "OBSERVATION", 67, 88]]], ["Understanding the extent and causes of biases in codon usage is essential to the understanding of viral evolution.", [["biases in codon usage", "PROBLEM", 39, 60], ["viral", "OBSERVATION", 98, 103]]], ["However, the factors shaping synonymous codon usage bias and nucleotide composition in human RV-A are currently unknown.", [["nucleotide", "CHEMICAL", 61, 71], ["nucleotide", "CHEMICAL", 61, 71], ["human", "ORGANISM", 87, 92], ["RV-A", "CANCER", 93, 97], ["human", "SPECIES", 87, 92], ["human RV-A", "SPECIES", 87, 97], ["the factors", "PROBLEM", 9, 20], ["synonymous codon usage bias", "TREATMENT", 29, 56], ["nucleotide composition", "TEST", 61, 83], ["synonymous codon", "OBSERVATION", 29, 45], ["RV", "ANATOMY", 93, 95]]], ["In order to gain insight into these matters, we analyzed the codon usage and base composition constraints on the two genes that codify the two outer capsid proteins (VP4 [VP8*] and VP7) of 58 P[4]G2 RV-A strains isolated in Brazil and investigated the possible key evolutionary determinants of codon usage bias.", [["VP4", "GENE_OR_GENE_PRODUCT", 166, 169], ["outer capsid proteins", "PROTEIN", 143, 164], ["VP4", "PROTEIN", 166, 169], ["VP8", "PROTEIN", 171, 174], ["VP7", "PROTEIN", 181, 184], ["the codon usage", "TREATMENT", 57, 72], ["base composition constraints", "TREATMENT", 77, 105], ["VP4", "TEST", 166, 169], ["VP7", "TEST", 181, 184], ["P", "TEST", 192, 193], ["G2 RV", "TEST", 196, 201], ["A strains", "TEST", 202, 211]]], ["The results of these studies revealed that the frequencies of codon usage in both RV-A proteins studied are significantly different than the ones used by human cells.", [["cells", "ANATOMY", 160, 165], ["RV-A", "GENE_OR_GENE_PRODUCT", 82, 86], ["human", "ORGANISM", 154, 159], ["cells", "CELL", 160, 165], ["RV-A proteins", "PROTEIN", 82, 95], ["human cells", "CELL_TYPE", 154, 165], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["these studies", "TEST", 15, 28], ["codon usage", "TREATMENT", 62, 73], ["A proteins", "TEST", 85, 95], ["RV", "ANATOMY", 82, 84]]], ["In order to observe if similar trends of codon usage are found when RV-A complete genomes are considered, we compare these results with results found using a dataset of 10 reference strains for whom the complete codes of the 11 segments are known.", [["codon usage", "TREATMENT", 41, 52], ["RV", "TEST", 68, 70], ["11 segments", "ANATOMY_MODIFIER", 225, 236]]], ["Similar results were obtained using capsid proteins or complete genomes.", [["capsid proteins", "PROTEIN", 36, 51], ["capsid proteins", "TREATMENT", 36, 51]]], ["The general correlations found between the position of each sequence on the first axis generated by correspondence analysis and the relative dinucleotide abundances indicate that codon usage in RV-A can also be strongly influenced by underlying biases in dinucleotide frequencies.", [["dinucleotide", "CHEMICAL", 141, 153], ["dinucleotide", "CHEMICAL", 255, 267], ["dinucleotide", "CHEMICAL", 141, 153], ["dinucleotide", "CHEMICAL", 255, 267], ["RV-A", "GENE_OR_GENE_PRODUCT", 194, 198], ["dinucleotide", "SIMPLE_CHEMICAL", 255, 267], ["correspondence analysis", "TEST", 100, 123], ["the relative dinucleotide abundances", "PROBLEM", 128, 164], ["codon usage", "PROBLEM", 179, 190], ["underlying biases in dinucleotide frequencies", "PROBLEM", 234, 279], ["codon usage", "OBSERVATION", 179, 190], ["RV", "ANATOMY", 194, 196], ["dinucleotide frequencies", "OBSERVATION", 255, 279]]], ["CpG and GpC containing codons are markedly suppressed.", [["CpG", "CHEMICAL", 0, 3], ["GpC", "GENE_OR_GENE_PRODUCT", 8, 11], ["CpG", "DNA", 0, 3], ["GpC", "DNA", 8, 11], ["CpG and GpC containing codons", "TREATMENT", 0, 29], ["markedly suppressed", "PROBLEM", 34, 53], ["markedly", "OBSERVATION_MODIFIER", 34, 42], ["suppressed", "OBSERVATION_MODIFIER", 43, 53]]], ["Thus, the results of this study suggest that RV-A genomic biases are the result of the evolution of genome composition in relation to host adaptation and the ability to escape antiviral cell responses.Introduction\u00df 2011 Elsevier B.V. major codon preference, wherein a particular codon of an amino acid family pairs most optimally with the most abundant tRNA (Ikemura, 1982) .", [["cell", "ANATOMY", 186, 190], ["amino acid", "CHEMICAL", 291, 301], ["amino acid", "CHEMICAL", 291, 301], ["cell", "CELL", 186, 190], ["amino acid", "AMINO_ACID", 291, 301], ["this study", "TEST", 21, 31], ["RV", "TEST", 45, 47], ["A genomic biases", "PROBLEM", 48, 64], ["genome composition", "PROBLEM", 100, 118], ["an amino acid family pairs", "PROBLEM", 288, 314], ["RV", "ANATOMY", 45, 47], ["genomic biases", "OBSERVATION", 50, 64], ["antiviral cell", "OBSERVATION", 176, 190]]], ["The discrepancies of codon usage could also be due to genome compositional constraints and mutational biases .", [["The discrepancies of codon usage", "PROBLEM", 0, 32], ["codon usage", "OBSERVATION", 21, 32]]], ["Understanding the extent and causes of biases in codon usage is essential to comprehend the interplay between viruses and the immune response (Shackelton et al., 2006) .", [["biases in codon usage", "PROBLEM", 39, 60]]], ["However, the factors shaping synonymous codon usage bias, like mutational pressure, nucleotide composition or translational selection are currently unknown for human RV-A.IntroductionIn order to gain insight into these matters, we analyzed the codon usage and base composition constraints of VP4 [VP8*] and VP7 gene sequences of 72 P[4]G2 RV-A strains isolated in Brazil and investigated the possible key evolutionary determinants of codon usage bias.", [["nucleotide", "CHEMICAL", 84, 94], ["nucleotide", "CHEMICAL", 84, 94], ["human", "ORGANISM", 160, 165], ["RV-A.", "ORGANISM", 166, 171], ["VP4", "GENE_OR_GENE_PRODUCT", 292, 295], ["VP7", "GENE_OR_GENE_PRODUCT", 307, 310], ["VP4 [VP8*] and VP7 gene sequences", "DNA", 292, 325], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["nucleotide composition", "TREATMENT", 84, 106], ["translational selection", "TREATMENT", 110, 133], ["the codon usage", "TREATMENT", 240, 255], ["base composition constraints", "TEST", 260, 288], ["VP4", "TEST", 292, 295], ["VP7 gene sequences", "TEST", 307, 325], ["P", "TEST", 332, 333], ["G2 RV", "TEST", 336, 341], ["A strains", "PROBLEM", 342, 351], ["synonymous codon", "OBSERVATION", 29, 45], ["pressure", "OBSERVATION_MODIFIER", 74, 82], ["RV", "ANATOMY", 339, 341]]], ["In order to observe if similar trends of codon usage are found when RV-A complete genomes are considered, we compared these results with the ones found using a dataset of reference strains from which the complete sequences of the 11 segments are known.", [["codon usage", "TREATMENT", 41, 52], ["RV", "TEST", 68, 70]]], ["The results of these studies revealed a significant codon usage bias and compositional constraints in the human RV-A strains studied.Fecal samples, viral RNA extraction and PCR amplificationA total of 72 diarrheic stool specimens were collected from 1996 to 2009 from children up to 5 years old hospitalized with acute diarrhea.", [["Fecal samples", "ANATOMY", 133, 146], ["stool specimens", "ANATOMY", 214, 229], ["diarrhea", "DISEASE", 319, 327], ["human", "ORGANISM", 106, 111], ["RV-A strains", "ORGANISM", 112, 124], ["Fecal samples", "ORGANISM_SUBSTANCE", 133, 146], ["stool specimens", "CANCER", 214, 229], ["children", "ORGANISM", 268, 276], ["viral RNA", "RNA", 148, 157], ["human", "SPECIES", 106, 111], ["children", "SPECIES", 268, 276], ["human RV-A", "SPECIES", 106, 116], ["these studies", "TEST", 15, 28], ["a significant codon usage bias", "PROBLEM", 38, 68], ["compositional constraints", "PROBLEM", 73, 98], ["A strains studied", "PROBLEM", 115, 132], ["Fecal samples", "TEST", 133, 146], ["viral RNA extraction", "TREATMENT", 148, 168], ["PCR", "TEST", 173, 176], ["diarrheic stool specimens", "TEST", 204, 229], ["acute diarrhea", "PROBLEM", 313, 327], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["codon usage", "OBSERVATION", 52, 63], ["human RV", "ANATOMY", 106, 114], ["viral RNA", "OBSERVATION", 148, 157], ["acute", "OBSERVATION_MODIFIER", 313, 318], ["diarrhea", "OBSERVATION", 319, 327]]], ["These samples were obtained from children from the States of Acre (AC), Alagoas (AL), Bahia (BA), Espirito Santo (ES), Maranh\u00e3o (MA), Mato Grosso do Sul (MS), Minas Gerais (MG), Pernambuco (PE), Rio de Janeiro (RJ), Rio Grande do Sul (RS) and Sergipe (SE), and were genotyped as P[4]G2 as previously described (Fischer et al., 2000; Das et al., 1994) .", [["samples", "ANATOMY", 6, 13], ["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["Acre (AC)", "TREATMENT", 61, 70], ["Espirito Santo (ES)", "TREATMENT", 98, 117], ["Maranh\u00e3o (MA)", "TREATMENT", 119, 132], ["PE", "OBSERVATION", 190, 192]]], ["The viral dsRNA was extracted by the glass powder method (Boom et al., 1990) .", [["The viral dsRNA", "TREATMENT", 0, 15], ["viral dsRNA", "OBSERVATION", 4, 15]]], ["The dsRNA was reverse transcribed (RT) and amplified by polymerase chain reaction (PCR) using a pair of consensus primers corresponding to a conserved nucleotide sequence of the VP7 (Gouvea et al., 1990; Das et al., 1994) or VP4 (VP8 and VP7 genes were obtained by using the same set of primers utilized in the RT-PCR.", [["VP4", "GENE_OR_GENE_PRODUCT", 225, 228], ["VP8", "GENE_OR_GENE_PRODUCT", 230, 233], ["VP7", "GENE_OR_GENE_PRODUCT", 238, 241], ["consensus primers", "DNA", 104, 121], ["VP7", "DNA", 178, 181], ["VP4", "DNA", 225, 228], ["VP8", "DNA", 230, 233], ["VP7 genes", "DNA", 238, 247], ["The dsRNA", "TREATMENT", 0, 9], ["polymerase chain reaction", "PROBLEM", 56, 81], ["PCR", "TEST", 83, 86], ["a pair of consensus primers", "PROBLEM", 94, 121], ["VP4 (VP8 and VP7 genes", "TEST", 225, 247], ["primers", "TREATMENT", 287, 294], ["dsRNA", "OBSERVATION", 4, 9]]], ["From the initial 72 stool samples, a total of 58 VP4 [VP8]* and 60 VP7 sequences, 818 and 978 nucleotides inlength, respectively, were obtained.Codon usage analysesThe relative synonymous codon usage (RSCU) values of each codon in each gene (VP8* or VP7) were determined in order to measure the synonymous codon usage bias (Sharp and Li, 1986) .", [["stool samples", "ANATOMY", 20, 33], ["nucleotides", "CHEMICAL", 94, 105], ["VP4", "GENE_OR_GENE_PRODUCT", 49, 52], ["VP8", "GENE_OR_GENE_PRODUCT", 242, 245], ["VP7", "GENE_OR_GENE_PRODUCT", 250, 253], ["VP4 [VP8]* and 60 VP7 sequences", "DNA", 49, 80], ["VP8", "DNA", 242, 245], ["VP7", "DNA", 250, 253], ["VP8", "TEST", 54, 57], ["VP7 sequences", "TEST", 67, 80], ["nucleotides inlength", "TEST", 94, 114], ["Codon usage analyses", "TEST", 144, 164], ["synonymous codon", "OBSERVATION", 177, 193], ["synonymous codon", "OBSERVATION", 295, 311]]], ["This was done using the CodonW program (available at: http:// mobyle.pasteur.fr).", [["the CodonW program", "TREATMENT", 20, 38]]], ["The RSCU of P[4]G2 RV-A VP8* and VP7 genes were compared with corresponding values of human cells (International Human Genome Sequencing Consortium, 2001) .", [["cells", "ANATOMY", 92, 97], ["VP8", "GENE_OR_GENE_PRODUCT", 24, 27], ["VP7", "GENE_OR_GENE_PRODUCT", 33, 36], ["human", "ORGANISM", 86, 91], ["cells", "CELL", 92, 97], ["P[4]G2 RV-A VP8* and VP7 genes", "DNA", 12, 42], ["human cells", "CELL_TYPE", 86, 97], ["human", "SPECIES", 86, 91], ["Human", "SPECIES", 113, 118], ["human", "SPECIES", 86, 91], ["P", "TEST", 12, 13], ["G2 RV", "TEST", 16, 21], ["A VP8*", "TEST", 22, 28], ["VP7 genes", "TEST", 33, 42]]], ["The effective number of codons (ENC) and the frequency of use of G+C at synonymous variable third positions of codons (GC 3 S) (excluding Met, Trp, and termination codons) were also calculated with CodonW.", [["Met", "CHEMICAL", 138, 141], ["Trp", "CHEMICAL", 143, 146], ["G+C", "GENE_OR_GENE_PRODUCT", 65, 68], ["Met", "GENE_OR_GENE_PRODUCT", 138, 141], ["Trp", "AMINO_ACID", 143, 146], ["ENC", "DNA", 32, 35], ["Met, Trp, and termination codons", "DNA", 138, 170], ["codons (ENC)", "TREATMENT", 24, 36], ["G+C at synonymous variable third positions of codons", "TREATMENT", 65, 117], ["Trp, and termination codons", "TREATMENT", 143, 170], ["effective", "OBSERVATION_MODIFIER", 4, 13]]], ["ENC was used to quantify the codon usage bias of an ORF (Wrigth, 1990; Comeron and Aguade, 1998) .", [["ENC", "DNA", 0, 3], ["ORF", "DNA", 52, 55]]], ["Similarly, the fraction of the G+C nucleotides not involved in the GC 3 S fraction (GC 12 ) was also calculated.", [["nucleotides", "CHEMICAL", 35, 46], ["G+C", "SIMPLE_CHEMICAL", 31, 34], ["the G+C nucleotides", "TEST", 27, 46], ["GC", "TEST", 84, 86]]], ["Dinucleotides relative frequencies were also calculated using this program as implemented in the Mobyle server (http://mobyle.pasteur.fr).Correspondence analysis (COA)The relationship between variables and samples can be obtained using multivariate statistical analysis.", [["Dinucleotides relative frequencies", "PROBLEM", 0, 34], ["this program", "TREATMENT", 62, 74], ["Correspondence analysis", "TEST", 138, 161], ["multivariate statistical analysis", "TEST", 236, 269]]], ["COA is a type of multivariate analysis that allows a geometrical representation of the sets of rows and columns in a dataset (Wong et al., 2010; Greenacre, 1984) .", [["multivariate analysis", "TEST", 17, 38]]], ["Each ORF is represented as a 59-dimensional vector and each dimension correspond to the RSCU value of one codon (excluding AUG, UGG and stop codons).", [["ORF", "DNA", 5, 8], ["59-dimensional vector", "DNA", 29, 50], ["RSCU", "DNA", 88, 92], ["AUG", "DNA", 123, 126], ["UGG", "DNA", 128, 131]]], ["Major trends within a dataset can be determined using measures of relative inertia and genes ordered according to their position along the axis of major inertia (Tao et al., 2009) .", [["relative inertia and genes", "TREATMENT", 66, 92]]], ["COA was performed on the RSCU values of the ORFs studied using the CodonW program.Statistical analysisCorrelation analysis was carried out using Spearman's rank correlation analysis method (Wessa, 2010 ; available at: www.wessa.net).Sequence alignmentSequences were aligned using the MUSCLE program (Edgar, 2004) .Comparative analysisIn order to observe if the codon usage bias found in the outer capsid proteins of P[4]G2 RV-A strains isolated in Brazil, can also be found in other genome regions or considering complete genome codes of human RV-A strains of different genotypes and isolated elsewhere, a new dataset composed of 10 human RV-A reference strains for whom the complete codes of the 11 genome segments are known was constructed.", [["human", "ORGANISM", 538, 543], ["RV-A strains", "ORGANISM", 544, 556], ["human", "ORGANISM", 633, 638], ["RV-A reference strains", "ORGANISM", 639, 661], ["RSCU", "DNA", 25, 29], ["ORFs", "DNA", 44, 48], ["outer capsid proteins", "PROTEIN", 391, 412], ["genome regions", "DNA", 483, 497], ["human", "SPECIES", 538, 543], ["human", "SPECIES", 633, 638], ["human RV-A", "SPECIES", 538, 548], ["human", "SPECIES", 633, 638], ["COA", "TEST", 0, 3], ["the CodonW program", "TREATMENT", 63, 81], ["Statistical analysisCorrelation analysis", "TEST", 82, 122], ["Sequence alignmentSequences", "TEST", 233, 260], ["the codon usage bias", "PROBLEM", 357, 377], ["G2 RV", "TEST", 420, 425], ["A strains", "PROBLEM", 426, 435], ["different genotypes", "PROBLEM", 560, 579], ["MUSCLE", "ANATOMY", 284, 290], ["RV", "ANATOMY", 423, 425], ["human RV", "ANATOMY", 538, 546]]], ["For strain names, genotypes, accession numbers and genomic constellations see Supplementary Material Table 3 .ResultsIn order to study the extent of codon usage bias in P[4]G2 RV-A isolated in Brazil, the RSCU values of the codons in VP4 [VP8*] and VP7 ORFs were calculated, and the figures obtained for these genes, comprising a dataset of 58 and 60 sequences, respectively, are shown in Table 1 .ResultsInterestingly, the frequencies of codon usage in both VP4 [VP8*] and VP7 P[4]G2 RV-A ORFs are significantly different in relation to human cells.", [["cells", "ANATOMY", 544, 549], ["VP4 [VP8*]", "GENE_OR_GENE_PRODUCT", 234, 244], ["VP7", "GENE_OR_GENE_PRODUCT", 249, 252], ["VP4", "GENE_OR_GENE_PRODUCT", 459, 462], ["human", "ORGANISM", 538, 543], ["cells", "CELL", 544, 549], ["RSCU", "DNA", 205, 209], ["VP4", "DNA", 234, 237], ["VP7 ORFs", "DNA", 249, 257], ["58 and 60 sequences", "DNA", 341, 360], ["VP7 P[4]G2 RV-A ORFs", "DNA", 474, 494], ["human cells", "CELL_TYPE", 538, 549], ["human", "SPECIES", 538, 543], ["human", "SPECIES", 538, 543], ["genotypes", "PROBLEM", 18, 27], ["P", "TEST", 169, 170], ["G2 RV", "TEST", 173, 178], ["the codons", "TEST", 220, 230], ["VP4", "TEST", 234, 237], ["VP7 ORFs", "TEST", 249, 257], ["the figures", "TEST", 279, 290], ["a dataset", "TEST", 328, 337], ["codon usage", "TEST", 439, 450], ["VP4", "TEST", 459, 462], ["VP7", "TEST", 474, 477], ["G2 RV", "TEST", 482, 487], ["A ORFs", "TEST", 488, 494], ["RV", "ANATOMY", 485, 487], ["human cells", "OBSERVATION", 538, 549]]], ["Particularly, extremely high biased frequencies were found for UUU (Phe), UUA (Leu), GUU and GUA (Val), UCA (Ser), CCA (Pro), GCU (Ala), UAU (Tyr), CAU (His), CAA (Gln), AAU (Asn), AAA (Lys), GAA (Glu), UGU (Cys), AGA (Arg) and GGA (Gly) in both ORFs (see Table 1 ).", [["Phe", "CHEMICAL", 68, 71], ["CAA", "CHEMICAL", 159, 162], ["Gln", "CHEMICAL", 164, 167], ["Asn", "CHEMICAL", 175, 178], ["Glu", "CHEMICAL", 197, 200], ["Arg", "CHEMICAL", 219, 222], ["Phe", "CHEMICAL", 68, 71], ["Leu", "CHEMICAL", 79, 82], ["Val", "CHEMICAL", 98, 101], ["UCA", "CHEMICAL", 104, 107], ["Ser", "CHEMICAL", 109, 112], ["Pro", "CHEMICAL", 120, 123], ["GCU", "CHEMICAL", 126, 129], ["Ala", "CHEMICAL", 131, 134], ["UAU", "CHEMICAL", 137, 140], ["Tyr", "CHEMICAL", 142, 145], ["His", "CHEMICAL", 153, 156], ["CAA", "CHEMICAL", 159, 162], ["Gln", "CHEMICAL", 164, 167], ["Asn", "CHEMICAL", 175, 178], ["Lys", "CHEMICAL", 186, 189], ["GAA", "CHEMICAL", 192, 195], ["Glu", "CHEMICAL", 197, 200], ["UGU", "CHEMICAL", 203, 206], ["Cys", "CHEMICAL", 208, 211], ["Arg", "CHEMICAL", 219, 222], ["Gly", "CHEMICAL", 233, 236], ["Phe", "AMINO_ACID", 68, 71], ["UCA", "SIMPLE_CHEMICAL", 104, 107], ["Ser", "AMINO_ACID", 109, 112], ["CCA", "SIMPLE_CHEMICAL", 115, 118], ["Tyr", "AMINO_ACID", 142, 145], ["CAA", "SIMPLE_CHEMICAL", 159, 162], ["Gln", "AMINO_ACID", 164, 167], ["AAU", "SIMPLE_CHEMICAL", 170, 173], ["Asn", "AMINO_ACID", 175, 178], ["AAA", "SIMPLE_CHEMICAL", 181, 184], ["GAA", "SIMPLE_CHEMICAL", 192, 195], ["Glu", "AMINO_ACID", 197, 200], ["UGU", "SIMPLE_CHEMICAL", 203, 206], ["AGA", "SIMPLE_CHEMICAL", 214, 217], ["Arg", "AMINO_ACID", 219, 222], ["GGA", "SIMPLE_CHEMICAL", 228, 231], ["AAU", "PROTEIN", 170, 173], ["AAA", "PROTEIN", 181, 184], ["ORFs", "DNA", 246, 250], ["extremely high biased frequencies", "PROBLEM", 14, 47], ["UUA", "TEST", 74, 77], ["GUU", "TEST", 85, 88], ["GUA", "TEST", 93, 96], ["UCA", "TEST", 104, 107], ["CCA", "TEST", 115, 118], ["GCU", "TEST", 126, 129], ["CAA (Gln)", "PROBLEM", 159, 168], ["AAU (Asn)", "TEST", 170, 179], ["AAA (Lys)", "TEST", 181, 190], ["GAA (Glu)", "TEST", 192, 201], ["UGU (Cys", "TEST", 203, 211], ["AGA (Arg)", "PROBLEM", 214, 223], ["GGA (Gly) in both ORFs", "PROBLEM", 228, 250], ["GUA", "ANATOMY", 93, 96], ["CCA", "ANATOMY", 115, 118], ["AAA", "ANATOMY", 181, 184]]], ["As can be seen, highly preferred codons are all U/A ending, which strongly suggests that mutational bias is the main force shaping codon usage in these two genes.", [["U/A", "GENE_OR_GENE_PRODUCT", 48, 51], ["all U/A", "TEST", 44, 51], ["mutational bias", "PROBLEM", 89, 104], ["mutational bias", "OBSERVATION", 89, 104], ["codon usage", "OBSERVATION", 131, 142]]], ["It is interesting to note that CGC (Arg) is not used in both ORFs.ResultsIn order to investigate if these P An ENC-GC 3 S plot (ENC plotted against GC 3 S) can be used as a method that quantifies how far the codon usage of a gene departs from equal usage of synonymous codons (Wrigth, 1990) .", [["Arg", "CHEMICAL", 36, 39], ["Arg", "CHEMICAL", 36, 39], ["CGC", "SIMPLE_CHEMICAL", 31, 34], ["Arg", "AMINO_ACID", 36, 39], ["ORFs", "DNA", 61, 65], ["P", "DNA", 106, 107], ["ENC", "DNA", 111, 114], ["CGC (Arg)", "PROBLEM", 31, 40], ["An ENC", "TEST", 108, 114], ["GC 3 S plot", "TEST", 115, 126], ["synonymous codons", "OBSERVATION", 258, 275]]], ["As shown in Fig. 1 , the dotted continuous line in the plot represents a curve if codon usage is only determined by GC content at the third codon position.", [["the dotted continuous line", "TREATMENT", 21, 47], ["codon usage", "TREATMENT", 82, 93], ["Fig", "OBSERVATION", 12, 15], ["line", "OBSERVATION", 43, 47]]], ["In other words, if GC 3 S is the only determinant factor shaping the codon usage pattern, the values of ENC would fall on a continuous curve, which represents random codon usage (Jiang et al., 2007) .", [["ENC", "DNA", 104, 107], ["a continuous curve", "TEST", 122, 140]]], ["If G+C compositional constraint influences the codon usage, then the GC 3 S and ENC correlated spots would lie on or bellow the expected curve (Tsai et al., 2007) .", [["G+C", "CHEMICAL", 3, 6], ["G+C compositional constraint", "PROBLEM", 3, 31]]], ["Otherwise, the codon usage bias of genes may be affected by other factors such as translational selection.ResultsWhen the GC 3 S values were calculated for VP4 [VP8*] and VP7 ORFs and the ENC-GC 3 S plots constructed (for ENC and GC 3 S values obtained for Brazilian strains enrolled in these studies, see Supplementary Material Table 2 ), all spots lie below and ''parallel'' in relation to the expected curve for both ORFs studied, indicating that the codon usage bias may be influenced by the G+C compositional constraints (see Fig. 1 ).ResultsSince codon usage by its very nature is multivariate, it is necessary to analyze the data using multivariate statistical techniques (i.e. COA) in order to confirm these findings.", [["VP4", "GENE_OR_GENE_PRODUCT", 156, 159], ["VP4", "DNA", 156, 159], ["VP7 ORFs", "DNA", 171, 179], ["ENC", "DNA", 188, 191], ["ORFs", "DNA", 420, 424], ["translational selection", "TREATMENT", 82, 105], ["the GC 3 S values", "TEST", 118, 135], ["VP4", "TEST", 156, 159], ["VP8", "TEST", 161, 164], ["VP7 ORFs", "TEST", 171, 179], ["the ENC", "TEST", 184, 191], ["GC", "TEST", 192, 194], ["S plots", "TEST", 197, 204], ["ENC", "TEST", 222, 225], ["GC 3 S values", "TEST", 230, 243], ["Brazilian strains", "PROBLEM", 257, 274], ["these studies", "TEST", 287, 300], ["both ORFs", "TEST", 415, 424], ["the codon usage bias", "PROBLEM", 450, 470], ["multivariate statistical techniques", "TEST", 643, 678], ["may be", "UNCERTAINTY", 41, 47]]], ["COA is an ordination technique that identifies the major trends in the variation of the data and distributes genes along continuous axes in accordance with these trends.", [["an ordination technique", "TEST", 7, 30]]], ["COA creates a series of orthogonal axes to identify trends that explain the data variation, with each subsequent axis explaining a decreasing amount of the variation (Greenacre, 1984) .", [["decreasing", "OBSERVATION_MODIFIER", 131, 141], ["amount", "OBSERVATION_MODIFIER", 142, 148]]], ["The correlation between the position on the first axis generated by COA for each gene and the respective GC 3 S values of each strain was analyzed for both VP4 [VP8*] and VP7 ORFs studied.", [["VP4", "GENE_OR_GENE_PRODUCT", 156, 159], ["VP7", "GENE_OR_GENE_PRODUCT", 171, 174], ["VP4", "DNA", 156, 159], ["VP7 ORFs", "DNA", 171, 179], ["VP4", "TEST", 156, 159], ["VP7 ORFs", "TEST", 171, 179]]], ["We have found that the position of the sequences on the first axis from COA are highly correlated with the GC 3 S values in both VP4 [VP8*] and VP7 ORFs (r = 0.625, P < 0.0001 and r = \u00c00.469, P < 0.001 for VP4Results[VP8] and VP7, respectively).", [["COA", "GENE_OR_GENE_PRODUCT", 72, 75], ["VP4", "GENE_OR_GENE_PRODUCT", 129, 132], ["VP7", "GENE_OR_GENE_PRODUCT", 144, 147], ["VP7", "GENE_OR_GENE_PRODUCT", 226, 229], ["VP4", "PROTEIN", 129, 132], ["VP7 ORFs", "DNA", 144, 152], ["VP8", "PROTEIN", 217, 220], ["VP7", "PROTEIN", 226, 229], ["the sequences", "TEST", 35, 48], ["the GC", "TEST", 103, 109], ["S values", "TEST", 112, 120], ["VP4", "TEST", 129, 132], ["VP7 ORFs", "TEST", 144, 152], ["r", "TEST", 154, 155], ["P", "TEST", 165, 166], ["r", "TEST", 180, 181], ["P", "TEST", 192, 193], ["VP4Results", "TEST", 206, 216], ["VP8", "TEST", 217, 220], ["VP7", "TEST", 226, 229]]], ["Taking altogether, these results reveal that most of the codon usage bias is directly related to the nucleotide composition.", [["nucleotide", "CHEMICAL", 101, 111], ["nucleotide", "CHEMICAL", 101, 111], ["the nucleotide composition", "PROBLEM", 97, 123]]], ["Nevertheless, other factors may be also acting in shaping codon usage bias.ResultsIn order to analyze if the codon usage biases reported above can also be found using other genome regions or considering complete genome sequences, a new dataset was constructed composed of 10 human RV-A reference strains, for which the complete genomes of the 11 segments are known.", [["human", "ORGANISM", 275, 280], ["RV-A", "ORGANISM", 281, 285], ["genome regions", "DNA", 173, 187], ["genome sequences", "DNA", 212, 228], ["human", "SPECIES", 275, 280], ["human", "SPECIES", 275, 280], ["the codon usage biases", "PROBLEM", 105, 127]]], ["For strains names, genotypes, accession numbers and genomic constellations, see Supplementary Material Table 3 .", [["strains", "PROBLEM", 4, 11], ["genotypes", "PROBLEM", 19, 28]]], ["By concatenation of different genome ORF's sequences, the RSCU values of the different codons were calculated for different virus regions (outer capsid shell proteins, OC, VP4+VP7; intermediate protein shell, IM, VP6; inner capid shell proteins, IC, VP1+VP2+VP3; non-structural proteins, NSP, NSP1+NSP2+NSP3+NSP4+NSP5; and full genome, VP4+VP7+VP6+VP1+VP2+VP3+NSP1+NSP2+NSP3+ NSP4+NSP5, which accounts for a total of 54,318 codons).", [["OC", "GENE_OR_GENE_PRODUCT", 168, 170], ["VP4+VP7", "GENE_OR_GENE_PRODUCT", 172, 179], ["VP6", "GENE_OR_GENE_PRODUCT", 213, 216], ["VP1", "GENE_OR_GENE_PRODUCT", 250, 253], ["NSP", "GENE_OR_GENE_PRODUCT", 288, 291], ["NSP1", "GENE_OR_GENE_PRODUCT", 293, 297], ["NSP4", "GENE_OR_GENE_PRODUCT", 308, 312], ["VP4+VP7", "GENE_OR_GENE_PRODUCT", 336, 343], ["genome ORF", "DNA", 30, 40], ["RSCU", "DNA", 58, 62], ["virus regions", "DNA", 124, 137], ["outer capsid shell proteins", "PROTEIN", 139, 166], ["OC", "PROTEIN", 168, 170], ["VP4", "PROTEIN", 172, 175], ["VP7", "PROTEIN", 176, 179], ["intermediate protein shell", "PROTEIN", 181, 207], ["IM", "PROTEIN", 209, 211], ["VP6", "PROTEIN", 213, 216], ["inner capid shell proteins", "PROTEIN", 218, 244], ["IC", "PROTEIN", 246, 248], ["VP1", "PROTEIN", 250, 253], ["VP2", "PROTEIN", 254, 257], ["VP3", "PROTEIN", 258, 261], ["non-structural proteins", "PROTEIN", 263, 286], ["NSP", "PROTEIN", 288, 291], ["NSP1", "PROTEIN", 293, 297], ["NSP2", "PROTEIN", 298, 302], ["NSP3", "PROTEIN", 303, 307], ["NSP4", "PROTEIN", 308, 312], ["NSP5", "PROTEIN", 313, 317], ["VP4", "PROTEIN", 336, 339], ["VP7", "PROTEIN", 340, 343], ["VP6", "PROTEIN", 344, 347], ["VP1", "PROTEIN", 348, 351], ["VP2", "PROTEIN", 352, 355], ["VP3", "PROTEIN", 356, 359], ["NSP1", "PROTEIN", 360, 364], ["NSP2", "PROTEIN", 365, 369], ["NSP3", "PROTEIN", 370, 374], ["NSP4", "PROTEIN", 376, 380], ["NSP5", "PROTEIN", 381, 385], ["different genome ORF's sequences", "TEST", 20, 52], ["the RSCU values", "TEST", 54, 69], ["the different codons", "PROBLEM", 73, 93], ["different virus regions", "PROBLEM", 114, 137], ["outer capsid shell proteins", "TEST", 139, 166], ["OC", "TEST", 168, 170], ["VP4", "TEST", 172, 175], ["VP7", "TEST", 176, 179], ["intermediate protein shell", "TEST", 181, 207], ["IM", "TEST", 209, 211], ["VP6", "TEST", 213, 216], ["inner capid shell proteins", "TEST", 218, 244], ["IC", "TEST", 246, 248], ["VP1", "TEST", 250, 253], ["VP2", "TEST", 254, 257], ["VP3", "TEST", 258, 261], ["non-structural proteins", "TEST", 263, 286], ["NSP", "TEST", 288, 291], ["NSP1", "TEST", 293, 297], ["NSP2", "TEST", 298, 302], ["NSP3", "TEST", 303, 307], ["NSP4", "TEST", 308, 312], ["NSP5", "TEST", 313, 317], ["full genome", "TEST", 323, 334], ["VP4", "TEST", 336, 339], ["VP7", "TEST", 340, 343], ["VP6", "TEST", 344, 347], ["VP1", "TEST", 348, 351], ["VP2", "TEST", 352, 355], ["VP3", "TEST", 356, 359], ["NSP1", "TEST", 360, 364], ["NSP2", "TEST", 365, 369], ["NSP3", "TEST", 370, 374], ["NSP4", "TEST", 376, 380], ["NSP5", "TEST", 381, 385], ["shell proteins", "OBSERVATION", 152, 166], ["VP2", "ANATOMY_MODIFIER", 352, 355], ["VP3", "ANATOMY_MODIFIER", 356, 359]]], ["The results of these studies are shown in Table 2 .ResultsAgain, the frequencies of codon usage found in different genomic regions or considering complete genomes of RV-A are significantly different in relation to human cells (see Tables 1 and 2 ).", [["cells", "ANATOMY", 220, 225], ["RV-A", "GENE_OR_GENE_PRODUCT", 166, 170], ["human", "ORGANISM", 214, 219], ["cells", "CELL", 220, 225], ["genomic regions", "DNA", 115, 130], ["human cells", "CELL_TYPE", 214, 225], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["these studies", "TEST", 15, 28], ["codon usage", "TREATMENT", 84, 95], ["RV", "ANATOMY", 166, 168]]], ["Highly biased frequencies were also found for the same amino acids in all genomic regions or considering full genomes (Table 2 ) and in agreement with the previous results found using outer capsid proteins from P[4]G2 RV-A strains isolated in Brazil.", [["amino acids", "CHEMICAL", 55, 66], ["amino acids", "CHEMICAL", 55, 66], ["amino acids", "AMINO_ACID", 55, 66], ["genomic regions", "DNA", 74, 89], ["outer capsid proteins", "PROTEIN", 184, 205], ["Highly biased frequencies", "PROBLEM", 0, 25], ["the same amino acids", "TREATMENT", 46, 66], ["outer capsid proteins", "TEST", 184, 205], ["G2 RV", "TEST", 215, 220], ["A strains", "PROBLEM", 221, 230]]], ["The correlation between the position on the first axis generated by COA and the respective GC 3 S values of each strain was analyzed for the complete genome dataset.", [["COA", "TEST", 68, 71]]], ["A high and significant correlation among the position of the sequences on the first axis of COA and the GC 3 S values (r = \u00c00.9879, P < 0.01) was also found using full, complete genomes.ResultsIt has been suggested that dinucleotide biases can affect codon bias (Tao et al., 2009 ).", [["dinucleotide", "CHEMICAL", 220, 232], ["dinucleotide", "CHEMICAL", 220, 232], ["dinucleotide", "SIMPLE_CHEMICAL", 220, 232], ["the sequences", "TEST", 57, 70], ["COA", "TEST", 92, 95], ["the GC", "TEST", 100, 106], ["S values", "TEST", 109, 117], ["P", "TEST", 132, 133], ["dinucleotide biases", "PROBLEM", 220, 239], ["high", "OBSERVATION_MODIFIER", 2, 6], ["significant", "OBSERVATION_MODIFIER", 11, 22]]], ["To study this possibility, the relative abundances of the 16 dinucleotides in VP8* and/or VP7 ORFs was established.", [["dinucleotides", "CHEMICAL", 61, 74], ["VP8", "GENE_OR_GENE_PRODUCT", 78, 81], ["VP7", "GENE_OR_GENE_PRODUCT", 90, 93], ["VP8* and/or VP7 ORFs", "DNA", 78, 98], ["VP8", "TEST", 78, 81], ["VP7 ORFs", "TEST", 90, 98]]], ["The results of these studies are shown in Table 3 .", [["these studies", "TEST", 15, 28]]], ["As can be seen, the occurrences of dinucleotides are not random and no dinucleotides is present at the expected frequencies.ResultsIn the case of VP4 [VP8*] protein, the relative abundance of CpG and GpC showed a strong deviation from the expected frequencies (i.e. 1.0) (mean AE S.D. = 0.230 AE 0.035 and 0.282 AE 0.009, respectively) and were markedly underrepresented.", [["dinucleotides", "CHEMICAL", 35, 48], ["dinucleotides", "CHEMICAL", 71, 84], ["CpG", "CHEMICAL", 192, 195], ["VP4", "GENE_OR_GENE_PRODUCT", 146, 149], ["GpC", "GENE_OR_GENE_PRODUCT", 200, 203], ["VP4 [VP8*] protein", "PROTEIN", 146, 164], ["CpG", "DNA", 192, 195], ["GpC", "PROTEIN", 200, 203], ["dinucleotides", "PROBLEM", 71, 84], ["VP4 [VP8*] protein", "TEST", 146, 164], ["CpG", "PROBLEM", 192, 195], ["GpC", "TEST", 200, 203], ["a strong deviation", "PROBLEM", 211, 229], ["mean AE S.D.", "TEST", 272, 284], ["AE", "TEST", 293, 295], ["AE", "TEST", 312, 314], ["dinucleotides", "OBSERVATION", 35, 48], ["strong deviation", "OBSERVATION", 213, 229]]], ["On the other hand, ApU and ApA are markedly over-used (mean AE S.D. = 1.951 AE 0.033 and 1.979 AE 0.04, respectively) ( Table 3) .", [["ApA", "CHEMICAL", 27, 30], ["ApU", "GENE_OR_GENE_PRODUCT", 19, 22], ["ApA", "SIMPLE_CHEMICAL", 27, 30], ["ApA", "TEST", 27, 30], ["AE", "TEST", 76, 78], ["markedly", "OBSERVATION_MODIFIER", 35, 43]]], ["Among the 16 dinucleotides, 10 are correlated with the first axis value in COA (P values <0.01, Table 3 In the case of VP7 protein, again, the relative abundance of CpG and GpC showed a strong deviation from the expected frequencies (mean AE S.D. = 0.397 AE 0.014 and 0.330 AE 0.018, respectively) and were underrepresented.", [["dinucleotides", "CHEMICAL", 13, 26], ["CpG", "CHEMICAL", 165, 168], ["VP7", "GENE_OR_GENE_PRODUCT", 119, 122], ["VP7 protein", "PROTEIN", 119, 130], ["GpC", "PROTEIN", 173, 176], ["COA (P values", "TEST", 75, 88], ["VP7 protein", "TEST", 119, 130], ["CpG", "TEST", 165, 168], ["GpC", "TEST", 173, 176], ["a strong deviation", "PROBLEM", 184, 202], ["AE", "TEST", 255, 257], ["strong deviation", "OBSERVATION", 186, 202]]], ["Interestingly, the frequencies of ApU and ApA showed a sharp deviation from the expected frequencies and again we found a markedly over-use of these dinucleotides (mean AE S.D. = 2.056 AE 0.029 and 1.948 AE 0.038, respectively) ( Table 3) .", [["dinucleotides", "CHEMICAL", 149, 162], ["ApU", "GENE_OR_GENE_PRODUCT", 34, 37], ["ApA", "GENE_OR_GENE_PRODUCT", 42, 45], ["ApU", "PROTEIN", 34, 37], ["ApA", "PROTEIN", 42, 45], ["ApA", "TEST", 42, 45], ["a sharp deviation", "PROBLEM", 53, 70], ["these dinucleotides", "TEST", 143, 162], ["AE", "TEST", 185, 187], ["sharp", "OBSERVATION_MODIFIER", 55, 60], ["deviation", "OBSERVATION", 61, 70], ["markedly", "OBSERVATION_MODIFIER", 122, 130]]], ["Among the 16 dinucleotides, seven are correlated with the position of the sequences along the first axis in COA (P values <0.01, Table 3 ).ResultsThese results indicate that the composition of dinucleotides also determines the variation in synonymous codon usage among P[4]G2 RV-A VP7 ORFs.", [["dinucleotides", "CHEMICAL", 13, 26], ["dinucleotides", "CHEMICAL", 193, 206], ["P[4]G2 RV-A VP7 ORFs", "DNA", 269, 289], ["the sequences", "TEST", 70, 83], ["COA (P values", "TEST", 108, 121], ["the composition of dinucleotides", "PROBLEM", 174, 206], ["the variation", "PROBLEM", 223, 236], ["synonymous codon usage", "TREATMENT", 240, 262], ["G2 RV", "TEST", 273, 278], ["A VP7 ORFs", "PROBLEM", 279, 289], ["first axis", "ANATOMY", 94, 104], ["COA", "ANATOMY", 108, 111], ["synonymous codon", "OBSERVATION", 240, 256]]], ["The RSCU value for the VP7 protein of the 14 codons that contain CpG and GpC (see above) revealed that six [GCG (mean 0.28), CGC (mean 0.00), GCC (mean 0.13), GCG (mean 0.28), AGC (mean 0.26) and GGC (mean 0.24)] were markedly suppressed and five [CCG (mean 0.73), UCG (mean 0.59), CGG (mean 0.64), CGU (mean 0.64) and UGC (mean 0.75)] were slightly suppressed.", [["CpG", "CHEMICAL", 65, 68], ["VP7", "GENE_OR_GENE_PRODUCT", 23, 26], ["VP7 protein", "PROTEIN", 23, 34], ["GpC", "PROTEIN", 73, 76], ["The RSCU value", "TEST", 0, 14], ["the VP7 protein", "TEST", 19, 34], ["the 14 codons", "PROBLEM", 38, 51], ["CpG", "PROBLEM", 65, 68], ["GpC", "TEST", 73, 76], ["GCG", "TEST", 108, 111], ["mean", "TEST", 113, 117], ["CGC", "TEST", 125, 128], ["mean", "TEST", 130, 134], ["GCC", "TEST", 142, 145], ["mean", "TEST", 147, 151], ["GCG", "TEST", 159, 162], ["mean", "TEST", 164, 168], ["AGC", "TEST", 176, 179], ["mean", "TEST", 181, 185], ["GGC", "TEST", 196, 199], ["mean", "TEST", 201, 205], ["CCG", "TEST", 248, 251], ["mean", "TEST", 253, 257], ["UCG", "TEST", 265, 268], ["mean", "TEST", 270, 274], ["CGG", "TEST", 282, 285], ["mean", "TEST", 287, 291], ["CGU", "TEST", 299, 302], ["mean", "TEST", 304, 308], ["UGC", "TEST", 319, 322], ["slightly suppressed", "PROBLEM", 341, 360]]], ["Besides, the position of each codon in each of the four major axes of COA was determined for both proteins studied.", [["COA", "GENE_OR_GENE_PRODUCT", 70, 73], ["COA", "DNA", 70, 73], ["each codon", "TREATMENT", 25, 35], ["COA", "OBSERVATION", 70, 73]]], ["For VP4 [VP8*] ORFs, the first major axis accounted for the 28.67% of the observed variation, while the second, third and fourth axis accounted for the 21.57%, 18.56% and 12.39%, respectively.", [["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP4 [VP8*] ORFs", "DNA", 4, 19], ["VP4", "TEST", 4, 7], ["ORFs", "TEST", 15, 19], ["second", "ANATOMY_MODIFIER", 104, 110], ["fourth axis", "ANATOMY", 122, 133]]], ["For VP7 ORFs, the first major axis accounted for the 66.00% of the observed variation; the second, third and fourth major axis accounted for the 14.82%, 8.09% and 2.40% of the observed variation, respectively.", [["VP7", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP7 ORFs", "DNA", 4, 12], ["VP7 ORFs", "TEST", 4, 12], ["fourth", "ANATOMY_MODIFIER", 109, 115], ["major axis", "ANATOMY", 116, 126]]], ["Table 4 shows the codons for which the maximum and minimum values were obtained for each of the axes studied (i.e. the most divergent codons values), indicating a strong bias in their use by both VP4 and VP7 proteins.", [["VP4", "GENE_OR_GENE_PRODUCT", 196, 199], ["VP7", "GENE_OR_GENE_PRODUCT", 204, 207], ["VP4", "PROTEIN", 196, 199], ["VP7 proteins", "PROTEIN", 204, 216], ["the codons", "TREATMENT", 14, 24]]], ["As can be seen, the most divergent triplets tend to be GC-rich (considering the two ORFs, G+C explains 19/24 positions of these codons).", [["G+C", "GENE_OR_GENE_PRODUCT", 90, 93], ["ORFs", "DNA", 84, 88]]], ["Again, this can be explained in terms of a strong mutational bias.ResultsIn order to observe if the same results found using outer capsid proteins of P[4]G2 RV-A strains can be found using complete genomes, the same studies were repeated using a dataset of full complete genomes (for strains, accession numbers and genomic constellations, see Supplementary Material Table 3 ).", [["outer capsid proteins", "PROTEIN", 125, 146], ["a strong mutational bias", "PROBLEM", 41, 65], ["G2 RV", "TEST", 154, 159], ["A strains", "PROBLEM", 160, 169], ["the same studies", "TEST", 207, 223], ["strains", "PROBLEM", 284, 291], ["genomic constellations", "TEST", 315, 337]]], ["The results of these studies are shown in Supplementary Material Table 4 .", [["these studies", "TEST", 15, 28]]], ["Again, the relative abundance of CpG and GpC showed a strong deviation from the expected frequencies (i.e. 1.0) (mean AE S.D. = 0.360 AE 0.021) and (0.468 AE 0.038, respectively) and were markedly underrepresented.", [["CpG", "CHEMICAL", 33, 36], ["GpC", "GENE_OR_GENE_PRODUCT", 41, 44], ["CpG", "DNA", 33, 36], ["GpC", "PROTEIN", 41, 44], ["CpG", "PROBLEM", 33, 36], ["GpC", "TEST", 41, 44], ["a strong deviation", "PROBLEM", 52, 70], ["mean AE S.D.", "TEST", 113, 125], ["AE", "TEST", 134, 136], ["abundance", "OBSERVATION_MODIFIER", 20, 29], ["strong", "OBSERVATION_MODIFIER", 54, 60], ["deviation", "OBSERVATION", 61, 70], ["markedly", "OBSERVATION_MODIFIER", 188, 196]]], ["The frequencies of ApU and ApA also showed a sharp deviation from the expected frequencies and were markedly over-used (mean AE S.D. = 1.907 AE 0.069 and 2.089 AE 0.048, respectively).", [["ApU", "GENE_OR_GENE_PRODUCT", 19, 22], ["ApA", "GENE_OR_GENE_PRODUCT", 27, 30], ["ApU", "PROTEIN", 19, 22], ["ApA", "PROTEIN", 27, 30], ["ApA", "TEST", 27, 30], ["a sharp deviation", "PROBLEM", 43, 60], ["AE", "TEST", 141, 143], ["sharp", "OBSERVATION_MODIFIER", 45, 50], ["deviation", "OBSERVATION", 51, 60]]], ["Among the 16 dinucleotides, seven are correlated with the position of the sequences along the first axis in COA (P values <0.01, Supplementary Material Table 4 ).", [["dinucleotides", "CHEMICAL", 13, 26], ["the sequences", "TEST", 70, 83], ["COA (P values", "TEST", 108, 121], ["first axis", "ANATOMY", 94, 104], ["COA", "ANATOMY", 108, 111]]], ["Taking all these results together, it is possible to observe that the composition of dinucleotides also determines the variation in synonymous codon usage in the complete sequences of human RV-A.DiscussionThe results of these studies revealed that codon usage for VP4 [VP8*] and VP7 in P[4]G2 RV-A is quite different from that of human genes (see Table 1 ).", [["dinucleotides", "CHEMICAL", 85, 98], ["human", "ORGANISM", 184, 189], ["RV-A.", "ORGANISM", 190, 195], ["VP4", "GENE_OR_GENE_PRODUCT", 264, 267], ["VP8", "GENE_OR_GENE_PRODUCT", 269, 272], ["VP7", "GENE_OR_GENE_PRODUCT", 279, 282], ["human", "ORGANISM", 330, 335], ["VP4", "PROTEIN", 264, 267], ["VP7", "DNA", 279, 282], ["human genes", "DNA", 330, 341], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 330, 335], ["human RV-A.", "SPECIES", 184, 195], ["human", "SPECIES", 330, 335], ["the composition of dinucleotides", "PROBLEM", 66, 98], ["synonymous codon usage", "TREATMENT", 132, 154], ["these studies", "TEST", 220, 233], ["codon usage", "TEST", 248, 259], ["VP4", "TEST", 264, 267], ["VP7", "TEST", 279, 282], ["P", "TEST", 286, 287], ["RV", "TEST", 293, 295], ["synonymous codon", "OBSERVATION", 132, 148], ["RV", "ANATOMY", 190, 192], ["RV", "ANATOMY", 293, 295]]], ["Moreover, this is also observed considering all different genome regions or complete, full genome codes (see Table 2 ).", [["genome regions", "DNA", 58, 72]]], ["This is in agreement with results found for other viruses such as human immunodeficiency virus 1 (HIV-1) (Grantham and Perrin, 1986; Kypr and Mrazek, 1987) and hepatitis A virus (Aragones et al., 2008) .", [["human immunodeficiency virus", "DISEASE", 66, 94], ["hepatitis A virus", "DISEASE", 160, 177], ["human immunodeficiency virus 1", "ORGANISM", 66, 96], ["HIV-1", "ORGANISM", 98, 103], ["hepatitis A virus", "ORGANISM", 160, 177], ["human immunodeficiency virus 1", "SPECIES", 66, 96], ["HIV-1", "SPECIES", 98, 103], ["hepatitis A virus", "SPECIES", 160, 177], ["human immunodeficiency virus 1", "SPECIES", 66, 96], ["HIV-1", "SPECIES", 98, 103], ["hepatitis A virus", "SPECIES", 160, 177], ["other viruses", "PROBLEM", 44, 57], ["human immunodeficiency virus", "PROBLEM", 66, 94], ["HIV", "TEST", 98, 101], ["Grantham", "TEST", 106, 114], ["Kypr", "TEST", 133, 137], ["Mrazek", "TEST", 142, 148], ["hepatitis A virus", "PROBLEM", 160, 177]]], ["In other RNA viruses, like poliovirus or foot-and-mouth disease virus (FMDV) the codon usage is very (Sanchez et al., 2003) .", [["foot-and-mouth disease", "DISEASE", 41, 63], ["like poliovirus", "ORGANISM", 22, 37], ["foot-and-mouth disease virus", "ORGANISM", 41, 69], ["FMDV", "ORGANISM", 71, 75], ["foot-and-mouth disease virus", "SPECIES", 41, 69], ["FMDV", "SPECIES", 71, 75], ["foot-and-mouth disease virus", "SPECIES", 41, 69], ["FMDV", "SPECIES", 71, 75], ["other RNA viruses", "PROBLEM", 3, 20], ["poliovirus or foot", "PROBLEM", 27, 45], ["mouth disease virus", "PROBLEM", 50, 69], ["RNA viruses", "OBSERVATION", 9, 20], ["poliovirus", "OBSERVATION", 27, 37], ["foot", "ANATOMY", 41, 45], ["mouth", "ANATOMY", 50, 55]]], ["In these cases, competition is avoided by the induction of cellular shutoff of protein synthesis through carboxy cleavage of translation initiation factor 4G (eIF4G) by 2A and L proteases, respectively (Racaniello, 2001) .", [["cellular", "ANATOMY", 59, 67], ["carboxy", "CHEMICAL", 105, 112], ["cellular", "CELL", 59, 67], ["carboxy cleavage of translation initiation factor 4G", "GENE_OR_GENE_PRODUCT", 105, 157], ["eIF4G", "GENE_OR_GENE_PRODUCT", 159, 164], ["2A", "GENE_OR_GENE_PRODUCT", 169, 171], ["L proteases", "GENE_OR_GENE_PRODUCT", 176, 187], ["translation initiation factor 4G", "PROTEIN", 125, 157], ["eIF4G", "PROTEIN", 159, 164], ["2A and L proteases", "PROTEIN", 169, 187], ["cellular shutoff of protein synthesis", "TREATMENT", 59, 96], ["carboxy cleavage", "TREATMENT", 105, 121], ["2A and L proteases", "TREATMENT", 169, 187]]], ["Early during the infection process RV-A also takes over the host translation machinery of the cell, causing a shutoff of cell protein synthesis, although by a different mechanism of picornaviruses.", [["cell", "ANATOMY", 94, 98], ["cell", "ANATOMY", 121, 125], ["infection", "DISEASE", 17, 26], ["cell", "CELL", 94, 98], ["cell", "CELL", 121, 125], ["the infection process", "PROBLEM", 13, 34], ["cell protein synthesis", "PROBLEM", 121, 143], ["picornaviruses", "PROBLEM", 182, 196], ["infection", "OBSERVATION", 17, 26], ["cell", "OBSERVATION", 94, 98], ["cell protein synthesis", "OBSERVATION", 121, 143], ["picornaviruses", "OBSERVATION", 182, 196]]], ["After RV-A infection, the translation initiation factor 2a (eIF2a) becomes phosphorylated and remains in this state throughout the virus replication cycle, leading to a further inhibition of cell protein synthesis (Montero et al., 2008) .", [["cell", "ANATOMY", 191, 195], ["infection", "DISEASE", 11, 20], ["translation initiation factor 2a", "GENE_OR_GENE_PRODUCT", 26, 58], ["eIF2a", "GENE_OR_GENE_PRODUCT", 60, 65], ["cell", "CELL", 191, 195], ["translation initiation factor 2a", "PROTEIN", 26, 58], ["eIF2a", "PROTEIN", 60, 65], ["A infection", "PROBLEM", 9, 20], ["phosphorylated", "PROBLEM", 75, 89], ["cell protein synthesis", "TREATMENT", 191, 213], ["RV", "ANATOMY", 6, 8], ["infection", "OBSERVATION", 11, 20]]], ["However, recent studies have shown that under these restrictive conditions, the viral proteins and some cellular proteins are efficiently translated (Montero et al., 2008) .", [["cellular", "ANATOMY", 104, 112], ["cellular", "CELL", 104, 112], ["viral proteins", "PROTEIN", 80, 94], ["cellular proteins", "PROTEIN", 104, 121], ["recent studies", "TEST", 9, 23], ["these restrictive conditions", "PROBLEM", 46, 74], ["the viral proteins", "TEST", 76, 94], ["some cellular proteins", "PROBLEM", 99, 121], ["restrictive", "OBSERVATION", 52, 63], ["viral proteins", "OBSERVATION", 80, 94], ["cellular proteins", "OBSERVATION", 104, 121]]], ["Whether this extremely different strategy in codon usage among RV-A and human cells is related to this fact is currently unknown, but might allow RV-A to compete successfully for translation of viral RNAs.DiscussionWe analyzed synonymous codon usage and nucleotide compositional constraints in VP4 [VP8*] and VP7 genes of P[4]G2 RV-A and compare the results found with a dataset of RV-A reference strains from which the complete sequences for the 11 segments were previously known.", [["RV-A", "ANATOMY", 63, 67], ["cells", "ANATOMY", 78, 83], ["nucleotide", "CHEMICAL", 254, 264], ["RV-A", "CELL", 63, 67], ["human", "ORGANISM", 72, 77], ["cells", "CELL", 78, 83], ["RV-A", "GENE_OR_GENE_PRODUCT", 146, 150], ["VP4 [VP8*", "GENE_OR_GENE_PRODUCT", 294, 303], ["VP7", "GENE_OR_GENE_PRODUCT", 309, 312], ["human cells", "CELL_TYPE", 72, 83], ["viral RNAs", "RNA", 194, 204], ["VP7 genes", "DNA", 309, 318], ["human", "SPECIES", 72, 77], ["RV-A", "SPECIES", 63, 67], ["human", "SPECIES", 72, 77], ["codon usage", "TREATMENT", 45, 56], ["RV", "TEST", 63, 65], ["A and human cells", "PROBLEM", 66, 83], ["RV", "TEST", 146, 148], ["viral RNAs", "PROBLEM", 194, 204], ["synonymous codon usage", "TREATMENT", 227, 249], ["nucleotide compositional constraints", "TREATMENT", 254, 290], ["VP4", "TEST", 294, 297], ["VP7 genes", "TEST", 309, 318], ["P", "TEST", 322, 323], ["G2 RV", "TEST", 326, 331], ["RV", "TEST", 382, 384], ["A reference strains", "PROBLEM", 385, 404], ["viral RNAs", "OBSERVATION", 194, 204], ["synonymous codon", "OBSERVATION", 227, 243], ["RV", "ANATOMY", 382, 384]]], ["Interestingly, in contrary to previous results found for other viruses such H5N1 influenza A Virus (mean ENC = 50.91) (Ahn et al., 2006; Zhou et al., 2005) ; SARS (mean ENC = 48.99) (Zhao et al., 2008) ; FMDV (mean ENC = 51.42) (Zhong et al., 2007) ; classical swine fever virus (mean ENC = 51.7) (Tao et al., 2009 ) and duck enteritis virus (mean ENC = 52.17) (Jia et al., 2009) , the ENC values found for human P[4]G2 RV-A are comparatively low (mean ENC values of 37.36 and 40.56 for VP8* and VP7, respectively).", [["influenza A Virus", "DISEASE", 81, 98], ["SARS", "DISEASE", 158, 162], ["swine fever", "DISEASE", 261, 272], ["duck enteritis", "DISEASE", 321, 335], ["H5N1 influenza A Virus", "ORGANISM", 76, 98], ["classical swine fever virus", "ORGANISM", 251, 278], ["duck enteritis virus", "ORGANISM", 321, 341], ["human", "ORGANISM", 407, 412], ["VP7", "GENE_OR_GENE_PRODUCT", 496, 499], ["VP8", "PROTEIN", 487, 490], ["VP7", "PROTEIN", 496, 499], ["H5N1 influenza A Virus", "SPECIES", 76, 98], ["FMDV", "SPECIES", 204, 208], ["swine fever virus", "SPECIES", 261, 278], ["duck enteritis virus", "SPECIES", 321, 341], ["human", "SPECIES", 407, 412], ["swine fever virus", "SPECIES", 261, 278], ["duck enteritis virus", "SPECIES", 321, 341], ["human", "SPECIES", 407, 412], ["other viruses", "PROBLEM", 57, 70], ["H5N1 influenza A Virus", "PROBLEM", 76, 98], ["ENC", "TEST", 105, 108], ["SARS", "PROBLEM", 158, 162], ["mean ENC", "TEST", 164, 172], ["ENC", "TEST", 215, 218], ["classical swine fever virus", "PROBLEM", 251, 278], ["mean ENC", "TEST", 280, 288], ["Tao et al.", "TEST", 298, 308], ["duck enteritis virus", "PROBLEM", 321, 341], ["mean ENC", "TEST", 343, 351], ["the ENC values", "TEST", 382, 396], ["G2 RV", "TEST", 417, 422], ["mean ENC values", "TEST", 448, 463], ["VP8", "TEST", 487, 490], ["VP7", "TEST", 496, 499], ["duck", "ANATOMY", 321, 325], ["enteritis", "OBSERVATION", 326, 335]]], ["Moreover, when the complete genomes are studied (accounting for 54,318 codons), the mean ENC value obtained is 41.60.", [["ENC", "DNA", 89, 92], ["the mean ENC value", "TEST", 80, 98]]], ["This indicates that the overall extent of codon usage bias in RV-A genomes is significant.DiscussionWe observed a general correlation between codon usage bias and base composition was observed, since all spots in the ENC-GC 3 S plot lie below the curve of the predicted values (Fig. 1) .", [["RV-A", "CANCER", 62, 66], ["RV-A genomes", "DNA", 62, 74], ["ENC", "DNA", 217, 220], ["RV-A", "SPECIES", 62, 66], ["codon usage bias", "PROBLEM", 42, 58], ["codon usage bias", "TREATMENT", 142, 158], ["all spots", "PROBLEM", 200, 209], ["the ENC", "TEST", 213, 220], ["GC 3 S plot", "TEST", 221, 232], ["extent", "OBSERVATION_MODIFIER", 32, 38], ["codon usage", "OBSERVATION", 42, 53], ["RV", "ANATOMY", 62, 64], ["significant", "OBSERVATION_MODIFIER", 78, 89]]], ["Highly significant correlations between the first axis of COA and GC 3 S values were obtained for both outer surface protein shells.", [["outer surface", "ANATOMY", 103, 116], ["COA", "TEST", 58, 61], ["GC 3 S values", "TEST", 66, 79], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["protein shells", "OBSERVATION", 117, 131]]], ["Moreover, concatenation of complete sequences of the 11 segments of 10 reference human RV-A strains also show this significant correlation.", [["human", "ORGANISM", 81, 86], ["RV-A strains", "ORGANISM", 87, 99], ["human", "SPECIES", 81, 86], ["human RV-A", "SPECIES", 81, 91], ["complete sequences", "TEST", 27, 45], ["RV", "ANATOMY", 87, 89]]], ["All these results strongly suggest that mutational pressure is an important factor in determining codon usage bias in human RV-A.", [["human", "ORGANISM", 118, 123], ["human", "SPECIES", 118, 123], ["human RV-A.", "SPECIES", 118, 129], ["mutational pressure", "PROBLEM", 40, 59], ["RV", "ANATOMY", 124, 126]]], ["Nevertheless, we cannot completely discard other factors that may also account for codon usage bias.DiscussionThe frequencies of dinucleotides were not random and no dinucleotides was present at the expected frequencies for both ORFs studied (VP8* and VP7, see Table 3 ).", [["dinucleotides", "CHEMICAL", 129, 142], ["dinucleotides", "CHEMICAL", 166, 179], ["ORFs", "DNA", 229, 233], ["VP7", "DNA", 252, 255], ["codon usage bias", "PROBLEM", 83, 99], ["dinucleotides", "TREATMENT", 129, 142], ["dinucleotides", "PROBLEM", 166, 179], ["VP8", "TEST", 243, 246], ["VP7", "TEST", 252, 255]]], ["CpG and GpC containing codons are markedly suppressed (see Tables 1 and 2 ).", [["CpG", "CHEMICAL", 0, 3], ["GpC", "GENE_OR_GENE_PRODUCT", 8, 11], ["CpG", "DNA", 0, 3], ["GpC", "DNA", 8, 11], ["CpG and GpC containing codons", "TREATMENT", 0, 29], ["markedly suppressed", "PROBLEM", 34, 53], ["markedly", "OBSERVATION_MODIFIER", 34, 42], ["suppressed", "OBSERVATION_MODIFIER", 43, 53]]], ["Marked CpG deficiency has been also observed in Coronaviruses (Woo et al., 2007) , vertebrateinfecting members of the family Flaviviridae (Lobo et al., 2009) , poliovirus (Rothberg and Wimmer, 1981) and other RNA viruses (Karlin et al., 1994) .", [["CpG", "CHEMICAL", 7, 10], ["poliovirus", "ORGANISM", 160, 170], ["Marked CpG deficiency", "PROBLEM", 0, 21], ["poliovirus", "PROBLEM", 160, 170], ["CpG deficiency", "OBSERVATION", 7, 21]]], ["The CpG deficiency was proposed to be related to the immunostimulatory properties of unmethylated CpG, which were recognized by the host's innate immune system as a pathogen signature (Shackelton et al., 2006; Woo et al., 2007) .", [["CpG", "CHEMICAL", 4, 7], ["CpG", "CHEMICAL", 98, 101], ["unmethylated CpG", "DNA", 85, 101], ["The CpG deficiency", "PROBLEM", 0, 18], ["the immunostimulatory properties of unmethylated CpG", "TREATMENT", 49, 101], ["CpG deficiency", "OBSERVATION", 4, 18]]], ["This is now known to be triggered by the intracellular Pattern Recognition Receptor (PRR) Toll-like 9 (TLR9), which recognizes CpG-unmethylated DNA, and triggers several immune response pathways (Dorn and Kippenberger, 2008) .", [["intracellular", "ANATOMY", 41, 54], ["CpG", "CHEMICAL", 127, 130], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["Pattern Recognition Receptor", "GENE_OR_GENE_PRODUCT", 55, 83], ["PRR", "GENE_OR_GENE_PRODUCT", 85, 88], ["Toll-like 9", "GENE_OR_GENE_PRODUCT", 90, 101], ["TLR9", "GENE_OR_GENE_PRODUCT", 103, 107], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["intracellular Pattern Recognition Receptor (PRR) Toll-like 9", "PROTEIN", 41, 101], ["TLR9", "PROTEIN", 103, 107], ["CpG-unmethylated DNA", "DNA", 127, 147], ["unmethylated DNA", "PROBLEM", 131, 147]]], ["Since the vertebrate immune system relies on unmethylated CpG recognition in DNA molecules as a sign of infection, and CpG under-representation in RNA viruses is exclusively observed in vertebrate viruses (Lobo et al., 2009) , it is reasonable to suggest that a TLR9-like mechanism exists in the vertebrate immune system which recognizes CpG when in RNA context (such as in the genomes of RNA viruses) and triggers immune responses (Lobo et al., 2009) .", [["immune system", "ANATOMY", 21, 34], ["immune system", "ANATOMY", 307, 320], ["infection", "DISEASE", 104, 113], ["CpG", "CHEMICAL", 58, 61], ["CpG", "CHEMICAL", 119, 122], ["CpG", "CHEMICAL", 338, 341], ["immune system", "ANATOMICAL_SYSTEM", 21, 34], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["TLR9", "GENE_OR_GENE_PRODUCT", 262, 266], ["DNA molecules", "PROTEIN", 77, 90], ["TLR9", "PROTEIN", 262, 266], ["unmethylated CpG recognition", "TREATMENT", 45, 73], ["DNA molecules", "PROBLEM", 77, 90], ["infection", "PROBLEM", 104, 113], ["CpG", "TREATMENT", 119, 122], ["RNA viruses", "PROBLEM", 147, 158], ["a TLR9-like mechanism", "PROBLEM", 260, 281], ["infection", "OBSERVATION", 104, 113], ["RNA viruses", "OBSERVATION", 147, 158], ["vertebrate viruses", "OBSERVATION", 186, 204]]], ["Moreover, recent studies on influenza A viruses, which have originated from an avian reservoir and have been infecting human hosts since 1918, were selected under strong pressure to reduce the frequency of CpG in its genome (Greenbaum et al., 2008) .DiscussionThe results of this work provide a basic knowledge of the mechanisms that give rise to codon usage bias in human RV-A and are also useful in understanding the processes involved in RV-A evolution.", [["influenza A viruses", "DISEASE", 28, 47], ["CpG", "CHEMICAL", 206, 209], ["CpG", "CHEMICAL", 206, 209], ["influenza A viruses", "ORGANISM", 28, 47], ["human", "ORGANISM", 119, 124], ["human", "ORGANISM", 367, 372], ["RV-A", "CANCER", 373, 377], ["RV-A", "GENE_OR_GENE_PRODUCT", 441, 445], ["CpG", "DNA", 206, 209], ["influenza A viruses", "SPECIES", 28, 47], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 367, 372], ["influenza A viruses", "SPECIES", 28, 47], ["human", "SPECIES", 119, 124], ["human RV-A", "SPECIES", 367, 377], ["recent studies", "TEST", 10, 24], ["influenza A viruses", "PROBLEM", 28, 47], ["an avian reservoir", "TREATMENT", 76, 94], ["RV", "ANATOMY", 441, 443]]], ["Further studies will be needed to reveal more about RV-A viral genome.", [["RV-A viral genome", "DNA", 52, 69], ["Further studies", "TEST", 0, 15], ["RV", "TEST", 52, 54], ["A viral genome", "PROBLEM", 55, 69], ["viral genome", "OBSERVATION", 57, 69]]]], "24c9985dfabc010c381bee3b22324dadb1214d69": [["IntroductionThe T cell response is critical for pathogen clearance and tumor eradication and is mediated by interactions between the T cell receptor and MHC class I or II/peptide (MHCp) complex.", [["T cell", "ANATOMY", 16, 22], ["tumor", "ANATOMY", 71, 76], ["T cell", "ANATOMY", 133, 139], ["tumor", "DISEASE", 71, 76], ["T cell", "CELL", 16, 22], ["tumor", "CANCER", 71, 76], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 133, 148], ["MHC class I", "GENE_OR_GENE_PRODUCT", 153, 164], ["II", "GENE_OR_GENE_PRODUCT", 168, 170], ["MHCp", "GENE_OR_GENE_PRODUCT", 180, 184], ["T cell receptor", "PROTEIN", 133, 148], ["MHC class I or II/peptide (MHCp) complex", "PROTEIN", 153, 193], ["pathogen clearance", "PROBLEM", 48, 66], ["tumor eradication", "TREATMENT", 71, 88], ["the T cell receptor", "TREATMENT", 129, 148], ["II/peptide (MHCp) complex", "TREATMENT", 168, 193], ["tumor", "OBSERVATION", 71, 76]]], ["Multiple factors, including the kinetics and affinity of the interaction, size of the T cell precursor pool, kinetics of peptide presentation and affinity of the peptide for the MHC antigen are critical for understanding the T cell response in a given physiological or pathological setting.", [["T cell", "ANATOMY", 86, 92], ["T cell", "ANATOMY", 225, 231], ["T cell", "CELL", 86, 92], ["MHC antigen", "GENE_OR_GENE_PRODUCT", 178, 189], ["T cell", "CELL", 225, 231], ["MHC antigen", "PROTEIN", 178, 189], ["Multiple factors", "PROBLEM", 0, 16], ["the MHC antigen", "PROBLEM", 174, 189], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["Further, the response to a single epitope is generally complex, involving T cells with a variety of affinities for the MHCp complex.", [["T cells", "ANATOMY", 74, 81], ["T cells", "CELL", 74, 81], ["MHCp", "GENE_OR_GENE_PRODUCT", 119, 123], ["T cells", "CELL_TYPE", 74, 81], ["MHCp complex", "PROTEIN", 119, 131], ["a single epitope", "PROBLEM", 25, 41]]], ["In addition, expansion of a specific T cell in a single immune response is partly stochastic, depending on access of the T cell in question to the MHCp.", [["T cell", "ANATOMY", 37, 43], ["T cell", "ANATOMY", 121, 127], ["T cell", "CELL", 37, 43], ["T cell", "CELL", 121, 127], ["MHCp", "GENE_OR_GENE_PRODUCT", 147, 151], ["T cell", "CELL_TYPE", 37, 43], ["T cell", "CELL_TYPE", 121, 127], ["MHCp", "DNA", 147, 151], ["a specific T cell", "PROBLEM", 26, 43], ["the T cell", "TREATMENT", 117, 127], ["expansion", "OBSERVATION_MODIFIER", 13, 22]]], ["Finally, the number of epitopespecific cells in the na\u00efve T cell pool is small, ranging from less than 100 to 1000 cells (Pewe et al., 2004; Moon et al., 2007; Obar et al., 2008; La Gruta et al., 2010; Zhao et al., 2011) , making it difficult to monitor endogenous T cell responses at early times after stimulation.IntroductionMany of these problems are circumvented by the use of T cell receptor (TCR) transgenic (Tg) mice.", [["epitopespecific cells", "ANATOMY", 23, 44], ["T cell", "ANATOMY", 58, 64], ["cells", "ANATOMY", 115, 120], ["T cell", "ANATOMY", 265, 271], ["T cell", "ANATOMY", 381, 387], ["epitopespecific cells", "CELL", 23, 44], ["T cell", "CELL", 58, 64], ["cells", "CELL", 115, 120], ["T cell", "CELL", 265, 271], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 381, 396], ["TCR", "GENE_OR_GENE_PRODUCT", 398, 401], ["epitopespecific cells", "CELL_TYPE", 23, 44], ["T cell receptor", "PROTEIN", 381, 396], ["TCR", "PROTEIN", 398, 401], ["mice", "SPECIES", 419, 423], ["mice", "SPECIES", 419, 423], ["epitopespecific cells", "PROBLEM", 23, 44], ["the na\u00efve T cell pool", "TEST", 48, 69], ["these problems", "PROBLEM", 335, 349], ["T cell receptor (TCR)", "TREATMENT", 381, 402], ["epitopespecific cells", "OBSERVATION", 23, 44], ["cell pool", "OBSERVATION", 60, 69], ["small", "OBSERVATION_MODIFIER", 73, 78]]], ["While in some cases only the TCR-\u03b2 or TCR-\u03b1 chain is engineered (e.g., (Turner et al., 1996) , most commonly, both the alpha and beta chains of the TCR are fixed in TCR Tg mice, increasing the fraction of cells in the na\u00efve pool that recognize the epitope in question (Barnden et al., 1998) .", [["cells", "ANATOMY", 205, 210], ["TCR", "CHEMICAL", 38, 41], ["TCR", "CHEMICAL", 165, 168], ["TCR-\u03b2", "GENE_OR_GENE_PRODUCT", 29, 34], ["TCR-\u03b1 chain", "GENE_OR_GENE_PRODUCT", 38, 49], ["alpha", "GENE_OR_GENE_PRODUCT", 119, 124], ["beta chains", "GENE_OR_GENE_PRODUCT", 129, 140], ["TCR", "GENE_OR_GENE_PRODUCT", 148, 151], ["Tg mice", "ORGANISM", 169, 176], ["cells", "CELL", 205, 210], ["TCR", "PROTEIN", 29, 32], ["\u03b2", "PROTEIN", 33, 34], ["TCR", "PROTEIN", 38, 41], ["\u03b1 chain", "PROTEIN", 42, 49], ["alpha and beta chains", "PROTEIN", 119, 140], ["TCR", "PROTEIN", 148, 151], ["TCR", "PROTEIN", 165, 168], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 172, 176], ["the TCR", "TEST", 25, 32]]], ["The majority of the T cells in these mice express the Tg T cell receptor, making them an excellent source for large numbers of clonotype-specific cells.", [["T cells", "ANATOMY", 20, 27], ["T cell", "ANATOMY", 57, 63], ["cells", "ANATOMY", 146, 151], ["T cells", "CELL", 20, 27], ["mice", "ORGANISM", 37, 41], ["Tg T cell receptor", "GENE_OR_GENE_PRODUCT", 54, 72], ["clonotype-specific cells", "CELL", 127, 151], ["T cells", "CELL_TYPE", 20, 27], ["Tg T cell receptor", "PROTEIN", 54, 72], ["clonotype-specific cells", "CELL_TYPE", 127, 151], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["the T cells", "PROBLEM", 16, 27], ["clonotype-specific cells", "PROBLEM", 127, 151], ["excellent", "OBSERVATION_MODIFIER", 89, 98], ["clonotype-specific cells", "OBSERVATION", 127, 151]]], ["Transgenic TCR T cells generally recognize MHCp complexes and function similarly to polyclonal T cells recognizing the same epitope.", [["TCR T cells", "ANATOMY", 11, 22], ["T cells", "ANATOMY", 95, 102], ["TCR T cells", "CELL", 11, 22], ["MHCp", "GENE_OR_GENE_PRODUCT", 43, 47], ["T cells", "CELL", 95, 102], ["TCR T cells", "CELL_TYPE", 11, 22], ["MHCp complexes", "PROTEIN", 43, 57], ["polyclonal T cells", "CELL_TYPE", 84, 102], ["Transgenic TCR T cells", "PROBLEM", 0, 22], ["polyclonal T cells", "PROBLEM", 84, 102]]], ["Development of transgenic mice is most often preceded by the generation of T cell clones specific for the epitope under study.", [["T cell clones", "ANATOMY", 75, 88], ["mice", "ORGANISM", 26, 30], ["T cell clones", "CELL", 75, 88], ["T cell clones", "CELL_LINE", 75, 88], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["transgenic mice", "PROBLEM", 15, 30], ["T cell clones", "PROBLEM", 75, 88], ["the epitope under study", "TEST", 102, 125], ["transgenic mice", "OBSERVATION", 15, 30]]], ["Epitope-specific T cell clones are isolated after repeated stimulation in vitro and limiting dilution; it is well established that the conditions under which T cells are expanded contribute to the selection of T cells with varying affinity for the MHCp.", [["T cell clones", "ANATOMY", 17, 30], ["T cells", "ANATOMY", 158, 165], ["T cells", "ANATOMY", 210, 217], ["T cell clones", "CELL", 17, 30], ["T cells", "CELL", 158, 165], ["T cells", "CELL", 210, 217], ["MHCp", "GENE_OR_GENE_PRODUCT", 248, 252], ["T cell clones", "CELL_LINE", 17, 30], ["T cells", "CELL_TYPE", 158, 165], ["T cells", "CELL_TYPE", 210, 217], ["MHCp", "PROTEIN", 248, 252], ["T cell clones", "PROBLEM", 17, 30], ["repeated stimulation in vitro", "TREATMENT", 50, 79], ["T cells", "PROBLEM", 210, 217], ["cell clones", "OBSERVATION", 19, 30]]], ["Thus, CD8 T cells selected in the presence of low levels of antigen exhibit high affinity for MHCp whereas exposure to high levels of antigen results in the outgrowth of cells with low affinity (Alexander-Miller et al., 1996) .", [["CD8 T cells", "ANATOMY", 6, 17], ["cells", "ANATOMY", 170, 175], ["CD8", "GENE_OR_GENE_PRODUCT", 6, 9], ["MHCp", "GENE_OR_GENE_PRODUCT", 94, 98], ["cells", "CELL", 170, 175], ["CD8 T cells", "CELL_TYPE", 6, 17], ["MHCp", "PROTEIN", 94, 98], ["CD8 T cells", "TEST", 6, 17], ["low levels of antigen", "PROBLEM", 46, 67], ["high affinity", "PROBLEM", 76, 89], ["MHCp", "PROBLEM", 94, 98], ["high levels of antigen", "PROBLEM", 119, 141], ["low affinity", "PROBLEM", 181, 193], ["low levels", "OBSERVATION_MODIFIER", 46, 56], ["low affinity", "OBSERVATION_MODIFIER", 181, 193]]], ["T cells with high versus low affinity for MHCp will behave differently in an infected or cancerous animal and neither type of cell may represent a cell with average functionality in the general population of T cells responding to an epitope.IntroductionMice infected with the neurotropic JHM strain of mouse hepatitis virus (JHMV) develop acute and chronic encephalitis and demyelination (Stohlman et al., 1998) .", [["T cells", "ANATOMY", 0, 7], ["cancerous animal", "ANATOMY", 89, 105], ["cell", "ANATOMY", 126, 130], ["cell", "ANATOMY", 147, 151], ["T cells", "ANATOMY", 208, 215], ["mouse hepatitis virus", "DISEASE", 302, 323], ["encephalitis", "DISEASE", 357, 369], ["demyelination", "DISEASE", 374, 387], ["T cells", "CELL", 0, 7], ["MHCp", "GENE_OR_GENE_PRODUCT", 42, 46], ["cell", "CELL", 126, 130], ["cell", "CELL", 147, 151], ["T cells", "CELL", 208, 215], ["Mice", "ORGANISM", 253, 257], ["neurotropic", "ORGANISM", 276, 287], ["JHM strain", "ORGANISM", 288, 298], ["mouse hepatitis virus", "ORGANISM", 302, 323], ["JHMV", "ORGANISM", 325, 329], ["T cells", "CELL_TYPE", 0, 7], ["MHCp", "PROTEIN", 42, 46], ["T cells", "CELL_TYPE", 208, 215], ["Mice", "SPECIES", 253, 257], ["mouse", "SPECIES", 302, 307], ["hepatitis virus", "SPECIES", 308, 323], ["mouse hepatitis virus", "SPECIES", 302, 323], ["JHMV", "SPECIES", 325, 329], ["T cells", "PROBLEM", 0, 7], ["high versus low affinity", "PROBLEM", 13, 37], ["MHCp", "PROBLEM", 42, 46], ["a cell", "PROBLEM", 145, 151], ["average functionality", "PROBLEM", 157, 178], ["T cells", "PROBLEM", 208, 215], ["an epitope", "TREATMENT", 230, 240], ["the neurotropic JHM strain", "TREATMENT", 272, 298], ["mouse hepatitis virus", "PROBLEM", 302, 323], ["acute and chronic encephalitis", "PROBLEM", 339, 369], ["demyelination", "PROBLEM", 374, 387], ["infected", "OBSERVATION", 77, 85], ["cancerous", "OBSERVATION", 89, 98], ["cell", "OBSERVATION", 126, 130], ["may represent", "UNCERTAINTY", 131, 144], ["cell", "OBSERVATION", 147, 151], ["average", "OBSERVATION_MODIFIER", 157, 164], ["functionality", "OBSERVATION_MODIFIER", 165, 178], ["acute", "OBSERVATION_MODIFIER", 339, 344], ["chronic", "OBSERVATION_MODIFIER", 349, 356], ["encephalitis", "OBSERVATION", 357, 369], ["demyelination", "OBSERVATION", 374, 387]]], ["We and others showed previously that demyelination is T cell mediated, involving virus-specific CD4 and CD8 T cells (Wang et al., 1990; Wu et al., 2000) .", [["T cell", "ANATOMY", 54, 60], ["CD4", "ANATOMY", 96, 99], ["CD8 T cells", "ANATOMY", 104, 115], ["demyelination", "DISEASE", 37, 50], ["T cell", "CELL", 54, 60], ["CD4", "CELL", 96, 99], ["CD8", "GENE_OR_GENE_PRODUCT", 104, 107], ["CD4 and CD8 T cells", "CELL_TYPE", 96, 115], ["demyelination", "PROBLEM", 37, 50], ["T cell", "PROBLEM", 54, 60], ["demyelination", "OBSERVATION", 37, 50]]], ["Further, clinical disease in mice with acute encephalitis is largely CD4 T cell-driven (Anghelina et al., 2006) .", [["CD4 T cell", "ANATOMY", 69, 79], ["encephalitis", "DISEASE", 45, 57], ["mice", "ORGANISM", 29, 33], ["CD4 T cell", "CELL", 69, 79], ["CD4", "PROTEIN", 69, 72], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["clinical disease in mice", "PROBLEM", 9, 33], ["acute encephalitis", "PROBLEM", 39, 57], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["encephalitis", "OBSERVATION", 45, 57]]], ["Thus, mutation of the immunodominant CD4 T cell epitope (M133, spanning residues 133-147 of the transmembrane M protein, TVYVRPIIEDYHTLLT) recognized in C57Bl/6 mice resulted in a loss of virulence in this strain, but not BALB/c mice (H-2 d ) or in RAG1 -/mice, which lack T or B cells.", [["CD4 T cell", "ANATOMY", 37, 47], ["transmembrane", "ANATOMY", 96, 109], ["strain", "ANATOMY", 206, 212], ["T", "ANATOMY", 273, 274], ["B cells", "ANATOMY", 278, 285], ["CD4 T cell epitope", "GENE_OR_GENE_PRODUCT", 37, 55], ["C57Bl/6 mice", "ORGANISM", 153, 165], ["BALB/c mice", "ORGANISM", 222, 233], ["H-2 d", "ORGANISM", 235, 240], ["RAG1 -/mice", "ORGANISM", 249, 260], ["T", "CELL", 273, 274], ["B cells", "CELL", 278, 285], ["immunodominant CD4 T cell epitope", "PROTEIN", 22, 55], ["M133", "PROTEIN", 57, 61], ["residues 133-147", "PROTEIN", 72, 88], ["transmembrane M protein", "PROTEIN", 96, 119], ["TVYVRPIIEDYHTLLT", "PROTEIN", 121, 137], ["RAG1", "PROTEIN", 249, 253], ["T or B cells", "CELL_TYPE", 273, 285], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 229, 233], ["mice", "SPECIES", 256, 260], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 229, 233], ["mice", "SPECIES", 256, 260], ["spanning residues", "TEST", 63, 80], ["the transmembrane M protein", "TEST", 92, 119], ["TVYVRPIIEDYHTLLT", "TEST", 121, 137], ["a loss of virulence", "PROBLEM", 178, 197], ["this strain", "PROBLEM", 201, 212], ["BALB", "TEST", 222, 226]]], ["Virulence could be restored if another immunodominant CD4 T cell epitope (from Listeria monocytogenes) was introduced into the M133-mutated virus, indicating that the CD4 T cell response was pathogenic.", [["CD4 T cell", "ANATOMY", 54, 64], ["CD4 T cell", "ANATOMY", 167, 177], ["CD4 T cell epitope", "GENE_OR_GENE_PRODUCT", 54, 72], ["Listeria monocytogenes", "ORGANISM", 79, 101], ["M133", "GENE_OR_GENE_PRODUCT", 127, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 167, 170], ["immunodominant CD4 T cell epitope", "PROTEIN", 39, 72], ["CD4", "PROTEIN", 167, 170], ["Listeria monocytogenes", "SPECIES", 79, 101], ["Listeria monocytogenes", "SPECIES", 79, 101], ["Virulence", "PROBLEM", 0, 9], ["another immunodominant CD4 T cell epitope", "PROBLEM", 31, 72], ["Listeria monocytogenes", "PROBLEM", 79, 101], ["mutated virus", "PROBLEM", 132, 145], ["the CD4 T cell response", "TEST", 163, 186], ["pathogenic", "PROBLEM", 191, 201], ["cell epitope", "OBSERVATION", 60, 72]]], ["On the other hand, our results also demonstrated that the memory CD4 T cell response was protective.", [["memory CD4 T cell", "ANATOMY", 58, 75], ["CD4", "PROTEIN", 65, 68]]], ["In another report, we showed that a population of regulatory CD4 T cells in the brains of mice infected with a neuroattenuated variant of JHMV (rJ2.2) recognized epitope M133 (Zhao et al., 2011) .", [["CD4 T cells", "ANATOMY", 61, 72], ["brains", "ANATOMY", 80, 86], ["CD4 T cells", "CELL", 61, 72], ["brains", "ORGAN", 80, 86], ["mice", "ORGANISM", 90, 94], ["JHMV", "GENE_OR_GENE_PRODUCT", 138, 142], ["regulatory CD4 T cells", "CELL_TYPE", 50, 72], ["epitope M133", "PROTEIN", 162, 174], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["JHMV", "SPECIES", 138, 142], ["CD4 T cells", "OBSERVATION", 61, 72]]], ["Understanding the relationship between effector, memory and regulatory CD4 T cells responding to a single epitope would be facilitated by the availability of an M133-specific TCR Tg mouse.IntroductionHere, we describe an approach to developing TCR Tg mice that does not require in vitro cell culturing or limiting dilution.", [["CD4 T cells", "ANATOMY", 71, 82], ["cell", "ANATOMY", 287, 291], ["TCR", "CHEMICAL", 244, 247], ["CD4 T cells", "CELL", 71, 82], ["M133", "GENE_OR_GENE_PRODUCT", 161, 165], ["TCR", "GENE_OR_GENE_PRODUCT", 175, 178], ["mouse", "ORGANISM", 182, 187], ["TCR", "GENE_OR_GENE_PRODUCT", 244, 247], ["mice", "ORGANISM", 251, 255], ["cell", "CELL", 287, 291], ["memory and regulatory CD4 T cells", "CELL_TYPE", 49, 82], ["M133", "PROTEIN", 161, 165], ["TCR", "PROTEIN", 175, 178], ["TCR", "PROTEIN", 244, 247], ["mouse", "SPECIES", 182, 187], ["mice", "SPECIES", 251, 255], ["mouse", "SPECIES", 182, 187], ["mice", "SPECIES", 251, 255], ["a single epitope", "TREATMENT", 97, 113], ["TCR Tg mice", "TREATMENT", 244, 255], ["vitro cell culturing", "TREATMENT", 281, 301]]], ["The beta chain of an M133-specific CD4 T cell receptor was initially selected on the basis of its expression in 3/3 JHMVinfected mice.", [["CD4 T cell", "ANATOMY", 35, 45], ["beta chain", "GENE_OR_GENE_PRODUCT", 4, 14], ["M133", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD4 T cell receptor", "GENE_OR_GENE_PRODUCT", 35, 54], ["mice", "ORGANISM", 129, 133], ["beta chain", "PROTEIN", 4, 14], ["M133", "PROTEIN", 21, 25], ["CD4 T cell receptor", "PROTEIN", 35, 54], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["an M133", "TEST", 18, 25], ["beta chain", "OBSERVATION_MODIFIER", 4, 14]]], ["The alpha chain was then selected using infected single chain TCR retrogenic mice in which the beta chain identified in the initial studies was fixed.", [["alpha chain", "GENE_OR_GENE_PRODUCT", 4, 15], ["TCR", "GENE_OR_GENE_PRODUCT", 62, 65], ["mice", "ORGANISM", 77, 81], ["beta chain", "GENE_OR_GENE_PRODUCT", 95, 105], ["alpha chain", "PROTEIN", 4, 15], ["TCR", "PROTEIN", 62, 65], ["beta chain", "PROTEIN", 95, 105], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["The alpha chain", "TREATMENT", 0, 15], ["infected single chain TCR retrogenic mice", "TREATMENT", 40, 81], ["the beta chain", "TEST", 91, 105], ["the initial studies", "TEST", 120, 139], ["alpha chain", "ANATOMY", 4, 15], ["beta chain", "OBSERVATION_MODIFIER", 95, 105]]], ["Subsequent analyses showed that these M133-specific TCR Tg cells, upon transfer to mice prior to infection with rJ2.2, proliferated and trafficked to the infected brain.MiceSpecific pathogen-free 6 week old C57BL/6 (B6) and Thy1.1 congenic mice were purchased from the National Cancer Institute.", [["TCR Tg cells", "ANATOMY", 52, 64], ["brain", "ANATOMY", 163, 168], ["infection", "DISEASE", 97, 106], ["Cancer", "DISEASE", 278, 284], ["M133", "GENE_OR_GENE_PRODUCT", 38, 42], ["TCR", "GENE_OR_GENE_PRODUCT", 52, 55], ["mice", "ORGANISM", 83, 87], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 112, 117], ["brain", "ORGAN", 163, 168], ["C57BL/6 (B6)", "ORGANISM", 207, 219], ["Thy1.1 congenic mice", "ORGANISM", 224, 244], ["M133", "PROTEIN", 38, 42], ["TCR Tg cells", "CELL_LINE", 52, 64], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 240, 244], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 240, 244], ["Subsequent analyses", "TEST", 0, 19], ["these M133", "TEST", 32, 42], ["infection", "PROBLEM", 97, 106], ["MiceSpecific pathogen", "TEST", 169, 190], ["infection", "OBSERVATION", 97, 106], ["infected", "OBSERVATION", 154, 162], ["brain", "ANATOMY", 163, 168], ["Cancer", "OBSERVATION", 278, 284]]], ["Mice were maintained in the animal care facility at the University of Iowa.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["After viral inoculation, mice were examined and weighed daily.", [["mice", "ORGANISM", 25, 29], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["viral inoculation", "TREATMENT", 6, 23], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["inoculation", "OBSERVATION", 12, 23]]], ["Clinical evaluation was based on the following scoring system: 0, asymptomatic; 1, limp tail or slightly hunched; 2, wobbly gait or hunched and ruffled fur; 3, hindlimb paresis or moderate wasting; 4, hindlimb paralysis or severe wasting; 5, moribund.", [["hindlimb", "ANATOMY", 160, 168], ["hindlimb", "ANATOMY", 201, 209], ["hindlimb paresis", "DISEASE", 160, 176], ["wasting", "DISEASE", 189, 196], ["paralysis", "DISEASE", 210, 219], ["wasting", "DISEASE", 230, 237], ["hindlimb", "ORGANISM_SUBDIVISION", 160, 168], ["hindlimb", "ORGANISM_SUBDIVISION", 201, 209], ["Clinical evaluation", "TEST", 0, 19], ["asymptomatic", "PROBLEM", 66, 78], ["limp tail", "TEST", 83, 92], ["slightly hunched", "PROBLEM", 96, 112], ["wobbly gait", "PROBLEM", 117, 128], ["hunched", "PROBLEM", 132, 139], ["ruffled fur", "PROBLEM", 144, 155], ["hindlimb paresis", "PROBLEM", 160, 176], ["moderate wasting", "PROBLEM", 180, 196], ["hindlimb paralysis", "PROBLEM", 201, 219], ["severe wasting", "PROBLEM", 223, 237], ["ruffled fur", "OBSERVATION", 144, 155], ["hindlimb", "ANATOMY", 160, 168], ["paresis", "OBSERVATION", 169, 176], ["moderate", "OBSERVATION_MODIFIER", 180, 188], ["wasting", "OBSERVATION", 189, 196], ["hindlimb", "ANATOMY", 201, 209], ["paralysis", "OBSERVATION", 210, 219], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["wasting", "OBSERVATION", 230, 237]]], ["All animal studies were approved by the University of Iowa Animal Care and Use Committee (Iowa City, IA).VirusNeurovirulent JHMV and its neuroattenuated variant, rJ2.2 (a recombinant version of the J2.2-V-1 virus) were grown and titered as described (Pewe et al., 2005) .", [["rJ2.2", "GENE_OR_GENE_PRODUCT", 162, 167], ["J2.2-V-1 virus", "ORGANISM", 198, 212], ["JHMV", "PROTEIN", 124, 128], ["rJ2.2", "PROTEIN", 162, 167], ["JHMV", "SPECIES", 124, 128], ["All animal studies", "TEST", 0, 18], ["VirusNeurovirulent JHMV", "TEST", 105, 128], ["its neuroattenuated variant", "PROBLEM", 133, 160], ["neuroattenuated variant", "OBSERVATION", 137, 160]]], ["B6 mice were infected intraperitoneally with 1.5 \u00d7 10 5 PFU JHMV or intracranially with 600-700 PFU of rJ2.2.IFN-\u03b3 capture assayCells were harvested from the spleens of JHMV-infected B6 mice 7 days after infection.", [["intraperitoneally", "ANATOMY", 22, 39], ["intracranially", "ANATOMY", 68, 82], ["spleens", "ANATOMY", 158, 165], ["JHMV", "CHEMICAL", 60, 64], ["infection", "DISEASE", 204, 213], ["B6 mice", "ORGANISM", 0, 7], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 109, 114], ["spleens", "ORGAN", 158, 165], ["JHMV", "ORGANISM", 169, 173], ["B6 mice", "ORGANISM", 183, 190], ["IFN", "PROTEIN", 109, 112], ["\u03b3", "PROTEIN", 113, 114], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 3, 7], ["JHMV", "SPECIES", 60, 64], ["JHMV", "SPECIES", 169, 173], ["mice", "SPECIES", 186, 190], ["IFN", "TEST", 109, 112], ["infection", "PROBLEM", 204, 213], ["infected", "OBSERVATION", 13, 21], ["spleens", "ANATOMY", 158, 165], ["infection", "OBSERVATION", 204, 213]]], ["To isolate epitope M133-specific CD4 T cells, 1 \u00d7 10 7 unfractionated splenocytes/ml were stimulated 1:2 with CHB3 cells for 4 h with 1 \u03bcM of M133 peptide (TVYVRPIIEDYHTLT) (Xue et al., 1995) .", [["CD4 T cells", "ANATOMY", 33, 44], ["splenocytes", "ANATOMY", 70, 81], ["CHB3 cells", "ANATOMY", 110, 120], ["M133", "GENE_OR_GENE_PRODUCT", 19, 23], ["splenocytes", "CELL", 70, 81], ["CHB3 cells", "CELL", 110, 120], ["M133 peptide", "SIMPLE_CHEMICAL", 142, 154], ["epitope M133", "PROTEIN", 11, 23], ["CD4 T cells", "CELL_TYPE", 33, 44], ["splenocytes", "CELL_TYPE", 70, 81], ["CHB3 cells", "CELL_LINE", 110, 120], ["isolate epitope M133", "TEST", 3, 23], ["CD4 T cells", "TEST", 33, 44], ["unfractionated splenocytes", "TEST", 55, 81], ["CHB3 cells", "TEST", 110, 120], ["splenocytes", "ANATOMY", 70, 81]]], ["After stimulation, M133-specific CD4 T cells were identified using a mouse IFN-\u03b3 secretion assay kit (Miltenyi Biotec, Auburn, CA) following the manufacturer's protocol for frequencies of IFN-\u03b3-secreting T cells b2%.", [["M133", "ANATOMY", 19, 23], ["CD4 T cells", "ANATOMY", 33, 44], ["T cells", "ANATOMY", 204, 211], ["M133", "SIMPLE_CHEMICAL", 19, 23], ["CD4 T cells", "CELL", 33, 44], ["mouse", "ORGANISM", 69, 74], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 75, 80], ["T cells", "CELL", 204, 211], ["M133-specific CD4 T cells", "CELL_LINE", 19, 44], ["IFN", "PROTEIN", 75, 78], ["\u03b3", "PROTEIN", 79, 80], ["Miltenyi Biotec", "PROTEIN", 102, 117], ["IFN", "PROTEIN", 188, 191], ["T cells", "CELL_TYPE", 204, 211], ["mouse", "SPECIES", 69, 74], ["mouse", "SPECIES", 69, 74], ["stimulation", "TEST", 6, 17], ["M133", "TEST", 19, 23], ["a mouse IFN", "TEST", 67, 78], ["the manufacturer's protocol", "TREATMENT", 141, 168], ["IFN", "TEST", 188, 191]]], ["IFN-\u03b3 + cells were detected with PE-conjugated anti-IFN-\u03b3 antibody.", [["IFN-\u03b3 + cells", "ANATOMY", 0, 13], ["PE", "CHEMICAL", 33, 35], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["PE", "SIMPLE_CHEMICAL", 33, 35], ["anti-IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 47, 57], ["IFN", "PROTEIN", 0, 3], ["anti-IFN", "PROTEIN", 47, 55], ["\u03b3 antibody", "PROTEIN", 56, 66], ["IFN-\u03b3 + cells", "TEST", 0, 13], ["PE", "TEST", 33, 35], ["conjugated anti-IFN", "TEST", 36, 55], ["PE", "OBSERVATION", 33, 35]]], ["Cells were additionally stained with FITCconjugated anti-CD4 Abs.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["anti-CD4", "GENE_OR_GENE_PRODUCT", 52, 60], ["FITCconjugated anti-CD4 Abs", "PROTEIN", 37, 64], ["FITCconjugated anti-CD4 Abs", "TREATMENT", 37, 64]]], ["IFN-\u03b3-expressing CD4 T cells were sorted with a FACS DiVa (BD Biosciences, San Jose, CA).", [["CD4 T cells", "ANATOMY", 17, 28], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN-\u03b3-expressing CD4 T cells", "CELL_LINE", 0, 28], ["FACS DiVa", "PROTEIN", 48, 57], ["IFN", "TEST", 0, 3], ["CD4 T cells", "PROBLEM", 17, 28]]], ["A total of 40,000-50,000 epitope M133-specific cells were obtained from each sort.", [["cells", "ANATOMY", 47, 52], ["M133", "GENE_OR_GENE_PRODUCT", 33, 37], ["cells", "CELL", 47, 52], ["M133-specific cells", "CELL_LINE", 33, 52]]], ["Under our sorting conditions, very few IFN-\u03b3-expressing CD4 T cells were detected when cells were stimulated in the absence of added peptide (Fig. 1 ).Isolation of RNA from lymphocytes and TCR-\u03b2 sequence analysisRNA was isolated from lymphocytes using an RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized from each entire sorted lymphocyte RNA preparation in a 60 \u03bcl reaction, as described (Pewe et al., 1996) .", [["CD4 T cells", "ANATOMY", 56, 67], ["cells", "ANATOMY", 87, 92], ["lymphocytes", "ANATOMY", 173, 184], ["lymphocytes", "ANATOMY", 234, 245], ["lymphocyte", "ANATOMY", 340, 350], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 39, 45], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["cells", "CELL", 87, 92], ["lymphocytes", "CELL", 173, 184], ["TCR-\u03b2", "GENE_OR_GENE_PRODUCT", 189, 194], ["lymphocytes", "CELL", 234, 245], ["lymphocyte", "CELL", 340, 350], ["IFN", "PROTEIN", 39, 42], ["CD4 T cells", "CELL_TYPE", 56, 67], ["lymphocytes", "CELL_TYPE", 173, 184], ["TCR", "PROTEIN", 189, 192], ["lymphocytes", "CELL_TYPE", 234, 245], ["cDNA", "DNA", 295, 299], ["CD4 T cells", "PROBLEM", 56, 67], ["RNA from lymphocytes", "TEST", 164, 184], ["TCR", "TEST", 189, 192], ["\u03b2 sequence analysisRNA", "TEST", 193, 215], ["lymphocytes", "PROBLEM", 234, 245], ["RNA", "OBSERVATION_MODIFIER", 164, 167], ["lymphocyte RNA", "OBSERVATION", 340, 354]]], ["A total of 5 \u03bcl of cDNA was used for PCR.", [["cDNA", "DNA", 19, 23], ["5 \u03bcl of cDNA", "TREATMENT", 11, 23], ["PCR", "TEST", 37, 40]]], ["V\u03b28 was the commonly used V\u03b2 element in the M133-specific CD4 T cell response (Haring et al., 2001) .", [["M133", "ANATOMY", 44, 48], ["CD4 T cell", "ANATOMY", 58, 68], ["V\u03b28", "GENE_OR_GENE_PRODUCT", 0, 3], ["M133", "CELL", 44, 48], ["CD4 T cell", "CELL", 58, 68], ["V\u03b28", "DNA", 0, 3], ["V\u03b2 element", "DNA", 26, 36], ["CD4", "PROTEIN", 58, 61], ["the M133", "TEST", 40, 48]]], ["For synthesis of V\u03b28-specific PCR products, a V\u03b28-specific forward primer (5\u2032-CATGGGCTGAGGCTGATCCATT-3\u2032) was used with a common C\u03b2 reverse primer (5\u2032-GCAATCTCTGCT TTTGATGGCTC-3\u2032) and Taq polymerase (AmpliTaq Gold DNA Polymerase; Applied Biosystems, Foster City, CA).", [["V\u03b28", "GENE_OR_GENE_PRODUCT", 17, 20], ["V\u03b28", "GENE_OR_GENE_PRODUCT", 46, 49], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 183, 197], ["V\u03b28", "PROTEIN", 17, 20], ["V\u03b28-specific forward primer", "DNA", 46, 73], ["C\u03b2 reverse primer", "DNA", 128, 145], ["Taq polymerase", "PROTEIN", 183, 197], ["synthesis of V\u03b28", "TEST", 4, 20], ["CATGGGCTGAGGCTGATCCATT", "TEST", 78, 100], ["a common C\u03b2 reverse primer", "TREATMENT", 119, 145], ["TTTGATGGCTC", "TEST", 163, 174], ["Taq polymerase", "TEST", 183, 197], ["AmpliTaq Gold DNA Polymerase", "TREATMENT", 199, 227]]], ["The PCR error rate was 0.12% (Pewe et al., 2004) .", [["The PCR error rate", "TEST", 0, 18]]], ["PCR products were cloned into plasmid vector pCR2.1-TOPO, as described by the manufacturer (Invitrogen, Carlsbad, CA).", [["TOPO", "GENE_OR_GENE_PRODUCT", 52, 56], ["PCR products", "DNA", 0, 12], ["plasmid vector pCR2.1-TOPO", "DNA", 30, 56], ["PCR products", "TREATMENT", 0, 12]]], ["Colonies containing inserts were identified and sequenced with an automated ABI Prism 3700 Sequencer (Applied Biosystems).AntibodiesThe following antibodies were used in this study: CD4-PerCP-Cy5.5 or -FITC (RM 4-5), TCRV\u03b28.3-FITC or -PE (1B3.3) (BD Pharmingen, San Diego, CA); CD8-APC (53-6.7), CD16/ CD32-biotin (93), IFN-\u03b3-allophycocyanin (APC; XMG1.2), TNF-PE (MP6-XT22), TCRV\u03b12-PE or -APC (B20.1) (eBioscience, San Diego, CA); IL-10-APC (JES5-16E3) (BioLegend, San Diego, CA).MHC class II/peptide M133 tetramer stainingHeparinized whole blood or central nervous system (CNS)derived mononuclear cells were stained with 8 \u03bcg/ml PEconjugated I-A b /M133 tetramers (obtained from the National Institutes of Health/National Institute of Allergy and Infectious Diseases MHC Tetramer Core Facility, Atlanta, GA) in RP10 media for 1 h at 37\u00b0C. Cells were then incubated with anti-CD16/CD32-biotin and anti-CD4-PerCP-Cy5.5, followed by streptavidin-APC and were analyzed using a FACSCalibur (BD Biosciences).", [["whole blood", "ANATOMY", 536, 547], ["central nervous system", "ANATOMY", 551, 573], ["CNS", "ANATOMY", 575, 578], ["mononuclear cells", "ANATOMY", 587, 604], ["Cells", "ANATOMY", 841, 846], ["FITC", "CHEMICAL", 202, 206], ["FITC", "CHEMICAL", 226, 230], ["biotin", "CHEMICAL", 307, 313], ["biotin", "CHEMICAL", 887, 893], ["APC", "CHEMICAL", 945, 948], ["CD4", "GENE_OR_GENE_PRODUCT", 182, 185], ["-FITC", "SIMPLE_CHEMICAL", 201, 206], ["RM 4-5", "SIMPLE_CHEMICAL", 208, 214], ["TCRV\u03b28.3-FITC", "SIMPLE_CHEMICAL", 217, 230], ["-PE", "SIMPLE_CHEMICAL", 234, 237], ["1B3.3", "SIMPLE_CHEMICAL", 239, 244], ["CD8", "GENE_OR_GENE_PRODUCT", 278, 281], ["APC", "GENE_OR_GENE_PRODUCT", 282, 285], ["CD16", "GENE_OR_GENE_PRODUCT", 296, 300], ["CD32", "GENE_OR_GENE_PRODUCT", 302, 306], ["biotin", "SIMPLE_CHEMICAL", 307, 313], ["IFN-\u03b3-allophycocyanin", "GENE_OR_GENE_PRODUCT", 320, 341], ["APC", "GENE_OR_GENE_PRODUCT", 343, 346], ["TNF-PE", "SIMPLE_CHEMICAL", 357, 363], ["MP6-XT22", "SIMPLE_CHEMICAL", 365, 373], ["TCRV\u03b12-PE", "SIMPLE_CHEMICAL", 376, 385], ["-APC", "SIMPLE_CHEMICAL", 389, 393], ["B20.1", "SIMPLE_CHEMICAL", 395, 400], ["IL-10-APC", "SIMPLE_CHEMICAL", 432, 441], ["JES5-16E3", "SIMPLE_CHEMICAL", 443, 452], ["MHC class II", "GENE_OR_GENE_PRODUCT", 481, 493], ["blood", "ORGANISM_SUBSTANCE", 542, 547], ["central nervous system (CNS)derived mononuclear cells", "CELL", 551, 604], ["Cells", "CELL", 841, 846], ["anti-CD16", "GENE_OR_GENE_PRODUCT", 872, 881], ["CD32", "GENE_OR_GENE_PRODUCT", 882, 886], ["biotin", "SIMPLE_CHEMICAL", 887, 893], ["anti-CD4", "SIMPLE_CHEMICAL", 898, 906], ["PerCP-Cy5.5", "SIMPLE_CHEMICAL", 907, 918], ["streptavidin-APC", "SIMPLE_CHEMICAL", 932, 948], ["CD4", "PROTEIN", 182, 185], ["PerCP", "PROTEIN", 186, 191], ["FITC", "PROTEIN", 226, 230], ["BD Pharmingen", "PROTEIN", 247, 260], ["CD8", "PROTEIN", 278, 281], ["APC", "PROTEIN", 282, 285], ["CD16", "PROTEIN", 296, 300], ["CD32", "PROTEIN", 302, 306], ["IFN", "PROTEIN", 320, 323], ["\u03b3-allophycocyanin", "PROTEIN", 324, 341], ["APC", "PROTEIN", 343, 346], ["XMG1", "PROTEIN", 348, 352], ["TNF", "PROTEIN", 357, 360], ["MP6", "PROTEIN", 365, 368], ["\u03b12", "PROTEIN", 380, 382], ["APC", "PROTEIN", 390, 393], ["IL", "PROTEIN", 432, 434], ["APC", "PROTEIN", 438, 441], ["JES5", "DNA", 443, 447], ["16E3", "DNA", 448, 452], ["MHC class II", "PROTEIN", 481, 493], ["central nervous system (CNS)derived mononuclear cells", "CELL_TYPE", 551, 604], ["MHC", "PROTEIN", 769, 772], ["anti-CD16", "PROTEIN", 872, 881], ["CD32", "PROTEIN", 882, 886], ["anti-CD4", "PROTEIN", 898, 906], ["PerCP", "PROTEIN", 907, 912], ["Cy5.5", "PROTEIN", 913, 918], ["streptavidin", "PROTEIN", 932, 944], ["APC", "CELL_TYPE", 945, 948], ["this study", "TEST", 170, 180], ["CD4", "TEST", 182, 185], ["PerCP", "TEST", 186, 191], ["Cy", "TEST", 192, 194], ["FITC", "TEST", 202, 206], ["RM", "TEST", 208, 210], ["TCRV", "TEST", 217, 221], ["\u03b2", "TEST", 221, 222], ["FITC", "TEST", 226, 230], ["PE", "TEST", 235, 237], ["BD Pharmingen", "TEST", 247, 260], ["CA", "TEST", 273, 275], ["CD8", "TEST", 278, 281], ["APC", "TEST", 282, 285], ["CD16", "TEST", 296, 300], ["CD32", "TEST", 302, 306], ["biotin", "TEST", 307, 313], ["IFN", "TEST", 320, 323], ["allophycocyanin (APC", "TREATMENT", 326, 346], ["XMG1", "TREATMENT", 348, 352], ["TNF", "TEST", 357, 360], ["PE", "TEST", 361, 363], ["MP6", "TEST", 365, 368], ["TCRV", "TEST", 376, 380], ["PE", "PROBLEM", 383, 385], ["APC", "PROBLEM", 390, 393], ["eBioscience", "TEST", 403, 414], ["CA", "TEST", 427, 429], ["IL", "TEST", 432, 434], ["APC", "PROBLEM", 438, 441], ["JES5", "TEST", 443, 447], ["II/peptide", "TEST", 491, 501], ["tetramer staining", "TEST", 507, 524], ["Heparinized whole blood or central nervous system", "PROBLEM", 524, 573], ["mononuclear cells", "TEST", 587, 604], ["Atlanta, GA", "TREATMENT", 797, 808], ["anti-CD16", "TREATMENT", 872, 881], ["CD32", "TREATMENT", 882, 886], ["biotin", "TREATMENT", 887, 893], ["anti-CD4", "TREATMENT", 898, 906], ["PerCP", "TREATMENT", 907, 912], ["Cy5.5", "TREATMENT", 913, 918], ["streptavidin-APC", "TREATMENT", 932, 948], ["a FACSCalibur (BD Biosciences", "TREATMENT", 973, 1002], ["PE", "OBSERVATION", 235, 237], ["TNF", "ANATOMY", 357, 360], ["PE", "OBSERVATION", 361, 363], ["PE", "OBSERVATION", 383, 385], ["central", "ANATOMY_MODIFIER", 551, 558], ["nervous system", "ANATOMY", 559, 573], ["CNS", "ANATOMY", 575, 578], ["mononuclear cells", "OBSERVATION", 587, 604]]], ["Results are shown after gating on CD16/ CD32-negative cell populations.Isolation of mononuclear cells from brainsBrains harvested after PBS perfusion were dispersed and digested with 1 mg/ml collagenase D (Roche Applied Science, Indianapolis, IN) and 0.1 mg/ml DNase I (Roche Applied Science) at 37\u00b0C for 30 min.", [["cell", "ANATOMY", 54, 58], ["mononuclear cells", "ANATOMY", 84, 101], ["brains", "ANATOMY", 107, 113], ["Brains", "ANATOMY", 113, 119], ["CD16", "GENE_OR_GENE_PRODUCT", 34, 38], ["CD32", "GENE_OR_GENE_PRODUCT", 40, 44], ["mononuclear cells", "CELL", 84, 101], ["brains", "ORGAN", 107, 113], ["collagenase D", "SIMPLE_CHEMICAL", 191, 204], ["CD16", "PROTEIN", 34, 38], ["CD32", "PROTEIN", 40, 44], ["mononuclear cells", "CELL_TYPE", 84, 101], ["DNase I", "PROTEIN", 261, 268], ["CD16", "TEST", 34, 38], ["CD32", "TEST", 40, 44], ["mononuclear cells", "PROBLEM", 84, 101], ["PBS perfusion", "TEST", 136, 149], ["negative cell populations", "OBSERVATION", 45, 70], ["mononuclear cells", "OBSERVATION", 84, 101], ["brains", "ANATOMY", 107, 113]]], ["Dissociated brain tissue was passed through a 70-\u03bcm cell strainer, followed by Percoll gradient (70/37%) centrifugation.", [["brain tissue", "ANATOMY", 12, 24], ["cell", "ANATOMY", 52, 56], ["brain tissue", "TISSUE", 12, 24], ["cell", "CELL", 52, 56], ["Dissociated brain tissue", "PROBLEM", 0, 24], ["a 70-\u03bcm cell strainer", "TREATMENT", 44, 65], ["Percoll gradient", "TEST", 79, 95], ["brain tissue", "ANATOMY", 12, 24]]], ["Mononuclear cells were collected from the interphase, washed, and resuspended in culture medium for further analysis.Development of M133-specific TCR-\u03b2 retrogenic miceM133 TCR-\u03b2 retrogenic mice were engineered as previously described (Holst et al., 2006a; Holst et al., 2006b; Zhao et al., 2011) .", [["Mononuclear cells", "ANATOMY", 0, 17], ["interphase", "ANATOMY", 42, 52], ["Mononuclear cells", "CELL", 0, 17], ["interphase", "CELLULAR_COMPONENT", 42, 52], ["M133", "GENE_OR_GENE_PRODUCT", 132, 136], ["TCR", "GENE_OR_GENE_PRODUCT", 146, 149], ["\u03b2", "GENE_OR_GENE_PRODUCT", 150, 151], ["mice", "ORGANISM", 163, 167], ["TCR", "GENE_OR_GENE_PRODUCT", 172, 175], ["mice", "ORGANISM", 189, 193], ["Mononuclear cells", "CELL_TYPE", 0, 17], ["M133", "PROTEIN", 132, 136], ["TCR", "PROTEIN", 146, 149], ["\u03b2", "PROTEIN", 150, 151], ["TCR", "PROTEIN", 172, 175], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 189, 193], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 189, 193], ["Mononuclear cells", "PROBLEM", 0, 17], ["further analysis", "TEST", 100, 116], ["M133", "TEST", 132, 136], ["TCR", "TEST", 146, 149], ["TCR", "TEST", 172, 175]]], ["Briefly, an M133-specific TCR-\u03b2 (V\u03b28.3, TRBV13-1) was produced synthetically (GeneArt, Invitrogen, Regensburg, Germany) and cloned into a retroviral vector containing an IRES-GFP cassette to allow identification of transfected cells by GFP expression (MSCV-IRES-GFP, pMIG, kindly provided by Dr. Dario Vignali, St. Jude Children's Hospital).", [["cells", "ANATOMY", 227, 232], ["M133", "GENE_OR_GENE_PRODUCT", 12, 16], ["TCR-\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["TRBV13-1", "GENE_OR_GENE_PRODUCT", 40, 48], ["retroviral", "ORGANISM", 138, 148], ["GFP", "GENE_OR_GENE_PRODUCT", 175, 178], ["cells", "CELL", 227, 232], ["GFP", "GENE_OR_GENE_PRODUCT", 236, 239], ["GFP", "GENE_OR_GENE_PRODUCT", 262, 265], ["pMIG", "GENE_OR_GENE_PRODUCT", 267, 271], ["St. Jude Children", "ORGANISM", 311, 328], ["M133", "PROTEIN", 12, 16], ["TCR", "PROTEIN", 26, 29], ["TRBV13", "PROTEIN", 40, 46], ["IRES", "DNA", 170, 174], ["GFP cassette", "DNA", 175, 187], ["transfected cells", "CELL_LINE", 215, 232], ["MSCV", "PROTEIN", 252, 256], ["IRES", "DNA", 257, 261], ["GFP", "DNA", 262, 265], ["pMIG", "DNA", 267, 271], ["retroviral", "SPECIES", 138, 148], ["an M133", "TEST", 9, 16], ["TCR", "TEST", 26, 29], ["V", "TEST", 33, 34], ["TRBV13", "TEST", 40, 46], ["a retroviral vector", "TREATMENT", 136, 155], ["an IRES-GFP cassette", "TREATMENT", 167, 187], ["transfected cells", "PROBLEM", 215, 232], ["GFP expression", "TEST", 236, 250], ["MSCV", "TEST", 252, 256], ["IRES", "TEST", 257, 261], ["transfected cells", "OBSERVATION", 215, 232]]], ["Retroviral producer cells were sorted based on GFP expression and expanded.", [["producer cells", "ANATOMY", 11, 25], ["Retroviral", "ORGANISM", 0, 10], ["cells", "CELL", 20, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 47, 50], ["Retroviral producer cells", "CELL_TYPE", 0, 25], ["GFP", "PROTEIN", 47, 50], ["Retroviral", "SPECIES", 0, 10], ["Retroviral producer cells", "PROBLEM", 0, 25], ["GFP expression", "TEST", 47, 61], ["producer cells", "OBSERVATION", 11, 25], ["expanded", "OBSERVATION_MODIFIER", 66, 74]]], ["These cells produced retroviral particles that were coated with the VSV glycoprotein (G) and expressed M133 TCR-\u03b2.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["retroviral", "ORGANISM", 21, 31], ["VSV", "ORGANISM", 68, 71], ["G", "GENE_OR_GENE_PRODUCT", 86, 87], ["M133 TCR", "GENE_OR_GENE_PRODUCT", 103, 111], ["VSV glycoprotein", "PROTEIN", 68, 84], ["M133", "PROTEIN", 103, 107], ["TCR", "PROTEIN", 108, 111], ["VSV", "SPECIES", 68, 71], ["retroviral particles", "PROBLEM", 21, 41], ["the VSV glycoprotein", "TREATMENT", 64, 84], ["retroviral particles", "OBSERVATION", 21, 41]]], ["B6 donor bone marrow cells were transduced with these particles and then infused into lethally irradiated (950 rad) recipient B6 mice as described previously (Holst et al., 2006a ; Specificity of M133-specific T cell sorting after staining with IFN-\u03b3 capture assay.", [["bone marrow cells", "ANATOMY", 9, 26], ["T cell", "ANATOMY", 210, 216], ["B6", "CELL", 0, 2], ["bone marrow cells", "CELL", 9, 26], ["B6 mice", "ORGANISM", 126, 133], ["M133", "SIMPLE_CHEMICAL", 196, 200], ["T cell", "CELL", 210, 216], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 245, 250], ["B6 donor bone marrow cells", "CELL_TYPE", 0, 26], ["M133", "PROTEIN", 196, 200], ["IFN", "PROTEIN", 245, 248], ["\u03b3", "PROTEIN", 249, 250], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["B6 donor bone marrow cells", "TREATMENT", 0, 26], ["these particles", "TREATMENT", 48, 63], ["Specificity", "TEST", 181, 192], ["M133", "TEST", 196, 200], ["staining", "TEST", 231, 239], ["IFN", "TEST", 245, 248], ["bone", "ANATOMY", 9, 13], ["marrow cells", "OBSERVATION", 14, 26]]], ["Cells were harvested from the spleen of a naive B6 mouse or a mouse infected i.p. with JHMV and stained for IFN-\u03b3 production in response to peptide M133 or no peptide using an IFN-\u03b3 capture assay.", [["Cells", "ANATOMY", 0, 5], ["spleen", "ANATOMY", 30, 36], ["Cells", "CELL", 0, 5], ["spleen", "ORGAN", 30, 36], ["B6 mouse", "ORGANISM", 48, 56], ["mouse", "ORGANISM", 62, 67], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 108, 113], ["M133", "SIMPLE_CHEMICAL", 148, 152], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 176, 181], ["IFN", "PROTEIN", 108, 111], ["\u03b3", "PROTEIN", 112, 113], ["IFN", "PROTEIN", 176, 179], ["mouse", "SPECIES", 51, 56], ["mouse", "SPECIES", 62, 67], ["mouse", "SPECIES", 51, 56], ["mouse", "SPECIES", 62, 67], ["JHMV", "SPECIES", 87, 91], ["IFN", "PROBLEM", 108, 111], ["peptide M133", "TREATMENT", 140, 152], ["peptide", "TREATMENT", 159, 166], ["an IFN", "TREATMENT", 173, 179], ["spleen", "ANATOMY", 30, 36]]], ["Gates for sorting were chosen to minimize nonspecific staining.", [["nonspecific staining", "PROBLEM", 42, 62], ["nonspecific", "OBSERVATION_MODIFIER", 42, 53], ["staining", "OBSERVATION", 54, 62]]], ["Mice were infected with rJ2.2 at 6-10 weeks after reconstitution.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["infected", "OBSERVATION", 10, 18]]], ["The majority of CD4 T cells in the infected CNS were GFP + .", [["CD4 T cells", "ANATOMY", 16, 27], ["CNS", "ANATOMY", 44, 47], ["CD4 T", "GENE_OR_GENE_PRODUCT", 16, 21], ["CNS", "ANATOMICAL_SYSTEM", 44, 47], ["GFP", "GENE_OR_GENE_PRODUCT", 53, 56], ["CD4 T cells", "CELL_TYPE", 16, 27], ["GFP", "PROTEIN", 53, 56], ["CD4 T cells", "PROBLEM", 16, 27], ["CD4 T cells", "OBSERVATION", 16, 27], ["infected CNS", "ANATOMY", 35, 47]]], ["Using I-A b /M133 tetramers (NIH Tetramer Facility, Atlanta, GA), we sorted 7.5 \u00d7 10 5 M133-specific GFP + cells from the infected CNS and analyzed them for TCR-\u03b1 chain expression. pool 5: V\u03b118: CAAATGAGAGAGAGAAGCGC; V\u03b119: TGGTTT GAAGGACAGTGGGC; V\u03b120: GACATGACTGGCTTCCTGAAGGCC TTGC) was used in conjunction with a common C\u03b1 reverse primer (TGGCGTTGGTCTCTTTTGAAG).", [["GFP + cells", "ANATOMY", 101, 112], ["CNS", "ANATOMY", 131, 134], ["M133", "GENE_OR_GENE_PRODUCT", 87, 91], ["GFP", "GENE_OR_GENE_PRODUCT", 101, 104], ["cells", "CELL", 107, 112], ["CNS", "ANATOMICAL_SYSTEM", 131, 134], ["TCR-\u03b1 chain", "GENE_OR_GENE_PRODUCT", 157, 168], ["M133 tetramers", "PROTEIN", 13, 27], ["M133-specific GFP + cells", "CELL_LINE", 87, 112], ["TCR", "PROTEIN", 157, 160], ["\u03b1 chain", "PROTEIN", 161, 168], ["V\u03b120", "PROTEIN", 246, 250], ["C\u03b1 reverse primer", "DNA", 321, 338], ["TCR", "TEST", 157, 160], ["infected CNS", "ANATOMY", 122, 134]]], ["Four TCR-\u03b1 chains were identified, differing only by single amino acid in the CDR3 region.", [["amino acid", "CHEMICAL", 60, 70], ["amino acid", "CHEMICAL", 60, 70], ["TCR-\u03b1 chains", "GENE_OR_GENE_PRODUCT", 5, 17], ["amino acid", "AMINO_ACID", 60, 70], ["TCR", "PROTEIN", 5, 8], ["\u03b1 chains", "PROTEIN", 9, 17], ["CDR3 region", "PROTEIN", 78, 89], ["single amino acid in the CDR3 region", "PROBLEM", 53, 89], ["CDR3", "ANATOMY", 78, 82]]], ["One of these TCR-\u03b1 chains was produced synthetically and cloned into the retroviral vector described above (Holst et al., 2006a) .", [["TCR", "CHEMICAL", 13, 16], ["TCR-\u03b1 chains", "GENE_OR_GENE_PRODUCT", 13, 25], ["retroviral", "ORGANISM", 73, 83], ["TCR", "PROTEIN", 13, 16], ["\u03b1 chains", "PROTEIN", 17, 25], ["TCR", "OBSERVATION", 13, 16], ["retroviral vector", "OBSERVATION", 73, 90]]], ["In this vector, the TCR-\u03b1 and TCR-\u03b2 chains are linked via a self-cleaving protease (protease 2A), enabling stoichiometric production of the two chains.Development of M133-specific TCR transgenic (Tg) miceM133 TCR Tg mice were engineered as previously described (Barnden et al., 1998) .", [["TCR", "CHEMICAL", 20, 23], ["TCR", "CHEMICAL", 30, 33], ["TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 20, 25], ["TCR-\u03b2 chains", "GENE_OR_GENE_PRODUCT", 30, 42], ["protease 2A", "GENE_OR_GENE_PRODUCT", 84, 95], ["M133", "GENE_OR_GENE_PRODUCT", 166, 170], ["TCR", "GENE_OR_GENE_PRODUCT", 180, 183], ["Tg) miceM133 TCR Tg mice", "ORGANISM", 196, 220], ["TCR", "PROTEIN", 20, 23], ["\u03b1", "PROTEIN", 24, 25], ["TCR", "PROTEIN", 30, 33], ["\u03b2 chains", "PROTEIN", 34, 42], ["self-cleaving protease", "PROTEIN", 60, 82], ["protease 2A", "PROTEIN", 84, 95], ["M133", "PROTEIN", 166, 170], ["TCR", "PROTEIN", 180, 183], ["TCR", "PROTEIN", 209, 212], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 216, 220], ["mice", "SPECIES", 216, 220], ["the TCR", "TEST", 16, 23], ["TCR", "TEST", 30, 33], ["a self-cleaving protease (protease 2A", "TREATMENT", 58, 95], ["enabling stoichiometric production of the two chains", "PROBLEM", 98, 150], ["M133", "TEST", 166, 170], ["stoichiometric production", "OBSERVATION", 107, 132], ["two chains", "ANATOMY_MODIFIER", 140, 150]]], ["Briefly, the TCR-\u03b1 and TCR-\u03b2 chains identified above were cloned into plasmids pES4 and p3A9c\u03b2TCR, respectively (kindly provided by Dr. Frank Carbone, University of Melbourne).", [["plasmids", "ANATOMY", 70, 78], ["TCR", "CHEMICAL", 13, 16], ["TCR", "CHEMICAL", 23, 26], ["TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 13, 18], ["TCR-\u03b2 chains", "GENE_OR_GENE_PRODUCT", 23, 35], ["pES4", "GENE_OR_GENE_PRODUCT", 79, 83], ["p3A9c\u03b2TCR", "GENE_OR_GENE_PRODUCT", 88, 97], ["TCR", "PROTEIN", 13, 16], ["\u03b1", "PROTEIN", 17, 18], ["TCR", "PROTEIN", 23, 26], ["\u03b2 chains", "PROTEIN", 27, 35], ["plasmids", "DNA", 70, 78], ["pES4", "DNA", 79, 83], ["p3A9c\u03b2TCR", "DNA", 88, 97], ["the TCR", "TEST", 9, 16], ["TCR-\u03b2 chains", "TREATMENT", 23, 35]]], ["The transgenes were excised, purified, and microinjected into pronuclei of B6SJL mice (C57Bl/6 J \u00d7 SJL/J F2).", [["pronuclei", "ANATOMY", 62, 71], ["B6SJL mice", "ORGANISM", 75, 85], ["C57Bl/6 J \u00d7 SJL/J F2", "CELL", 87, 107], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["C57Bl/6 J \u00d7 SJL/J F2", "TREATMENT", 87, 107]]], ["Genotyping was performed by PCR of tail DNA using the following primers: TCR-\u03b1 (forward) 5\u2032-CCCTTGGTATCAGCAGTTCC-3\u2032 and (reverse) 5\u2032-GGT AGGTGGCGTTTGTCTCT-3\u2032; TCR-\u03b2 (forward) 5\u2032-TGACATC ATCAGGCTTTGTCTT-3\u2032 and (reverse) 5\u2032-CCCAGCTCACCTAACA CGAG-3\u2032.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 73, 78], ["TCR-\u03b2", "GENE_OR_GENE_PRODUCT", 159, 164], ["tail DNA", "DNA", 35, 43], ["TCR", "PROTEIN", 73, 76], ["\u03b1", "DNA", 77, 78], ["TCR", "PROTEIN", 159, 162], ["\u03b2", "DNA", 163, 164], ["CGAG-3\u2032", "DNA", 239, 246], ["Genotyping", "TEST", 0, 10], ["TCR", "TEST", 73, 76], ["CCCTTGGTATCAGCAGTTCC", "TEST", 92, 112], ["GGT", "TEST", 133, 136], ["AGGTGGCGTTTGTCTCT", "TEST", 137, 154], ["TCR", "TEST", 159, 162], ["TGACATC", "TEST", 178, 185], ["ATCAGGCTTTGTCTT", "TEST", 186, 201], ["CGAG", "TEST", 239, 243]]], ["Mice were backcrossed onto a B6 mouse background using speed congenic genotyping (Harlan Laboratories).", [["Mice", "ORGANISM", 0, 4], ["mouse", "ORGANISM", 32, 37], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 32, 37], ["mouse", "SPECIES", 32, 37]]], ["After 4 rounds of backcrossing, mice were 99.7% identical to B6 mice, as measured by SNP analysis.", [["SNP", "CHEMICAL", 85, 88], ["mice", "ORGANISM", 32, 36], ["B6 mice", "ORGANISM", 61, 68], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 64, 68], ["backcrossing", "TREATMENT", 18, 30], ["SNP analysis", "TEST", 85, 97]]], ["Mice were maintained by backcrossing with B6 mice.", [["Mice", "ORGANISM", 0, 4], ["B6 mice", "ORGANISM", 42, 49], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49]]], ["After four additional generations, male and female TCR Tg mice were crossed to develop mice that were homozygous for the transgene.Intracellular cytokine stainingTo detect cytokine production by antigen-specific CD4 T cells, mononuclear cells isolated from the brain were stimulated with 5 \u03bcM of peptide M133 in complete RPMI 1640 medium for 6 h at 37\u00b0C, in the presence of 1 \u03bcl/ml Golgiplug (BD Pharmingen) and antigen-presenting cells (CHB3 cells, B cell line, H-2D b , I-A b ).", [["Intracellular", "ANATOMY", 131, 144], ["CD4 T cells", "ANATOMY", 212, 223], ["mononuclear cells", "ANATOMY", 225, 242], ["brain", "ANATOMY", 261, 266], ["antigen-presenting cells", "ANATOMY", 412, 436], ["CHB3 cells", "ANATOMY", 438, 448], ["B cell line", "ANATOMY", 450, 461], ["M133", "CHEMICAL", 304, 308], ["TCR", "GENE_OR_GENE_PRODUCT", 51, 54], ["Tg mice", "ORGANISM", 55, 62], ["mice", "ORGANISM", 87, 91], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 144], ["CD4 T cells", "CELL", 212, 223], ["mononuclear cells", "CELL", 225, 242], ["brain", "ORGAN", 261, 266], ["Pharmingen", "GENE_OR_GENE_PRODUCT", 396, 406], ["cells", "CELL", 431, 436], ["CHB3 cells", "CELL", 438, 448], ["B cell line", "CELL", 450, 461], ["H-2D b", "CELL", 463, 469], ["cytokine", "PROTEIN", 145, 153], ["cytokine", "PROTEIN", 172, 180], ["CD4 T cells", "CELL_TYPE", 212, 223], ["mononuclear cells", "CELL_TYPE", 225, 242], ["BD Pharmingen", "PROTEIN", 393, 406], ["antigen-presenting cells", "CELL_TYPE", 412, 436], ["CHB3 cells", "CELL_LINE", 438, 448], ["B cell line", "CELL_LINE", 450, 461], ["H-2D b", "CELL_LINE", 463, 469], ["I-A b", "CELL_LINE", 472, 477], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 87, 91], ["Intracellular cytokine staining", "TEST", 131, 162], ["cytokine production", "TEST", 172, 191], ["antigen", "TEST", 195, 202], ["mononuclear cells", "TEST", 225, 242], ["peptide", "TREATMENT", 296, 303], ["BD Pharmingen", "TEST", 393, 406], ["antigen", "TEST", 412, 419], ["CHB3 cells", "TEST", 438, 448], ["B cell line", "TEST", 450, 461], ["H", "TEST", 463, 464], ["cytokine staining", "OBSERVATION", 145, 162], ["mononuclear cells", "OBSERVATION", 225, 242], ["brain", "ANATOMY", 261, 266]]], ["Intracellular expression of IFN-\u03b3, IL-10, and TNF was assayed.Adoptive transferM133 TCR Tg mice were crossed onto a Thy1.1 background.", [["Intracellular", "ANATOMY", 0, 13], ["M133 TCR", "CHEMICAL", 79, 87], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 28, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 35, 40], ["TNF", "GENE_OR_GENE_PRODUCT", 46, 49], ["mice", "ORGANISM", 91, 95], ["IFN", "PROTEIN", 28, 31], ["IL-10", "PROTEIN", 35, 40], ["TNF", "PROTEIN", 46, 49], ["TCR", "PROTEIN", 84, 87], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["IFN", "TEST", 28, 31], ["IL", "TEST", 35, 37], ["TNF", "TREATMENT", 46, 49]]], ["Splenocytes were harvested from these mice and CD4 T cells enriched using magnetic beads (Miltenyi).", [["Splenocytes", "ANATOMY", 0, 11], ["CD4 T cells", "ANATOMY", 47, 58], ["Splenocytes", "CELL", 0, 11], ["mice", "ORGANISM", 38, 42], ["CD4 T cells", "CELL", 47, 58], ["Splenocytes", "CELL_TYPE", 0, 11], ["CD4 T cells", "CELL_TYPE", 47, 58], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42]]], ["10 5 cells were transferred to 6 week B6 mice 24 h prior to rJ2.2 infection.StatisticsTwo-tailed, unpaired Student t tests were used to analyze differences in mean values between groups.", [["cells", "ANATOMY", 5, 10], ["infection", "DISEASE", 66, 75], ["cells", "CELL", 5, 10], ["mice", "ORGANISM", 41, 45], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["rJ2.2 infection", "PROBLEM", 60, 75], ["Student t tests", "TEST", 107, 122], ["infection", "OBSERVATION", 66, 75]]], ["P values b 0.05 were considered significant.Identification of the \u03b2 chains of M133-specific T cell receptorsIn previous studies designed to determine the diversity of the T cell response to single epitopes, we developed methods to isolate virus epitope-specific T cells and prepare cDNA clones encompassing the CDR3 region (Pewe et al., 1999; Pewe et al., 2004) .", [["T cell", "ANATOMY", 92, 98], ["T cell", "ANATOMY", 171, 177], ["T cells", "ANATOMY", 262, 269], ["M133", "GENE_OR_GENE_PRODUCT", 78, 82], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 92, 108], ["T cell", "CELL", 171, 177], ["T cells", "CELL", 262, 269], ["\u03b2 chains", "PROTEIN", 66, 74], ["M133", "PROTEIN", 78, 82], ["T cell receptors", "PROTEIN", 92, 108], ["T cells", "CELL_TYPE", 262, 269], ["cDNA clones", "DNA", 282, 293], ["CDR3 region", "DNA", 311, 322], ["P values b", "TEST", 0, 10], ["the \u03b2 chains", "TEST", 62, 74], ["M133", "TEST", 78, 82], ["previous studies", "TEST", 111, 127], ["single epitopes", "PROBLEM", 190, 205], ["methods", "TREATMENT", 220, 227], ["isolate virus epitope", "TREATMENT", 231, 252], ["specific T cells", "TREATMENT", 253, 269], ["cDNA clones", "PROBLEM", 282, 293]]], ["These studies described diversity of the T cell response to CD8 T cell epitopes recognized in B6 mice infected with JHMV (epitopes S510 and S598) or lymphocytic choriomeningitis virus (LCMV, epitope gp33).", [["T cell", "ANATOMY", 41, 47], ["CD8 T cell", "ANATOMY", 60, 70], ["lymphocytic choriomeningitis virus", "DISEASE", 149, 183], ["T cell", "CELL", 41, 47], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["B6 mice", "ORGANISM", 94, 101], ["JHMV", "ORGANISM", 116, 120], ["S598", "GENE_OR_GENE_PRODUCT", 140, 144], ["lymphocytic choriomeningitis virus", "ORGANISM", 149, 183], ["LCMV", "ORGANISM", 185, 189], ["gp33", "GENE_OR_GENE_PRODUCT", 199, 203], ["CD8 T cell epitopes", "PROTEIN", 60, 79], ["epitopes", "PROTEIN", 122, 130], ["S598", "PROTEIN", 140, 144], ["epitope gp33", "PROTEIN", 191, 203], ["mice", "SPECIES", 97, 101], ["lymphocytic choriomeningitis virus", "SPECIES", 149, 183], ["mice", "SPECIES", 97, 101], ["JHMV", "SPECIES", 116, 120], ["lymphocytic choriomeningitis virus", "SPECIES", 149, 183], ["LCMV", "SPECIES", 185, 189], ["These studies", "TEST", 0, 13], ["the T cell response", "PROBLEM", 37, 56], ["CD8 T cell epitopes", "TREATMENT", 60, 79], ["JHMV (epitopes S510", "TEST", 116, 135], ["lymphocytic choriomeningitis virus", "PROBLEM", 149, 183], ["lymphocytic choriomeningitis virus", "OBSERVATION", 149, 183]]], ["We next extended our analyses to the immunodominant CD4 T cell epitope (epitope M133) recognized in B6 mice (Xue et al., 1995) .", [["CD4 T cell", "ANATOMY", 52, 62], ["CD4 T cell epitope", "GENE_OR_GENE_PRODUCT", 52, 70], ["B6 mice", "ORGANISM", 100, 107], ["immunodominant CD4 T cell epitope", "PROTEIN", 37, 70], ["epitope M133", "PROTEIN", 72, 84], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 103, 107], ["the immunodominant CD4 T cell epitope (epitope M133", "TREATMENT", 33, 84]]], ["Up to 25% of the CD4 T cells in the acutely infected brain respond to epitope M133 (Zhao et al., 2009 ).", [["CD4 T cells", "ANATOMY", 17, 28], ["brain", "ANATOMY", 53, 58], ["CD4 T cells", "CELL", 17, 28], ["brain", "ORGAN", 53, 58], ["CD4 T cells", "CELL_TYPE", 17, 28], ["the CD4 T cells", "TREATMENT", 13, 28], ["the acutely infected brain", "PROBLEM", 32, 58], ["infected", "OBSERVATION", 44, 52], ["brain", "ANATOMY", 53, 58]]], ["At the time that these experiments were initiated, an I-A b /M133 tetramer was not available so we identified epitope-specific cells using an IFN-\u03b3 capture assay, as described in Materials and Methods.", [["cells", "ANATOMY", 127, 132], ["M133", "GENE_OR_GENE_PRODUCT", 61, 65], ["cells", "CELL", 127, 132], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 142, 147], ["M133 tetramer", "PROTEIN", 61, 74], ["epitope", "PROTEIN", 110, 117], ["IFN", "PROTEIN", 142, 145], ["A b /M133 tetramer", "TREATMENT", 56, 74], ["epitope-specific cells", "PROBLEM", 110, 132], ["an IFN", "TREATMENT", 139, 145]]], ["The IFN-\u03b3 capture assay captured no more than 50% of M133-specific T cells (data not shown), making analyses of infected brains difficult.", [["T cells", "ANATOMY", 67, 74], ["brains", "ANATOMY", 121, 127], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 4, 9], ["M133", "GENE_OR_GENE_PRODUCT", 53, 57], ["T cells", "CELL", 67, 74], ["brains", "ORGAN", 121, 127], ["IFN", "PROTEIN", 4, 7], ["\u03b3", "PROTEIN", 8, 9], ["M133-specific T cells", "CELL_LINE", 53, 74], ["The IFN", "TEST", 0, 7], ["\u03b3 capture assay", "TEST", 8, 23], ["M133", "TEST", 53, 57], ["infected brains", "PROBLEM", 112, 127], ["infected", "OBSERVATION", 112, 120]]], ["Therefore, in order to obtain sufficient cells for analysis, we stained and sorted M133-specific cells from the spleens of mice after intraperitoneal infection with JHMV.", [["cells", "ANATOMY", 41, 46], ["M133-specific cells", "ANATOMY", 83, 102], ["spleens", "ANATOMY", 112, 119], ["intraperitoneal", "ANATOMY", 134, 149], ["infection", "DISEASE", 150, 159], ["JHMV", "CHEMICAL", 165, 169], ["cells", "CELL", 41, 46], ["M133", "CELL", 83, 87], ["cells", "CELL", 97, 102], ["spleens", "ORGAN", 112, 119], ["mice", "ORGANISM", 123, 127], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 149], ["M133-specific cells", "CELL_LINE", 83, 102], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 123, 127], ["JHMV", "SPECIES", 165, 169], ["analysis", "TEST", 51, 59], ["M133", "TEST", 83, 87], ["intraperitoneal infection", "PROBLEM", 134, 159], ["JHMV", "TREATMENT", 165, 169], ["spleens", "ANATOMY", 112, 119], ["intraperitoneal", "ANATOMY", 134, 149], ["infection", "OBSERVATION", 150, 159]]], ["As shown in Fig. 1 , M133-specific CD4 T cells were readily detected in the spleen using an IFN-\u03b3 capture assay.", [["CD4 T cells", "ANATOMY", 35, 46], ["spleen", "ANATOMY", 76, 82], ["M133", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD4 T cells", "CELL", 35, 46], ["spleen", "ORGAN", 76, 82], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 92, 97], ["M133-specific CD4 T cells", "CELL_LINE", 21, 46], ["IFN", "PROTEIN", 92, 95], ["M133", "TEST", 21, 25], ["an IFN", "TREATMENT", 89, 95], ["spleen", "ANATOMY", 76, 82]]], ["Next, these CD4 T cells were sorted from three individual mice and RNA prepared.", [["CD4 T cells", "ANATOMY", 12, 23], ["CD4 T cells", "CELL", 12, 23], ["mice", "ORGANISM", 58, 62], ["CD4 T cells", "CELL_TYPE", 12, 23], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["these CD4 T cells", "TEST", 6, 23]]], ["V\u03b28 is the most commonly expressed V\u03b2 element, used by approximately 20% of all M133-specific CD4 T cells (Haring et al., 2001) , so primers encoding V\u03b28 and C\u03b2 sequences were used to develop cDNA clones that spanned the CDR3.", [["CD4 T cells", "ANATOMY", 94, 105], ["V\u03b28", "GENE_OR_GENE_PRODUCT", 0, 3], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 35, 37], ["M133", "CELL", 80, 84], ["CD4 T cells", "CELL", 94, 105], ["V\u03b28", "GENE_OR_GENE_PRODUCT", 150, 153], ["C\u03b2", "GENE_OR_GENE_PRODUCT", 158, 160], ["CDR3", "GENE_OR_GENE_PRODUCT", 221, 225], ["V\u03b28", "DNA", 0, 3], ["V\u03b2 element", "DNA", 35, 45], ["M133-specific CD4 T cells", "CELL_LINE", 80, 105], ["V\u03b28 and C\u03b2 sequences", "DNA", 150, 170], ["cDNA clones", "DNA", 192, 203], ["CDR3", "DNA", 221, 225], ["C\u03b2 sequences", "TEST", 158, 170], ["cDNA clones", "PROBLEM", 192, 203]]], ["The CDR3 is the region of greatest variability in TCR-\u03b1 and TCR-\u03b2 chains so can be used to determine the diversity of the response.", [["CDR3", "GENE_OR_GENE_PRODUCT", 4, 8], ["TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 50, 55], ["TCR-\u03b2 chains", "GENE_OR_GENE_PRODUCT", 60, 72], ["CDR3", "DNA", 4, 8], ["TCR", "PROTEIN", 50, 53], ["\u03b1", "PROTEIN", 54, 55], ["TCR", "PROTEIN", 60, 63], ["\u03b2 chains", "PROTEIN", 64, 72], ["TCR", "TEST", 50, 53], ["CDR3", "OBSERVATION", 4, 8], ["greatest", "OBSERVATION_MODIFIER", 26, 34], ["variability", "OBSERVATION_MODIFIER", 35, 46]]], ["87-100 cDNA clones were sequenced from each mouse.", [["cDNA", "ORGANISM", 7, 11], ["clones", "CELL", 12, 18], ["mouse", "ORGANISM", 44, 49], ["87-100 cDNA clones", "DNA", 0, 18], ["mouse", "SPECIES", 44, 49], ["mouse", "SPECIES", 44, 49], ["cDNA clones", "TREATMENT", 7, 18]]], ["The results indicated that there was extensive TCR-\u03b2 chain diversity, with 39-46 unique \u03b2 chains identified per mouse (Table 1) .Generation of TCR retrogenic miceTo begin the process of engineering a TCR Tg mouse, we identified several CDR3 sequences that were common to all three mice (Table 2) .", [["TCR", "CHEMICAL", 143, 146], ["TCR", "CHEMICAL", 200, 203], ["TCR", "GENE_OR_GENE_PRODUCT", 47, 50], ["\u03b2 chains", "GENE_OR_GENE_PRODUCT", 88, 96], ["mouse", "ORGANISM", 112, 117], ["TCR", "GENE_OR_GENE_PRODUCT", 143, 146], ["Tg mouse", "ORGANISM", 204, 212], ["mice", "ORGANISM", 281, 285], ["TCR", "PROTEIN", 47, 50], ["\u03b2 chain", "PROTEIN", 51, 58], ["\u03b2 chains", "PROTEIN", 88, 96], ["TCR", "PROTEIN", 143, 146], ["TCR", "PROTEIN", 200, 203], ["CDR3 sequences", "DNA", 236, 250], ["mouse", "SPECIES", 112, 117], ["mouse", "SPECIES", 207, 212], ["mice", "SPECIES", 281, 285], ["mouse", "SPECIES", 112, 117], ["mouse", "SPECIES", 207, 212], ["mice", "SPECIES", 281, 285], ["extensive TCR-\u03b2 chain diversity", "PROBLEM", 37, 68], ["TCR retrogenic miceTo", "TREATMENT", 143, 164], ["several CDR3 sequences", "TEST", 228, 250], ["extensive", "OBSERVATION_MODIFIER", 37, 46], ["TCR", "OBSERVATION", 47, 50]]], ["One TCR-\u03b2 chain, containing TRBV13-1 and TRBJ2-2 elements (CDR3: ARDM) was abundant in 2/3 mice and was chosen for further studies.", [["TCR-\u03b2 chain", "GENE_OR_GENE_PRODUCT", 4, 15], ["TRBV13-1", "GENE_OR_GENE_PRODUCT", 28, 36], ["TRBJ2-2", "GENE_OR_GENE_PRODUCT", 41, 48], ["CDR3: ARDM", "GENE_OR_GENE_PRODUCT", 59, 69], ["mice", "ORGANISM", 91, 95], ["TCR", "PROTEIN", 4, 7], ["\u03b2 chain", "PROTEIN", 8, 15], ["TRBV13-1 and TRBJ2-2 elements", "DNA", 28, 57], ["CDR3", "DNA", 59, 63], ["ARDM", "DNA", 65, 69], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["TRBV13", "TEST", 28, 34], ["further studies", "TEST", 115, 130], ["\u03b2 chain", "OBSERVATION_MODIFIER", 8, 15]]], ["A complete TCR-\u03b2 chain was produced and single chain M133 TCR retrogenic mice were developed, as described in Materials and Methods.", [["TCR", "CHEMICAL", 11, 14], ["TCR-\u03b2 chain", "GENE_OR_GENE_PRODUCT", 11, 22], ["TCR", "GENE_OR_GENE_PRODUCT", 58, 61], ["mice", "ORGANISM", 73, 77], ["TCR", "PROTEIN", 11, 14], ["\u03b2 chain", "PROTEIN", 15, 22], ["TCR", "PROTEIN", 58, 61], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["A complete TCR", "TEST", 0, 14]]], ["By 5 weeks after reconstitution, 20-35% of CD4 T cells in the blood of each mouse expressed GFP ( Fig. 2A) .", [["CD4 T cells", "ANATOMY", 43, 54], ["blood", "ANATOMY", 62, 67], ["CD4 T cells", "CELL", 43, 54], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["mouse", "ORGANISM", 76, 81], ["GFP", "GENE_OR_GENE_PRODUCT", 92, 95], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 98, 105], ["CD4 T cells", "CELL_TYPE", 43, 54], ["GFP", "PROTEIN", 92, 95], ["Fig. 2A", "PROTEIN", 98, 105], ["mouse", "SPECIES", 76, 81], ["mouse", "SPECIES", 76, 81], ["reconstitution", "TEST", 17, 31], ["CD4 T cells", "PROBLEM", 43, 54], ["blood", "ANATOMY", 62, 67]]], ["After infection with rJ2.2, these cells trafficked to the brain, comprising 55% of the total and N 90% of the M133-specific CD4 T cell response (Fig. 2B) .", [["cells", "ANATOMY", 34, 39], ["brain", "ANATOMY", 58, 63], ["CD4 T cell", "ANATOMY", 124, 134], ["infection", "DISEASE", 6, 15], ["cells", "CELL", 34, 39], ["brain", "ORGAN", 58, 63], ["M133", "GENE_OR_GENE_PRODUCT", 110, 114], ["CD4 T cell", "CELL", 124, 134], ["rJ2.2", "PROTEIN", 21, 26], ["M133", "PROTEIN", 110, 114], ["CD4", "PROTEIN", 124, 127], ["infection", "PROBLEM", 6, 15], ["these cells", "TEST", 28, 39], ["the M133", "TEST", 106, 114], ["infection", "OBSERVATION", 6, 15], ["brain", "ANATOMY", 58, 63], ["CD4 T cell", "OBSERVATION", 124, 134]]], ["To identify the TCR-\u03b1 chain(s) associated with the fixed TCR-\u03b2 chain, cells were stained with I-A b / M133 tetramers and tetramer + GFP + CD4 T cells were sorted.", [["cells", "ANATOMY", 70, 75], ["tetramer + GFP + CD4 T cells", "ANATOMY", 121, 149], ["TCR-\u03b1 chain", "GENE_OR_GENE_PRODUCT", 16, 27], ["TCR-\u03b2 chain", "GENE_OR_GENE_PRODUCT", 57, 68], ["cells", "CELL", 70, 75], ["M133", "GENE_OR_GENE_PRODUCT", 102, 106], ["GFP", "GENE_OR_GENE_PRODUCT", 132, 135], ["TCR", "PROTEIN", 16, 19], ["\u03b1 chain", "PROTEIN", 20, 27], ["TCR", "PROTEIN", 57, 60], ["\u03b2 chain", "PROTEIN", 61, 68], ["M133 tetramers", "PROTEIN", 102, 116], ["tetramer", "PROTEIN", 121, 129], ["GFP", "PROTEIN", 132, 135], ["CD4 T cells", "CELL_TYPE", 138, 149], ["the TCR", "TEST", 12, 19], ["the fixed TCR", "TEST", 47, 60], ["I", "TEST", 94, 95], ["A b / M133 tetramers", "TEST", 96, 116], ["tetramer", "TEST", 121, 129], ["GFP", "TEST", 132, 135], ["CD4 T cells", "PROBLEM", 138, 149], ["CD4 T cells", "OBSERVATION", 138, 149]]], ["RNA was isolated from these cells and used to prepare cDNA.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["RNA", "RNA", 0, 3], ["cDNA", "DNA", 54, 58]]], ["Using a panel of pools of PCR primers for the most commonly used V\u03b1 elements, we sequenced 71 cDNA clones.", [["PCR primers", "DNA", 26, 37], ["V\u03b1 elements", "DNA", 65, 76], ["71 cDNA clones", "DNA", 91, 105], ["PCR primers", "TREATMENT", 26, 37]]], ["Twenty four of these 71 cDNA clones contained in frame sequences and all 24 cDNA clones encoded the V\u03b12.3 (TRAV14-1) and J\u03b133 (TRAJ33) elements, with the following sequences: CASS [DP (11 clones)/AP (11 clones)/LP (1 clone)/AG (1 clone)] TGNYKYVFGA.", [["V\u03b12.3", "GENE_OR_GENE_PRODUCT", 100, 105], ["TRAV14-1", "GENE_OR_GENE_PRODUCT", 107, 115], ["J\u03b133", "GENE_OR_GENE_PRODUCT", 121, 125], ["cDNA clones", "DNA", 24, 35], ["cDNA clones", "DNA", 76, 87], ["V\u03b12.3", "DNA", 100, 105], ["TRAV14", "DNA", 107, 113], ["J\u03b133", "DNA", 121, 125], ["TRAJ33", "DNA", 127, 133], ["CASS", "DNA", 175, 179], ["DP", "DNA", 181, 183], ["AP", "DNA", 196, 198], ["TGNYKYVFGA", "DNA", 238, 248], ["cDNA clones", "TEST", 24, 35], ["frame sequences", "TEST", 49, 64], ["cDNA clones", "TEST", 76, 87], ["the V", "TEST", 96, 101], ["TRAV14", "TEST", 107, 113], ["CASS", "TEST", 175, 179], ["DP", "TEST", 181, 183], ["clones", "TEST", 188, 194], ["AP", "TEST", 196, 198], ["clones", "TEST", 203, 209], ["LP", "TEST", 211, 213], ["AG", "TEST", 224, 226], ["TGNYKYVFGA", "PROBLEM", 238, 248]]], ["Additional sequence analysis revealed that the \u03b1 chain contained the TRAV14-1*01 element.", [["\u03b1 chain", "GENE_OR_GENE_PRODUCT", 47, 54], ["\u03b1 chain", "PROTEIN", 47, 54], ["TRAV14-1*01 element", "DNA", 69, 88], ["Additional sequence analysis", "TEST", 0, 28]]], ["A complete M133 TCR-\u03b1 containing one of the common CDR3 (AP) was expressed synthetically, and introduced into the same retroviral transduction vector as above.", [["TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 16, 21], ["CDR3 (AP)", "GENE_OR_GENE_PRODUCT", 51, 60], ["retroviral", "ORGANISM", 119, 129], ["M133 TCR", "PROTEIN", 11, 19], ["\u03b1", "PROTEIN", 20, 21], ["CDR3", "DNA", 51, 55], ["AP", "DNA", 57, 59], ["retroviral transduction vector", "DNA", 119, 149], ["A complete M133 TCR", "TEST", 0, 19], ["common CDR3", "ANATOMY", 44, 55], ["retroviral transduction vector", "OBSERVATION", 119, 149]]], ["Retrogenic mice expressing both the M133 TCR-\u03b1 and TCR-\u03b2 chains were generated by bone marrow transduction and reconstitution of lethally irradiated mice (Fig. 3A) .", [["bone marrow", "ANATOMY", 82, 93], ["mice", "ORGANISM", 11, 15], ["TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 41, 46], ["TCR-\u03b2 chains", "GENE_OR_GENE_PRODUCT", 51, 63], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 82, 93], ["lethally", "ORGANISM", 129, 137], ["mice", "ORGANISM", 149, 153], ["TCR", "PROTEIN", 41, 44], ["\u03b1", "PROTEIN", 45, 46], ["TCR", "PROTEIN", 51, 54], ["\u03b2 chains", "PROTEIN", 55, 63], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 149, 153], ["the M133 TCR", "TEST", 32, 44], ["bone marrow transduction", "TREATMENT", 82, 106], ["bone marrow", "ANATOMY", 82, 93]]], ["CD4 T cells expressing the retrogenic M133specific TCR trafficked to the CNS after infection with rJ2.2 and expressed both IFN-\u03b3 and IL-10 after peptide stimulation directly ex vivo (Fig. 3B, C) .Generation and rJ2.2 infection of M133 TCR Tg miceWhile M133 TCR retrogenic mice are useful for many studies, M133-specific CD4 T cells comprised only a minority of the total CD4 T cell population in na\u00efve mice and there was sufficient variability in numbers of M133-specific cells between different M133 TCR retrogenic mice to make direct comparisons after infection difficult.", [["CD4 T cells", "ANATOMY", 0, 11], ["CNS", "ANATOMY", 73, 76], ["CD4 T cells", "ANATOMY", 320, 331], ["CD4 T cell", "ANATOMY", 371, 381], ["cells", "ANATOMY", 472, 477], ["TCR", "CHEMICAL", 51, 54], ["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 217, 226], ["TCR", "CHEMICAL", 257, 260], ["TCR", "CHEMICAL", 501, 504], ["infection", "DISEASE", 554, 563], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["M133specific TCR", "GENE_OR_GENE_PRODUCT", 38, 54], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 123, 128], ["IL-10", "GENE_OR_GENE_PRODUCT", 133, 138], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 211, 216], ["M133", "ORGANISM", 230, 234], ["TCR", "GENE_OR_GENE_PRODUCT", 235, 238], ["TCR", "GENE_OR_GENE_PRODUCT", 257, 260], ["M133", "SIMPLE_CHEMICAL", 306, 310], ["CD4 T cells", "CELL", 320, 331], ["CD4 T cell", "CELL", 371, 381], ["mice", "ORGANISM", 402, 406], ["M133", "GENE_OR_GENE_PRODUCT", 458, 462], ["cells", "CELL", 472, 477], ["TCR", "GENE_OR_GENE_PRODUCT", 501, 504], ["mice", "ORGANISM", 516, 520], ["CD4 T cells", "CELL_TYPE", 0, 11], ["retrogenic M133specific TCR", "PROTEIN", 27, 54], ["rJ2.2", "PROTEIN", 98, 103], ["IFN", "PROTEIN", 123, 126], ["IL", "PROTEIN", 133, 135], ["TCR", "PROTEIN", 235, 238], ["TCR", "PROTEIN", 257, 260], ["M133-specific CD4 T cells", "CELL_LINE", 306, 331], ["CD4 T cell population", "CELL_TYPE", 371, 392], ["M133-specific cells", "CELL_LINE", 458, 477], ["TCR", "PROTEIN", 501, 504], ["mice", "SPECIES", 272, 276], ["mice", "SPECIES", 402, 406], ["mice", "SPECIES", 516, 520], ["mice", "SPECIES", 272, 276], ["mice", "SPECIES", 402, 406], ["mice", "SPECIES", 516, 520], ["CD4 T cells", "TEST", 0, 11], ["infection", "PROBLEM", 83, 92], ["IFN", "TEST", 123, 126], ["IL", "TEST", 133, 135], ["peptide stimulation", "TREATMENT", 145, 164], ["TCR", "TEST", 235, 238], ["many studies", "TEST", 292, 304], ["M133", "TEST", 306, 310], ["M133", "TEST", 458, 462], ["infection", "PROBLEM", 554, 563], ["CNS", "ANATOMY", 73, 76], ["infection", "OBSERVATION", 83, 92], ["variability", "OBSERVATION_MODIFIER", 432, 443]]], ["Therefore, to develop a reliable supply of M133-specific cells, we engineered a transgenic mouse expressing the same TCR as used in the TCR retrogenic mice as described in Materials and Methods (section 2.9).", [["M133-specific cells", "ANATOMY", 43, 62], ["TCR", "CHEMICAL", 117, 120], ["TCR", "CHEMICAL", 136, 139], ["M133-specific cells", "CELL", 43, 62], ["mouse", "ORGANISM", 91, 96], ["TCR", "GENE_OR_GENE_PRODUCT", 117, 120], ["TCR", "GENE_OR_GENE_PRODUCT", 136, 139], ["mice", "ORGANISM", 151, 155], ["M133-specific cells", "CELL_LINE", 43, 62], ["TCR", "PROTEIN", 117, 120], ["TCR", "PROTEIN", 136, 139], ["mouse", "SPECIES", 91, 96], ["mice", "SPECIES", 151, 155], ["mouse", "SPECIES", 91, 96], ["mice", "SPECIES", 151, 155], ["a transgenic mouse", "TREATMENT", 78, 96], ["the TCR retrogenic mice", "TREATMENT", 132, 155]]], ["Unlike the TCR retrogenic mice, M133-specific cells in the Tg mice did not express GFP, limiting detection to use of I-A b / M133 tetramers or dual V\u03b28.3/V\u03b12 staining.", [["M133-specific cells", "ANATOMY", 32, 51], ["TCR", "CHEMICAL", 11, 14], ["TCR", "GENE_OR_GENE_PRODUCT", 11, 14], ["mice", "ORGANISM", 26, 30], ["M133", "GENE_OR_GENE_PRODUCT", 32, 36], ["cells", "CELL", 46, 51], ["Tg mice", "ORGANISM", 59, 66], ["GFP", "GENE_OR_GENE_PRODUCT", 83, 86], ["I-A b", "GENE_OR_GENE_PRODUCT", 117, 122], ["M133", "GENE_OR_GENE_PRODUCT", 125, 129], ["V\u03b12", "GENE_OR_GENE_PRODUCT", 154, 157], ["TCR", "PROTEIN", 11, 14], ["M133-specific cells", "CELL_LINE", 32, 51], ["GFP", "PROTEIN", 83, 86], ["I-A b", "PROTEIN", 117, 122], ["M133 tetramers", "PROTEIN", 125, 139], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 62, 66], ["M133", "TEST", 32, 36], ["the Tg mice", "TEST", 55, 66], ["dual V", "TEST", 143, 149]]], ["As expected for a TCR Tg mouse recognizing a CD4 T cell epitope, the great majority of T cells in the blood were CD4 + (Fig. 4A) .", [["CD4 T cell", "ANATOMY", 45, 55], ["T cells", "ANATOMY", 87, 94], ["blood", "ANATOMY", 102, 107], ["TCR", "CHEMICAL", 18, 21], ["Tg mouse", "ORGANISM", 22, 30], ["CD4", "GENE_OR_GENE_PRODUCT", 45, 48], ["T cells", "CELL", 87, 94], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["CD4", "GENE_OR_GENE_PRODUCT", 113, 116], ["TCR", "PROTEIN", 18, 21], ["CD4 T cell epitope", "PROTEIN", 45, 63], ["T cells", "CELL_TYPE", 87, 94], ["CD4", "PROTEIN", 113, 116], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 25, 30], ["a CD4 T cell epitope", "PROBLEM", 43, 63], ["T cells", "PROBLEM", 87, 94], ["the blood", "TEST", 98, 107], ["CD4", "TEST", 113, 116], ["blood", "ANATOMY", 102, 107]]], ["Further, M133-specific CD4 T cells were readily detected in the blood of the TCR transgenic mice, after staining with either anti-V\u03b28.3/ V\u03b12 antibodies (Fig. 4B ) or I-A b /M133 tetramers (Fig. 4C) .", [["CD4 T cells", "ANATOMY", 23, 34], ["blood", "ANATOMY", 64, 69], ["M133", "SIMPLE_CHEMICAL", 9, 13], ["CD4 T cells", "CELL", 23, 34], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["TCR", "GENE_OR_GENE_PRODUCT", 77, 80], ["mice", "ORGANISM", 92, 96], ["anti-V\u03b28.3", "GENE_OR_GENE_PRODUCT", 125, 135], ["V\u03b12", "GENE_OR_GENE_PRODUCT", 137, 140], ["M133", "PROTEIN", 9, 13], ["CD4 T cells", "CELL_TYPE", 23, 34], ["TCR", "PROTEIN", 77, 80], ["anti-V\u03b28.3", "PROTEIN", 125, 135], ["V\u03b12 antibodies", "PROTEIN", 137, 151], ["Fig. 4B", "PROTEIN", 153, 160], ["I-A b", "PROTEIN", 166, 171], ["M133 tetramers", "PROTEIN", 173, 187], ["Fig. 4C", "PROTEIN", 189, 196], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["M133", "TEST", 9, 13], ["specific CD4 T cells", "TEST", 14, 34], ["staining", "TEST", 104, 112], ["anti-V\u03b2", "TEST", 125, 132], ["V\u03b12 antibodies", "TEST", 137, 151], ["I", "TEST", 166, 167]]], ["Homozygous Tg mice bred normally and no physiological abnormalities were observed.Generation and rJ2.2 infection of M133 TCR Tg miceWe next assessed the functionality of these M133 TCR Tg CD4 T cells.", [["M133 TCR Tg CD4 T cells", "ANATOMY", 176, 199], ["infection", "DISEASE", 103, 112], ["TCR", "CHEMICAL", 121, 124], ["Tg mice", "ORGANISM", 11, 18], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 97, 102], ["TCR", "PROTEIN", 121, 124], ["M133 TCR Tg CD4 T cells", "CELL_LINE", 176, 199], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["Homozygous Tg mice", "TEST", 0, 18], ["physiological abnormalities", "PROBLEM", 40, 67], ["rJ2.2 infection", "PROBLEM", 97, 112], ["no", "UNCERTAINTY", 37, 39], ["abnormalities", "OBSERVATION", 54, 67]]], ["First, we directly infected M133 TCR Tg mice with rJ2.2.", [["TCR", "GENE_OR_GENE_PRODUCT", 33, 36], ["mice", "ORGANISM", 40, 44], ["TCR", "PROTEIN", 33, 36], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["rJ2", "TEST", 50, 53]]], ["Infection of wild type B6 mice with 700 PFU of rJ2.2 results in mild encephalitis, with a mortality of 0-20% during the first 10 days after infection (Zhao et al., 2009) .", [["rJ2.2", "CHEMICAL", 47, 52], ["encephalitis", "DISEASE", 69, 81], ["infection", "DISEASE", 140, 149], ["wild type B6 mice", "ORGANISM", 13, 30], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 47, 52], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["Infection", "PROBLEM", 0, 9], ["mild encephalitis", "PROBLEM", 64, 81], ["infection", "PROBLEM", 140, 149], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["encephalitis", "OBSERVATION", 69, 81]]], ["A variable percentage then develops hindlimb paralysis and demyelination on histological examination over the following 1-2 weeks.", [["hindlimb", "ANATOMY", 36, 44], ["paralysis", "DISEASE", 45, 54], ["demyelination", "DISEASE", 59, 72], ["hindlimb", "ORGANISM_SUBDIVISION", 36, 44], ["A variable percentage", "PROBLEM", 0, 21], ["hindlimb paralysis", "PROBLEM", 36, 54], ["demyelination", "PROBLEM", 59, 72], ["histological examination", "TEST", 76, 100], ["variable", "OBSERVATION_MODIFIER", 2, 10], ["percentage", "OBSERVATION_MODIFIER", 11, 21], ["hindlimb", "ANATOMY", 36, 44], ["paralysis", "OBSERVATION", 45, 54], ["demyelination", "OBSERVATION", 59, 72]]], ["In marked contrast, infected M133 TCR Tg mice developed severe clinical disease, succumbing to the infection by day 13-15 post infection (p.i.)", [["TCR", "CHEMICAL", 34, 37], ["infection", "DISEASE", 99, 108], ["infection", "DISEASE", 127, 136], ["M133 TCR Tg mice", "ORGANISM", 29, 45], ["TCR", "PROTEIN", 34, 37], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["severe clinical disease", "PROBLEM", 56, 79], ["the infection", "PROBLEM", 95, 108], ["infection", "PROBLEM", 127, 136], ["marked", "OBSERVATION_MODIFIER", 3, 9], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["disease", "OBSERVATION", 72, 79], ["infection", "OBSERVATION", 99, 108], ["infection", "OBSERVATION", 127, 136]]], ["Notably, infected M133 TCR Tg mice exhibited diminished weight loss compared to B6 mice at early times p.i., even though the great majority eventually succumbed to the infection.Generation and rJ2.2 infection of M133 TCR Tg micePreviously, we showed that M133-specific CD4 T cells were pathogenic in mice acutely infected with neurovirulent JHMV (Anghelina et al., 2006) but the role of these cells in rJ2.2-infected mice was not investigated in those studies; the results in Fig. 4 suggest that M133-specific CD4 T cells were pathogenic even in a neuroattenuated infection if the CD4 T cell response was primarily directed at this epitope.", [["CD4 T cells", "ANATOMY", 269, 280], ["cells", "ANATOMY", 393, 398], ["CD4 T cells", "ANATOMY", 510, 521], ["CD4 T cell", "ANATOMY", 581, 591], ["TCR", "CHEMICAL", 23, 26], ["weight loss", "DISEASE", 56, 67], ["infection", "DISEASE", 168, 177], ["M133", "CHEMICAL", 496, 500], ["infection", "DISEASE", 564, 573], ["Tg mice", "ORGANISM", 27, 34], ["B6 mice", "ORGANISM", 80, 87], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 193, 198], ["TCR", "GENE_OR_GENE_PRODUCT", 217, 220], ["M133", "GENE_OR_GENE_PRODUCT", 255, 259], ["CD4 T cells", "CELL", 269, 280], ["mice", "ORGANISM", 300, 304], ["cells", "CELL", 393, 398], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 402, 407], ["mice", "ORGANISM", 417, 421], ["M133", "SIMPLE_CHEMICAL", 496, 500], ["CD4 T cells", "CELL", 510, 521], ["CD4 T cell", "CELL", 581, 591], ["TCR", "PROTEIN", 23, 26], ["TCR", "PROTEIN", 217, 220], ["M133", "PROTEIN", 255, 259], ["CD4 T cells", "CELL_TYPE", 269, 280], ["M133", "PROTEIN", 496, 500], ["CD4 T cells", "CELL_TYPE", 510, 521], ["CD4", "PROTEIN", 581, 584], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 300, 304], ["mice", "SPECIES", 417, 421], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 300, 304], ["JHMV", "SPECIES", 341, 345], ["mice", "SPECIES", 417, 421], ["diminished weight loss", "PROBLEM", 45, 67], ["B6 mice", "TREATMENT", 80, 87], ["the infection", "PROBLEM", 164, 177], ["M133", "TEST", 255, 259], ["specific CD4 T cells", "TEST", 260, 280], ["these cells", "TEST", 387, 398], ["infected mice", "PROBLEM", 408, 421], ["those studies", "TEST", 446, 459], ["M133", "TEST", 496, 500], ["pathogenic", "PROBLEM", 527, 537], ["a neuroattenuated infection", "PROBLEM", 546, 573], ["the CD4 T cell response", "TEST", 577, 600], ["infected", "OBSERVATION", 9, 17], ["diminished", "OBSERVATION_MODIFIER", 45, 55], ["weight loss", "OBSERVATION", 56, 67], ["infection", "OBSERVATION", 168, 177], ["infection", "OBSERVATION", 564, 573]]], ["To verify that the T cell response at the site of inflammation was epitope M133-specific, we harvested lymphocytes from the brains of infected M133 TCR Tg mice and analyzed them directly ex vivo for cytokine expression.", [["T cell", "ANATOMY", 19, 25], ["lymphocytes", "ANATOMY", 103, 114], ["brains", "ANATOMY", 124, 130], ["M133", "ANATOMY", 143, 147], ["inflammation", "DISEASE", 50, 62], ["TCR", "CHEMICAL", 148, 151], ["T cell", "CELL", 19, 25], ["M133", "GENE_OR_GENE_PRODUCT", 75, 79], ["lymphocytes", "CELL", 103, 114], ["brains", "ORGAN", 124, 130], ["Tg mice", "ORGANISM", 152, 159], ["M133", "PROTEIN", 75, 79], ["lymphocytes", "CELL_TYPE", 103, 114], ["TCR", "PROTEIN", 148, 151], ["cytokine", "PROTEIN", 199, 207], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 155, 159], ["the T cell response", "PROBLEM", 15, 34], ["inflammation", "PROBLEM", 50, 62], ["epitope M133", "TEST", 67, 79], ["cytokine expression", "TREATMENT", 199, 218], ["inflammation", "OBSERVATION", 50, 62]]], ["At both days 7 and 14 p.i., the majority of cells in the infected brain predominantly responded to epitope M133 (Fig. 4E) .", [["cells", "ANATOMY", 44, 49], ["brain", "ANATOMY", 66, 71], ["cells", "CELL", 44, 49], ["brain", "ORGAN", 66, 71], ["epitope M133", "PROTEIN", 99, 111], ["Fig. 4E", "PROTEIN", 113, 120], ["the infected brain", "PROBLEM", 53, 71], ["infected", "OBSERVATION", 57, 65], ["brain", "ANATOMY", 66, 71]]], ["Unexpectedly, the majority of cells at day 7 p.i. expressed TNF but not IFN-\u03b3 but by 14 days p.i., the predominant populations expressed IFN-\u03b3.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["TNF", "GENE_OR_GENE_PRODUCT", 60, 63], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 72, 77], ["TNF", "PROTEIN", 60, 63], ["IFN", "PROTEIN", 72, 75], ["IFN", "PROTEIN", 137, 140], ["TNF", "PROBLEM", 60, 63], ["IFN", "PROBLEM", 72, 75]]], ["Whether this temporal difference in cytokine expression contributes to disease pathogenesis requires further investigation.", [["cytokine", "PROTEIN", 36, 44], ["this temporal difference in cytokine expression", "PROBLEM", 8, 55], ["disease pathogenesis", "PROBLEM", 71, 91], ["further investigation", "TEST", 101, 122], ["temporal", "OBSERVATION_MODIFIER", 13, 21], ["difference", "OBSERVATION_MODIFIER", 22, 32], ["cytokine expression", "OBSERVATION", 36, 55], ["disease", "OBSERVATION", 71, 78]]], ["These M133-specific CD4 T cells were not able, however, to clear virus from the infected brain (Fig. 4F ).", [["T cells", "ANATOMY", 24, 31], ["brain", "ANATOMY", 89, 94], ["M133", "GENE_OR_GENE_PRODUCT", 6, 10], ["CD4", "GENE_OR_GENE_PRODUCT", 20, 23], ["T cells", "CELL", 24, 31], ["brain", "ORGAN", 89, 94], ["M133", "PROTEIN", 6, 10], ["CD4", "PROTEIN", 20, 23], ["T cells", "CELL_TYPE", 24, 31], ["These M133", "TEST", 0, 10], ["T cells", "PROBLEM", 24, 31], ["clear virus", "PROBLEM", 59, 70], ["infected", "OBSERVATION", 80, 88], ["brain", "ANATOMY", 89, 94]]], ["Virus is cleared by 10-14 days p.i. from the brains of B6 mice ( (Parra et al., 1999) , Fig. 4F ).", [["brains", "ANATOMY", 45, 51], ["Virus", "ORGANISM", 0, 5], ["brains", "ORGAN", 45, 51], ["B6 mice", "ORGANISM", 55, 62], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["Virus", "PROBLEM", 0, 5], ["cleared", "OBSERVATION_MODIFIER", 9, 16]]], ["However, in marked contrast, virus titers in M133 TCR Tg mice were elevated compared to B6 mice and did not diminish between days 7 and 10 p.i., providing an explanation for the increased mortality observed in the M133 TCR Tg mice.", [["TCR", "CHEMICAL", 50, 53], ["TCR", "CHEMICAL", 219, 222], ["Tg mice", "ORGANISM", 54, 61], ["B6 mice", "ORGANISM", 88, 95], ["TCR", "GENE_OR_GENE_PRODUCT", 219, 222], ["TCR", "PROTEIN", 50, 53], ["TCR", "PROTEIN", 219, 222], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 226, 230], ["M133", "SPECIES", 45, 49], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 91, 95], ["virus titers", "TEST", 29, 41], ["elevated", "PROBLEM", 67, 75], ["the increased mortality", "PROBLEM", 174, 197]]], ["These stably high virus titers reflect a requirement for an effective anti-virus CD8 T cell response for optimal virus clearance (Bergmann et al., 2006) and a lack of MHC class II expression on oligodendrocytes, the predominant cell type infected in the brain (Redwine et al., 2001) .Use of M133-specific TCR Tg CD4 T cells for tracking studiesTo prove the utility of these mice in tracking studies, we crossed the M133 TCR Tg mice onto a Thy1.1 background and transferred 10 5 CD4 T cells to 6 week old B6 mice 24 h prior to infection with rJ2.2.", [["anti-virus CD8 T cell", "ANATOMY", 70, 91], ["oligodendrocytes", "ANATOMY", 194, 210], ["cell type", "ANATOMY", 228, 237], ["brain", "ANATOMY", 254, 259], ["CD4 T cells", "ANATOMY", 312, 323], ["CD4 T cells", "ANATOMY", 478, 489], ["infection", "DISEASE", 526, 535], ["CD8 T cell", "CELL", 81, 91], ["MHC class II", "GENE_OR_GENE_PRODUCT", 167, 179], ["oligodendrocytes", "CELL", 194, 210], ["cell type", "CELL", 228, 237], ["brain", "ORGAN", 254, 259], ["M133", "GENE_OR_GENE_PRODUCT", 291, 295], ["TCR", "GENE_OR_GENE_PRODUCT", 305, 308], ["mice", "ORGANISM", 374, 378], ["TCR", "GENE_OR_GENE_PRODUCT", 420, 423], ["mice", "ORGANISM", 427, 431], ["CD4 T cells", "CELL", 478, 489], ["mice", "ORGANISM", 507, 511], ["CD8", "PROTEIN", 81, 84], ["MHC class II", "PROTEIN", 167, 179], ["oligodendrocytes", "CELL_TYPE", 194, 210], ["M133", "PROTEIN", 291, 295], ["TCR Tg CD4 T cells", "CELL_TYPE", 305, 323], ["M133 TCR Tg", "PROTEIN", 415, 426], ["CD4 T cells", "CELL_TYPE", 478, 489], ["mice", "SPECIES", 374, 378], ["mice", "SPECIES", 427, 431], ["mice", "SPECIES", 507, 511], ["mice", "SPECIES", 374, 378], ["mice", "SPECIES", 507, 511], ["These stably high virus titers", "PROBLEM", 0, 30], ["a requirement", "PROBLEM", 39, 52], ["an effective anti-virus CD8 T cell response", "TREATMENT", 57, 100], ["optimal virus clearance", "PROBLEM", 105, 128], ["the predominant cell type infected in the brain", "PROBLEM", 212, 259], ["M133", "TREATMENT", 291, 295], ["tracking studies", "TEST", 328, 344], ["tracking studies", "TEST", 382, 398], ["infection", "PROBLEM", 526, 535], ["rJ2", "TEST", 541, 544], ["high virus", "OBSERVATION", 13, 23], ["predominant cell type infected", "OBSERVATION", 216, 246], ["brain", "ANATOMY", 254, 259], ["infection", "OBSERVATION", 526, 535]]], ["At day one p.i., these cells could be Table 1 Diversity of epitope M133-specific CD4 T cells in spleen.MouseNo. of cDNA clones analyzed No. of different cDNA clones 1 8 7 3 9 2 9 0 4 6 3 100 40 detected in the spleen and lymph nodes at very low levels (Fig. 5A ).", [["cells", "ANATOMY", 23, 28], ["CD4 T cells", "ANATOMY", 81, 92], ["spleen", "ANATOMY", 96, 102], ["spleen", "ANATOMY", 210, 216], ["lymph nodes", "ANATOMY", 221, 232], ["MouseNo", "CHEMICAL", 103, 110], ["cells", "CELL", 23, 28], ["M133", "GENE_OR_GENE_PRODUCT", 67, 71], ["spleen", "ORGAN", 96, 102], ["spleen", "ORGAN", 210, 216], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 221, 232], ["epitope M133", "PROTEIN", 59, 71], ["CD4 T cells", "CELL_TYPE", 81, 92], ["cDNA clones", "DNA", 115, 126], ["cDNA clones", "DNA", 153, 164], ["these cells", "PROBLEM", 17, 28], ["epitope M133", "TEST", 59, 71], ["cDNA clones", "TEST", 115, 126], ["different cDNA clones", "TEST", 143, 164], ["lymph nodes", "TEST", 221, 232], ["spleen", "ANATOMY", 96, 102], ["spleen", "ANATOMY", 210, 216], ["lymph nodes", "OBSERVATION", 221, 232], ["low levels", "OBSERVATION_MODIFIER", 241, 251]]], ["By day 8 p.i., these cells proliferated and migrated to the brain, accounting for 51 \u00b1 6.6% (n = 4) of the total CD4 T cell response (Fig. 5B ).DiscussionIn the current study, we describe a modified method for generating TCR Tg mice that does not depend upon repeated antigen stimulation or limiting dilution in vitro.", [["cells", "ANATOMY", 21, 26], ["brain", "ANATOMY", 60, 65], ["CD4 T cell", "ANATOMY", 113, 123], ["cells", "CELL", 21, 26], ["brain", "ORGAN", 60, 65], ["TCR", "GENE_OR_GENE_PRODUCT", 221, 224], ["mice", "ORGANISM", 228, 232], ["CD4", "PROTEIN", 113, 116], ["TCR", "PROTEIN", 221, 224], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 228, 232], ["these cells", "PROBLEM", 15, 26], ["the current study", "TEST", 157, 174], ["a modified method", "TREATMENT", 188, 205], ["generating TCR Tg mice", "TREATMENT", 210, 232], ["repeated antigen stimulation", "TREATMENT", 259, 287], ["brain", "ANATOMY", 60, 65]]], ["The resultant mouse encodes a TCR selected on the basis of its \"public\" sequence based on its detection in all of the mice examined.", [["mouse", "ORGANISM", 14, 19], ["TCR", "GENE_OR_GENE_PRODUCT", 30, 33], ["mice", "ORGANISM", 118, 122], ["TCR", "PROTEIN", 30, 33], ["mouse", "SPECIES", 14, 19], ["mice", "SPECIES", 118, 122], ["mouse", "SPECIES", 14, 19], ["mice", "SPECIES", 118, 122], ["its detection", "TEST", 90, 103]]], ["In this approach, the TCR-\u03b2 chain was identified initially and on further analysis, using TCR-\u03b2 retrogenic mice, was found to pair with a limited number of closely related TCR-\u03b1 chains, simplifying selection of the second TCR chain.", [["TCR", "CHEMICAL", 22, 25], ["TCR-\u03b2 chain", "GENE_OR_GENE_PRODUCT", 22, 33], ["TCR-\u03b2", "GENE_OR_GENE_PRODUCT", 90, 95], ["mice", "ORGANISM", 107, 111], ["TCR-\u03b1 chains", "GENE_OR_GENE_PRODUCT", 172, 184], ["TCR chain", "GENE_OR_GENE_PRODUCT", 222, 231], ["TCR", "PROTEIN", 22, 25], ["\u03b2 chain", "PROTEIN", 26, 33], ["TCR", "PROTEIN", 90, 93], ["\u03b2", "PROTEIN", 94, 95], ["TCR", "PROTEIN", 172, 175], ["\u03b1 chains", "PROTEIN", 176, 184], ["TCR chain", "PROTEIN", 222, 231], ["mice", "SPECIES", 107, 111], ["further analysis", "TEST", 66, 82], ["TCR", "TEST", 90, 93], ["selection of the second TCR chain", "TREATMENT", 198, 231], ["second TCR", "OBSERVATION", 215, 225], ["chain", "OBSERVATION_MODIFIER", 226, 231]]], ["Thus, consistent with previous reports, fixation of one of the TCR chains resulted in very limited diversity in the other chain, illustrating how only some combinations of TCR-\u03b1 and TCR-\u03b2 chains allow recognition of specific peptide/MHC complexes (Turner et al., 1996) .", [["TCR", "CHEMICAL", 63, 66], ["TCR", "CHEMICAL", 172, 175], ["TCR", "CHEMICAL", 182, 185], ["TCR", "GENE_OR_GENE_PRODUCT", 63, 66], ["TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 172, 177], ["TCR-\u03b2 chains", "GENE_OR_GENE_PRODUCT", 182, 194], ["TCR chains", "PROTEIN", 63, 73], ["TCR", "PROTEIN", 172, 175], ["\u03b1", "PROTEIN", 176, 177], ["TCR", "PROTEIN", 182, 185], ["\u03b2 chains", "PROTEIN", 186, 194], ["MHC complexes", "PROTEIN", 233, 246], ["fixation", "TREATMENT", 40, 48], ["the TCR chains", "TREATMENT", 59, 73], ["TCR", "TEST", 172, 175], ["TCR-\u03b2 chains", "TREATMENT", 182, 194], ["consistent with", "UNCERTAINTY", 6, 21], ["very", "OBSERVATION_MODIFIER", 86, 90], ["limited", "OBSERVATION_MODIFIER", 91, 98], ["diversity", "OBSERVATION", 99, 108]]], ["After adoptive transfer, M133 TCR Tg cells are useful for tracking the epitope-specific CD4 T cell response.", [["cells", "ANATOMY", 37, 42], ["CD4 T cell", "ANATOMY", 88, 98], ["TCR", "CHEMICAL", 30, 33], ["Tg cells", "CELL", 34, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 88, 91], ["TCR", "PROTEIN", 30, 33], ["Tg cells", "CELL_TYPE", 34, 42], ["CD4", "PROTEIN", 88, 91], ["the epitope", "TEST", 67, 78], ["cell response", "OBSERVATION", 94, 107]]], ["This will be useful in mice infected with neurotropic strains of murine coronaviruses, in which cells responding to the M133 epitope are pathogenic (primary), protective (memory) or immunomodulatory (Treg) (Anghelina et al., 2006; Savarin et al., 2008; Zhao et al., 2011) .DiscussionIn summary, this approach should be generally useful for generating related sets of epitope-specific TCR retrogenic or transgenic mice expressing public sequences, since it is Analysis of CD4 T cells from the blood and brains of TCR-\u03b2 retrogenic mice.", [["cells", "ANATOMY", 96, 101], ["Treg", "ANATOMY", 200, 204], ["CD4 T cells", "ANATOMY", 471, 482], ["blood", "ANATOMY", 492, 497], ["brains", "ANATOMY", 502, 508], ["mice", "ORGANISM", 23, 27], ["murine", "ORGANISM", 65, 71], ["coronaviruses", "ORGANISM", 72, 85], ["cells", "CELL", 96, 101], ["Treg", "CELL", 200, 204], ["TCR", "GENE_OR_GENE_PRODUCT", 384, 387], ["mice", "ORGANISM", 413, 417], ["CD4 T cells", "CELL", 471, 482], ["blood", "ORGANISM_SUBSTANCE", 492, 497], ["brains", "ORGAN", 502, 508], ["TCR", "GENE_OR_GENE_PRODUCT", 512, 515], ["\u03b2", "GENE_OR_GENE_PRODUCT", 516, 517], ["mice", "ORGANISM", 529, 533], ["M133 epitope", "PROTEIN", 120, 132], ["Treg", "CELL_TYPE", 200, 204], ["TCR", "PROTEIN", 384, 387], ["CD4 T cells", "CELL_TYPE", 471, 482], ["TCR", "PROTEIN", 512, 515], ["mice", "SPECIES", 23, 27], ["murine", "SPECIES", 65, 71], ["mice", "SPECIES", 413, 417], ["mice", "SPECIES", 529, 533], ["mice", "SPECIES", 23, 27], ["murine coronaviruses", "SPECIES", 65, 85], ["mice", "SPECIES", 413, 417], ["murine coronaviruses", "PROBLEM", 65, 85], ["immunomodulatory (Treg)", "TREATMENT", 182, 205], ["epitope", "TEST", 367, 374], ["CD4 T cells", "PROBLEM", 471, 482], ["the blood", "TEST", 488, 497], ["TCR", "TEST", 512, 515]]], ["A. Blood was obtained from M133 TCR-\u03b2 retrogenic mice at 6 weeks after bone marrow infusion and analyzed for the expression of GFP.", [["Blood", "ANATOMY", 3, 8], ["bone marrow", "ANATOMY", 71, 82], ["Blood", "ORGANISM_SUBSTANCE", 3, 8], ["TCR", "GENE_OR_GENE_PRODUCT", 32, 35], ["mice", "ORGANISM", 49, 53], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 71, 82], ["GFP", "GENE_OR_GENE_PRODUCT", 127, 130], ["TCR", "PROTEIN", 32, 35], ["GFP", "PROTEIN", 127, 130], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["TCR", "TEST", 32, 35], ["bone marrow infusion", "TREATMENT", 71, 91], ["GFP", "TEST", 127, 130]]], ["Cells from B6 mice were used as a control.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["B6 mice", "ORGANISM", 11, 18], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["Cells", "TEST", 0, 5], ["B6 mice", "TREATMENT", 11, 18]]], ["B. TCR-\u03b2 retrogenic mice were infected with rJ2.2.", [["TCR", "CHEMICAL", 3, 6], ["TCR-\u03b2", "GENE_OR_GENE_PRODUCT", 3, 8], ["mice", "ORGANISM", 20, 24], ["TCR", "PROTEIN", 3, 6], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["rJ2", "TEST", 44, 47]]], ["Mice were sacrificed at d.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["7 p.i. and brain-derived lymphocytes were prepared and stained with I-A b /M133 or I-A b /hCLIP (control) tetramers.", [["brain-derived lymphocytes", "ANATOMY", 11, 36], ["brain-derived lymphocytes", "CELL", 11, 36], ["I-A b", "GENE_OR_GENE_PRODUCT", 83, 88], ["hCLIP", "SIMPLE_CHEMICAL", 90, 95], ["brain-derived lymphocytes", "CELL_TYPE", 11, 36], ["M133", "PROTEIN", 75, 79], ["hCLIP (control) tetramers", "PROTEIN", 90, 115], ["A b /hCLIP (control) tetramers", "TREATMENT", 85, 115], ["brain", "ANATOMY", 11, 16]]], ["Cells were gated for CD4 expression.Discussionsimple to determine TCR-\u03b2 chain sequences once epitopespecific cells have been selected by MHC/peptide tetramer staining or an IFN-\u03b3 capture assay.", [["Cells", "ANATOMY", 0, 5], ["epitopespecific cells", "ANATOMY", 93, 114], ["Cells", "CELL", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["TCR", "GENE_OR_GENE_PRODUCT", 66, 69], ["epitopespecific cells", "CELL", 93, 114], ["CD4", "PROTEIN", 21, 24], ["TCR", "PROTEIN", 66, 69], ["\u03b2 chain sequences", "DNA", 70, 87], ["epitopespecific cells", "CELL_TYPE", 93, 114], ["MHC", "PROTEIN", 137, 140], ["IFN", "PROTEIN", 173, 176], ["TCR", "TEST", 66, 69], ["epitopespecific cells", "PROBLEM", 93, 114], ["an IFN", "TEST", 170, 176]]], ["Alternatively, TCRs that are public can be identified using single cell RT-PCR techniques (Dash et al., 2011) .", [["cell", "ANATOMY", 67, 71], ["TCRs", "GENE_OR_GENE_PRODUCT", 15, 19], ["cell", "CELL", 67, 71], ["TCRs", "PROTEIN", 15, 19], ["single cell RT-PCR techniques", "TREATMENT", 60, 89]]], ["These mice will allow for probing of the relationship between T cell clonotypes that are present in the Fig. 3 .", [["T cell", "ANATOMY", 62, 68], ["mice", "ORGANISM", 6, 10], ["T cell", "CELL", 62, 68], ["T cell clonotypes", "CELL_TYPE", 62, 79], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["T cell clonotypes", "PROBLEM", 62, 79], ["cell clonotypes", "OBSERVATION", 64, 79]]], ["Analysis of CD4 T cells from the spleens and brains of M133 TCR-\u03b1/\u03b2 retrogenic mice.", [["CD4 T cells", "ANATOMY", 12, 23], ["spleens", "ANATOMY", 33, 40], ["brains", "ANATOMY", 45, 51], ["CD4 T cells", "CELL", 12, 23], ["spleens", "ORGAN", 33, 40], ["brains", "ORGAN", 45, 51], ["TCR", "GENE_OR_GENE_PRODUCT", 60, 63], ["\u03b1", "GENE_OR_GENE_PRODUCT", 64, 65], ["\u03b2", "GENE_OR_GENE_PRODUCT", 66, 67], ["CD4 T cells", "CELL_TYPE", 12, 23], ["TCR", "PROTEIN", 60, 63], ["mice", "SPECIES", 79, 83], ["Analysis", "TEST", 0, 8], ["CD4 T cells", "PROBLEM", 12, 23], ["the spleens", "TEST", 29, 40], ["brains", "TEST", 45, 51], ["M133", "TEST", 55, 59], ["TCR", "TEST", 60, 63], ["CD4 T cells", "OBSERVATION", 12, 23], ["spleens", "ANATOMY", 33, 40]]], ["(A) Spleens were harvested from uninfected TCR-\u03b1/\u03b2 retrogenic mice and analyzed for the presence of M133-specific (GFP + ) CD4 T cells.", [["Spleens", "ANATOMY", 4, 11], ["M133-specific (GFP + ) CD4 T cells", "ANATOMY", 100, 134], ["Spleens", "ORGAN", 4, 11], ["TCR", "GENE_OR_GENE_PRODUCT", 43, 46], ["\u03b1", "GENE_OR_GENE_PRODUCT", 47, 48], ["\u03b2", "GENE_OR_GENE_PRODUCT", 49, 50], ["mice", "ORGANISM", 62, 66], ["M133", "GENE_OR_GENE_PRODUCT", 100, 104], ["GFP", "GENE_OR_GENE_PRODUCT", 115, 118], ["TCR", "PROTEIN", 43, 46], ["M133", "PROTEIN", 100, 104], ["GFP", "PROTEIN", 115, 118], ["CD4 T cells", "CELL_TYPE", 123, 134], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66], ["uninfected TCR", "TEST", 32, 46], ["M133", "TEST", 100, 104], ["CD4 T cells", "PROBLEM", 123, 134], ["Spleens", "ANATOMY", 4, 11]]], ["(B,C) TCR-\u03b1/\u03b2 retrogenic mice were infected with rJ2.2 and lymphocytes were prepared from infected brains.", [["lymphocytes", "ANATOMY", 59, 70], ["brains", "ANATOMY", 99, 105], ["B,C) TCR-\u03b1", "GENE_OR_GENE_PRODUCT", 1, 11], ["\u03b2", "GENE_OR_GENE_PRODUCT", 12, 13], ["mice", "ORGANISM", 25, 29], ["rJ2.2", "GENE_OR_GENE_PRODUCT", 49, 54], ["lymphocytes", "CELL", 59, 70], ["brains", "ORGAN", 99, 105], ["TCR", "PROTEIN", 6, 9], ["\u03b1", "PROTEIN", 10, 11], ["\u03b2", "PROTEIN", 12, 13], ["lymphocytes", "CELL_TYPE", 59, 70], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["TCR", "TEST", 6, 9], ["\u03b1", "TEST", 10, 11], ["\u03b2 retrogenic mice", "PROBLEM", 12, 29], ["lymphocytes", "PROBLEM", 59, 70], ["infected", "OBSERVATION", 35, 43], ["infected brains", "OBSERVATION", 90, 105]]], ["Cells were gated for CD4 expression and then analyzed for GFP expression (B) and the expression of IFN-\u03b3 and IL-10 after M133 peptide stimulation (C).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["GFP", "GENE_OR_GENE_PRODUCT", 58, 61], ["B", "GENE_OR_GENE_PRODUCT", 74, 75], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 99, 104], ["IL-10", "GENE_OR_GENE_PRODUCT", 109, 114], ["M133 peptide", "SIMPLE_CHEMICAL", 121, 133], ["CD4", "PROTEIN", 21, 24], ["IFN", "PROTEIN", 99, 102], ["IL", "PROTEIN", 109, 111], ["CD4 expression", "TEST", 21, 35], ["GFP expression", "TEST", 58, 72], ["IFN", "TEST", 99, 102], ["IL", "TEST", 109, 111]]], ["Approximately 90% and 45% of GFP + cells expressed IFN-\u03b3 and IL-10, respectively. precursor pool in all mice (those bearing public sequences) and functional avidity and, in the context of infection, protective function.", [["GFP + cells", "ANATOMY", 29, 40], ["infection", "DISEASE", 188, 197], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-10", "GENE_OR_GENE_PRODUCT", 61, 66], ["mice", "ORGANISM", 104, 108], ["GFP", "PROTEIN", 29, 32], ["IFN", "PROTEIN", 51, 54], ["IL", "PROTEIN", 61, 63], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["GFP", "TEST", 29, 32], ["cells", "TEST", 35, 40], ["IFN", "TEST", 51, 54], ["IL", "TEST", 61, 63], ["precursor pool", "PROBLEM", 82, 96], ["functional avidity", "PROBLEM", 146, 164], ["infection", "PROBLEM", 188, 197], ["avidity", "OBSERVATION", 157, 164], ["infection", "OBSERVATION", 188, 197]]]], "PMC7132398": [["IntroductionThree quarters of all emerging infectious diseases are zoonoses; diseases that are transmissible between vertebrate animals and humans (Taylor et al., 2001).", [["infectious diseases", "DISEASE", 43, 62], ["zoonoses", "DISEASE", 67, 75], ["humans", "ORGANISM", 140, 146], ["humans", "SPECIES", 140, 146], ["humans", "SPECIES", 140, 146], ["diseases", "PROBLEM", 77, 85], ["infectious", "OBSERVATION", 43, 53]]], ["The management of such diseases usually benefits from a One Health multidisciplinary approach as it requires the collaboration of veterinary and medical professionals to mitigate biosecurity and public health risks.", [["such diseases", "PROBLEM", 18, 31]]], ["Many zoonoses have been known for decades or even centuries (e.g., Q fever, brucellosis, leptospirosis, salmonellosis) while others have only been recently recognised (emerging zoonotic diseases).", [["zoonoses", "DISEASE", 5, 13], ["Q fever", "DISEASE", 67, 74], ["brucellosis", "DISEASE", 76, 87], ["leptospirosis", "DISEASE", 89, 102], ["salmonellosis", "DISEASE", 104, 117], ["zoonotic diseases", "DISEASE", 177, 194], ["Q fever", "PROBLEM", 67, 74], ["brucellosis", "PROBLEM", 76, 87], ["leptospirosis", "PROBLEM", 89, 102], ["salmonellosis", "PROBLEM", 104, 117], ["zoonoses", "OBSERVATION", 5, 13], ["brucellosis", "OBSERVATION", 76, 87]]], ["Some emerging zoonoses spill over into humans and progress no further.", [["humans", "ORGANISM", 39, 45], ["humans", "SPECIES", 39, 45], ["humans", "SPECIES", 39, 45], ["zoonoses spill", "OBSERVATION", 14, 28]]], ["Others spill over and succeed in making the next transition into human-to-human dissemination, becoming a major threat to human health (e.g., Human Immunodeficiency Virus (HIV), Severe Acute Respiratory Syndrome (SARS), swine influenza H1N12009, Ebola virus).", [["Human Immunodeficiency Virus (HIV)", "DISEASE", 142, 176], ["Acute Respiratory Syndrome", "DISEASE", 185, 211], ["SARS", "DISEASE", 213, 217], ["swine influenza H1N12009", "DISEASE", 220, 244], ["Ebola virus", "DISEASE", 246, 257], ["human", "ORGANISM", 65, 70], ["human", "ORGANISM", 74, 79], ["human", "ORGANISM", 122, 127], ["Human Immunodeficiency Virus", "ORGANISM", 142, 170], ["swine influenza H1N12009", "ORGANISM", 220, 244], ["Ebola virus", "ORGANISM", 246, 257], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 122, 127], ["Human Immunodeficiency Virus", "SPECIES", 142, 170], ["HIV", "SPECIES", 172, 175], ["swine influenza", "SPECIES", 220, 235], ["Ebola virus", "SPECIES", 246, 257], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 122, 127], ["Human Immunodeficiency Virus", "SPECIES", 142, 170], ["HIV", "SPECIES", 172, 175], ["swine influenza H1N12009", "SPECIES", 220, 244], ["Ebola virus", "SPECIES", 246, 257], ["Human Immunodeficiency Virus (HIV)", "PROBLEM", 142, 176], ["Severe Acute Respiratory Syndrome", "PROBLEM", 178, 211], ["SARS)", "PROBLEM", 213, 218], ["swine influenza", "PROBLEM", 220, 235], ["Ebola virus", "PROBLEM", 246, 257], ["spill", "OBSERVATION", 7, 12], ["Severe", "OBSERVATION_MODIFIER", 178, 184], ["Acute", "OBSERVATION_MODIFIER", 185, 190], ["Respiratory Syndrome", "OBSERVATION", 191, 211]]], ["Although some of the emerging zoonoses that remain confined to the first generation of human victims have a low-incidence, they remain a public health threat because of the severity of their pathogenicity in humans (Belay and Monroe, 2014).", [["zoonoses", "DISEASE", 30, 38], ["human", "ORGANISM", 87, 92], ["humans", "ORGANISM", 208, 214], ["human", "SPECIES", 87, 92], ["humans", "SPECIES", 208, 214], ["human", "SPECIES", 87, 92], ["humans", "SPECIES", 208, 214], ["pathogenicity", "OBSERVATION", 191, 204]]], ["Hendra virus (HeV) is a good example of such a zoonosis.", [["zoonosis", "DISEASE", 47, 55], ["Hendra virus", "ORGANISM", 0, 12], ["HeV", "ORGANISM", 14, 17], ["Hendra virus", "SPECIES", 0, 12], ["Hendra virus", "SPECIES", 0, 12], ["HeV", "SPECIES", 14, 17], ["Hendra virus", "PROBLEM", 0, 12], ["a zoonosis", "PROBLEM", 45, 55], ["zoonosis", "OBSERVATION", 47, 55]]], ["It emerged in humans in Australia in 1993 after spilling over from flying foxes (Pteropus spp.) to horses to humans (Murray et al., 1995a, Murray et al., 1995b, Halpin et al., 2000, Halpin et al., 2011).", [["humans", "ORGANISM", 14, 20], ["Pteropus spp.", "ORGANISM", 81, 94], ["horses", "ORGANISM_SUBDIVISION", 99, 105], ["humans", "ORGANISM", 109, 115], ["humans", "SPECIES", 14, 20], ["Pteropus spp.", "SPECIES", 81, 94], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 14, 20], ["Pteropus spp.", "SPECIES", 81, 94], ["humans", "SPECIES", 109, 115]]], ["Since its emergence it has remained a uniquely Australian zoonosis where 49 equine outbreaks have occurred on the eastern coast between Far North Queensland (QLD) and Northern New South Wales (Department of Agriculture, Fisheries and Forestry Queensland (DAFF QLD), 2014).", [["zoonosis", "DISEASE", 58, 66], ["equine", "ORGANISM", 76, 82]]], ["During this time, 91 horses have been suspected of HeV infection, 71 of which were confirmed positive; while only seven people have been infected (Murray et al., 1995a, Murray et al., 1995b, O'Sullivan et al., 1997, Hanna et al., 2006, Field et al., 2010, Playford et al., 2010, Mahalingam et al., 2012, DAFF QLD, 2014).", [["HeV infection", "DISEASE", 51, 64], ["horses", "ORGANISM", 21, 27], ["HeV", "ORGANISM", 51, 54], ["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126], ["HeV", "SPECIES", 51, 54], ["HeV infection", "PROBLEM", 51, 64], ["HeV", "OBSERVATION_MODIFIER", 51, 54], ["infection", "OBSERVATION", 55, 64], ["infected", "OBSERVATION", 137, 145]]], ["Compared to pandemic Influenza and SARS, HeV could be considered a minor threat to public health.", [["Influenza", "DISEASE", 21, 30], ["SARS", "DISEASE", 35, 39], ["HeV", "DISEASE", 41, 44], ["HeV", "ORGANISM", 41, 44], ["HeV", "SPECIES", 41, 44], ["pandemic Influenza", "PROBLEM", 12, 30], ["SARS", "PROBLEM", 35, 39], ["HeV", "PROBLEM", 41, 44]]], ["However, HeV has a 57.1% case fatality rate in humans and all four who died of HeV had professional or direct caring roles for the ill horses.", [["HeV", "DISEASE", 79, 82], ["HeV", "ORGANISM", 9, 12], ["humans", "ORGANISM", 47, 53], ["HeV", "ORGANISM", 79, 82], ["humans", "SPECIES", 47, 53], ["HeV", "SPECIES", 9, 12], ["humans", "SPECIES", 47, 53], ["HeV", "SPECIES", 79, 82], ["the ill horses", "PROBLEM", 127, 141]]], ["Two were equine veterinarians, one was a person assisting a veterinarian during a horse necropsy, and one was a horse trainer.", [["equine", "ORGANISM", 9, 15], ["horse", "ORGANISM", 112, 117], ["person", "SPECIES", 41, 47], ["horse", "SPECIES", 82, 87], ["horse", "SPECIES", 112, 117], ["horse", "SPECIES", 82, 87]]], ["Another veterinarian, a veterinary nurse, and a stable hand also became infected with HeV but survived.", [["hand", "ANATOMY", 55, 59], ["HeV", "DISEASE", 86, 89], ["hand", "ORGANISM_SUBDIVISION", 55, 59], ["HeV", "ORGANISM", 86, 89], ["HeV", "SPECIES", 86, 89], ["infected", "PROBLEM", 72, 80], ["HeV", "PROBLEM", 86, 89], ["infected", "OBSERVATION", 72, 80]]], ["Those who became infected with HeV, did so through close exposure to infectious blood and/or other bodily fluids such as respiratory secretions from an infected horse (Animal Health Australia, 2013, DAFF QLD, 2014).", [["blood", "ANATOMY", 80, 85], ["bodily fluids", "ANATOMY", 99, 112], ["respiratory secretions", "ANATOMY", 121, 143], ["HeV", "ORGANISM", 31, 34], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["horse", "ORGANISM_SUBDIVISION", 161, 166], ["horse", "SPECIES", 161, 166], ["HeV", "SPECIES", 31, 34], ["infected", "PROBLEM", 17, 25], ["HeV", "PROBLEM", 31, 34], ["infectious blood", "PROBLEM", 69, 85], ["other bodily fluids", "PROBLEM", 93, 112], ["respiratory secretions", "PROBLEM", 121, 143], ["infected", "OBSERVATION", 17, 25], ["infectious", "OBSERVATION", 69, 79], ["respiratory", "ANATOMY", 121, 132], ["secretions", "OBSERVATION", 133, 143], ["infected", "OBSERVATION_MODIFIER", 152, 160]]], ["Currently there is no cure available for those who become infected with HeV.", [["no", "UNCERTAINTY", 19, 21], ["infected", "OBSERVATION", 58, 66]]], ["A human monoclonal antibody has been shown to neutralise HeV in primates and has been used as experimental prophylaxis in humans but it is not currently licenced or available commercially (Bossart et al., 2011).IntroductionConsequently public health, biosecurity and occupational health and safety government authorities primarily targeted their HeV preventative recommendations to equine veterinarians and their staff.", [["human", "ORGANISM", 2, 7], ["HeV", "ORGANISM", 57, 60], ["primates", "ORGANISM", 64, 72], ["humans", "ORGANISM", 122, 128], ["HeV", "ORGANISM", 346, 349], ["equine", "ORGANISM", 382, 388], ["human monoclonal antibody", "PROTEIN", 2, 27], ["human", "SPECIES", 2, 7], ["humans", "SPECIES", 122, 128], ["human", "SPECIES", 2, 7], ["HeV", "SPECIES", 57, 60], ["humans", "SPECIES", 122, 128], ["HeV", "SPECIES", 346, 349], ["equine", "SPECIES", 382, 388], ["A human monoclonal antibody", "TREATMENT", 0, 27], ["experimental prophylaxis", "TREATMENT", 94, 118]]], ["In 2010, all private veterinarians registered with the Veterinary Surgeons Board of Queensland (VSBQ) received a comprehensive information package about HeV and its management (DAFF QLD, 2010).", [["HeV", "ORGANISM", 153, 156], ["HeV", "SPECIES", 153, 156], ["HeV and its management", "TREATMENT", 153, 175]]], ["Up until 2011, the prevention of HeV was solely based on avoiding exposure, through contact with horses potentially infected with the virus, by implementing adequate infection control (IC) measures such as following hygiene and quarantine protocols and the use of personal protective equipment (PPE).", [["HeV", "DISEASE", 33, 36], ["infection", "DISEASE", 166, 175], ["HeV", "ORGANISM", 33, 36], ["HeV", "SPECIES", 33, 36], ["the virus", "PROBLEM", 130, 139], ["adequate infection control (IC) measures", "TREATMENT", 157, 197], ["quarantine protocols", "TREATMENT", 228, 248], ["personal protective equipment", "TREATMENT", 264, 293], ["infection", "OBSERVATION", 166, 175]]], ["In October 2012 a new HeV vaccine for horses was also released and promoted as a One Health measure that would protect both horses and the people coming into contact with horses, and in particular horse owners and veterinary personnel (Pallister et al., 2011a, Pallister et al., 2011b, Animal Health Australia, 2013, Middleton et al., 2014).", [["HeV", "ORGANISM", 22, 25], ["horses", "ORGANISM", 38, 44], ["horses", "ORGANISM", 124, 130], ["people", "ORGANISM", 139, 145], ["horse", "ORGANISM", 197, 202], ["horses", "SPECIES", 38, 44], ["people", "SPECIES", 139, 145], ["horse", "SPECIES", 197, 202], ["HeV", "SPECIES", 22, 25], ["horses", "SPECIES", 38, 44], ["horse", "SPECIES", 197, 202]]], ["However, after more than a year in circulation the vaccine uptake seems to have been moderate despite the initial motivation of veterinarians to encourage horse owners to vaccinate their horses (Mendez et al., 2013a, DPI NSW, 2013.", [["horse", "ORGANISM", 155, 160], ["horse", "SPECIES", 155, 160], ["horse", "SPECIES", 155, 160], ["moderate", "OBSERVATION_MODIFIER", 85, 93]]], ["Veterinary IC therefore remains a major component of the management of HeV in private practices providing equine veterinary services.IntroductionIn the winter of 2011, as part of a cross-sectional study of private veterinarians registered in QLD we investigated: HeV management strategies implemented by eligible veterinarians including their use of PPE, with the aim of identifying the strategies implemented by private veterinarians who treated horses; and to determine if they modified their use of PPE depending on the health status of their equine patients.Study design ::: MethodsThis study was conducted as a cross-sectional study of private veterinarians providing equine services in QLD, Australia.", [["HeV", "DISEASE", 71, 74], ["HeV", "ORGANISM", 71, 74], ["HeV", "ORGANISM", 263, 266], ["horses", "ORGANISM", 447, 453], ["equine", "ORGANISM", 546, 552], ["patients", "ORGANISM", 553, 561], ["equine", "ORGANISM", 673, 679], ["patients", "SPECIES", 553, 561], ["HeV", "SPECIES", 71, 74], ["HeV", "SPECIES", 263, 266], ["equine veterinary services", "TREATMENT", 106, 132], ["a cross-sectional study", "TEST", 179, 202], ["HeV management strategies", "TREATMENT", 263, 288], ["PPE", "TREATMENT", 350, 353], ["PPE", "TREATMENT", 502, 505], ["Methods", "TREATMENT", 579, 586], ["This study", "TEST", 586, 596], ["a cross-sectional study", "TEST", 614, 637]]], ["Eligibility criteria for participation were as follow: (1) being a qualified veterinarian; (2) being registered in QLD; (3) working in private practice in QLD; and (4) to have provided veterinary services to at least one horse in the previous 12 months.", [["horse", "ORGANISM", 221, 226]]], ["Participation was voluntary and participants could withdraw from the study at any time.", [["participants", "SPECIES", 32, 44], ["the study", "TEST", 65, 74]]], ["This study was conducted with the approval of the James Cook University Human Ethics Committee (Ethics Approval No.", [["Human", "ORGANISM", 72, 77], ["Human", "SPECIES", 72, 77], ["This study", "TEST", 0, 10]]], ["H3687)Questionnaire design ::: MethodsThe questionnaire used for this study was based on the results from a previous qualitative study which explored the HeV-risk related perceptions and barriers to IC and HeV management in equine veterinary practices in QLD between 2009 and 2010 (Mendez et al., 2012a, Mendez et al., 2012b, Mendez et al., 2013b).", [["HeV", "ORGANISM", 154, 157], ["HeV", "ORGANISM", 206, 209], ["equine", "ORGANISM", 224, 230], ["HeV", "SPECIES", 154, 157], ["HeV", "SPECIES", 206, 209], ["equine", "SPECIES", 224, 230], ["Methods", "TREATMENT", 31, 38], ["this study", "TEST", 65, 75], ["a previous qualitative study", "TEST", 106, 134], ["barriers to IC", "TREATMENT", 187, 201], ["HeV management", "TREATMENT", 206, 220]]], ["The questionnaire also took into account the HeV management recommendations and Workplace Health and Safety (WHS) regulations in place at the time of the study design (DAFF QLD 2010; Workplace Health and Safety Queensland (WHS QLD); 2011a).", [["HeV", "ORGANISM", 45, 48], ["HeV", "SPECIES", 45, 48], ["Safety (WHS) regulations", "TREATMENT", 101, 125]]], ["The questionnaire was piloted with 6 eligible veterinarians within the target population prior to its implementation.Questionnaire design ::: MethodsThe questionnaire comprised of a number of socio-demographic, professional and practice profile questions and a number of multiple choice and open-ended questions on the topics of HeV management: management plan; IC facilities in the veterinary practice; HeV field kit; and HeV risk communication with clients.", [["HeV", "ORGANISM", 329, 332], ["HeV", "ORGANISM", 423, 426], ["HeV", "SPECIES", 329, 332], ["HeV", "SPECIES", 423, 426], ["Methods", "TREATMENT", 142, 149], ["HeV management", "TREATMENT", 329, 343]]], ["Participants\u2019 geographic locations within QLD were categorised according to their postcodes into two regions: Brisbane and Moreton, and other; and five Accessibility/Remoteness Index of Australia (ARIA) categories: highly accessible, accessible, moderately accessible, remote, and very remote.", [["Participants", "SPECIES", 0, 12], ["moderately", "OBSERVATION_MODIFIER", 246, 256]]], ["Moreover, participants were asked how often they used PPE depending on the health status of a horse: a healthy horse (HH); a sick horse (SH); or when they were conducting a necropsy on a dead horse (NH).", [["horse", "ORGANISM_SUBDIVISION", 94, 99], ["horse", "ORGANISM_SUBDIVISION", 111, 116], ["horse", "ORGANISM_SUBDIVISION", 130, 135], ["horse", "ORGANISM_SUBDIVISION", 192, 197], ["participants", "SPECIES", 10, 22], ["horse", "SPECIES", 94, 99], ["horse", "SPECIES", 111, 116], ["horse", "SPECIES", 130, 135], ["horse", "SPECIES", 192, 197]]], ["Participants were also asked to detail which items of PPE they used in each of the different horse health scenarios as well as in the case a horse was suspected to be infected with HeV (HeVH).", [["HeV", "DISEASE", 181, 184], ["HeVH", "DISEASE", 186, 190], ["horse", "ORGANISM", 141, 146], ["HeV", "ORGANISM", 181, 184], ["Participants", "SPECIES", 0, 12], ["horse", "SPECIES", 141, 146], ["horse", "SPECIES", 141, 146], ["HeV", "SPECIES", 181, 184], ["PPE", "TREATMENT", 54, 57]]], ["Participants could choose PPE items from 9 different types of PPE: body (overalls, gown or apron), head (hat), feet (gumboots or boot covers), oro-nasal only (surgical mask, surgical mask with fluid barrier or particulate mask [N95/P2]), oro-nasal and ocular (surgical mask with eye shield or face shield), ocular only (goggles), hand (gloves or arm length gloves) PPE; dressing to cover open wounds or skin abrasions; and powered air respirator (PAR).", [["body", "ANATOMY", 67, 71], ["head", "ANATOMY", 99, 103], ["feet", "ANATOMY", 111, 115], ["gumboots", "ANATOMY", 117, 125], ["fluid", "ANATOMY", 193, 198], ["oro-nasal", "ANATOMY", 238, 247], ["ocular", "ANATOMY", 252, 258], ["eye", "ANATOMY", 279, 282], ["face", "ANATOMY", 293, 297], ["ocular", "ANATOMY", 307, 313], ["hand", "ANATOMY", 330, 334], ["wounds", "ANATOMY", 393, 399], ["skin", "ANATOMY", 403, 407], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["head", "ORGANISM_SUBDIVISION", 99, 103], ["feet", "ORGANISM_SUBDIVISION", 111, 115], ["ocular", "ORGAN", 252, 258], ["hand", "ORGANISM_SUBDIVISION", 330, 334], ["wounds", "PATHOLOGICAL_FORMATION", 393, 399], ["skin", "ORGAN", 403, 407], ["Participants", "SPECIES", 0, 12], ["head (hat), feet (gumboots or boot covers", "TREATMENT", 99, 140], ["oro-nasal", "TREATMENT", 143, 152], ["surgical mask", "TREATMENT", 159, 172], ["surgical mask", "TREATMENT", 174, 187], ["fluid barrier", "TREATMENT", 193, 206], ["particulate mask", "TREATMENT", 210, 226], ["N95/P2", "TREATMENT", 228, 234], ["oro-nasal", "TREATMENT", 238, 247], ["ocular (surgical mask", "TREATMENT", 252, 273], ["eye shield or face shield", "TREATMENT", 279, 304], ["hand (gloves or arm length gloves", "TREATMENT", 330, 363], ["PPE", "PROBLEM", 365, 368], ["dressing", "TREATMENT", 370, 378], ["open wounds", "PROBLEM", 388, 399], ["skin abrasions", "PROBLEM", 403, 417], ["powered air respirator", "TREATMENT", 423, 445], ["body", "ANATOMY", 67, 71], ["head", "ANATOMY", 99, 103], ["feet", "ANATOMY", 111, 115], ["ocular", "ANATOMY", 252, 258], ["ocular", "ANATOMY", 307, 313], ["hand", "ANATOMY", 330, 334], ["arm", "ANATOMY", 346, 349], ["wounds", "OBSERVATION", 393, 399], ["skin", "ANATOMY", 403, 407], ["abrasions", "OBSERVATION", 408, 417]]], ["For each scenario respondents scored one point for each type of PPE they used.Questionnaire implementation ::: MethodsThe questionnaire was first mailed out in June 2011 to 1604 veterinarians registered with the VSBQ and who were identified as working in private practice in QLD.", [["Methods", "TREATMENT", 111, 118]]], ["Each mail out contained an information page, the questionnaire and a pre-paid envelop to return participants\u2019 responses.", [["participants", "SPECIES", 96, 108]]], ["IBM SPSS Statistics for Windows, Version 21.0.", [["Version", "TEST", 33, 40]]], ["Armonk, NY: IBM Corp.) for analysis.", [["analysis", "TEST", 27, 35]]], ["Categorical data were reported using percentages.", [["Categorical data", "TEST", 0, 16]]], ["Numerical data were reported using mean and standard deviations (SD) when symmetrical, and median and interquartile range (IQR) when skewed.", [["Numerical data", "TEST", 0, 14], ["mean", "TEST", 35, 39]]], ["Participants who \u201calways or sometimes\u201d used PPE in a range of scenarios related to the health status of horses were compared to those who used PPE \u201cless often\u201d using Pearson's Chi-square, Chi-square for trend, and, Fisher's exact test.", [["horses", "ORGANISM", 104, 110], ["Participants", "SPECIES", 0, 12], ["Fisher's exact test", "TEST", 215, 234]]], ["Participants\u2019 PPE usage score according to the health status of horses were compared using a Friedman's test.", [["horses", "ORGANISM", 64, 70], ["Participants", "SPECIES", 0, 12], ["a Friedman's test", "TEST", 91, 108]]], ["Participants with a PPE usage score above or equal to the median score in a range of scenarios related to the health status of horses were also compared to those who scored below the median score using Pearson's Chi-square.", [["horses", "ORGANISM", 127, 133], ["Participants", "SPECIES", 0, 12]]], ["Bivariate analyses were conducted with respect to socio-demographic, practice, professional and HeV experience characteristics.", [["HeV", "ORGANISM", 96, 99], ["HeV", "SPECIES", 96, 99], ["Bivariate analyses", "TEST", 0, 18]]], ["The assumptions for these statistical tests were met.", [["these statistical tests", "TEST", 20, 43]]], ["An alpha level of 0.05 was used for all statistical analyses.Socio-demographic and veterinary education (Table 1tbl0005table) ::: ResultsOf the 200 respondents, 96 were male (48%); 116 were 40 years or younger (58%); 156 (78%) graduated from a QLD University.", [["An alpha level", "TEST", 0, 14], ["all statistical analyses", "TEST", 36, 60]]]], "PMC7166686": [["IntroductionHepatitis B virus (HBV) infects the liver as primary target, resulting in the majority of cases in self\u2010limiting acute hepatitis.", [["liver", "ANATOMY", 48, 53], ["IntroductionHepatitis B", "DISEASE", 0, 23], ["hepatitis", "DISEASE", 131, 140], ["IntroductionHepatitis B virus", "ORGANISM", 0, 29], ["HBV", "ORGANISM", 31, 34], ["liver", "ORGAN", 48, 53], ["IntroductionHepatitis B virus", "SPECIES", 0, 29], ["IntroductionHepatitis B virus", "SPECIES", 0, 29], ["HBV", "SPECIES", 31, 34], ["IntroductionHepatitis B virus (HBV) infects the liver", "PROBLEM", 0, 53], ["self\u2010limiting acute hepatitis", "PROBLEM", 111, 140], ["virus", "OBSERVATION", 24, 29], ["liver", "ANATOMY", 48, 53], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["hepatitis", "OBSERVATION", 131, 140]]], ["Nevertheless, more than 350 million people are chronically infected with HBV worldwide [1].", [["people", "ORGANISM", 36, 42], ["HBV", "ORGANISM", 73, 76], ["people", "SPECIES", 36, 42], ["HBV", "SPECIES", 73, 76]]], ["Despite the high incidence of infection, a cellular receptor for HBV entry is still unknown.", [["cellular", "ANATOMY", 43, 51], ["infection", "DISEASE", 30, 39], ["cellular", "CELL", 43, 51], ["HBV", "ORGANISM", 65, 68], ["cellular receptor", "PROTEIN", 43, 60], ["HBV", "SPECIES", 65, 68], ["infection", "PROBLEM", 30, 39], ["a cellular receptor", "TEST", 41, 60], ["HBV entry", "TEST", 65, 74], ["high incidence", "OBSERVATION_MODIFIER", 12, 26], ["infection", "OBSERVATION", 30, 39]]], ["Several putative binding factors have been described for the HBV surface antigens (HBsAg), such as human serum albumin [2], asialoglycoprotein receptor [3], heparin [4] and mannose binding lectin [5], but their exact role in HBV attachment and uptake remains unclear [6].IntroductionHepatitis B virus is a DNA virus, consisting of a core particle enveloped by small (S), middle (M) and large (L) surface antigens, generally referred to as HBsAg.", [["serum", "ANATOMY", 105, 110], ["HBsAg", "CHEMICAL", 83, 88], ["heparin", "CHEMICAL", 157, 164], ["Hepatitis B", "DISEASE", 283, 294], ["mannose", "CHEMICAL", 173, 180], ["HBV surface antigens", "GENE_OR_GENE_PRODUCT", 61, 81], ["HBsAg", "GENE_OR_GENE_PRODUCT", 83, 88], ["human", "ORGANISM", 99, 104], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["albumin", "GENE_OR_GENE_PRODUCT", 111, 118], ["2", "GENE_OR_GENE_PRODUCT", 120, 121], ["asialoglycoprotein receptor [3]", "SIMPLE_CHEMICAL", 124, 155], ["heparin [4]", "SIMPLE_CHEMICAL", 157, 168], ["mannose binding lectin", "SIMPLE_CHEMICAL", 173, 195], ["HBV", "ORGANISM", 225, 228], ["Hepatitis B virus", "ORGANISM", 283, 300], ["DNA", "CELLULAR_COMPONENT", 306, 309], ["large (L) surface antigens", "GENE_OR_GENE_PRODUCT", 386, 412], ["putative binding factors", "PROTEIN", 8, 32], ["HBV surface antigens", "PROTEIN", 61, 81], ["HBsAg", "PROTEIN", 83, 88], ["human serum albumin [2], asialoglycoprotein receptor", "PROTEIN", 99, 151], ["mannose binding lectin", "PROTEIN", 173, 195], ["small (S), middle (M) and large (L) surface antigens", "PROTEIN", 360, 412], ["HBs", "PROTEIN", 439, 442], ["human", "SPECIES", 99, 104], ["Hepatitis B virus", "SPECIES", 283, 300], ["HBV", "SPECIES", 61, 64], ["human", "SPECIES", 99, 104], ["HBV", "SPECIES", 225, 228], ["Hepatitis B virus", "SPECIES", 283, 300], ["Several putative binding factors", "PROBLEM", 0, 32], ["the HBV surface antigens", "TEST", 57, 81], ["HBsAg", "TEST", 83, 88], ["human serum albumin", "TEST", 99, 118], ["asialoglycoprotein receptor", "TREATMENT", 124, 151], ["heparin", "TREATMENT", 157, 164], ["mannose binding lectin", "TREATMENT", 173, 195], ["HBV attachment", "PROBLEM", 225, 239], ["Hepatitis B virus", "PROBLEM", 283, 300], ["a DNA virus", "PROBLEM", 304, 315], ["a core particle", "TEST", 331, 346], ["small (S), middle (M) and large (L) surface antigens", "PROBLEM", 360, 412], ["core particle", "OBSERVATION_MODIFIER", 333, 346], ["small", "OBSERVATION_MODIFIER", 360, 365], ["middle", "ANATOMY_MODIFIER", 371, 377], ["large", "OBSERVATION_MODIFIER", 386, 391]]], ["All three surface antigens contain a common S domain, both M and L proteins contain a preS2 domain and L exclusively contains a preS1 domain [7].", [["surface", "ANATOMY", 10, 17], ["surface antigens", "PROTEIN", 10, 26], ["S domain", "PROTEIN", 44, 52], ["M and L proteins", "PROTEIN", 59, 75], ["preS2 domain", "PROTEIN", 86, 98], ["L", "PROTEIN", 103, 104], ["preS1 domain", "PROTEIN", 128, 140], ["a preS2 domain", "TREATMENT", 84, 98], ["a preS1 domain", "TREATMENT", 126, 140]]], ["The liver and peripheral blood of HBV infected individuals can reach levels of 109\u20131010 infectious particles per mL.", [["liver", "ANATOMY", 4, 9], ["peripheral blood", "ANATOMY", 14, 30], ["HBV infected", "DISEASE", 34, 46], ["liver", "ORGAN", 4, 9], ["peripheral blood", "ORGANISM_SUBSTANCE", 14, 30], ["HBV", "ORGANISM", 34, 37], ["individuals", "ORGANISM", 47, 58], ["HBV", "SPECIES", 34, 37], ["HBV infected individuals", "PROBLEM", 34, 58], ["liver", "ANATOMY", 4, 9], ["peripheral", "ANATOMY_MODIFIER", 14, 24], ["blood", "ANATOMY", 25, 30], ["HBV", "OBSERVATION_MODIFIER", 34, 37], ["infected", "OBSERVATION", 38, 46]]], ["In addition, HBsAg is secreted from infected hepatocytes as spherical subviral particles and filaments, which can accumulate up to 100 \u03bcg/mL in peripheral blood [7, 8].", [["hepatocytes", "ANATOMY", 45, 56], ["filaments", "ANATOMY", 93, 102], ["peripheral blood", "ANATOMY", 144, 160], ["HBsAg", "CHEMICAL", 13, 18], ["HBsAg", "GENE_OR_GENE_PRODUCT", 13, 18], ["hepatocytes", "CELL", 45, 56], ["filaments", "CELLULAR_COMPONENT", 93, 102], ["peripheral", "ORGANISM_SUBSTANCE", 144, 154], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["HBsAg", "PROTEIN", 13, 18], ["infected hepatocytes", "CELL_TYPE", 36, 56], ["HBsAg", "TEST", 13, 18], ["infected hepatocytes", "PROBLEM", 36, 56], ["peripheral blood", "TEST", 144, 160], ["HBsAg", "OBSERVATION", 13, 18], ["infected", "OBSERVATION", 36, 44], ["subviral particles", "OBSERVATION", 70, 88], ["peripheral", "ANATOMY_MODIFIER", 144, 154], ["blood", "ANATOMY", 155, 160]]], ["S is the main component of both HBV virions and HBsAg subviral particles, while M and L are highly enriched on HBV virions.", [["virions", "ANATOMY", 36, 43], ["virions", "ANATOMY", 115, 122], ["HBsAg", "CHEMICAL", 48, 53], ["HBV", "ORGANISM", 32, 35], ["HBsAg", "GENE_OR_GENE_PRODUCT", 48, 53], ["HBV virions", "ORGANISM", 111, 122], ["HBV", "SPECIES", 32, 35], ["HBV", "SPECIES", 111, 114], ["both HBV virions", "PROBLEM", 27, 43], ["HBsAg subviral particles", "PROBLEM", 48, 72], ["HBV virions", "TREATMENT", 111, 122], ["main", "OBSERVATION_MODIFIER", 9, 13], ["both", "OBSERVATION_MODIFIER", 27, 31], ["HBV virions", "OBSERVATION", 32, 43], ["HBsAg subviral particles", "OBSERVATION", 48, 72], ["highly", "OBSERVATION_MODIFIER", 92, 98], ["enriched", "OBSERVATION", 99, 107], ["HBV virions", "OBSERVATION", 111, 122]]], ["Post\u2010translational modifications of the surface antigens are crucial for HBV life cycle; myristoylation of the preS1 domain is essential for infectivity [6, 9], while inhibition of N\u2010glycosylation of the preS2 domain prevents secretion of viral particles [10, 11].", [["surface", "ANATOMY", 40, 47], ["HBV", "ORGANISM", 73, 76], ["preS1", "GENE_OR_GENE_PRODUCT", 111, 116], ["preS2", "GENE_OR_GENE_PRODUCT", 204, 209], ["surface antigens", "PROTEIN", 40, 56], ["preS1 domain", "PROTEIN", 111, 123], ["preS2 domain", "PROTEIN", 204, 216], ["HBV", "SPECIES", 73, 76], ["the surface antigens", "TREATMENT", 36, 56], ["HBV life cycle", "TREATMENT", 73, 87], ["myristoylation of the preS1 domain", "TREATMENT", 89, 123], ["infectivity", "PROBLEM", 141, 152], ["N\u2010glycosylation", "TREATMENT", 181, 196], ["the preS2 domain", "TREATMENT", 200, 216], ["secretion of viral particles", "PROBLEM", 226, 254]]], ["Recently, post\u2010translational N\u2010glycosylation of the preS1 domain has been reported as well and although it seems dispensable for HBV morphogenesis it might be involved in viral attachment [12].IntroductionThe first step in clearance of a viral infection involves recognition of the virus by the innate immune system, mediated through host pattern recognition receptors (PRR) such as Toll\u2010like receptors and C\u2010type lectins [13, 14].", [["viral infection", "DISEASE", 238, 253], ["preS1", "GENE_OR_GENE_PRODUCT", 52, 57], ["HBV", "ORGANISM", 129, 132], ["immune system", "ANATOMICAL_SYSTEM", 302, 315], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 339, 368], ["PRR", "GENE_OR_GENE_PRODUCT", 370, 373], ["Toll\u2010like receptors", "GENE_OR_GENE_PRODUCT", 383, 402], ["C\u2010type lectins", "GENE_OR_GENE_PRODUCT", 407, 421], ["preS1 domain", "PROTEIN", 52, 64], ["host pattern recognition receptors", "PROTEIN", 334, 368], ["PRR", "PROTEIN", 370, 373], ["Toll\u2010like receptors", "PROTEIN", 383, 402], ["C\u2010type lectins", "PROTEIN", 407, 421], ["HBV", "SPECIES", 129, 132], ["the preS1 domain", "PROBLEM", 48, 64], ["HBV morphogenesis", "PROBLEM", 129, 146], ["a viral infection", "PROBLEM", 236, 253], ["the virus", "PROBLEM", 278, 287], ["viral", "OBSERVATION_MODIFIER", 238, 243], ["infection", "OBSERVATION", 244, 253]]], ["C\u2010type lectins recognize highly conserved pathogen\u2010derived carbohydrate structures, leading to internalization, antigen processing and presentation to T cells [14].", [["carbohydrate structures", "ANATOMY", 59, 82], ["T cells", "ANATOMY", 151, 158], ["carbohydrate", "CHEMICAL", 59, 71], ["C\u2010type lectins", "GENE_OR_GENE_PRODUCT", 0, 14], ["T cells", "CELL", 151, 158], ["C\u2010type lectins", "PROTEIN", 0, 14], ["T cells", "CELL_TYPE", 151, 158], ["C\u2010type lectins", "TEST", 0, 14]]], ["A prototypical member of the C\u2010type lectin family is the dendritic cell\u2010specific lectin DC\u2010SIGN [15], which recognizes a broad range of glycosylated pathogens through mannose or fucose containing carbohydrates, including HIV\u20101, hepatitis C virus (HCV), Ebola virus, Dengue virus, measles virus, human herpesvirus 8, SARS coronavirus, cytomegalovirus, Mycobacterium tubercolosis, Helicobacter pylori, Streptococcus pneumonia and Neisseria meningitidis [16, 17, 18].", [["mannose", "CHEMICAL", 167, 174], ["fucose", "CHEMICAL", 178, 184], ["HIV\u20101, hepatitis C", "DISEASE", 221, 239], ["Ebola virus", "DISEASE", 253, 264], ["Dengue virus", "DISEASE", 266, 278], ["measles virus", "DISEASE", 280, 293], ["SARS coronavirus", "DISEASE", 316, 332], ["cytomegalovirus", "DISEASE", 334, 349], ["Mycobacterium tubercolosis", "DISEASE", 351, 377], ["Helicobacter pylori", "DISEASE", 379, 398], ["Streptococcus pneumonia", "DISEASE", 400, 423], ["Neisseria meningitidis", "DISEASE", 428, 450], ["mannose", "CHEMICAL", 167, 174], ["fucose", "CHEMICAL", 178, 184], ["carbohydrates", "CHEMICAL", 196, 209], ["C\u2010type lectin", "GENE_OR_GENE_PRODUCT", 29, 42], ["mannose", "SIMPLE_CHEMICAL", 167, 174], ["fucose", "SIMPLE_CHEMICAL", 178, 184], ["HIV\u20101,", "ORGANISM", 221, 227], ["hepatitis C virus", "ORGANISM", 228, 245], ["HCV", "ORGANISM", 247, 250], ["Ebola virus", "ORGANISM", 253, 264], ["Dengue virus", "ORGANISM", 266, 278], ["measles virus", "ORGANISM", 280, 293], ["human herpesvirus 8", "ORGANISM", 295, 314], ["SARS coronavirus", "ORGANISM", 316, 332], ["cytomegalovirus", "ORGANISM", 334, 349], ["Mycobacterium tubercolosis", "ORGANISM", 351, 377], ["Helicobacter pylori", "ORGANISM", 379, 398], ["Streptococcus pneumonia", "ORGANISM", 400, 423], ["Neisseria meningitidis", "ORGANISM", 428, 450], ["C\u2010type lectin family", "PROTEIN", 29, 49], ["dendritic cell\u2010specific lectin DC", "PROTEIN", 57, 90], ["SIGN", "PROTEIN", 91, 95], ["HIV", "SPECIES", 221, 224], ["hepatitis C virus", "SPECIES", 228, 245], ["Ebola virus", "SPECIES", 253, 264], ["Dengue virus", "SPECIES", 266, 278], ["measles virus", "SPECIES", 280, 293], ["human", "SPECIES", 295, 300], ["herpesvirus", "SPECIES", 301, 312], ["SARS coronavirus", "SPECIES", 316, 332], ["Mycobacterium tubercolosis", "SPECIES", 351, 377], ["Helicobacter pylori", "SPECIES", 379, 398], ["Streptococcus pneumonia", "SPECIES", 400, 423], ["Neisseria meningitidis", "SPECIES", 428, 450], ["HIV\u20101", "SPECIES", 221, 226], ["hepatitis C virus", "SPECIES", 228, 245], ["HCV", "SPECIES", 247, 250], ["Ebola virus", "SPECIES", 253, 264], ["Dengue virus", "SPECIES", 266, 278], ["measles virus", "SPECIES", 280, 293], ["human herpesvirus 8", "SPECIES", 295, 314], ["SARS coronavirus", "SPECIES", 316, 332], ["Mycobacterium tubercolosis", "SPECIES", 351, 377], ["Helicobacter pylori", "SPECIES", 379, 398], ["Streptococcus pneumonia", "SPECIES", 400, 423], ["Neisseria meningitidis", "SPECIES", 428, 450], ["glycosylated pathogens", "PROBLEM", 136, 158], ["mannose", "TREATMENT", 167, 174], ["fucose containing carbohydrates", "TREATMENT", 178, 209], ["HIV\u20101", "TREATMENT", 221, 226], ["hepatitis C virus", "PROBLEM", 228, 245], ["HCV", "PROBLEM", 247, 250], ["Ebola virus", "PROBLEM", 253, 264], ["Dengue virus", "PROBLEM", 266, 278], ["measles virus", "PROBLEM", 280, 293], ["human herpesvirus", "PROBLEM", 295, 312], ["SARS coronavirus", "PROBLEM", 316, 332], ["cytomegalovirus", "PROBLEM", 334, 349], ["Mycobacterium tubercolosis", "PROBLEM", 351, 377], ["Helicobacter pylori", "PROBLEM", 379, 398], ["Streptococcus pneumonia", "PROBLEM", 400, 423], ["Neisseria meningitidis", "PROBLEM", 428, 450], ["Mycobacterium tubercolosis", "OBSERVATION", 351, 377], ["Helicobacter pylori", "OBSERVATION", 379, 398], ["Streptococcus pneumonia", "OBSERVATION", 400, 423]]], ["Many of these DC\u2010SIGN\u2010binding pathogens have evolved to subvert the immune surveillance function of DC\u2010SIGN for their own benefit and re\u2010direct the internalization route to nonlysosomal compartments for protection and transmission to target cells [16].", [["DC", "ANATOMY", 14, 16], ["DC", "ANATOMY", 100, 102], ["nonlysosomal compartments", "ANATOMY", 173, 198], ["cells", "ANATOMY", 241, 246], ["DC", "CELL", 14, 16], ["SIGN", "GENE_OR_GENE_PRODUCT", 17, 21], ["SIGN", "GENE_OR_GENE_PRODUCT", 103, 107], ["cells", "CELL", 241, 246], ["DC", "CELL_TYPE", 14, 16], ["SIGN", "PROTEIN", 17, 21], ["DC", "CELL_TYPE", 100, 102], ["SIGN", "PROTEIN", 103, 107], ["target cells", "CELL_TYPE", 234, 246], ["binding pathogens", "PROBLEM", 22, 39], ["the internalization route", "TREATMENT", 144, 169]]], ["Some pathogens can also modulate adaptive immune responses through interaction with DC\u2010SIGN; e.g. M. tuberculosis exploits DC\u2010SIGN to escape immune surveillance by inhibition of the immunostimulatory function of dendritic cells [16, 19].IntroductionIt is well established that envelope glycoproteins E1 and E2 of HCV interact with both DC\u2010SIGN [15] and its homologue L\u2010SIGN [20] expressed on sinusoidal endothelial cells in liver and lymph nodes.", [["DC", "ANATOMY", 84, 86], ["DC", "ANATOMY", 123, 125], ["dendritic cells", "ANATOMY", 212, 227], ["DC", "ANATOMY", 336, 338], ["sinusoidal endothelial cells", "ANATOMY", 392, 420], ["liver", "ANATOMY", 424, 429], ["lymph nodes", "ANATOMY", 434, 445], ["E2", "CHEMICAL", 307, 309], ["SIGN", "GENE_OR_GENE_PRODUCT", 87, 91], ["M. tuberculosis", "ORGANISM", 98, 113], ["SIGN", "GENE_OR_GENE_PRODUCT", 126, 130], ["dendritic cells", "CELL", 212, 227], ["E1", "GENE_OR_GENE_PRODUCT", 300, 302], ["E2", "GENE_OR_GENE_PRODUCT", 307, 309], ["HCV", "ORGANISM", 313, 316], ["SIGN [15]", "GENE_OR_GENE_PRODUCT", 339, 348], ["L\u2010SIGN [20]", "GENE_OR_GENE_PRODUCT", 367, 378], ["sinusoidal endothelial cells", "CELL", 392, 420], ["liver", "ORGAN", 424, 429], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 434, 445], ["DC", "CELL_TYPE", 84, 86], ["SIGN", "PROTEIN", 87, 91], ["DC", "CELL_TYPE", 123, 125], ["SIGN", "PROTEIN", 126, 130], ["dendritic cells", "CELL_TYPE", 212, 227], ["envelope glycoproteins", "PROTEIN", 277, 299], ["E1", "PROTEIN", 300, 302], ["E2", "PROTEIN", 307, 309], ["DC", "CELL_TYPE", 336, 338], ["SIGN", "PROTEIN", 339, 343], ["SIGN [20", "PROTEIN", 369, 377], ["sinusoidal endothelial cells", "CELL_TYPE", 392, 420], ["M. tuberculosis", "SPECIES", 98, 113], ["M. tuberculosis", "SPECIES", 98, 113], ["HCV", "SPECIES", 313, 316], ["Some pathogens", "PROBLEM", 0, 14], ["immune surveillance", "TEST", 141, 160], ["dendritic cells", "PROBLEM", 212, 227], ["envelope glycoproteins E1", "TREATMENT", 277, 302], ["HCV interact", "TREATMENT", 313, 325], ["its homologue L\u2010SIGN", "TEST", 353, 373], ["sinusoidal endothelial cells in liver and lymph nodes", "PROBLEM", 392, 445], ["dendritic cells", "OBSERVATION", 212, 227], ["sinusoidal endothelial cells", "OBSERVATION", 392, 420], ["liver", "ANATOMY", 424, 429], ["lymph nodes", "OBSERVATION", 434, 445]]], ["For HCV virus\u2010like particles, DC\u2010SIGN interaction leads to efficient capture, internalization and transport to nonlysosomal compartments within immature dendritic cells, thereby protecting the virus from degradation [21, 22].", [["DC", "ANATOMY", 30, 32], ["nonlysosomal compartments", "ANATOMY", 111, 136], ["dendritic cells", "ANATOMY", 153, 168], ["DC", "CELL", 30, 32], ["SIGN", "GENE_OR_GENE_PRODUCT", 33, 37], ["dendritic cells", "CELL", 153, 168], ["DC", "CELL_TYPE", 30, 32], ["SIGN", "PROTEIN", 33, 37], ["immature dendritic cells", "CELL_TYPE", 144, 168], ["HCV", "SPECIES", 4, 7], ["HCV virus\u2010like particles", "PROBLEM", 4, 28], ["immature dendritic cells", "PROBLEM", 144, 168], ["the virus", "PROBLEM", 189, 198], ["dendritic cells", "OBSERVATION", 153, 168]]], ["Similarly, HCV virus\u2010like particles interact with L\u2010SIGN expressed on liver sinusoidal endothelial cells (LSEC) in situ, and are targeted to nonlysosomal early endosomes in L\u2010SIGN transfected Raji cells [22].", [["liver sinusoidal endothelial cells", "ANATOMY", 70, 104], ["LSEC", "ANATOMY", 106, 110], ["situ", "ANATOMY", 115, 119], ["nonlysosomal early endosomes", "ANATOMY", 141, 169], ["L\u2010SIGN", "ANATOMY", 173, 179], ["Raji cells", "ANATOMY", 192, 202], ["HCV virus\u2010like particles", "ORGANISM", 11, 35], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 50, 56], ["liver sinusoidal endothelial cells", "CELL", 70, 104], ["LSEC", "CELL", 106, 110], ["early endosomes", "CELLULAR_COMPONENT", 154, 169], ["L\u2010SIGN", "CELL", 173, 179], ["Raji cells", "CELL", 192, 202], ["L\u2010SIGN", "PROTEIN", 50, 56], ["liver sinusoidal endothelial cells", "CELL_TYPE", 70, 104], ["LSEC", "CELL_TYPE", 106, 110], ["L\u2010SIGN transfected Raji cells", "CELL_LINE", 173, 202], ["HCV", "SPECIES", 11, 14], ["HCV virus\u2010like particles", "PROBLEM", 11, 35], ["HCV", "OBSERVATION", 11, 14], ["liver", "ANATOMY", 70, 75], ["sinusoidal", "ANATOMY_MODIFIER", 76, 86], ["endothelial cells", "OBSERVATION", 87, 104], ["LSEC", "ANATOMY", 106, 110], ["transfected Raji cells", "OBSERVATION", 180, 202]]], ["DC\u2010SIGN and L\u2010SIGN are also thought to play an important role in HCV viral dissemination by transferring HCV from the circulation to hepatocytes, the main HCV target cells [23].IntroductionSeveral reports have shown the presence of HBV on or within dendritic cells [24, 25, 26, 27], suggesting the involvement of a dendritic cell\u2010specific receptor such as DC\u2010SIGN.", [["DC", "ANATOMY", 0, 2], ["hepatocytes", "ANATOMY", 133, 144], ["cells", "ANATOMY", 166, 171], ["dendritic cells", "ANATOMY", 249, 264], ["dendritic cell\u2010specific", "ANATOMY", 315, 338], ["DC", "ANATOMY", 356, 358], ["SIGN", "GENE_OR_GENE_PRODUCT", 3, 7], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 12, 18], ["HCV", "ORGANISM", 65, 68], ["HCV", "ORGANISM", 105, 108], ["hepatocytes", "CELL", 133, 144], ["HCV", "ORGANISM", 155, 158], ["cells", "CELL", 166, 171], ["HBV", "ORGANISM", 232, 235], ["dendritic cells", "CELL", 249, 264], ["SIGN", "GENE_OR_GENE_PRODUCT", 359, 363], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7], ["L\u2010SIGN", "PROTEIN", 12, 18], ["hepatocytes", "CELL_TYPE", 133, 144], ["HCV target cells", "CELL_TYPE", 155, 171], ["dendritic cells", "CELL_TYPE", 249, 264], ["dendritic cell\u2010specific receptor", "PROTEIN", 315, 347], ["DC", "CELL_TYPE", 356, 358], ["SIGN", "PROTEIN", 359, 363], ["HCV", "SPECIES", 65, 68], ["HCV", "SPECIES", 105, 108], ["HCV", "SPECIES", 155, 158], ["HBV", "SPECIES", 232, 235], ["HCV viral dissemination", "PROBLEM", 65, 88], ["HBV", "PROBLEM", 232, 235], ["hepatocytes", "ANATOMY", 133, 144], ["HBV", "OBSERVATION", 232, 235]]], ["Patient\u2010derived HBsAg is preferentially internalised by human LSEC in a mixed culture with human hepatocytes (K. Esser and U. Protzer, unpublished data) \u2013 as it has also been reported for duck HBV [28] \u2013 implying a potential interaction between HBV and L\u2010SIGN.", [["LSEC", "ANATOMY", 62, 66], ["hepatocytes", "ANATOMY", 97, 108], ["HBsAg", "CHEMICAL", 16, 21], ["HBsAg", "GENE_OR_GENE_PRODUCT", 16, 21], ["human", "ORGANISM", 56, 61], ["LSEC", "CELL", 62, 66], ["human", "ORGANISM", 91, 96], ["hepatocytes", "CELL", 97, 108], ["duck HBV", "ORGANISM", 188, 196], ["HBV", "ORGANISM", 245, 248], ["HBsAg", "PROTEIN", 16, 21], ["human LSEC", "CELL_TYPE", 56, 66], ["human hepatocytes", "CELL_TYPE", 91, 108], ["Patient", "SPECIES", 0, 7], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 91, 96], ["duck", "SPECIES", 188, 192], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 91, 96], ["duck HBV", "SPECIES", 188, 196], ["HBV", "SPECIES", 245, 248], ["a mixed culture", "TEST", 70, 85], ["duck HBV", "PROBLEM", 188, 196], ["hepatocytes", "ANATOMY", 97, 108], ["HBV", "OBSERVATION", 245, 248]]], ["The HBV glycosylation pattern together with the cellular localization prompted us to investigate the possible role of both DC\u2010SIGN and L\u2010SIGN in binding of HBV.Antibodies and viral glycoproteins ::: MethodsThe following antibodies were used: DC\u2010SIGN and L\u2010SIGN specific antibody AZN\u2010D2 [29]; mouse anti\u2010DC\u2010SIGN conjugated with fluorescein isothiocyanate (FITC) (clone DCN46; BD Biosciences, San Jose, CA, USA); mouse anti\u2010HCV E2 (4H6B2; Innogenetics, Ghent, Belgium); sheep anti\u2010HBsAg preS1, mouse anti\u2010HBsAg preS2 and biotinylated human anti\u2010HBsAg (F\u20109H9\u2010E, all kind gifts of R. Heijtink, Erasmus MC, Rotterdam, The Netherlands); rabbit anti\u2010HBsAg\u2010FITC (Acris Antibodies GmbH, Hiddenhausen, Germany); peroxidase\u2010conjugated goat anti\u2010human immunoglobulin G1 (Jackson Immunoresearch, West Grove, PA, USA); peroxidase\u2010conjugated rabbit anti\u2010FITC (Dako, Glostrup, Denmark); peroxidase\u2010conjugated goat anti\u2010mouse (Caltag, Carlsbad, CA, USA); peroxidase\u2010conjugated streptavidin (Dako).Antibodies and viral glycoproteins ::: MethodsRecombinant HBV surface antigen HBsAg (containing both S and preS2 domains) purified from transfected Chinese Hamster Ovary (CHO) cells was kindly provided by M. van Roosmalen (bioM\u00e9rieux, Boxtel, The Netherlands).", [["cellular", "ANATOMY", 48, 56], ["DC", "ANATOMY", 123, 125], ["DC", "ANATOMY", 242, 244], ["Hamster Ovary (CHO) cells", "ANATOMY", 1136, 1161], ["fluorescein isothiocyanate", "CHEMICAL", 327, 353], ["E2", "CHEMICAL", 426, 428], ["HBsAg", "CHEMICAL", 543, 548], ["HBsAg", "CHEMICAL", 643, 648], ["HBsAg", "CHEMICAL", 1058, 1063], ["fluorescein isothiocyanate", "CHEMICAL", 327, 353], ["FITC", "CHEMICAL", 355, 359], ["FITC", "CHEMICAL", 649, 653], ["FITC", "CHEMICAL", 839, 843], ["HBV", "ORGANISM", 4, 7], ["cellular", "CELL", 48, 56], ["SIGN", "GENE_OR_GENE_PRODUCT", 126, 130], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 135, 141], ["HBV", "ORGANISM", 156, 159], ["SIGN", "GENE_OR_GENE_PRODUCT", 245, 249], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 254, 260], ["mouse", "ORGANISM", 292, 297], ["SIGN", "SIMPLE_CHEMICAL", 306, 310], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 327, 353], ["FITC", "SIMPLE_CHEMICAL", 355, 359], ["mouse", "ORGANISM", 411, 416], ["sheep", "ORGANISM", 468, 473], ["anti\u2010HBsAg preS1", "ORGANISM", 474, 490], ["mouse", "ORGANISM", 492, 497], ["anti\u2010HBsAg preS2", "ORGANISM", 498, 514], ["human", "ORGANISM", 532, 537], ["anti\u2010HBsAg", "ORGANISM", 538, 548], ["F\u20109H9\u2010E", "CELL", 550, 557], ["rabbit", "ORGANISM", 631, 637], ["FITC", "GENE_OR_GENE_PRODUCT", 649, 653], ["peroxidase", "GENE_OR_GENE_PRODUCT", 702, 712], ["peroxidase", "GENE_OR_GENE_PRODUCT", 805, 815], ["rabbit", "ORGANISM", 827, 833], ["FITC", "SIMPLE_CHEMICAL", 839, 843], ["Dako", "GENE_OR_GENE_PRODUCT", 845, 849], ["peroxidase", "GENE_OR_GENE_PRODUCT", 871, 881], ["peroxidase\u2010conjugated streptavidin", "SIMPLE_CHEMICAL", 938, 972], ["Dako", "GENE_OR_GENE_PRODUCT", 974, 978], ["HBV surface antigen HBsAg", "GENE_OR_GENE_PRODUCT", 1038, 1063], ["preS2", "GENE_OR_GENE_PRODUCT", 1087, 1092], ["CHO) cells", "CELL", 1151, 1161], ["DC", "CELL_TYPE", 123, 125], ["SIGN", "PROTEIN", 126, 130], ["L\u2010SIGN", "PROTEIN", 135, 141], ["viral glycoproteins", "PROTEIN", 175, 194], ["DC", "CELL_TYPE", 242, 244], ["SIGN", "PROTEIN", 245, 249], ["L\u2010SIGN specific antibody", "PROTEIN", 254, 278], ["AZN\u2010D2", "PROTEIN", 279, 285], ["mouse anti\u2010DC", "PROTEIN", 292, 305], ["sheep anti\u2010HBsAg preS1", "PROTEIN", 468, 490], ["mouse anti\u2010HBsAg preS2", "PROTEIN", 492, 514], ["biotinylated human anti\u2010HBsAg", "PROTEIN", 519, 548], ["rabbit anti\u2010HBsAg\u2010FITC", "PROTEIN", 631, 653], ["Acris Antibodies GmbH, Hiddenhausen, Germany); peroxidase\u2010conjugated goat anti\u2010human immunoglobulin G1", "PROTEIN", 655, 757], ["peroxidase", "PROTEIN", 805, 815], ["FITC (Dako, Glostrup, Denmark); peroxidase", "PROTEIN", 839, 881], ["\u2010conjugated goat anti\u2010mouse", "PROTEIN", 881, 908], ["Caltag, Carlsbad, CA, USA); peroxidase", "PROTEIN", 910, 948], ["conjugated streptavidin", "PROTEIN", 949, 972], ["Dako", "PROTEIN", 974, 978], ["viral glycoproteins", "PROTEIN", 995, 1014], ["MethodsRecombinant HBV surface antigen HBsAg", "PROTEIN", 1019, 1063], ["S", "PROTEIN", 1081, 1082], ["preS2 domains", "PROTEIN", 1087, 1100], ["transfected Chinese Hamster Ovary (CHO) cells", "CELL_LINE", 1116, 1161], ["mouse", "SPECIES", 292, 297], ["mouse", "SPECIES", 411, 416], ["sheep", "SPECIES", 468, 473], ["mouse", "SPECIES", 492, 497], ["human", "SPECIES", 532, 537], ["rabbit", "SPECIES", 631, 637], ["goat", "SPECIES", 724, 728], ["rabbit", "SPECIES", 827, 833], ["goat", "SPECIES", 893, 897], ["HBV", "SPECIES", 4, 7], ["HBV", "SPECIES", 156, 159], ["mouse", "SPECIES", 292, 297], ["mouse", "SPECIES", 411, 416], ["sheep", "SPECIES", 468, 473], ["mouse", "SPECIES", 492, 497], ["human", "SPECIES", 532, 537], ["rabbit", "SPECIES", 631, 637], ["goat", "SPECIES", 724, 728], ["rabbit anti\u2010", "SPECIES", 827, 839], ["HBV", "SPECIES", 1038, 1041], ["M. van Roosmalen", "SPECIES", 1185, 1201], ["The HBV glycosylation pattern", "TREATMENT", 0, 29], ["the cellular localization", "TEST", 44, 69], ["HBV", "PROBLEM", 156, 159], ["Antibodies", "TEST", 160, 170], ["Methods", "TREATMENT", 199, 206], ["L\u2010SIGN specific antibody AZN\u2010D2", "TEST", 254, 285], ["fluorescein isothiocyanate (FITC) (clone DCN46", "TREATMENT", 327, 373], ["mouse anti\u2010HCV E2", "TREATMENT", 411, 428], ["Innogenetics", "TREATMENT", 437, 449], ["sheep anti\u2010HBsAg preS1", "TREATMENT", 468, 490], ["mouse anti\u2010HBsAg preS2", "TREATMENT", 492, 514], ["biotinylated human anti\u2010HBsAg", "TEST", 519, 548], ["rabbit anti\u2010HBsAg", "TEST", 631, 648], ["Antibodies", "TEST", 661, 671], ["peroxidase", "TEST", 702, 712], ["peroxidase", "TREATMENT", 805, 815], ["peroxidase\u2010conjugated goat anti\u2010mouse", "TREATMENT", 871, 908], ["Caltag", "TEST", 910, 916], ["peroxidase\u2010conjugated streptavidin", "TREATMENT", 938, 972], ["Antibodies", "TEST", 980, 990], ["MethodsRecombinant HBV surface antigen", "TEST", 1019, 1057], ["HBsAg", "TEST", 1058, 1063], ["both S and preS2 domains", "TEST", 1076, 1100], ["HBV", "OBSERVATION", 156, 159], ["viral glycoproteins", "OBSERVATION", 175, 194], ["viral glycoproteins", "OBSERVATION", 995, 1014]]], ["Yeast cell\u2010derived HCV glycoproteins E1 and E2 reconstituted as virus\u2010like particles (VLP) were kindly provided by S. Depraetere (Innogenetics).HepG2.2.15\u2010derived HBV ::: MethodsHepG2.2.15 cells [30] were grown until confluence in Williams\u2019 E medium (Gibco, Paisley, UK) supplemented with 5% foetal calf serum (FCS, Hyclone, Logan, UT, USA).", [["HepG2.2.15\u2010", "ANATOMY", 144, 155], ["cells", "ANATOMY", 189, 194], ["foetal calf serum", "ANATOMY", 292, 309], ["E2", "CHEMICAL", 44, 46], ["E1", "GENE_OR_GENE_PRODUCT", 37, 39], ["E2", "GENE_OR_GENE_PRODUCT", 44, 46], ["HepG2.2.15\u2010", "CELL", 144, 155], ["HBV", "ORGANISM", 163, 166], ["MethodsHepG2.2.15 cells", "CELL", 171, 194], ["calf", "ORGANISM", 299, 303], ["serum", "ORGANISM_SUBSTANCE", 304, 309], ["FCS", "ORGANISM_SUBSTANCE", 311, 314], ["Hyclone", "ORGANISM_SUBSTANCE", 316, 323], ["Yeast cell\u2010derived HCV glycoproteins", "PROTEIN", 0, 36], ["E1", "PROTEIN", 37, 39], ["E2", "PROTEIN", 44, 46], ["HepG2.2.15", "CELL_LINE", 144, 154], ["MethodsHepG2.2.15 cells", "CELL_LINE", 171, 194], ["Yeast", "SPECIES", 0, 5], ["calf", "SPECIES", 299, 303], ["Yeast", "SPECIES", 0, 5], ["HCV", "SPECIES", 19, 22], ["HBV", "SPECIES", 163, 166], ["Yeast cell\u2010derived HCV glycoproteins E1", "TREATMENT", 0, 39], ["E2 reconstituted as virus\u2010like particles (VLP", "TREATMENT", 44, 89], ["HepG2", "TEST", 144, 149], ["Gibco", "TEST", 251, 256], ["5% foetal calf serum", "TEST", 289, 309], ["FCS", "TEST", 311, 314], ["calf", "ANATOMY", 299, 303]]], ["Secreted HBV and subviral particles were concentrated from the medium as described before [27], to a final concentration of 0.96 \u00d7 10E9 HBV particles/mL.", [["subviral particles", "ANATOMY", 17, 35], ["HBV", "ORGANISM", 9, 12], ["HBV", "ORGANISM", 136, 139], ["HBV", "SPECIES", 9, 12], ["Secreted HBV", "PROBLEM", 0, 12], ["subviral particles", "TREATMENT", 17, 35], ["a final concentration", "TEST", 99, 120], ["HBV", "OBSERVATION", 9, 12], ["subviral particles", "OBSERVATION", 17, 35]]], ["To enrich for HBV over subviral particles, HepG2.2.15 culture supernatants were loaded on a PBS equilibrated 1 mL bed volume Hi TrapTM Heparin HP column (GE Healthcare Bio\u2010Sciences AB, Uppsala, Sweden).", [["HepG2", "ANATOMY", 43, 48], ["supernatants", "ANATOMY", 62, 74], ["HBV", "ORGANISM", 14, 17], ["HepG2", "CELL", 43, 48], ["HepG2", "CELL_LINE", 43, 48], ["HBV", "SPECIES", 14, 17], ["HBV over subviral particles", "TREATMENT", 14, 41], ["culture supernatants", "TEST", 54, 74], ["a PBS equilibrated", "TREATMENT", 90, 108], ["volume Hi TrapTM Heparin HP column", "TREATMENT", 118, 152], ["HepG2", "ANATOMY", 43, 48]]], ["After fifteen column volumes PBS wash, HBV particles were eluted in 20 mL elution buffer (350 mM NaCl, 20 mM Tris\u2013HCl, pH 7.4) and collected in elution fractions of 2 mL at a flow rate of 1 mL/min.", [["NaCl", "CHEMICAL", 97, 101], ["Tris\u2013HCl", "CHEMICAL", 109, 117], ["NaCl", "CHEMICAL", 97, 101], ["Tris\u2013HCl", "CHEMICAL", 109, 117], ["HBV", "ORGANISM", 39, 42], ["HBV", "SPECIES", 39, 42], ["fifteen column volumes PBS wash", "TREATMENT", 6, 37], ["HBV particles", "TREATMENT", 39, 52], ["NaCl", "TEST", 97, 101], ["Tris\u2013HCl", "TEST", 109, 117], ["pH", "TEST", 119, 121], ["elution fractions", "TEST", 144, 161], ["a flow rate", "TEST", 173, 184]]], ["Elution fractions were dialyzed against PBS.", [["Elution fractions", "TREATMENT", 0, 17], ["PBS", "PROBLEM", 40, 43]]], ["As a negative control, the same procedure was followed with supernatant from untransfected HepG2 cells.", [["supernatant", "ANATOMY", 60, 71], ["HepG2 cells", "ANATOMY", 91, 102], ["HepG2 cells", "CELL", 91, 102], ["untransfected HepG2 cells", "CELL_LINE", 77, 102], ["the same procedure", "TREATMENT", 23, 41], ["negative", "OBSERVATION", 5, 13], ["HepG2 cells", "OBSERVATION", 91, 102]]], ["The elution fractions were assessed for the presence of HBV particles with L, M and S\u2010specific enzyme\u2010linked immunosorbent assay (ELISA), by capturing HBV with anti\u2010preS1, anti\u2010preS2 and anti\u2010S specific antibodies respectively.", [["HBV", "ORGANISM", 56, 59], ["HBV", "ORGANISM", 151, 154], ["anti\u2010preS1", "GENE_OR_GENE_PRODUCT", 160, 170], ["anti\u2010preS2", "GENE_OR_GENE_PRODUCT", 172, 182], ["anti\u2010S", "GENE_OR_GENE_PRODUCT", 187, 193], ["anti\u2010preS1", "PROTEIN", 160, 170], ["anti\u2010preS2", "PROTEIN", 172, 182], ["anti\u2010S specific antibodies", "PROTEIN", 187, 213], ["HBV", "SPECIES", 56, 59], ["HBV", "SPECIES", 151, 154], ["The elution fractions", "TEST", 0, 21], ["HBV particles", "PROBLEM", 56, 69], ["S\u2010specific enzyme\u2010linked immunosorbent assay", "TEST", 84, 128], ["anti\u2010preS1", "TREATMENT", 160, 170], ["anti\u2010preS2", "TREATMENT", 172, 182], ["anti\u2010S specific antibodies", "TREATMENT", 187, 213], ["HBV", "OBSERVATION", 56, 59]]], ["Bound HBV was detected with a biotinylated human anti\u2010HBsAg (F\u20109H9\u2010E).", [["HBsAg", "CHEMICAL", 54, 59], ["HBV", "ORGANISM", 6, 9], ["human", "ORGANISM", 43, 48], ["biotinylated human anti\u2010HBsAg", "PROTEIN", 30, 59], ["F", "PROTEIN", 61, 62], ["9H9", "PROTEIN", 63, 66], ["human", "SPECIES", 43, 48], ["HBV", "SPECIES", 6, 9], ["human", "SPECIES", 43, 48], ["Bound HBV", "PROBLEM", 0, 9], ["a biotinylated human anti\u2010HBsAg", "TEST", 28, 59], ["HBV", "OBSERVATION", 6, 9]]], ["Quantification of HBV particles was done by COBAS\u00ae TaqMan HBV Test (Roche Diagnostics GmbH, Mannheim, Germany) after viral DNA isolation using the High Pure System Viral Nucleic Acid Kit (Roche Diagnostics, Penzberg, Germany).", [["HBV", "ORGANISM", 18, 21], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["HBV", "SPECIES", 18, 21], ["HBV", "SPECIES", 58, 61], ["HBV particles", "PROBLEM", 18, 31], ["TaqMan HBV Test", "TEST", 51, 66], ["Mannheim", "TEST", 92, 100], ["viral DNA isolation", "TREATMENT", 117, 136], ["HBV", "OBSERVATION", 18, 21]]], ["To generate highly mannosylated HBV, HepG2.2.15 cells were treated with the \u03b1\u2010mannosidase I inhibitor kifunensine (5 days, 20 \u03bcg/mL; Calbiochem, Darmstadt, Germany).", [["HepG2", "ANATOMY", 37, 42], ["2.15 cells", "ANATOMY", 43, 53], ["kifunensine", "CHEMICAL", 102, 113], ["kifunensine", "CHEMICAL", 102, 113], ["HBV", "ORGANISM", 32, 35], ["HepG2", "CELL", 37, 42], ["2.15 cells", "CELL", 43, 53], ["\u03b1\u2010mannosidase I", "GENE_OR_GENE_PRODUCT", 76, 91], ["kifunensine", "SIMPLE_CHEMICAL", 102, 113], ["HepG2", "CELL_LINE", 37, 42], ["HBV", "SPECIES", 32, 35], ["the \u03b1\u2010mannosidase I inhibitor kifunensine", "TREATMENT", 72, 113], ["Calbiochem", "TREATMENT", 133, 143], ["highly", "OBSERVATION_MODIFIER", 12, 18], ["mannosylated HBV", "OBSERVATION", 19, 35]]], ["Untreated HepG2.2.15 cells and kifunsine treated HepG2 cells served as negative controls.", [["HepG2.2.15 cells", "ANATOMY", 10, 26], ["HepG2 cells", "ANATOMY", 49, 60], ["kifunsine", "CHEMICAL", 31, 40], ["kifunsine", "CHEMICAL", 31, 40], ["HepG2.2.15 cells", "CELL", 10, 26], ["kifunsine", "SIMPLE_CHEMICAL", 31, 40], ["HepG2 cells", "CELL", 49, 60], ["HepG2.2.15 cells", "CELL_LINE", 10, 26], ["kifunsine treated HepG2 cells", "CELL_LINE", 31, 60], ["Untreated HepG2.2.15 cells", "TREATMENT", 0, 26], ["kifunsine", "TREATMENT", 31, 40], ["HepG2 cells", "TEST", 49, 60], ["HepG2.2.15 cells", "OBSERVATION", 10, 26]]], ["The final concentrations of highly mannosylated and native HBV were 1.4 \u00d7 10E8 and 2.2 \u00d7 10E8 HBV particles/mL, respectively.Cells ::: MethodsStable Raji transfectants expressing wild\u2010type DC\u2010SIGN or L\u2010SIGN were generated as previously described [31, 32].", [["Cells", "ANATOMY", 125, 130], ["Raji transfectants", "ANATOMY", 149, 167], ["DC", "ANATOMY", 189, 191], ["HBV", "ORGANISM", 59, 62], ["Cells", "CELL", 125, 130], ["Raji transfectants", "CELL", 149, 167], ["SIGN", "GENE_OR_GENE_PRODUCT", 192, 196], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 200, 206], ["Raji transfectants", "CELL_LINE", 149, 167], ["wild\u2010type DC", "CELL_LINE", 179, 191], ["SIGN", "PROTEIN", 192, 196], ["L\u2010SIGN", "PROTEIN", 200, 206], ["HBV", "SPECIES", 59, 62], ["HBV", "SPECIES", 94, 97], ["native HBV", "TEST", 52, 62], ["HBV particles", "TEST", 94, 107], ["MethodsStable Raji transfectants", "TREATMENT", 135, 167]]], ["Monocyte\u2010derived dendritic cells (moDC) were cultured from monocytes in the presence of IL\u20104 and GM\u2010CSF (500 and 800 U/mL, respectively; Schering\u2010Plough, Brussels, Belgium).", [["Monocyte\u2010derived dendritic cells", "ANATOMY", 0, 32], ["moDC", "ANATOMY", 34, 38], ["monocytes", "ANATOMY", 59, 68], ["Monocyte\u2010derived dendritic cells", "CELL", 0, 32], ["moDC", "CELL", 34, 38], ["monocytes", "CELL", 59, 68], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 88, 92], ["GM\u2010CSF", "GENE_OR_GENE_PRODUCT", 97, 103], ["Monocyte\u2010derived dendritic cells", "CELL_TYPE", 0, 32], ["moDC", "CELL_TYPE", 34, 38], ["monocytes", "CELL_TYPE", 59, 68], ["IL\u20104", "PROTEIN", 88, 92], ["Monocyte\u2010derived dendritic cells", "PROBLEM", 0, 32], ["monocytes", "TEST", 59, 68], ["IL", "TEST", 88, 90], ["GM\u2010CSF", "TEST", 97, 103], ["dendritic cells", "OBSERVATION", 17, 32]]], ["At day 6, the phenotype of the cultured moDC was confirmed by flow cytometric analysis [22].", [["moDC", "ANATOMY", 40, 44], ["moDC", "CELL", 40, 44], ["cultured moDC", "CELL_LINE", 31, 44], ["flow cytometric analysis", "TEST", 62, 86]]], ["Expression levels of DC\u2010SIGN and L\u2010SIGN on transfected Raji cells and moDC were determined by flow cytometry with the DC\u2010SIGN and L\u2010SIGN specific AZN\u2010D2 antibody.Plant lectin ELISA ::: MethodsHeparin purified, glycan modified or native HepG2.2.15\u2010derived HBV were captured on ELISA plates (Maxisorb, Nunc, Roskilde, Denmark) with mouse anti\u2010preS2.", [["DC", "ANATOMY", 21, 23], ["Raji cells", "ANATOMY", 55, 65], ["moDC", "ANATOMY", 70, 74], ["DC", "ANATOMY", 118, 120], ["HepG2", "ANATOMY", 236, 241], ["SIGN", "GENE_OR_GENE_PRODUCT", 24, 28], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 33, 39], ["Raji cells", "CELL", 55, 65], ["moDC", "CELL", 70, 74], ["SIGN", "GENE_OR_GENE_PRODUCT", 121, 125], ["L\u2010SIGN", "SIMPLE_CHEMICAL", 130, 136], ["AZN\u2010D2 antibody", "GENE_OR_GENE_PRODUCT", 146, 161], ["HepG2", "CELL", 236, 241], ["HBV", "ORGANISM", 255, 258], ["mouse", "ORGANISM", 330, 335], ["anti\u2010preS2", "GENE_OR_GENE_PRODUCT", 336, 346], ["DC", "CELL_TYPE", 21, 23], ["SIGN", "PROTEIN", 24, 28], ["L\u2010SIGN", "PROTEIN", 33, 39], ["Raji cells", "CELL_LINE", 55, 65], ["moDC", "CELL_LINE", 70, 74], ["DC", "CELL_TYPE", 118, 120], ["SIGN", "PROTEIN", 121, 125], ["L\u2010SIGN specific AZN\u2010D2 antibody", "PROTEIN", 130, 161], ["native HepG2", "CELL_LINE", 229, 241], ["mouse anti\u2010preS2", "DNA", 330, 346], ["mouse", "SPECIES", 330, 335], ["HBV", "SPECIES", 255, 258], ["mouse", "SPECIES", 330, 335], ["transfected Raji cells", "TREATMENT", 43, 65], ["flow cytometry", "TEST", 94, 108], ["MethodsHeparin", "TREATMENT", 185, 199], ["glycan modified", "TREATMENT", 210, 225], ["native HepG2", "TREATMENT", 229, 241], ["derived HBV", "PROBLEM", 247, 258], ["ELISA plates", "TREATMENT", 276, 288], ["Maxisorb", "TREATMENT", 290, 298], ["mouse anti\u2010preS2", "TREATMENT", 330, 346], ["lectin ELISA", "OBSERVATION", 168, 180], ["HepG2", "ANATOMY", 236, 241]]], ["Recombinant HBsAg (0.5 \u03bcg/well), HCV VLP (0.25 \u03bcg/well) and mannan (0.25 \u03bcg/well; Sigma\u2010Aldrich, St Louis, MO, USA) were coated directly onto the plate for 18 h at 4 \u00b0C. After blocking with 1% bovine serum albumin for 1 h at 37 \u00b0C, the following biotinylated plant lectins were added for 2 h at room temperature at a concentration of 5 \u03bcg/mL: Con A (Concavalin A; recognizes \u03b1\u2010glucose and \u03b1\u2010mannose), GNA (Galanthus nivalis agglutinin; \u03b1\u2010mannose), WGA (wheat germ agglutinin; N\u2010acetylglucosamine), PNA (Arachis hypogaea agglutinin; \u03b2\u2010galactose, N\u2010acetylgalactosamine), RCAII (Ricinus communis agglutinin; \u03b2\u2010galactose, N\u2010acetylgalactosamine) or LTA (Lotus tetragonolobus agglutinin; fucose; all from Sigma Aldrich [33]).", [["serum", "ANATOMY", 200, 205], ["HBsAg", "CHEMICAL", 12, 17], ["mannan", "CHEMICAL", 60, 66], ["Concavalin A", "CHEMICAL", 350, 362], ["\u03b1\u2010glucose", "CHEMICAL", 375, 384], ["\u03b1\u2010mannose", "CHEMICAL", 436, 445], ["N\u2010acetylglucosamine", "CHEMICAL", 476, 495], ["\u03b2\u2010galactose", "CHEMICAL", 532, 543], ["N\u2010acetylgalactosamine", "CHEMICAL", 545, 566], ["\u03b2\u2010galactose", "CHEMICAL", 605, 616], ["N\u2010acetylgalactosamine", "CHEMICAL", 618, 639], ["LTA", "CHEMICAL", 644, 647], ["Concavalin A", "CHEMICAL", 350, 362], ["\u03b1\u2010glucose", "CHEMICAL", 375, 384], ["\u03b1\u2010mannose", "CHEMICAL", 389, 398], ["fucose", "CHEMICAL", 682, 688], ["HBsAg", "GENE_OR_GENE_PRODUCT", 12, 17], ["HCV VLP", "ORGANISM", 33, 40], ["mannan", "SIMPLE_CHEMICAL", 60, 66], ["bovine", "ORGANISM", 193, 199], ["serum", "ORGANISM_SUBSTANCE", 200, 205], ["albumin", "GENE_OR_GENE_PRODUCT", 206, 213], ["Con A", "SIMPLE_CHEMICAL", 343, 348], ["Concavalin A", "SIMPLE_CHEMICAL", 350, 362], ["\u03b1\u2010glucose", "SIMPLE_CHEMICAL", 375, 384], ["\u03b1\u2010mannose", "SIMPLE_CHEMICAL", 389, 398], ["GNA", "SIMPLE_CHEMICAL", 401, 404], ["Galanthus nivalis agglutinin", "SIMPLE_CHEMICAL", 406, 434], ["\u03b1\u2010mannose", "SIMPLE_CHEMICAL", 436, 445], ["WGA", "SIMPLE_CHEMICAL", 448, 451], ["wheat germ agglutinin", "ORGANISM", 453, 474], ["N\u2010acetylglucosamine", "SIMPLE_CHEMICAL", 476, 495], ["PNA", "SIMPLE_CHEMICAL", 498, 501], ["Arachis hypogaea agglutinin", "ORGANISM", 503, 530], ["\u03b2\u2010galactose", "SIMPLE_CHEMICAL", 532, 543], ["N\u2010acetylgalactosamine", "SIMPLE_CHEMICAL", 545, 566], ["RCAII", "SIMPLE_CHEMICAL", 569, 574], ["Ricinus communis agglutinin", "ORGANISM", 576, 603], ["\u03b2\u2010galactose", "SIMPLE_CHEMICAL", 605, 616], ["N\u2010acetylgalactosamine", "SIMPLE_CHEMICAL", 618, 639], ["LTA", "SIMPLE_CHEMICAL", 644, 647], ["Lotus tetragonolobus agglutinin", "ORGANISM", 649, 680], ["fucose", "SIMPLE_CHEMICAL", 682, 688], ["HBsAg", "PROTEIN", 12, 17], ["LTA", "PROTEIN", 644, 647], ["bovine", "SPECIES", 193, 199], ["Galanthus nivalis", "SPECIES", 406, 423], ["wheat", "SPECIES", 453, 458], ["Arachis hypogaea", "SPECIES", 503, 519], ["Ricinus communis", "SPECIES", 576, 592], ["Lotus tetragonolobus", "SPECIES", 649, 669], ["HCV", "SPECIES", 33, 36], ["bovine", "SPECIES", 193, 199], ["Galanthus nivalis", "SPECIES", 406, 423], ["Arachis hypogaea", "SPECIES", 503, 519], ["Ricinus communis", "SPECIES", 576, 592], ["Lotus tetragonolobus", "SPECIES", 649, 669], ["Recombinant HBsAg", "TEST", 0, 17], ["HCV VLP", "TREATMENT", 33, 40], ["mannan", "TREATMENT", 60, 66], ["1% bovine serum albumin", "TREATMENT", 190, 213], ["the following biotinylated plant lectins", "TREATMENT", 232, 272], ["A (Concavalin A", "TREATMENT", 347, 362], ["GNA (Galanthus nivalis agglutinin", "TREATMENT", 401, 434], ["WGA (wheat germ agglutinin", "TREATMENT", 448, 474], ["N\u2010acetylglucosamine", "TREATMENT", 476, 495], ["PNA", "PROBLEM", 498, 501], ["Arachis hypogaea agglutinin", "TREATMENT", 503, 530], ["\u03b2\u2010galactose", "TREATMENT", 532, 543], ["N\u2010acetylgalactosamine", "TREATMENT", 545, 566], ["RCAII (Ricinus communis agglutinin", "TREATMENT", 569, 603], ["\u03b2\u2010galactose", "TREATMENT", 605, 616], ["N\u2010acetylgalactosamine", "TREATMENT", 618, 639], ["LTA", "PROBLEM", 644, 647], ["PNA", "OBSERVATION", 498, 501]]], ["Lectin binding was detected using peroxidase\u2010conjugated streptavidin and absorbance was measured at 450 nm.Recombinant DC\u2010SIGN\u2010Fc binding ELISA ::: MethodsThe DC\u2010SIGN\u2010Fc binding assay was performed as previously described [34].", [["DC", "ANATOMY", 119, 121], ["DC", "ANATOMY", 159, 161], ["Lectin", "GENE_OR_GENE_PRODUCT", 0, 6], ["peroxidase", "SIMPLE_CHEMICAL", 34, 44], ["streptavidin", "SIMPLE_CHEMICAL", 56, 68], ["Fc", "GENE_OR_GENE_PRODUCT", 167, 169], ["peroxidase", "PROTEIN", 34, 44], ["DC", "CELL_TYPE", 119, 121], ["SIGN", "PROTEIN", 122, 126], ["DC", "CELL_TYPE", 159, 161], ["SIGN", "PROTEIN", 162, 166], ["Lectin binding", "PROBLEM", 0, 14], ["peroxidase\u2010conjugated streptavidin", "TREATMENT", 34, 68], ["Fc binding assay", "TEST", 167, 183]]], ["In short, recombinant HBsAg (0.5 \u03bcg/well), HepG2.2.15\u2010derived HBV and HepG2 controls were captured on Maxisorb ELISA plates (Nunc) with mouse anti\u2010preS2.", [["HepG2.2", "ANATOMY", 43, 50], ["HepG2", "ANATOMY", 70, 75], ["HBsAg", "CHEMICAL", 22, 27], ["HBsAg", "GENE_OR_GENE_PRODUCT", 22, 27], ["HepG2.2", "CELL", 43, 50], ["HBV", "ORGANISM", 62, 65], ["HepG2 controls", "CELL", 70, 84], ["mouse", "ORGANISM", 136, 141], ["anti\u2010preS2", "GENE_OR_GENE_PRODUCT", 142, 152], ["recombinant HBsAg", "PROTEIN", 10, 27], ["HepG2.2", "CELL_LINE", 43, 50], ["mouse anti\u2010preS2", "DNA", 136, 152], ["mouse", "SPECIES", 136, 141], ["HBV", "SPECIES", 62, 65], ["mouse", "SPECIES", 136, 141], ["recombinant HBsAg", "TEST", 10, 27], ["HepG2", "TEST", 43, 48], ["HBV", "TREATMENT", 62, 65], ["HepG2 controls", "TREATMENT", 70, 84], ["Maxisorb ELISA plates", "TREATMENT", 102, 123], ["mouse anti\u2010preS2", "TREATMENT", 136, 152]]], ["HCV VLP (0.25 \u03bcg/well) were coated directly on the plates.", [["HCV VLP", "ORGANISM", 0, 7], ["HCV", "SPECIES", 0, 3], ["HCV VLP", "TREATMENT", 0, 7]]], ["After blocking with 1% bovine serum albumin for 30 min at 37 \u00b0C, soluble DC\u2010SIGN\u2010Fc was added and bound DC\u2010SIGN was detected after incubation with peroxidase\u2010labelled anti\u2010human immunoglobulin G1 antibody.", [["serum", "ANATOMY", 30, 35], ["DC", "ANATOMY", 73, 75], ["DC", "ANATOMY", 104, 106], ["bovine", "ORGANISM", 23, 29], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["albumin", "GENE_OR_GENE_PRODUCT", 36, 43], ["SIGN", "GENE_OR_GENE_PRODUCT", 76, 80], ["Fc", "GENE_OR_GENE_PRODUCT", 81, 83], ["SIGN", "GENE_OR_GENE_PRODUCT", 107, 111], ["immunoglobulin G1 antibody", "GENE_OR_GENE_PRODUCT", 178, 204], ["DC", "CELL_TYPE", 73, 75], ["SIGN", "PROTEIN", 76, 80], ["Fc", "PROTEIN", 81, 83], ["DC", "CELL_TYPE", 104, 106], ["SIGN", "PROTEIN", 107, 111], ["peroxidase\u2010labelled anti\u2010human immunoglobulin G1 antibody", "PROTEIN", 147, 204], ["bovine", "SPECIES", 23, 29], ["1% bovine serum albumin", "TREATMENT", 20, 43], ["peroxidase\u2010labelled anti\u2010human immunoglobulin G1 antibody", "TREATMENT", 147, 204]]], ["Specificity of DC\u2010SIGN\u2010Fc binding was determined by blocking with either mannan (100 \u03bcg/mL; Sigma\u2010Aldrich) or EGTA (10 mM; Sigma\u2010Aldrich).", [["DC", "ANATOMY", 15, 17], ["mannan", "CHEMICAL", 73, 79], ["EGTA", "CHEMICAL", 110, 114], ["EGTA", "CHEMICAL", 110, 114], ["Fc", "GENE_OR_GENE_PRODUCT", 23, 25], ["mannan", "SIMPLE_CHEMICAL", 73, 79], ["Sigma\u2010Aldrich", "SIMPLE_CHEMICAL", 92, 105], ["EGTA", "SIMPLE_CHEMICAL", 110, 114], ["DC", "CELL_TYPE", 15, 17], ["SIGN", "PROTEIN", 18, 22]]], ["To assess the coating efficiency, HBsAg and HBV were detected with biotinylated human anti\u2010HBsAg (F\u20109H9\u2010E) and HCV VLP were detected with mouse anti\u2010HCV E2 (4H6B2).", [["HBsAg", "CHEMICAL", 34, 39], ["HBsAg", "CHEMICAL", 91, 96], ["E2", "CHEMICAL", 153, 155], ["HBsAg", "GENE_OR_GENE_PRODUCT", 34, 39], ["HBV", "ORGANISM", 44, 47], ["human", "ORGANISM", 80, 85], ["HBsAg", "GENE_OR_GENE_PRODUCT", 91, 96], ["F\u20109H9\u2010E", "GENE_OR_GENE_PRODUCT", 98, 105], ["HCV VLP", "ORGANISM", 111, 118], ["mouse", "ORGANISM", 138, 143], ["anti\u2010HCV E2", "ORGANISM", 144, 155], ["4H6B2", "CANCER", 157, 162], ["HBsAg", "PROTEIN", 34, 39], ["biotinylated human anti", "PROTEIN", 67, 90], ["HBsAg", "PROTEIN", 91, 96], ["F", "PROTEIN", 98, 99], ["9H9\u2010E", "PROTEIN", 100, 105], ["HCV VLP", "PROTEIN", 111, 118], ["mouse anti\u2010HCV E2", "PROTEIN", 138, 155], ["4H6B2", "PROTEIN", 157, 162], ["human", "SPECIES", 80, 85], ["mouse", "SPECIES", 138, 143], ["HBV", "SPECIES", 44, 47], ["human", "SPECIES", 80, 85], ["F\u20109H9\u2010E", "SPECIES", 98, 105], ["HCV", "SPECIES", 111, 114], ["mouse", "SPECIES", 138, 143], ["anti\u2010HCV", "SPECIES", 144, 152], ["the coating efficiency", "PROBLEM", 10, 32], ["HBsAg", "TEST", 34, 39], ["HBV", "PROBLEM", 44, 47], ["biotinylated human anti\u2010HBsAg", "TEST", 67, 96], ["HCV VLP", "PROBLEM", 111, 118], ["mouse anti\u2010HCV E2", "TREATMENT", 138, 155], ["coating efficiency", "OBSERVATION", 14, 32]]], ["HBV concentrated by centrifugation or purified by heparin column gave similar results in DC\u2010SIGN\u2010Fc binding assays.Soluble DC\u2010SIGN/L\u2010SIGN lysate ELISA ::: MethodsRaji DC\u2010SIGN/L\u2010SIGN transfectants were lysed for 4 h at 4 \u00b0C in lysis buffer (1% NP40, 150 mM NaCl, 1 mm MgCl2 and 1 mM CaCl2 in PBS) supplemented with ethylenediamine tetraacetic acid (EDTA)\u2010free protease inhibitors (Roche Diagnostics).", [["DC", "ANATOMY", 89, 91], ["DC", "ANATOMY", 123, 125], ["DC", "ANATOMY", 167, 169], ["transfectants", "ANATOMY", 182, 195], ["heparin", "CHEMICAL", 50, 57], ["NaCl", "CHEMICAL", 256, 260], ["CaCl2", "CHEMICAL", 282, 287], ["ethylenediamine tetraacetic acid", "CHEMICAL", 314, 346], ["EDTA", "CHEMICAL", 348, 352], ["NaCl", "CHEMICAL", 256, 260], ["MgCl2", "CHEMICAL", 267, 272], ["CaCl2", "CHEMICAL", 282, 287], ["ethylenediamine tetraacetic acid", "CHEMICAL", 314, 346], ["EDTA", "CHEMICAL", 348, 352], ["HBV", "ORGANISM", 0, 3], ["heparin", "SIMPLE_CHEMICAL", 50, 57], ["Fc", "GENE_OR_GENE_PRODUCT", 97, 99], ["L\u2010SIGN transfectants", "CELL", 175, 195], ["ethylenediamine tetraacetic acid", "SIMPLE_CHEMICAL", 314, 346], ["EDTA", "SIMPLE_CHEMICAL", 348, 352], ["DC", "CELL_TYPE", 89, 91], ["DC", "CELL_TYPE", 123, 125], ["Raji DC", "CELL_LINE", 162, 169], ["SIGN/L\u2010SIGN transfectants", "CELL_LINE", 170, 195], ["HBV", "SPECIES", 0, 3], ["HBV", "TREATMENT", 0, 3], ["heparin column", "TREATMENT", 50, 64], ["SIGN", "TEST", 170, 174], ["L\u2010SIGN transfectants", "TREATMENT", 175, 195], ["lysis buffer", "TREATMENT", 226, 238], ["NaCl", "TREATMENT", 256, 260], ["1 mm MgCl2", "TREATMENT", 262, 272], ["1 mM CaCl2 in PBS", "TREATMENT", 277, 294], ["ethylenediamine tetraacetic acid (EDTA)", "TREATMENT", 314, 353], ["free protease inhibitors", "TREATMENT", 354, 378]]], ["HBsAg, HBV and medium controls were captured on ELISA plates with a mouse anti\u2010preS2 antibody.", [["HBsAg", "CHEMICAL", 0, 5], ["HBsAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBV", "ORGANISM", 7, 10], ["mouse", "ORGANISM", 68, 73], ["anti\u2010preS2", "GENE_OR_GENE_PRODUCT", 74, 84], ["HBsAg", "PROTEIN", 0, 5], ["mouse anti\u2010preS2 antibody", "PROTEIN", 68, 93], ["mouse", "SPECIES", 68, 73], ["HBV", "SPECIES", 7, 10], ["mouse", "SPECIES", 68, 73], ["HBsAg", "TEST", 0, 5], ["HBV", "TEST", 7, 10], ["medium controls", "TEST", 15, 30], ["ELISA plates", "TEST", 48, 60], ["a mouse anti\u2010preS2 antibody", "TREATMENT", 66, 93], ["HBV", "OBSERVATION", 7, 10]]], ["HCV VLP were coated directly on the plates.", [["HCV VLP", "ORGANISM", 0, 7], ["HCV", "SPECIES", 0, 3], ["HCV VLP", "TREATMENT", 0, 7]]], ["After blocking with 5% bovine serum albumin for 30 min at 37 \u00b0C, Raji DC\u2010SIGN/L\u2010SIGN lysates were added for 2 h at RT.", [["serum", "ANATOMY", 30, 35], ["DC", "ANATOMY", 70, 72], ["lysates", "ANATOMY", 85, 92], ["bovine", "ORGANISM", 23, 29], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["albumin", "GENE_OR_GENE_PRODUCT", 36, 43], ["Raji DC", "CELL", 65, 72], ["lysates", "ORGANISM_SUBSTANCE", 85, 92], ["Raji DC", "CELL_LINE", 65, 72], ["SIGN/L", "CELL_LINE", 73, 79], ["bovine", "SPECIES", 23, 29], ["5% bovine serum albumin", "TREATMENT", 20, 43], ["L\u2010SIGN lysates", "TREATMENT", 78, 92]]], ["Bound DC\u2010SIGN/L\u2010SIGN was detected with a FITC\u2010conjugated DC\u2010SIGN/L\u2010SIGN specific antibody (clone DCN46) followed by a peroxidase\u2010conjugated rabbit anti\u2010FITC antibody.", [["DC", "ANATOMY", 6, 8], ["DC", "ANATOMY", 57, 59], ["FITC", "CHEMICAL", 41, 45], ["SIGN", "GENE_OR_GENE_PRODUCT", 16, 20], ["FITC", "SIMPLE_CHEMICAL", 41, 45], ["L\u2010SIGN", "SIMPLE_CHEMICAL", 65, 71], ["clone", "ORGANISM", 91, 96], ["peroxidase", "GENE_OR_GENE_PRODUCT", 118, 128], ["rabbit", "ORGANISM", 140, 146], ["DC", "CELL_TYPE", 6, 8], ["SIGN", "PROTEIN", 9, 13], ["L", "PROTEIN", 14, 15], ["SIGN", "PROTEIN", 16, 20], ["FITC\u2010conjugated DC\u2010SIGN/L\u2010SIGN specific antibody", "PROTEIN", 41, 89], ["clone DCN46", "PROTEIN", 91, 102], ["peroxidase\u2010conjugated rabbit anti\u2010FITC antibody", "PROTEIN", 118, 165], ["rabbit", "SPECIES", 140, 146], ["rabbit", "SPECIES", 140, 146], ["a FITC", "TEST", 39, 45], ["a peroxidase\u2010conjugated rabbit anti\u2010FITC antibody", "TREATMENT", 116, 165]]], ["Specificity of binding was determined in the presence of mannan (100 \u03bcg/mL; Sigma\u2010Aldrich).", [["mannan", "CHEMICAL", 57, 63], ["mannan", "SIMPLE_CHEMICAL", 57, 63]]], ["To assess the coating efficiency, HBsAg, HBV and HCV VLP were detected with specific antibodies.", [["HBsAg", "CHEMICAL", 34, 39], ["HBsAg", "GENE_OR_GENE_PRODUCT", 34, 39], ["HBV", "ORGANISM", 41, 44], ["HCV VLP", "ORGANISM", 49, 56], ["HBsAg", "PROTEIN", 34, 39], ["specific antibodies", "PROTEIN", 76, 95], ["HBV", "SPECIES", 41, 44], ["HCV", "SPECIES", 49, 52], ["the coating efficiency", "TEST", 10, 32], ["HBsAg", "TEST", 34, 39], ["HBV", "PROBLEM", 41, 44], ["HCV VLP", "PROBLEM", 49, 56], ["coating efficiency", "OBSERVATION", 14, 32]]], ["HBV concentrated by centrifugation or purified by heparin column gave similar results in soluble DC\u2010SIGN/L\u2010SIGN lysate ELISA.Cellular DC\u2010SIGN/L\u2010SIGN bindings assay ::: MethodsUntransfected Raji cells, DC\u2010SIGN or L\u2010SIGN\u2010transfected Raji cells and moDC were incubated with or without HBsAg (5 \u03bcg/mL) for 2 or 18 h at 37 \u00b0C and binding was measured by flow cytometry after intracellular staining with an anti\u2010HBsAg\u2010FITC antibody (Acris Antibodies GmbH).", [["DC", "ANATOMY", 97, 99], ["DC", "ANATOMY", 134, 136], ["Raji cells", "ANATOMY", 189, 199], ["DC", "ANATOMY", 201, 203], ["SIGN", "ANATOMY", 204, 208], ["Raji cells", "ANATOMY", 231, 241], ["moDC", "ANATOMY", 246, 250], ["intracellular", "ANATOMY", 370, 383], ["heparin", "CHEMICAL", 50, 57], ["HBsAg", "CHEMICAL", 282, 287], ["FITC", "CHEMICAL", 412, 416], ["HBV", "ORGANISM", 0, 3], ["heparin", "SIMPLE_CHEMICAL", 50, 57], ["Raji cells", "CELL", 189, 199], ["DC\u2010SIGN", "CELL", 201, 208], ["L\u2010SIGN\u2010", "CELL", 212, 219], ["Raji cells", "CELL", 231, 241], ["moDC", "CELL", 246, 250], ["HBsAg", "GENE_OR_GENE_PRODUCT", 282, 287], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 370, 383], ["FITC", "GENE_OR_GENE_PRODUCT", 412, 416], ["DC", "CELL_TYPE", 97, 99], ["DC", "CELL_TYPE", 134, 136], ["MethodsUntransfected Raji cells", "CELL_LINE", 168, 199], ["DC", "CELL_TYPE", 201, 203], ["SIGN", "CELL_LINE", 204, 208], ["L\u2010SIGN\u2010transfected Raji cells", "CELL_LINE", 212, 241], ["moDC", "CELL_LINE", 246, 250], ["HBsAg", "PROTEIN", 282, 287], ["anti\u2010HBsAg", "PROTEIN", 401, 411], ["FITC antibody", "PROTEIN", 412, 425], ["Acris Antibodies GmbH", "PROTEIN", 427, 448], ["HBV", "SPECIES", 0, 3], ["HBV", "TREATMENT", 0, 3], ["heparin column", "TREATMENT", 50, 64], ["Cellular DC", "TEST", 125, 136], ["MethodsUntransfected Raji cells", "TREATMENT", 168, 199], ["L\u2010SIGN\u2010transfected Raji cells", "TREATMENT", 212, 241], ["HBsAg", "TEST", 282, 287], ["flow cytometry", "TEST", 349, 363], ["intracellular staining", "TEST", 370, 392], ["an anti\u2010HBsAg\u2010FITC antibody", "TEST", 398, 425], ["L", "ANATOMY_MODIFIER", 105, 106], ["lysate ELISA", "OBSERVATION", 112, 124], ["Raji cells", "OBSERVATION", 189, 199], ["Raji cells", "OBSERVATION", 231, 241]]], ["Uptake was compared to lectin\u2010mediated binding of dextran\u2010FITC (100 \u03bcg/mL, 40 000 MW; Molecular Probes, Invitrogen, Carlsbad, CA, USA).", [["dextran", "CHEMICAL", 50, 57], ["FITC", "CHEMICAL", 58, 62], ["dextran", "SIMPLE_CHEMICAL", 50, 57], ["FITC", "SIMPLE_CHEMICAL", 58, 62], ["dextran", "TREATMENT", 50, 57], ["FITC", "TEST", 58, 62], ["Molecular Probes", "TEST", 86, 102], ["Invitrogen", "TEST", 104, 114]]], ["Specificity of binding was determined by 30 min preincubation with mannan (100 \u03bcg/mL).Characterisation of purified HBV particles ::: ResultsSecreted HBsAg subviral particles outnumber the HBV virions at least 100\u2010fold in both patient serum and culture supernatant of HepG2.2.15 cells [7].", [["serum", "ANATOMY", 234, 239], ["supernatant", "ANATOMY", 252, 263], ["HepG2", "ANATOMY", 267, 272], ["2.15 cells", "ANATOMY", 273, 283], ["mannan", "CHEMICAL", 67, 73], ["HBsAg", "CHEMICAL", 149, 154], ["mannan", "SIMPLE_CHEMICAL", 67, 73], ["HBV", "ORGANISM", 115, 118], ["HBsAg", "GENE_OR_GENE_PRODUCT", 149, 154], ["HBV", "ORGANISM", 188, 191], ["patient", "ORGANISM", 226, 233], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["HepG2", "CELL", 267, 272], ["HepG2", "CELL_LINE", 267, 272], ["patient", "SPECIES", 226, 233], ["HBV", "SPECIES", 115, 118], ["HBV", "SPECIES", 188, 191], ["mannan", "TREATMENT", 67, 73], ["HBsAg subviral particles", "TEST", 149, 173], ["the HBV virions", "TEST", 184, 199], ["both patient serum", "TEST", 221, 239], ["culture", "TEST", 244, 251], ["HBV", "OBSERVATION", 115, 118], ["HBV virions", "OBSERVATION", 188, 199], ["HepG2", "ANATOMY", 267, 272]]], ["To enrich for HBV virions, culture supernantant of HepG2.2.15 cells was fractionated over a heparin column and different elution fractions were assessed by HBV L, M and S\u2010specific ELISA.", [["virions", "ANATOMY", 18, 25], ["HepG2.2.15 cells", "ANATOMY", 51, 67], ["heparin", "CHEMICAL", 92, 99], ["HBV", "ORGANISM", 14, 17], ["HepG2.2.15 cells", "CELL", 51, 67], ["heparin", "SIMPLE_CHEMICAL", 92, 99], ["HepG2.2.15 cells", "CELL_LINE", 51, 67], ["HBV", "SPECIES", 14, 17], ["HBV", "SPECIES", 156, 159], ["HBV virions", "PROBLEM", 14, 25], ["culture", "TEST", 27, 34], ["HepG2", "TEST", 51, 56], ["a heparin column", "TREATMENT", 90, 106], ["different elution fractions", "TREATMENT", 111, 138], ["heparin column", "OBSERVATION_MODIFIER", 92, 106], ["elution fractions", "OBSERVATION", 121, 138]]], ["The input fraction contained mainly the S protein, representing the relative high level of secreted spherical subviral particles (Fig. 1a).", [["S protein", "PROTEIN", 40, 49], ["secreted spherical subviral particles", "CELL_TYPE", 91, 128], ["The input fraction", "TEST", 0, 18], ["the S protein", "TEST", 36, 49], ["S protein", "OBSERVATION_MODIFIER", 40, 49], ["high", "OBSERVATION_MODIFIER", 77, 81], ["secreted spherical", "OBSERVATION", 91, 109], ["subviral particles", "OBSERVATION", 110, 128]]], ["Elution fraction 1 and 2 however, were highly enriched for both M and L proteins confirming the increased level of HBV virions in these fractions.", [["HBV", "ORGANISM", 115, 118], ["M and L proteins", "PROTEIN", 64, 80], ["HBV", "SPECIES", 115, 118], ["Elution fraction", "TEST", 0, 16], ["HBV virions", "PROBLEM", 115, 126], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["HBV virions", "OBSERVATION", 115, 126]]], ["Quantification of HBV\u2010DNA of the input fraction and elution fraction 1\u20133 confirmed an almost 50\u2010fold enrichment of HBV virions in fraction 1 (0.026 to 1.27 \u00d7 109 HBV particles per mL, Fig. 1b).HBsAg and HBV do not interact with recombinant DC\u2010SIGN\u2010Fc ::: ResultsThe interaction between DC\u2010SIGN and recombinant HBsAg or HepG2.2.15\u2010derived HBV was determined in a binding ELISA where coated HBsAg, HBV, HCV VLP or HepG2 medium controls were incubated with soluble recombinant DC\u2010SIGN\u2010Fc.", [["virions", "ANATOMY", 119, 126], ["DC", "ANATOMY", 240, 242], ["DC", "ANATOMY", 286, 288], ["HepG2", "ANATOMY", 319, 324], ["HepG2", "ANATOMY", 412, 417], ["DC", "ANATOMY", 474, 476], ["HBsAg", "CHEMICAL", 193, 198], ["HBsAg", "CHEMICAL", 310, 315], ["HBsAg", "CHEMICAL", 389, 394], ["HBV", "ORGANISM", 18, 21], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["HBV", "ORGANISM", 115, 118], ["HBsAg", "GENE_OR_GENE_PRODUCT", 193, 198], ["HBV", "ORGANISM", 203, 206], ["SIGN", "GENE_OR_GENE_PRODUCT", 289, 293], ["HBsAg", "GENE_OR_GENE_PRODUCT", 310, 315], ["HepG2", "CELL", 319, 324], ["HBV", "ORGANISM", 338, 341], ["HBsAg", "GENE_OR_GENE_PRODUCT", 389, 394], ["HBV", "ORGANISM", 396, 399], ["HCV VLP", "ORGANISM", 401, 408], ["HepG2", "CELL", 412, 417], ["HBV\u2010DNA", "DNA", 18, 25], ["HBsAg", "PROTEIN", 193, 198], ["DC", "CELL_TYPE", 240, 242], ["SIGN\u2010Fc", "PROTEIN", 243, 250], ["DC", "CELL_TYPE", 286, 288], ["SIGN", "PROTEIN", 289, 293], ["recombinant HBsAg", "PROTEIN", 298, 315], ["HepG2", "CELL_LINE", 319, 324], ["HBsAg", "PROTEIN", 389, 394], ["DC", "CELL_TYPE", 474, 476], ["SIGN", "PROTEIN", 477, 481], ["HBV", "SPECIES", 18, 21], ["HBV", "SPECIES", 115, 118], ["HBV", "SPECIES", 203, 206], ["HBV", "SPECIES", 338, 341], ["HBV", "SPECIES", 396, 399], ["HCV", "SPECIES", 401, 404], ["HBV", "PROBLEM", 18, 21], ["the input fraction", "TEST", 29, 47], ["elution fraction", "TEST", 52, 68], ["HBV virions in fraction", "PROBLEM", 115, 138], ["HBV particles", "TEST", 162, 175], ["HBsAg", "TEST", 193, 198], ["HBV", "PROBLEM", 203, 206], ["derived HBV", "PROBLEM", 330, 341], ["a binding ELISA", "TEST", 360, 375], ["coated HBsAg", "TEST", 382, 394], ["HBV", "PROBLEM", 396, 399], ["HCV VLP", "TREATMENT", 401, 408], ["HepG2 medium controls", "TREATMENT", 412, 433], ["HBV", "OBSERVATION", 18, 21], ["HBV virions", "OBSERVATION", 115, 126]]], ["The detected signal of the HepG2 medium control was never above background.", [["HepG2", "ANATOMY", 27, 32], ["HepG2", "CELL", 27, 32], ["the HepG2 medium control", "TREATMENT", 23, 47], ["HepG2", "ANATOMY", 27, 32]]], ["Strikingly, DC\u2010SIGN did not interact with HBsAg nor with whole virus particles, whereas DC\u2010SIGN did interact with HCV virus\u2010like particles, consisting of purified yeast recombinant E1 and E2 HCV envelope proteins (Fig. 2a and [22]).", [["DC", "ANATOMY", 12, 14], ["DC", "ANATOMY", 88, 90], ["HBsAg", "CHEMICAL", 42, 47], ["HBsAg", "GENE_OR_GENE_PRODUCT", 42, 47], ["whole virus particles", "ORGANISM", 57, 78], ["SIGN", "GENE_OR_GENE_PRODUCT", 91, 95], ["HCV virus\u2010like particles", "ORGANISM", 114, 138], ["yeast recombinant E1", "ORGANISM", 163, 183], ["E2 HCV", "ORGANISM", 188, 194], ["DC", "CELL_TYPE", 12, 14], ["SIGN", "PROTEIN", 15, 19], ["HBsAg", "PROTEIN", 42, 47], ["DC", "CELL_TYPE", 88, 90], ["SIGN", "PROTEIN", 91, 95], ["purified yeast recombinant E1 and E2 HCV envelope proteins", "PROTEIN", 154, 212], ["yeast", "SPECIES", 163, 168], ["HCV", "SPECIES", 114, 117], ["yeast", "SPECIES", 163, 168], ["HCV", "SPECIES", 191, 194], ["HBsAg", "PROBLEM", 42, 47], ["whole virus particles", "PROBLEM", 57, 78], ["HCV virus\u2010like particles", "PROBLEM", 114, 138], ["purified yeast recombinant E1 and E2 HCV envelope proteins", "PROBLEM", 154, 212]]], ["Specificity of binding was determined by blocking with either mannan, a yeast cell derived polycarbohydrate that competitively binds the carbohydrate binding site of mannose\u2010specific lectins, or the calcium chelator EGTA, and both agents indeed reduced DC\u2010SIGN binding to HCV to background level.", [["cell", "ANATOMY", 78, 82], ["DC", "ANATOMY", 253, 255], ["calcium", "CHEMICAL", 199, 206], ["EGTA", "CHEMICAL", 216, 220], ["carbohydrate", "CHEMICAL", 137, 149], ["calcium", "CHEMICAL", 199, 206], ["EGTA", "CHEMICAL", 216, 220], ["mannan", "SIMPLE_CHEMICAL", 62, 68], ["yeast cell", "CELL", 72, 82], ["polycarbohydrate", "SIMPLE_CHEMICAL", 91, 107], ["mannose\u2010specific lectins", "GENE_OR_GENE_PRODUCT", 166, 190], ["calcium", "SIMPLE_CHEMICAL", 199, 206], ["EGTA", "SIMPLE_CHEMICAL", 216, 220], ["SIGN", "GENE_OR_GENE_PRODUCT", 256, 260], ["HCV", "ORGANISM", 272, 275], ["carbohydrate binding site", "PROTEIN", 137, 162], ["mannose\u2010specific lectins", "PROTEIN", 166, 190], ["DC", "CELL_TYPE", 253, 255], ["SIGN", "PROTEIN", 256, 260], ["yeast", "SPECIES", 72, 77], ["yeast", "SPECIES", 72, 77], ["HCV", "SPECIES", 272, 275], ["a yeast cell derived polycarbohydrate", "PROBLEM", 70, 107], ["mannose\u2010specific lectins", "TREATMENT", 166, 190], ["the calcium chelator EGTA", "TREATMENT", 195, 220], ["both agents", "TREATMENT", 226, 237]]], ["Coating controls demonstrated that approximately equal amounts of HBsAg, HBV and HCV VLP were coated.HBsAg and HBV do not interact with recombinant DC\u2010SIGN\u2010Fc ::: ResultsBased on their oligosaccharide specificity, several plant lectins were used in a glycan analysis of HBsAg and heparin purified HBV (Fig. 2b).", [["DC", "ANATOMY", 148, 150], ["HBsAg", "CHEMICAL", 66, 71], ["HBsAg", "CHEMICAL", 101, 106], ["HBsAg", "CHEMICAL", 270, 275], ["heparin", "CHEMICAL", 280, 287], ["HBsAg", "GENE_OR_GENE_PRODUCT", 66, 71], ["HBV", "ORGANISM", 73, 76], ["HCV VLP", "ORGANISM", 81, 88], ["HBsAg", "GENE_OR_GENE_PRODUCT", 101, 106], ["HBV", "ORGANISM", 111, 114], ["HBsAg", "GENE_OR_GENE_PRODUCT", 270, 275], ["heparin", "SIMPLE_CHEMICAL", 280, 287], ["HBV", "ORGANISM", 297, 300], ["HBsAg", "PROTEIN", 66, 71], ["HBsAg", "PROTEIN", 101, 106], ["DC", "CELL_TYPE", 148, 150], ["SIGN\u2010Fc", "PROTEIN", 151, 158], ["HBsAg", "PROTEIN", 270, 275], ["HBV", "SPECIES", 73, 76], ["HCV", "SPECIES", 81, 84], ["HBV", "SPECIES", 111, 114], ["HBV", "SPECIES", 297, 300], ["HBsAg", "TEST", 66, 71], ["HBV", "TREATMENT", 73, 76], ["HCV VLP", "TREATMENT", 81, 88], ["HBsAg", "TEST", 101, 106], ["several plant lectins", "PROBLEM", 214, 235], ["a glycan analysis", "TEST", 249, 266], ["HBsAg", "TREATMENT", 270, 275], ["heparin", "TREATMENT", 280, 287], ["approximately", "OBSERVATION_MODIFIER", 35, 48], ["equal", "OBSERVATION_MODIFIER", 49, 54], ["amounts", "OBSERVATION_MODIFIER", 55, 62], ["HBsAg", "OBSERVATION", 66, 71]]], ["Strong binding to Con A, GNA, WGA, PNA, RCAII and LTA demonstrated the presence of high and/or complex mannose, N\u2010acetylglucosamine, galactose and fucose containing carbohydrate structures on both HBsAg and HBV.", [["RCAII", "CHEMICAL", 40, 45], ["LTA", "CHEMICAL", 50, 53], ["N\u2010acetylglucosamine", "CHEMICAL", 112, 131], ["galactose", "CHEMICAL", 133, 142], ["fucose", "CHEMICAL", 147, 153], ["HBsAg", "CHEMICAL", 197, 202], ["mannose", "CHEMICAL", 103, 110], ["N\u2010acetylglucosamine", "CHEMICAL", 112, 131], ["galactose", "CHEMICAL", 133, 142], ["fucose", "CHEMICAL", 147, 153], ["carbohydrate", "CHEMICAL", 165, 177], ["Con A", "SIMPLE_CHEMICAL", 18, 23], ["GNA", "SIMPLE_CHEMICAL", 25, 28], ["WGA", "SIMPLE_CHEMICAL", 30, 33], ["PNA", "SIMPLE_CHEMICAL", 35, 38], ["RCAII", "SIMPLE_CHEMICAL", 40, 45], ["LTA", "SIMPLE_CHEMICAL", 50, 53], ["mannose", "SIMPLE_CHEMICAL", 103, 110], ["N\u2010acetylglucosamine", "SIMPLE_CHEMICAL", 112, 131], ["galactose", "SIMPLE_CHEMICAL", 133, 142], ["fucose", "SIMPLE_CHEMICAL", 147, 153], ["HBsAg", "GENE_OR_GENE_PRODUCT", 197, 202], ["HBV", "ORGANISM", 207, 210], ["RCAII", "PROTEIN", 40, 45], ["HBsAg", "PROTEIN", 197, 202], ["HBV", "SPECIES", 207, 210], ["GNA", "PROBLEM", 25, 28], ["WGA", "PROBLEM", 30, 33], ["PNA", "PROBLEM", 35, 38], ["RCAII", "TEST", 40, 45], ["LTA", "TEST", 50, 53], ["high and/or complex mannose", "PROBLEM", 83, 110], ["N\u2010acetylglucosamine", "TREATMENT", 112, 131], ["galactose", "TREATMENT", 133, 142], ["fucose containing carbohydrate structures", "TREATMENT", 147, 188], ["HBV", "TREATMENT", 207, 210], ["PNA", "OBSERVATION", 35, 38], ["HBV", "OBSERVATION", 207, 210]]], ["For DC\u2010SIGN\u2010glycoprotein interaction the high mannose and fucose containing oligosaccharide structures are most important [35].", [["DC", "ANATOMY", 4, 6], ["fucose", "CHEMICAL", 58, 64], ["mannose", "CHEMICAL", 46, 53], ["fucose", "CHEMICAL", 58, 64], ["SIGN\u2010glycoprotein", "GENE_OR_GENE_PRODUCT", 7, 24], ["mannose", "SIMPLE_CHEMICAL", 46, 53], ["fucose", "SIMPLE_CHEMICAL", 58, 64], ["DC", "CELL_TYPE", 4, 6], ["SIGN", "PROTEIN", 7, 11], ["fucose containing oligosaccharide structures", "TREATMENT", 58, 102]]], ["Of note, carbohydrate structures on both HCV VLP and mannan mainly consist of mannose, as indicated by the exclusive binding to Con A and GNA.HBsAg and HBV do not interact with soluble DC\u2010SIGN from cell lysates ::: ResultsTo exclude the possibility that the lack of interaction between HBV and recombinant DC\u2010SIGN was because of improper multimerization of DC\u2010SIGN\u2010Fc, binding of HBsAg and HBV to native DC\u2010SIGN was studied with DC\u2010SIGN derived from transfected Raji cells [31, 32].", [["DC", "ANATOMY", 185, 187], ["cell lysates", "ANATOMY", 198, 210], ["DC", "ANATOMY", 306, 308], ["DC", "ANATOMY", 357, 359], ["DC", "ANATOMY", 404, 406], ["DC", "ANATOMY", 429, 431], ["Raji cells", "ANATOMY", 462, 472], ["mannose", "CHEMICAL", 78, 85], ["HBsAg", "CHEMICAL", 142, 147], ["HBsAg", "CHEMICAL", 380, 385], ["carbohydrate", "CHEMICAL", 9, 21], ["mannose", "CHEMICAL", 78, 85], ["HCV VLP", "ORGANISM", 41, 48], ["mannan", "GENE_OR_GENE_PRODUCT", 53, 59], ["mannose", "SIMPLE_CHEMICAL", 78, 85], ["Con A", "SIMPLE_CHEMICAL", 128, 133], ["GNA", "SIMPLE_CHEMICAL", 138, 141], ["HBsAg", "GENE_OR_GENE_PRODUCT", 142, 147], ["HBV", "ORGANISM", 152, 155], ["SIGN", "GENE_OR_GENE_PRODUCT", 188, 192], ["cell lysates", "CELL", 198, 210], ["HBV", "ORGANISM", 286, 289], ["recombinant DC\u2010", "ORGANISM", 294, 309], ["SIGN", "GENE_OR_GENE_PRODUCT", 309, 313], ["SIGN\u2010Fc", "GENE_OR_GENE_PRODUCT", 360, 367], ["HBsAg", "GENE_OR_GENE_PRODUCT", 380, 385], ["HBV", "ORGANISM", 390, 393], ["SIGN", "GENE_OR_GENE_PRODUCT", 407, 411], ["SIGN", "GENE_OR_GENE_PRODUCT", 432, 436], ["Raji cells", "CELL", 462, 472], ["Con A", "PROTEIN", 128, 133], ["HBsAg", "PROTEIN", 142, 147], ["DC", "CELL_TYPE", 185, 187], ["SIGN", "PROTEIN", 188, 192], ["DC", "CELL_TYPE", 306, 308], ["SIGN", "PROTEIN", 309, 313], ["DC", "CELL_TYPE", 357, 359], ["SIGN", "PROTEIN", 360, 364], ["Fc", "PROTEIN", 365, 367], ["HBsAg", "PROTEIN", 380, 385], ["DC", "CELL_TYPE", 404, 406], ["SIGN", "PROTEIN", 407, 411], ["DC", "CELL_TYPE", 429, 431], ["SIGN", "PROTEIN", 432, 436], ["transfected Raji cells", "CELL_LINE", 450, 472], ["HCV", "SPECIES", 41, 44], ["HBV", "SPECIES", 152, 155], ["HBV", "SPECIES", 286, 289], ["HBV", "SPECIES", 390, 393], ["both HCV VLP", "TREATMENT", 36, 48], ["mannan", "TREATMENT", 53, 59], ["mannose", "TREATMENT", 78, 85], ["HBsAg", "TEST", 142, 147], ["HBV", "PROBLEM", 152, 155], ["HBV", "PROBLEM", 286, 289], ["HBsAg", "TEST", 380, 385], ["HBV", "PROBLEM", 390, 393], ["Raji cells", "TEST", 462, 472]]], ["As described before, flow cytometric analysis of Raji transfectants showed high expression levels of DC\u2010SIGN (Fig. 3a, [22]).", [["Raji transfectants", "ANATOMY", 49, 67], ["DC", "ANATOMY", 101, 103], ["Raji transfectants", "CELL", 49, 67], ["Raji transfectants", "CELL_LINE", 49, 67], ["DC", "CELL_TYPE", 101, 103], ["SIGN", "PROTEIN", 104, 108], ["flow cytometric analysis", "TEST", 21, 45], ["Raji transfectants", "TEST", 49, 67], ["high expression levels", "PROBLEM", 75, 97]]], ["In a bindings ELISA, coated HBsAg or HCV VLP were incubated with lysates of mock or DC\u2010SIGN transfected Raji cells and bound DC\u2010SIGN was detected with an anti\u2010DC\u2010SIGN antibody.", [["lysates", "ANATOMY", 65, 72], ["DC", "ANATOMY", 84, 86], ["Raji cells", "ANATOMY", 104, 114], ["DC", "ANATOMY", 125, 127], ["HBsAg", "CHEMICAL", 28, 33], ["HBsAg", "GENE_OR_GENE_PRODUCT", 28, 33], ["HCV VLP", "ORGANISM", 37, 44], ["lysates", "ORGANISM_SUBSTANCE", 65, 72], ["DC", "CELL", 84, 86], ["SIGN", "CELL", 87, 91], ["Raji cells", "CELL", 104, 114], ["DC", "CELL", 125, 127], ["SIGN", "GENE_OR_GENE_PRODUCT", 128, 132], ["SIGN antibody", "GENE_OR_GENE_PRODUCT", 162, 175], ["HBsAg", "PROTEIN", 28, 33], ["HCV VLP", "PROTEIN", 37, 44], ["DC", "CELL_TYPE", 84, 86], ["SIGN transfected Raji cells", "CELL_LINE", 87, 114], ["DC", "CELL_TYPE", 125, 127], ["SIGN", "PROTEIN", 128, 132], ["anti\u2010DC", "PROTEIN", 154, 161], ["SIGN antibody", "PROTEIN", 162, 175], ["HCV", "SPECIES", 37, 40], ["a bindings ELISA", "TEST", 3, 19], ["coated HBsAg", "PROBLEM", 21, 33], ["HCV VLP", "TREATMENT", 37, 44], ["SIGN antibody", "TEST", 162, 175], ["Raji cells", "OBSERVATION", 104, 114], ["antibody", "OBSERVATION", 167, 175]]], ["DC\u2010SIGN derived from Raji transfectants did not bind HBsAg nor whole HBV particles, whereas HCV VLP showed mannan\u2010sensitive binding to DC\u2010SIGN (Fig. 3b).", [["DC", "ANATOMY", 0, 2], ["Raji transfectants", "ANATOMY", 21, 39], ["DC", "ANATOMY", 135, 137], ["HBsAg", "CHEMICAL", 53, 58], ["SIGN", "GENE_OR_GENE_PRODUCT", 3, 7], ["Raji transfectants", "CELL", 21, 39], ["HBsAg", "GENE_OR_GENE_PRODUCT", 53, 58], ["HBV", "ORGANISM", 69, 72], ["HCV VLP", "ORGANISM", 92, 99], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "CELL_LINE", 3, 7], ["Raji transfectants", "CELL_LINE", 21, 39], ["HBsAg", "PROTEIN", 53, 58], ["DC", "CELL_TYPE", 135, 137], ["HBV", "SPECIES", 69, 72], ["HCV", "SPECIES", 92, 95], ["Raji transfectants", "TREATMENT", 21, 39], ["HBsAg", "TEST", 53, 58], ["whole HBV particles", "PROBLEM", 63, 82], ["HCV VLP", "TEST", 92, 99], ["mannan\u2010sensitive binding", "PROBLEM", 107, 131]]], ["Control incubation with anti\u2010HCV and anti\u2010HBsAg specific antibodies indicated equal amounts were coated.", [["anti\u2010HCV", "SIMPLE_CHEMICAL", 24, 32], ["anti\u2010HBsAg", "SIMPLE_CHEMICAL", 37, 47], ["anti\u2010HCV", "PROTEIN", 24, 32], ["anti\u2010HBsAg specific antibodies", "PROTEIN", 37, 67], ["anti\u2010HCV", "SPECIES", 24, 32], ["Control incubation", "TREATMENT", 0, 18], ["anti\u2010HCV", "TREATMENT", 24, 32], ["anti\u2010HBsAg specific antibodies", "TREATMENT", 37, 67]]], ["No background binding was observed for either HBsAg or HCV VLP using the lysate of untransfected Raji cells (data not shown).HBsAg does not interact with cellular DC\u2010SIGN ::: ResultsIn addition to ELISA, HBsAg interaction with cellular DC\u2010SIGN was also determined.", [["lysate", "ANATOMY", 73, 79], ["Raji cells", "ANATOMY", 97, 107], ["cellular DC", "ANATOMY", 154, 165], ["cellular DC", "ANATOMY", 227, 238], ["HBsAg", "CHEMICAL", 46, 51], ["HBsAg", "CHEMICAL", 125, 130], ["HBsAg", "CHEMICAL", 204, 209], ["HBsAg", "GENE_OR_GENE_PRODUCT", 46, 51], ["HCV VLP", "ORGANISM", 55, 62], ["Raji cells", "CELL", 97, 107], ["HBsAg", "GENE_OR_GENE_PRODUCT", 125, 130], ["cellular", "CELL", 154, 162], ["HBsAg", "GENE_OR_GENE_PRODUCT", 204, 209], ["cellular", "CELL", 227, 235], ["SIGN", "GENE_OR_GENE_PRODUCT", 239, 243], ["HBsAg", "PROTEIN", 46, 51], ["HCV VLP", "PROTEIN", 55, 62], ["untransfected Raji cells", "CELL_LINE", 83, 107], ["HBsAg", "PROTEIN", 125, 130], ["DC", "CELL_TYPE", 163, 165], ["HBsAg", "PROTEIN", 204, 209], ["DC", "CELL_TYPE", 236, 238], ["SIGN", "PROTEIN", 239, 243], ["HCV", "SPECIES", 55, 58], ["background binding", "PROBLEM", 3, 21], ["HBsAg", "PROBLEM", 46, 51], ["HCV VLP", "TREATMENT", 55, 62], ["the lysate of untransfected Raji cells", "TREATMENT", 69, 107], ["HBsAg", "TEST", 125, 130], ["ELISA", "TEST", 197, 202], ["untransfected Raji cells", "OBSERVATION", 83, 107]]], ["DC\u2010SIGN is highly expressed on moDC (Fig. 3a).", [["DC", "ANATOMY", 0, 2], ["moDC", "ANATOMY", 31, 35], ["SIGN", "GENE_OR_GENE_PRODUCT", 3, 7], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7]]], ["Therefore, both Raji\u2010DC\u2010SIGN and moDC were incubated with HBsAg and binding was measured by flow cytometry.", [["HBsAg", "CHEMICAL", 58, 63], ["SIGN", "GENE_OR_GENE_PRODUCT", 24, 28], ["moDC", "CELL", 33, 37], ["HBsAg", "GENE_OR_GENE_PRODUCT", 58, 63], ["Raji\u2010DC", "PROTEIN", 16, 23], ["SIGN", "PROTEIN", 24, 28], ["moDC", "CELL_TYPE", 33, 37], ["HBsAg", "PROTEIN", 58, 63], ["HBsAg", "TREATMENT", 58, 63], ["flow cytometry", "TEST", 92, 106]]], ["Neither DC\u2010SIGN\u2010positive Raji cells nor moDC interacted with HBsAg after 2 and 18 h incubation (Fig. 3c and data not shown).", [["DC", "ANATOMY", 8, 10], ["Raji cells", "ANATOMY", 25, 35], ["moDC", "ANATOMY", 40, 44], ["HBsAg", "CHEMICAL", 61, 66], ["SIGN", "GENE_OR_GENE_PRODUCT", 11, 15], ["Raji cells", "CELL", 25, 35], ["moDC", "CELL", 40, 44], ["HBsAg", "GENE_OR_GENE_PRODUCT", 61, 66], ["DC", "CELL_TYPE", 8, 10], ["SIGN\u2010positive Raji cells", "CELL_LINE", 11, 35], ["HBsAg", "PROTEIN", 61, 66], ["positive Raji cells", "PROBLEM", 16, 35], ["HBsAg", "TEST", 61, 66], ["positive Raji cells", "OBSERVATION", 16, 35]]], ["In contrast, both DC\u2010SIGN\u2010transfected Raji cells and moDC efficiently internalised the DC\u2010SIGN ligand dextran\u2010FITC in a mannan\u2010sensitive manner (Fig. 3c).", [["DC", "ANATOMY", 18, 20], ["Raji cells", "ANATOMY", 38, 48], ["moDC", "ANATOMY", 53, 57], ["DC", "ANATOMY", 87, 89], ["dextran", "CHEMICAL", 102, 109], ["FITC", "CHEMICAL", 110, 114], ["SIGN", "GENE_OR_GENE_PRODUCT", 21, 25], ["Raji cells", "CELL", 38, 48], ["moDC", "CELL", 53, 57], ["SIGN", "GENE_OR_GENE_PRODUCT", 90, 94], ["dextran", "SIMPLE_CHEMICAL", 102, 109], ["FITC", "SIMPLE_CHEMICAL", 110, 114], ["DC", "CELL_TYPE", 18, 20], ["SIGN\u2010transfected Raji cells", "CELL_LINE", 21, 48], ["moDC", "CELL_LINE", 53, 57], ["DC", "CELL_TYPE", 87, 89], ["FITC", "PROTEIN", 110, 114], ["transfected Raji cells", "TREATMENT", 26, 48], ["SIGN ligand dextran", "TREATMENT", 90, 109], ["FITC", "TREATMENT", 110, 114]]], ["Mock transfected Raji cells remained dextran\u2010FITC negative (data not shown).", [["Raji cells", "ANATOMY", 17, 27], ["dextran", "CHEMICAL", 37, 44], ["FITC", "CHEMICAL", 45, 49], ["Raji cells", "CELL", 17, 27], ["dextran", "SIMPLE_CHEMICAL", 37, 44], ["FITC", "GENE_OR_GENE_PRODUCT", 45, 49], ["Mock transfected Raji cells", "CELL_LINE", 0, 27], ["dextran", "TREATMENT", 37, 44], ["FITC", "TEST", 45, 49], ["Raji cells", "OBSERVATION", 17, 27], ["negative", "OBSERVATION", 50, 58]]], ["Figure 3d summarizes the results of two independent binding assays.HBsAg and HBV do not interact with soluble L\u2010SIGN ::: ResultsIn a similar manner, the interaction between cellular L\u2010SIGN and both HBsAg and HBV was determined using L\u2010SIGN\u2010transfected Raji cells.", [["cellular", "ANATOMY", 173, 181], ["Raji cells", "ANATOMY", 252, 262], ["HBsAg", "CHEMICAL", 67, 72], ["HBsAg", "CHEMICAL", 198, 203], ["HBsAg", "GENE_OR_GENE_PRODUCT", 67, 72], ["HBV", "ORGANISM", 77, 80], ["cellular L\u2010SIGN", "CELL", 173, 188], ["HBsAg", "GENE_OR_GENE_PRODUCT", 198, 203], ["HBV", "ORGANISM", 208, 211], ["Raji cells", "CELL", 252, 262], ["HBsAg", "PROTEIN", 67, 72], ["L\u2010SIGN", "PROTEIN", 110, 116], ["cellular L\u2010SIGN", "PROTEIN", 173, 188], ["HBsAg", "PROTEIN", 198, 203], ["L\u2010SIGN\u2010transfected Raji cells", "CELL_LINE", 233, 262], ["HBV", "SPECIES", 77, 80], ["HBV", "SPECIES", 208, 211], ["HBsAg", "TEST", 67, 72], ["cellular L\u2010SIGN", "TEST", 173, 188], ["both HBsAg", "TEST", 193, 203], ["HBV", "TEST", 208, 211], ["L\u2010SIGN\u2010transfected Raji cells", "TREATMENT", 233, 262], ["transfected Raji cells", "OBSERVATION", 240, 262]]], ["Flow cytometric analysis showed L\u2010SIGN expression levels equal to DC\u2010SIGN expression (Fig. 4a [22]).", [["DC", "ANATOMY", 66, 68], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 32, 38], ["SIGN", "GENE_OR_GENE_PRODUCT", 69, 73], ["L\u2010SIGN", "PROTEIN", 32, 38], ["DC", "CELL_TYPE", 66, 68], ["SIGN", "PROTEIN", 69, 73], ["Flow cytometric analysis", "TEST", 0, 24], ["L\u2010SIGN expression levels", "PROBLEM", 32, 56]]], ["Soluble L\u2010SIGN interacted neither with HBV nor with HBsAg in ELISA, whereas L\u2010SIGN did interact with HCV VLP (Fig. 4b).", [["HBsAg", "CHEMICAL", 52, 57], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 8, 14], ["HBV", "ORGANISM", 39, 42], ["HBsAg", "GENE_OR_GENE_PRODUCT", 52, 57], ["HCV VLP", "ORGANISM", 101, 108], ["L\u2010SIGN", "PROTEIN", 8, 14], ["HBsAg", "PROTEIN", 52, 57], ["L\u2010SIGN", "PROTEIN", 76, 82], ["HBV", "SPECIES", 39, 42], ["HCV", "SPECIES", 101, 104], ["HBV", "PROBLEM", 39, 42], ["HBsAg in ELISA", "TEST", 52, 66], ["HCV VLP", "TREATMENT", 101, 108]]], ["Moreover, cellular L\u2010SIGN expressed by Raji transfectants did not bind to HBsAg, while it bound dextran\u2010FITC in a mannan\u2010sensitive manner (Fig. 4c,d).DC\u2010SIGN binds highly mannosylated HBV ::: ResultsThus, neither HBsAg nor HBV interacts with DC\u2010SIGN or L\u2010SIGN, whereas both C\u2010type lectins interact with HCV and other viruses such as HIV\u20101.", [["cellular", "ANATOMY", 10, 18], ["Raji transfectants", "ANATOMY", 39, 57], ["DC", "ANATOMY", 150, 152], ["DC", "ANATOMY", 242, 244], ["HBsAg", "CHEMICAL", 74, 79], ["dextran", "CHEMICAL", 96, 103], ["HBsAg", "CHEMICAL", 213, 218], ["FITC", "CHEMICAL", 104, 108], ["cellular", "CELL", 10, 18], ["Raji transfectants", "CELL", 39, 57], ["HBsAg", "GENE_OR_GENE_PRODUCT", 74, 79], ["dextran", "SIMPLE_CHEMICAL", 96, 103], ["FITC", "SIMPLE_CHEMICAL", 104, 108], ["SIGN", "GENE_OR_GENE_PRODUCT", 153, 157], ["HBV", "ORGANISM", 184, 187], ["HBsAg", "GENE_OR_GENE_PRODUCT", 213, 218], ["HBV", "ORGANISM", 223, 226], ["SIGN", "GENE_OR_GENE_PRODUCT", 245, 249], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 253, 259], ["C\u2010type lectins", "GENE_OR_GENE_PRODUCT", 274, 288], ["HCV", "ORGANISM", 303, 306], ["HIV", "ORGANISM", 333, 336], ["L\u2010SIGN", "PROTEIN", 19, 25], ["Raji transfectants", "CELL_LINE", 39, 57], ["HBsAg", "PROTEIN", 74, 79], ["FITC", "PROTEIN", 104, 108], ["DC", "CELL_TYPE", 150, 152], ["SIGN", "PROTEIN", 153, 157], ["HBsAg", "PROTEIN", 213, 218], ["DC", "CELL_TYPE", 242, 244], ["SIGN", "PROTEIN", 245, 249], ["L\u2010SIGN", "PROTEIN", 253, 259], ["C\u2010type lectins", "PROTEIN", 274, 288], ["HIV", "SPECIES", 333, 336], ["HBV", "SPECIES", 184, 187], ["HBV", "SPECIES", 223, 226], ["HCV", "SPECIES", 303, 306], ["HIV", "SPECIES", 333, 336], ["HBsAg", "TEST", 74, 79], ["FITC", "TREATMENT", 104, 108], ["L\u2010SIGN", "PROBLEM", 253, 259], ["HCV", "PROBLEM", 303, 306]]], ["These data suggest that the N\u2010linked glycosylation of HBV is distinct from that of other viruses.", [["HBV", "ORGANISM", 54, 57], ["HBV", "SPECIES", 54, 57], ["These data", "TEST", 0, 10], ["the N\u2010linked glycosylation of HBV", "PROBLEM", 24, 57], ["other viruses", "PROBLEM", 83, 96], ["HBV", "OBSERVATION", 54, 57], ["viruses", "OBSERVATION", 89, 96]]], ["To evaluate whether indeed native HBV glycosylation does not meet the requirements for DC\u2010SIGN interaction, glycan modified HBV was generated by treating HBV\u2010producing HepG2.2.15 cells with the \u03b1\u2010mannosidase I inhibitor kifunensine.", [["DC", "ANATOMY", 87, 89], ["HepG2.2.15 cells", "ANATOMY", 168, 184], ["kifunensine", "CHEMICAL", 220, 231], ["kifunensine", "CHEMICAL", 220, 231], ["HBV", "ORGANISM", 34, 37], ["SIGN", "GENE_OR_GENE_PRODUCT", 90, 94], ["HBV", "ORGANISM", 124, 127], ["HBV", "ORGANISM", 154, 157], ["HepG2.2.15 cells", "CELL", 168, 184], ["\u03b1\u2010mannosidase I", "GENE_OR_GENE_PRODUCT", 194, 209], ["kifunensine", "SIMPLE_CHEMICAL", 220, 231], ["DC", "CELL_TYPE", 87, 89], ["SIGN", "PROTEIN", 90, 94], ["HepG2.2.15 cells", "CELL_LINE", 168, 184], ["HBV", "SPECIES", 34, 37], ["HBV", "SPECIES", 124, 127], ["HBV", "SPECIES", 154, 157], ["indeed native HBV glycosylation", "PROBLEM", 20, 51], ["glycan modified HBV", "PROBLEM", 108, 127], ["HBV", "TREATMENT", 154, 157], ["HepG2.2.15 cells", "TREATMENT", 168, 184], ["the \u03b1\u2010mannosidase I inhibitor kifunensine", "TREATMENT", 190, 231], ["HBV", "OBSERVATION", 34, 37]]], ["Kifunensine causes the accumulation of Man7\u20139GlcNAc2 oligosaccharides on glycoproteins by inhibiting mannose trimming in the endoplasmic reticulum [36].", [["endoplasmic reticulum", "ANATOMY", 125, 146], ["Kifunensine", "CHEMICAL", 0, 11], ["Kifunensine", "CHEMICAL", 0, 11], ["mannose", "CHEMICAL", 101, 108], ["Kifunensine", "SIMPLE_CHEMICAL", 0, 11], ["Man7\u20139GlcNAc2 oligosaccharides", "GENE_OR_GENE_PRODUCT", 39, 69], ["mannose", "SIMPLE_CHEMICAL", 101, 108], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 125, 146], ["Kifunensine", "TREATMENT", 0, 11], ["Man7\u20139GlcNAc2 oligosaccharides", "TREATMENT", 39, 69], ["glycoproteins", "TREATMENT", 73, 86], ["mannose trimming", "TREATMENT", 101, 117], ["accumulation", "OBSERVATION_MODIFIER", 23, 35], ["endoplasmic reticulum", "ANATOMY", 125, 146]]], ["Carbohydrate analysis of glycan modified HBV indeed demonstrated an increased amount of mannose structures compared to native HBV, shown by a two\u2010fold increase in binding to the mannose\u2010specific plant lectins Con A and GNA while binding to the N\u2010acetylglucosamine\u2010specific lectin WGA was unchanged (Fig. 5b).", [["N\u2010acetylglucosamine", "CHEMICAL", 244, 263], ["Carbohydrate", "CHEMICAL", 0, 12], ["mannose", "CHEMICAL", 88, 95], ["N\u2010acetylglucosamine", "CHEMICAL", 244, 263], ["HBV", "ORGANISM", 41, 44], ["mannose", "SIMPLE_CHEMICAL", 88, 95], ["HBV", "ORGANISM", 126, 129], ["Con A", "GENE_OR_GENE_PRODUCT", 209, 214], ["GNA", "SIMPLE_CHEMICAL", 219, 222], ["N\u2010acetylglucosamine", "SIMPLE_CHEMICAL", 244, 263], ["mannose\u2010specific plant lectins Con A", "PROTEIN", 178, 214], ["N\u2010acetylglucosamine\u2010specific lectin", "PROTEIN", 244, 279], ["HBV", "SPECIES", 41, 44], ["HBV", "SPECIES", 126, 129], ["Carbohydrate analysis", "TEST", 0, 21], ["glycan modified HBV", "TREATMENT", 25, 44], ["an increased amount of mannose structures", "PROBLEM", 65, 106], ["native HBV", "PROBLEM", 119, 129], ["a two\u2010fold increase in binding", "PROBLEM", 140, 170], ["the N\u2010acetylglucosamine\u2010specific lectin WGA", "TEST", 240, 283], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["amount", "OBSERVATION_MODIFIER", 78, 84], ["mannose structures", "OBSERVATION", 88, 106], ["HBV", "OBSERVATION", 126, 129], ["unchanged", "OBSERVATION_MODIFIER", 288, 297]]], ["Control incubations with an anti\u2010HBsAg specific antibody showed that similar amounts of native and highly glycosylated HBV were coated (Fig. 5a).", [["anti\u2010HBsAg", "SIMPLE_CHEMICAL", 28, 38], ["HBV", "ORGANISM", 119, 122], ["anti\u2010HBsAg specific antibody", "PROTEIN", 28, 56], ["HBV", "SPECIES", 119, 122], ["Control incubations", "TREATMENT", 0, 19], ["an anti\u2010HBsAg specific antibody", "TEST", 25, 56], ["highly glycosylated HBV", "PROBLEM", 99, 122]]], ["The interaction between highly mannosylated HBV and DC\u2010SIGN was studied by DC\u2010SIGN\u2010Fc\u2010based ELISA (Fig. 5c).", [["DC", "ANATOMY", 52, 54], ["DC", "ANATOMY", 75, 77], ["HBV", "ORGANISM", 44, 47], ["DC", "CELL", 52, 54], ["DC", "CELL_TYPE", 52, 54], ["DC", "CELL_TYPE", 75, 77], ["HBV", "SPECIES", 44, 47]]], ["Strikingly, HBV binding to DC\u2010SIGN was observed after kifunensine treatment of the virus producing cells, and the binding could be inhibited by both mannan and EGTA.", [["DC", "ANATOMY", 27, 29], ["cells", "ANATOMY", 99, 104], ["kifunensine", "CHEMICAL", 54, 65], ["EGTA", "CHEMICAL", 160, 164], ["kifunensine", "CHEMICAL", 54, 65], ["EGTA", "CHEMICAL", 160, 164], ["HBV", "ORGANISM", 12, 15], ["SIGN", "GENE_OR_GENE_PRODUCT", 30, 34], ["kifunensine", "SIMPLE_CHEMICAL", 54, 65], ["cells", "CELL", 99, 104], ["mannan", "SIMPLE_CHEMICAL", 149, 155], ["EGTA", "SIMPLE_CHEMICAL", 160, 164], ["DC", "CELL_TYPE", 27, 29], ["SIGN", "PROTEIN", 30, 34], ["virus producing cells", "CELL_TYPE", 83, 104], ["HBV", "SPECIES", 12, 15], ["HBV binding", "PROBLEM", 12, 23], ["kifunensine treatment", "TREATMENT", 54, 75], ["the virus producing cells", "PROBLEM", 79, 104], ["HBV", "OBSERVATION", 12, 15]]], ["The protein structure of HBV is therefore compatible with DC\u2010SIGN binding, but the native glycosylation, that exclusively determines DC\u2010SIGN interaction, is not.", [["DC", "ANATOMY", 58, 60], ["DC", "ANATOMY", 133, 135], ["HBV", "ORGANISM", 25, 28], ["SIGN", "GENE_OR_GENE_PRODUCT", 61, 65], ["SIGN", "GENE_OR_GENE_PRODUCT", 136, 140], ["DC", "CELL_TYPE", 58, 60], ["SIGN", "PROTEIN", 61, 65], ["DC", "CELL_TYPE", 133, 135], ["SIGN", "PROTEIN", 136, 140], ["HBV", "SPECIES", 25, 28], ["HBV", "PROBLEM", 25, 28], ["SIGN binding", "PROBLEM", 61, 73], ["HBV", "OBSERVATION", 25, 28]]], ["This observation also excludes the possibility that lack of DC\u2010SIGN\u2010HBV interaction is observed due to too low sensitivity of the DC\u2010SIGN assays used in this study.", [["DC", "ANATOMY", 60, 62], ["DC", "ANATOMY", 130, 132], ["SIGN", "GENE_OR_GENE_PRODUCT", 63, 67], ["HBV", "ORGANISM", 68, 71], ["DC", "CELL_TYPE", 60, 62], ["DC", "CELL_TYPE", 130, 132], ["SIGN", "PROTEIN", 133, 137], ["HBV", "SPECIES", 68, 71], ["This observation", "TEST", 0, 16], ["HBV interaction", "PROBLEM", 68, 83], ["SIGN assays", "TEST", 133, 144], ["this study", "TEST", 153, 163]]], ["Supernatant of untreated HepG2.2.15 and HepG2 cells showed no binding to DC\u2010SIGN.", [["Supernatant", "ANATOMY", 0, 11], ["HepG2", "ANATOMY", 25, 30], ["HepG2 cells", "ANATOMY", 40, 51], ["DC", "ANATOMY", 73, 75], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["HepG2", "CELL", 25, 30], ["HepG2 cells", "CELL", 40, 51], ["DC", "CELL", 73, 75], ["HepG2", "CELL_LINE", 25, 30], ["HepG2 cells", "CELL_LINE", 40, 51], ["DC", "CELL_TYPE", 73, 75], ["untreated HepG2", "PROBLEM", 15, 30], ["HepG2 cells", "TEST", 40, 51], ["untreated", "OBSERVATION", 15, 24], ["HepG2", "ANATOMY", 25, 30], ["no", "UNCERTAINTY", 59, 61]]], ["Minor background binding was observed with supernatant of kifunensine\u2010treated HepG2 cells, due to the accumulation of large amounts of highly mannosylated proteins in the medium during treatment.", [["supernatant", "ANATOMY", 43, 54], ["HepG2 cells", "ANATOMY", 78, 89], ["kifunensine\u2010treated HepG2 cells", "CELL", 58, 89], ["kifunensine\u2010treated HepG2 cells", "CELL_LINE", 58, 89], ["highly mannosylated proteins", "PROTEIN", 135, 163], ["Minor background binding", "PROBLEM", 0, 24], ["kifunensine\u2010treated HepG2 cells", "TREATMENT", 58, 89], ["highly mannosylated proteins", "PROBLEM", 135, 163], ["treatment", "TREATMENT", 185, 194], ["binding", "OBSERVATION", 17, 24], ["HepG2 cells", "OBSERVATION", 78, 89], ["large", "OBSERVATION_MODIFIER", 118, 123], ["amounts", "OBSERVATION_MODIFIER", 124, 131], ["highly", "OBSERVATION_MODIFIER", 135, 141], ["mannosylated proteins", "OBSERVATION", 142, 163], ["medium", "OBSERVATION_MODIFIER", 171, 177]]], ["These data indicate that mannose trimming of the oligosaccharide structures present on HBV prevents interaction with DC\u2010SIGN.DiscussionOne of the key questions in HBV biology focuses on the attachment and entry mechanisms used by HBV to infect hepatocytes, the main target cells.", [["DC", "ANATOMY", 117, 119], ["hepatocytes", "ANATOMY", 244, 255], ["cells", "ANATOMY", 273, 278], ["mannose", "CHEMICAL", 25, 32], ["mannose", "SIMPLE_CHEMICAL", 25, 32], ["HBV", "ORGANISM", 87, 90], ["SIGN", "GENE_OR_GENE_PRODUCT", 120, 124], ["HBV", "ORGANISM", 163, 166], ["HBV", "ORGANISM", 230, 233], ["hepatocytes", "CELL", 244, 255], ["cells", "CELL", 273, 278], ["DC", "CELL_TYPE", 117, 119], ["SIGN", "PROTEIN", 120, 124], ["hepatocytes", "CELL_TYPE", 244, 255], ["target cells", "CELL_TYPE", 266, 278], ["HBV", "SPECIES", 87, 90], ["HBV", "SPECIES", 163, 166], ["HBV", "SPECIES", 230, 233], ["These data", "TEST", 0, 10], ["mannose trimming of the oligosaccharide structures", "PROBLEM", 25, 75], ["HBV to infect hepatocytes", "PROBLEM", 230, 255], ["mannose trimming", "OBSERVATION", 25, 41], ["main", "OBSERVATION_MODIFIER", 261, 265], ["target cells", "OBSERVATION", 266, 278]]], ["Several putative binding receptors are proposed, but none of them are confirmed as high affinity receptors for HBV.", [["HBV", "ORGANISM", 111, 114], ["putative binding receptors", "PROTEIN", 8, 34], ["high affinity receptors", "PROTEIN", 83, 106], ["HBV", "SPECIES", 111, 114], ["HBV", "PROBLEM", 111, 114], ["binding receptors", "OBSERVATION", 17, 34]]], ["Related to the issue of HBV entry is the way HBV reaches the hepatocyte: Is there direct contact between HBV in the circulation and hepatocytes, possibly through fenestrations in the LSEC [37]?", [["hepatocyte", "ANATOMY", 61, 71], ["hepatocytes", "ANATOMY", 132, 143], ["HBV", "ORGANISM", 24, 27], ["HBV", "ORGANISM", 45, 48], ["hepatocyte", "CELL", 61, 71], ["HBV", "ORGANISM", 105, 108], ["hepatocytes", "CELL", 132, 143], ["hepatocytes", "CELL_TYPE", 132, 143], ["HBV", "SPECIES", 24, 27], ["HBV", "SPECIES", 45, 48], ["HBV", "SPECIES", 105, 108], ["HBV entry", "PROBLEM", 24, 33], ["direct contact between HBV in the circulation and hepatocytes", "PROBLEM", 82, 143], ["HBV", "OBSERVATION", 24, 27], ["hepatocyte", "ANATOMY", 61, 71], ["circulation", "ANATOMY", 116, 127], ["hepatocytes", "ANATOMY", 132, 143], ["fenestrations", "OBSERVATION", 162, 175], ["LSEC", "ANATOMY", 183, 187]]], ["Or are other cell types involved in HBV dissemination, similar to HIV transport by dendritic cells for trans\u2010infection of T cells [31] and HCV capture by LSEC promoting infection of hepatocytes [38]?DiscussionSince HBsAg are glycoproteins, the involvement of a C\u2010type lectin receptor in viral recognition seems plausible.", [["cell", "ANATOMY", 13, 17], ["dendritic cells", "ANATOMY", 83, 98], ["T cells", "ANATOMY", 122, 129], ["LSEC", "ANATOMY", 154, 158], ["hepatocytes", "ANATOMY", 182, 193], ["infection", "DISEASE", 169, 178], ["HBsAg", "CHEMICAL", 215, 220], ["cell", "CELL", 13, 17], ["HBV", "ORGANISM", 36, 39], ["HIV", "ORGANISM", 66, 69], ["dendritic cells", "CELL", 83, 98], ["T cells", "CELL", 122, 129], ["HCV", "ORGANISM", 139, 142], ["LSEC", "GENE_OR_GENE_PRODUCT", 154, 158], ["hepatocytes", "CELL", 182, 193], ["HBsAg", "GENE_OR_GENE_PRODUCT", 215, 220], ["C\u2010type lectin receptor", "GENE_OR_GENE_PRODUCT", 261, 283], ["dendritic cells", "CELL_TYPE", 83, 98], ["T cells", "CELL_TYPE", 122, 129], ["hepatocytes", "CELL_TYPE", 182, 193], ["HBsAg", "PROTEIN", 215, 220], ["C\u2010type lectin receptor", "PROTEIN", 261, 283], ["HIV", "SPECIES", 66, 69], ["HBV", "SPECIES", 36, 39], ["HIV", "SPECIES", 66, 69], ["HCV", "SPECIES", 139, 142], ["HBV dissemination", "PROBLEM", 36, 53], ["T cells", "PROBLEM", 122, 129], ["HCV capture", "TREATMENT", 139, 150], ["infection of hepatocytes", "PROBLEM", 169, 193], ["a C\u2010type lectin receptor", "TREATMENT", 259, 283], ["cell types", "OBSERVATION", 13, 23], ["HBV dissemination", "OBSERVATION", 36, 53], ["infection", "OBSERVATION", 169, 178], ["hepatocytes", "ANATOMY", 182, 193]]], ["The best\u2010characterised C\u2010type lectins are the dendritic cell\u2010expressed DC\u2010SIGN and its LSEC\u2010expressed homologue L\u2010SIGN, both capable of recognizing a broad range of glycosylated pathogens, including viruses, bacteria and protozoa [16].", [["DC", "ANATOMY", 71, 73], ["C\u2010type lectins", "GENE_OR_GENE_PRODUCT", 23, 37], ["SIGN", "GENE_OR_GENE_PRODUCT", 74, 78], ["LSEC", "GENE_OR_GENE_PRODUCT", 87, 91], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 112, 118], ["best\u2010characterised C\u2010type lectins", "PROTEIN", 4, 37], ["dendritic cell\u2010expressed DC", "CELL_TYPE", 46, 73], ["SIGN", "PROTEIN", 74, 78], ["LSEC", "PROTEIN", 87, 91], ["L\u2010SIGN", "PROTEIN", 112, 118], ["The best\u2010characterised C\u2010type lectins", "TREATMENT", 0, 37], ["glycosylated pathogens", "PROBLEM", 165, 187], ["viruses", "PROBLEM", 199, 206], ["bacteria", "PROBLEM", 208, 216], ["protozoa", "PROBLEM", 221, 229]]], ["The fact that HBV has been found attached to both dendritic cells [24, 25, 26, 27], and LSEC [28] leads to DC\u2010SIGN and L\u2010SIGN as likely candidate receptors.DiscussionThe present study conclusively shows the lack of interaction between DC\u2010SIGN and purified HepG2.2.15\u2010derived HBV with its native glycosylation.", [["dendritic cells", "ANATOMY", 50, 65], ["DC", "ANATOMY", 107, 109], ["DC", "ANATOMY", 235, 237], ["HepG2", "ANATOMY", 256, 261], ["HBV", "ORGANISM", 14, 17], ["dendritic cells", "CELL", 50, 65], ["SIGN", "GENE_OR_GENE_PRODUCT", 110, 114], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 119, 125], ["SIGN", "GENE_OR_GENE_PRODUCT", 238, 242], ["HepG2", "CELL", 256, 261], ["HBV", "ORGANISM", 275, 278], ["dendritic cells", "CELL_TYPE", 50, 65], ["DC", "CELL_TYPE", 107, 109], ["SIGN", "PROTEIN", 110, 114], ["L\u2010SIGN", "PROTEIN", 119, 125], ["DC", "CELL_TYPE", 235, 237], ["SIGN", "CELL_LINE", 238, 242], ["purified HepG2", "CELL_LINE", 247, 261], ["HBV", "SPECIES", 14, 17], ["HBV", "SPECIES", 275, 278], ["HBV", "PROBLEM", 14, 17], ["LSEC", "TEST", 88, 92], ["The present study", "TEST", 166, 183], ["HBV", "PROBLEM", 275, 278], ["its native glycosylation", "TREATMENT", 284, 308], ["HBV", "OBSERVATION", 14, 17], ["dendritic cells", "OBSERVATION", 50, 65], ["HepG2", "ANATOMY", 256, 261]]], ["Moreover, recombinant HBsAg were recognized by neither DC\u2010SIGN nor L\u2010SIGN.", [["DC", "ANATOMY", 55, 57], ["HBsAg", "CHEMICAL", 22, 27], ["HBsAg", "GENE_OR_GENE_PRODUCT", 22, 27], ["L\u2010SIGN", "GENE_OR_GENE_PRODUCT", 67, 73], ["recombinant HBsAg", "PROTEIN", 10, 27], ["DC", "CELL_TYPE", 55, 57], ["L\u2010SIGN", "PROTEIN", 67, 73], ["recombinant HBsAg", "TEST", 10, 27], ["HBsAg", "OBSERVATION", 22, 27]]], ["Glycan analysis of both HBV and HBsAg demonstrated that lack of DC\u2010SIGN binding was not due to aberrant glycosylation of virions and glycoproteins used in this study, since the observed glycosylation pattern was consistent with previously reported complex\u2010type carbohydrate structures on HBV [39].", [["DC", "ANATOMY", 64, 66], ["HBsAg", "CHEMICAL", 32, 37], ["carbohydrate", "CHEMICAL", 261, 273], ["HBV", "ORGANISM", 24, 27], ["HBsAg", "GENE_OR_GENE_PRODUCT", 32, 37], ["SIGN", "GENE_OR_GENE_PRODUCT", 67, 71], ["HBsAg", "PROTEIN", 32, 37], ["DC", "CELL_TYPE", 64, 66], ["SIGN", "PROTEIN", 67, 71], ["glycoproteins", "PROTEIN", 133, 146], ["HBV", "SPECIES", 24, 27], ["HBV", "SPECIES", 288, 291], ["Glycan analysis", "TEST", 0, 15], ["both HBV", "TEST", 19, 27], ["HBsAg", "TEST", 32, 37], ["DC\u2010SIGN binding", "PROBLEM", 64, 79], ["aberrant glycosylation of virions and glycoproteins", "PROBLEM", 95, 146], ["this study", "TEST", 155, 165], ["the observed glycosylation pattern", "PROBLEM", 173, 207], ["complex\u2010type carbohydrate structures", "PROBLEM", 248, 284], ["HBV", "TEST", 288, 291], ["consistent with", "UNCERTAINTY", 212, 227]]], ["Notably, while mannose and N\u2010acetylglucosamine seem to be present in similar amounts on both HBV and HBsAg, glycan structures on virions are enriched for galactose, N\u2010acetylgalactosamine and fucose.", [["virions", "ANATOMY", 129, 136], ["mannose", "CHEMICAL", 15, 22], ["N\u2010acetylglucosamine", "CHEMICAL", 27, 46], ["HBsAg", "CHEMICAL", 101, 106], ["galactose", "CHEMICAL", 154, 163], ["N\u2010acetylgalactosamine", "CHEMICAL", 165, 186], ["fucose", "CHEMICAL", 191, 197], ["mannose", "CHEMICAL", 15, 22], ["N\u2010acetylglucosamine", "CHEMICAL", 27, 46], ["galactose", "CHEMICAL", 154, 163], ["N\u2010acetylgalactosamine", "CHEMICAL", 165, 186], ["fucose", "CHEMICAL", 191, 197], ["mannose", "SIMPLE_CHEMICAL", 15, 22], ["N\u2010acetylglucosamine", "SIMPLE_CHEMICAL", 27, 46], ["HBV", "ORGANISM", 93, 96], ["HBsAg", "GENE_OR_GENE_PRODUCT", 101, 106], ["galactose", "SIMPLE_CHEMICAL", 154, 163], ["N\u2010acetylgalactosamine", "SIMPLE_CHEMICAL", 165, 186], ["fucose", "SIMPLE_CHEMICAL", 191, 197], ["HBsAg", "PROTEIN", 101, 106], ["HBV", "SPECIES", 93, 96], ["mannose", "TREATMENT", 15, 22], ["N\u2010acetylglucosamine", "TREATMENT", 27, 46], ["both HBV and HBsAg, glycan structures on virions", "PROBLEM", 88, 136], ["galactose", "TREATMENT", 154, 163], ["N\u2010acetylgalactosamine", "TREATMENT", 165, 186], ["fucose", "TREATMENT", 191, 197], ["HBV", "OBSERVATION", 93, 96]]], ["This difference in observed glycosylation pattern might be the result of O\u2010glycans present on the preS1 domain [39].DiscussionDC\u2010SIGN has been shown to interact with high mannose\u2010containing glycans on various viruses, such as HCV, HIV and Ebola [16].", [["SIGN", "CHEMICAL", 129, 133], ["HCV, HIV and Ebola", "DISEASE", 226, 244], ["O\u2010glycans", "SIMPLE_CHEMICAL", 73, 82], ["HCV", "ORGANISM", 226, 229], ["Ebola [16]", "ORGANISM", 239, 249], ["O\u2010glycans", "PROTEIN", 73, 82], ["preS1 domain", "PROTEIN", 98, 110], ["DiscussionDC", "PROTEIN", 116, 128], ["SIGN", "PROTEIN", 129, 133], ["HIV", "SPECIES", 231, 234], ["HCV", "SPECIES", 226, 229], ["HIV", "SPECIES", 231, 234], ["O\u2010glycans", "PROBLEM", 73, 82], ["various viruses", "PROBLEM", 201, 216], ["HCV", "PROBLEM", 226, 229]]], ["Even though data demonstrate that these viruses can exploit DC\u2010SIGN for their own benefit, the majority of the captured virus is degraded and routed into the antigen presentation pathway [40, 41, 42], thereby allowing the induction of an anti\u2010viral immune response.", [["DC", "ANATOMY", 60, 62], ["SIGN", "GENE_OR_GENE_PRODUCT", 63, 67], ["antigen", "GENE_OR_GENE_PRODUCT", 158, 165], ["DC", "CELL_TYPE", 60, 62], ["SIGN", "PROTEIN", 63, 67], ["these viruses", "PROBLEM", 34, 47], ["the captured virus", "PROBLEM", 107, 125], ["an anti\u2010viral immune response", "TREATMENT", 235, 264], ["viruses", "OBSERVATION", 40, 47]]], ["Although HBV glycoproteins are involved in viral recognition, as they are known to bind mannose binding lectin and the asialoglycoprotein receptor, here it is shown that \u03b1\u2010mannosidase I trimming of N\u2010linked oligosaccharide structures prevents recognition by DC\u2010SIGN.", [["DC", "ANATOMY", 258, 260], ["mannose", "CHEMICAL", 88, 95], ["HBV", "ORGANISM", 9, 12], ["mannose binding lectin", "GENE_OR_GENE_PRODUCT", 88, 110], ["asialoglycoprotein receptor", "GENE_OR_GENE_PRODUCT", 119, 146], ["\u03b1\u2010mannosidase I", "GENE_OR_GENE_PRODUCT", 170, 185], ["SIGN", "GENE_OR_GENE_PRODUCT", 261, 265], ["HBV glycoproteins", "PROTEIN", 9, 26], ["mannose binding lectin", "PROTEIN", 88, 110], ["asialoglycoprotein receptor", "PROTEIN", 119, 146], ["\u03b1\u2010mannosidase I", "PROTEIN", 170, 185], ["DC", "CELL_TYPE", 258, 260], ["SIGN", "PROTEIN", 261, 265], ["HBV", "SPECIES", 9, 12], ["HBV glycoproteins", "PROBLEM", 9, 26], ["the asialoglycoprotein receptor", "TREATMENT", 115, 146], ["\u03b1\u2010mannosidase I trimming of N\u2010linked oligosaccharide structures", "TREATMENT", 170, 233]]], ["HBV is thus recognized by DC\u2010SIGN as soon as one of the enzymes in the formation of complex glycans, \u03b1\u2010mannosidase I, is inhibited and highly mannosylated virions are generated.", [["DC", "ANATOMY", 26, 28], ["HBV", "ORGANISM", 0, 3], ["SIGN", "GENE_OR_GENE_PRODUCT", 29, 33], ["\u03b1\u2010mannosidase I", "GENE_OR_GENE_PRODUCT", 101, 116], ["DC", "CELL_TYPE", 26, 28], ["SIGN", "PROTEIN", 29, 33], ["complex glycans", "PROTEIN", 84, 99], ["\u03b1\u2010mannosidase I", "PROTEIN", 101, 116], ["HBV", "SPECIES", 0, 3], ["HBV", "PROBLEM", 0, 3], ["the enzymes", "TEST", 52, 63], ["highly mannosylated virions", "TREATMENT", 135, 162]]], ["Previous reports have shown the importance of HBV glycosylation for viral secretion [11, 43] and indeed we observe a decrease in secretion of highly mannosylated vs native HBV, under similar culture conditions.DiscussionWe cannot rule out that patient sera contain a subpopulation of these highly glycosylated viremia that would allow interaction with DC\u2010SIGN.", [["sera", "ANATOMY", 252, 256], ["DC", "ANATOMY", 352, 354], ["viremia", "DISEASE", 310, 317], ["HBV", "ORGANISM", 46, 49], ["HBV", "ORGANISM", 172, 175], ["patient", "ORGANISM", 244, 251], ["sera", "ORGANISM_SUBSTANCE", 252, 256], ["SIGN", "GENE_OR_GENE_PRODUCT", 355, 359], ["DC", "CELL_TYPE", 352, 354], ["SIGN", "PROTEIN", 355, 359], ["patient", "SPECIES", 244, 251], ["HBV", "SPECIES", 46, 49], ["HBV", "SPECIES", 172, 175], ["HBV glycosylation", "TREATMENT", 46, 63], ["viral secretion", "PROBLEM", 68, 83], ["a decrease in secretion of highly mannosylated vs native HBV", "PROBLEM", 115, 175], ["these highly glycosylated viremia", "PROBLEM", 284, 317], ["decrease", "OBSERVATION_MODIFIER", 117, 125], ["HBV", "OBSERVATION", 172, 175]]], ["Preliminary data on HBV derived from several patient sera with a high viral load did not show binding to DC\u2010SIGN\u2010Fc (data not shown), thereby indicating that DC\u2010SIGN may not be involved in recognition of HBV in vivo either.", [["sera", "ANATOMY", 53, 57], ["DC", "ANATOMY", 105, 107], ["DC", "ANATOMY", 158, 160], ["HBV", "ORGANISM", 20, 23], ["patient", "ORGANISM", 45, 52], ["sera", "ORGANISM_SUBSTANCE", 53, 57], ["Fc", "GENE_OR_GENE_PRODUCT", 113, 115], ["SIGN", "GENE_OR_GENE_PRODUCT", 161, 165], ["HBV", "ORGANISM", 204, 207], ["DC", "CELL_TYPE", 105, 107], ["SIGN", "PROTEIN", 108, 112], ["Fc", "PROTEIN", 113, 115], ["DC", "CELL_TYPE", 158, 160], ["SIGN", "PROTEIN", 161, 165], ["patient", "SPECIES", 45, 52], ["HBV", "SPECIES", 20, 23], ["HBV", "SPECIES", 204, 207], ["Preliminary data", "TEST", 0, 16], ["HBV", "PROBLEM", 20, 23], ["several patient sera", "TEST", 37, 57], ["a high viral load", "PROBLEM", 63, 80], ["HBV", "TREATMENT", 204, 207], ["HBV", "OBSERVATION", 204, 207]]], ["On the basis of our findings, it is tempting to speculate that HBV exploits mannose trimming as a way to escape recognition by DC\u2010SIGN and thereby subvert a possible immune activation response.", [["DC", "ANATOMY", 127, 129], ["mannose", "CHEMICAL", 76, 83], ["HBV", "ORGANISM", 63, 66], ["mannose", "SIMPLE_CHEMICAL", 76, 83], ["SIGN", "GENE_OR_GENE_PRODUCT", 130, 134], ["DC", "CELL_TYPE", 127, 129], ["SIGN", "PROTEIN", 130, 134], ["HBV", "SPECIES", 63, 66], ["HBV exploits mannose trimming", "TREATMENT", 63, 92], ["immune activation response", "PROBLEM", 166, 192], ["HBV", "OBSERVATION", 63, 66]]], ["Further studies are needed to address this issue.Conflicts of interestAll authors have nothing to disclose.", [["Further studies", "TEST", 0, 15]]]], "PMC7118999": [["Ambulatory pneumonia ::: Etiologic agents that commonly cause community-acquired pneumoniaAlthough surprisingly few studies have attempted to define the etiology of CAP treated on an ambulatory basis [4], [5], [6], [7], a consistent picture has emerged.", [["pneumonia", "DISEASE", 11, 20], ["CAP", "DISEASE", 165, 168], ["[6]", "SIMPLE_CHEMICAL", 210, 213], ["Ambulatory pneumonia", "PROBLEM", 0, 20], ["community-acquired pneumoniaAlthough", "PROBLEM", 62, 98], ["CAP", "PROBLEM", 165, 168], ["an ambulatory basis", "TEST", 180, 199], ["pneumonia", "OBSERVATION", 11, 20]]], ["M pneumoniae is the most commonly identified agent at 20% to 30%, followed by Chlamydia pneumoniae at 2% to 16%, Streptococcus pneumoniae at 6% to 10%, Haemophilus influenzae at 5%, and Staphylococcus aureus and L pneumophila, both at 1% to 2%.Pneumonia requiring admission to hospital ::: Etiologic agents that commonly cause community-acquired pneumoniaMany studies have defined the etiology of CAP among patients requiring admission to hospital in many countries.", [["Chlamydia pneumoniae", "DISEASE", 78, 98], ["Streptococcus pneumoniae", "DISEASE", 113, 137], ["Haemophilus influenzae", "DISEASE", 152, 174], ["Staphylococcus aureus", "DISEASE", 186, 207], ["Pneumonia", "DISEASE", 244, 253], ["CAP", "DISEASE", 397, 400], ["M pneumoniae", "ORGANISM", 0, 12], ["Chlamydia pneumoniae", "ORGANISM", 78, 98], ["Streptococcus pneumoniae", "ORGANISM", 113, 137], ["Haemophilus influenzae", "ORGANISM", 152, 174], ["Staphylococcus aureus", "ORGANISM", 186, 207], ["L pneumophila", "ORGANISM", 212, 225], ["patients", "ORGANISM", 407, 415], ["M pneumoniae", "SPECIES", 0, 12], ["Chlamydia pneumoniae", "SPECIES", 78, 98], ["Streptococcus pneumoniae", "SPECIES", 113, 137], ["Haemophilus influenzae", "SPECIES", 152, 174], ["Staphylococcus aureus", "SPECIES", 186, 207], ["L pneumophila", "SPECIES", 212, 225], ["patients", "SPECIES", 407, 415], ["M pneumoniae", "SPECIES", 0, 12], ["Chlamydia pneumoniae", "SPECIES", 78, 98], ["Streptococcus pneumoniae", "SPECIES", 113, 137], ["Haemophilus influenzae", "SPECIES", 152, 174], ["Staphylococcus aureus", "SPECIES", 186, 207], ["L pneumophila", "SPECIES", 212, 225], ["pneumoniae", "PROBLEM", 2, 12], ["Chlamydia pneumoniae", "PROBLEM", 78, 98], ["Streptococcus pneumoniae", "PROBLEM", 113, 137], ["Haemophilus influenzae", "TEST", 152, 174], ["Staphylococcus aureus", "PROBLEM", 186, 207], ["L pneumophila", "PROBLEM", 212, 225], ["Pneumonia", "PROBLEM", 244, 253], ["acquired pneumoniaMany studies", "PROBLEM", 337, 367], ["CAP", "PROBLEM", 397, 400], ["pneumoniae", "OBSERVATION", 2, 12], ["Staphylococcus aureus", "OBSERVATION", 186, 207], ["L", "ANATOMY_MODIFIER", 212, 213], ["pneumophila", "OBSERVATION", 214, 225], ["CAP", "OBSERVATION_MODIFIER", 397, 400]]], ["Again, it was impossible to define the etiology in many patients [8].", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["Streptococcus pneumoniae is the most commonly identified pathogen in this setting and, depending on the methods used, it can be implicated as the cause of CAP in up to 50% of patients requiring admission to hospital [8].", [["Streptococcus pneumoniae", "DISEASE", 0, 24], ["CAP", "DISEASE", 155, 158], ["Streptococcus pneumoniae", "ORGANISM", 0, 24], ["patients", "ORGANISM", 175, 183], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["patients", "SPECIES", 175, 183], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae", "PROBLEM", 0, 24], ["CAP", "PROBLEM", 155, 158], ["pneumoniae", "OBSERVATION", 14, 24], ["most commonly", "OBSERVATION_MODIFIER", 32, 45], ["CAP", "OBSERVATION_MODIFIER", 155, 158]]], ["Chlamydia pneumoniae is the most commonly identified atypical agent in these patients.", [["Chlamydia pneumoniae", "DISEASE", 0, 20], ["Chlamydia pneumoniae", "ORGANISM", 0, 20], ["patients", "ORGANISM", 77, 85], ["Chlamydia pneumoniae", "SPECIES", 0, 20], ["patients", "SPECIES", 77, 85], ["Chlamydia pneumoniae", "SPECIES", 0, 20], ["Chlamydia pneumoniae", "PROBLEM", 0, 20], ["pneumoniae", "OBSERVATION", 10, 20], ["most commonly", "OBSERVATION_MODIFIER", 28, 41]]], ["M pneumoniae is less common than in patients who have ambulatory pneumonia, but is still implicated in a substantial number of patients\u201432%, in one study [8].", [["pneumonia", "DISEASE", 65, 74], ["M pneumoniae", "ORGANISM", 0, 12], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 127, 135], ["M pneumoniae", "SPECIES", 0, 12], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 127, 135], ["M pneumoniae", "SPECIES", 0, 12], ["M pneumoniae", "PROBLEM", 0, 12], ["ambulatory pneumonia", "PROBLEM", 54, 74], ["pneumoniae", "OBSERVATION", 2, 12], ["less common", "OBSERVATION_MODIFIER", 16, 27], ["ambulatory", "OBSERVATION_MODIFIER", 54, 64], ["pneumonia", "OBSERVATION", 65, 74]]], ["Legionella species are more common among patients who require admission to intensive care, but overall account for approximately 2% of patients requiring admission to hospital for treatment of CAP [8].Pneumonia requiring admission to hospital ::: Etiologic agents that commonly cause community-acquired pneumoniaUnfortunately, studies such as these do not capture pathogens that may occur in localized outbreaks, such as hantavirus [9], or pathogens that occur worldwide as outbreaks of short duration, such as SARS coronavirus [10].Pneumonia requiring admission to hospital ::: Etiologic agents that commonly cause community-acquired pneumoniaBecause in most studies the diagnosis of M pneumoniae, L pneumophila, and Chlamydia pneumoniae is made using serology, the criteria for a positive test can have a huge impact on the number of cases diagnosed.", [["CAP", "DISEASE", 193, 196], ["Pneumonia", "DISEASE", 201, 210], ["hantavirus [9]", "DISEASE", 421, 435], ["SARS coronavirus", "DISEASE", 511, 527], ["Pneumonia", "DISEASE", 533, 542], ["pneumoniaBecause", "DISEASE", 635, 651], ["L pneumophila", "DISEASE", 699, 712], ["Chlamydia pneumoniae", "DISEASE", 718, 738], ["Legionella species", "ORGANISM", 0, 18], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 135, 143], ["M pneumoniae", "ORGANISM", 685, 697], ["L pneumophila", "ORGANISM", 699, 712], ["Chlamydia pneumoniae", "ORGANISM", 718, 738], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 135, 143], ["M pneumoniae", "SPECIES", 685, 697], ["L pneumophila", "SPECIES", 699, 712], ["Chlamydia pneumoniae", "SPECIES", 718, 738], ["SARS coronavirus", "SPECIES", 511, 527], ["M pneumoniae", "SPECIES", 685, 697], ["L pneumophila", "SPECIES", 699, 712], ["Chlamydia pneumoniae", "SPECIES", 718, 738], ["Legionella species", "PROBLEM", 0, 18], ["treatment of CAP", "TREATMENT", 180, 196], ["Pneumonia", "PROBLEM", 201, 210], ["pathogens", "PROBLEM", 364, 373], ["hantavirus", "PROBLEM", 421, 431], ["pathogens", "PROBLEM", 440, 449], ["SARS coronavirus", "PROBLEM", 511, 527], ["Pneumonia", "PROBLEM", 533, 542], ["community-acquired pneumoniaBecause", "PROBLEM", 616, 651], ["M pneumoniae", "PROBLEM", 685, 697], ["L pneumophila", "PROBLEM", 699, 712], ["Chlamydia pneumoniae", "PROBLEM", 718, 738], ["serology", "TEST", 753, 761], ["a positive test", "PROBLEM", 780, 795], ["pneumoniae", "OBSERVATION", 687, 697], ["pneumophila", "OBSERVATION", 701, 712]]], ["A fourfold increase in antibody titer between acute and convalescent serum samples generally is considered definite evidence that an infection with the test agent has occurred.", [["serum samples", "ANATOMY", 69, 82], ["infection", "DISEASE", 133, 142], ["serum samples", "ORGANISM_SUBSTANCE", 69, 82], ["A fourfold increase in antibody titer", "PROBLEM", 0, 37], ["convalescent serum samples", "TEST", 56, 82], ["an infection", "PROBLEM", 130, 142], ["the test agent", "TEST", 148, 162], ["fourfold", "OBSERVATION_MODIFIER", 2, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["antibody titer", "OBSERVATION", 23, 37], ["infection", "OBSERVATION", 133, 142]]], ["A high single or stable titer is often considered diagnostic as well, however.", [["A high single or stable titer", "PROBLEM", 0, 29], ["high", "OBSERVATION_MODIFIER", 2, 6], ["stable", "OBSERVATION_MODIFIER", 17, 23]]], ["In one study, the incidence of M pneumoniae was 6.3 per 100,000 population when criteria for definite infection were used and 38.2 per 100,000 when a titer of 1:64 or higher was used; in the same study when the fourfold increase and single-titer criteria were applied, the incidence of Chlamydia pneumoniae was 2.8 per 100,000 and 16.5 per 100,000, respectively, and for L pneumophila it was 4.4 per 100,000 and 6.0 per 100,000, respectively [11].Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agentsMycoplasmas, including M pneumoniae, are the smallest free-living organisms with a size (125\u2013150 \u03bcm) similar to that of myxoviruses [12].", [["infection", "DISEASE", 102, 111], ["Chlamydia pneumoniae", "DISEASE", 286, 306], ["Mycoplasma pneumoniae", "DISEASE", 447, 468], ["Pneumonia", "DISEASE", 473, 482], ["Mycoplasmas", "CHEMICAL", 517, 528], ["M pneumoniae", "ORGANISM", 31, 43], ["Chlamydia pneumoniae", "ORGANISM", 286, 306], ["L pneumophila", "ORGANISM", 371, 384], ["Mycoplasma pneumoniae", "ORGANISM", 447, 468], ["M pneumoniae", "ORGANISM", 540, 552], ["M pneumoniae", "SPECIES", 31, 43], ["Chlamydia pneumoniae", "SPECIES", 286, 306], ["L pneumophila", "SPECIES", 371, 384], ["Mycoplasma pneumoniae", "SPECIES", 447, 468], ["M pneumoniae", "SPECIES", 540, 552], ["M pneumoniae", "SPECIES", 31, 43], ["Chlamydia pneumoniae", "SPECIES", 286, 306], ["L pneumophila", "SPECIES", 371, 384], ["Mycoplasma pneumoniae", "SPECIES", 447, 468], ["M pneumoniae", "SPECIES", 540, 552], ["one study", "TEST", 3, 12], ["M pneumoniae", "PROBLEM", 31, 43], ["definite infection", "PROBLEM", 93, 111], ["a titer", "TEST", 148, 155], ["the fourfold increase", "PROBLEM", 207, 228], ["Chlamydia pneumoniae", "PROBLEM", 286, 306], ["L pneumophila", "TEST", 371, 384], ["Mycoplasma pneumoniae", "PROBLEM", 447, 468], ["Pneumonia", "PROBLEM", 473, 482], ["selected atypical agentsMycoplasmas", "PROBLEM", 493, 528], ["M pneumoniae", "PROBLEM", 540, 552], ["pneumoniae", "OBSERVATION", 33, 43], ["infection", "OBSERVATION", 102, 111], ["increase", "OBSERVATION_MODIFIER", 220, 228], ["Chlamydia", "OBSERVATION_MODIFIER", 286, 295], ["pneumoniae", "OBSERVATION", 296, 306], ["pneumoniae", "OBSERVATION", 458, 468], ["atypical", "OBSERVATION_MODIFIER", 502, 510], ["agentsMycoplasmas", "OBSERVATION", 511, 528], ["pneumoniae", "OBSERVATION", 542, 552], ["smallest", "OBSERVATION_MODIFIER", 562, 570], ["free", "OBSERVATION_MODIFIER", 571, 575], ["size", "OBSERVATION_MODIFIER", 600, 604]]], ["The genome of M pneumoniae consists of 816,394 base pairs and has been sequenced in its entirety [13].", [["M pneumoniae", "ORGANISM", 14, 26], ["M pneumoniae", "SPECIES", 14, 26], ["M pneumoniae", "SPECIES", 14, 26], ["M pneumoniae", "PROBLEM", 14, 26], ["base pairs", "TEST", 47, 57], ["pneumoniae", "OBSERVATION", 16, 26]]], ["Adherence to host respiratory epithelial cells is mediated by a 169kDa protein (P1) located in the tip-like organelle of M pneumoniae.", [["respiratory epithelial cells", "ANATOMY", 18, 46], ["tip-like organelle", "ANATOMY", 99, 117], ["respiratory epithelial cells", "CELL", 18, 46], ["P1", "GENE_OR_GENE_PRODUCT", 80, 82], ["M pneumoniae", "ORGANISM", 121, 133], ["host respiratory epithelial cells", "CELL_TYPE", 13, 46], ["169kDa protein", "PROTEIN", 64, 78], ["P1", "PROTEIN", 80, 82], ["M pneumoniae", "SPECIES", 121, 133], ["M pneumoniae", "SPECIES", 121, 133], ["host respiratory epithelial cells", "PROBLEM", 13, 46], ["M pneumoniae", "PROBLEM", 121, 133], ["host", "OBSERVATION_MODIFIER", 13, 17], ["respiratory epithelial cells", "OBSERVATION", 18, 46], ["tip", "OBSERVATION_MODIFIER", 99, 102], ["M pneumoniae", "OBSERVATION", 121, 133]]], ["Once M pneumoniae adheres to the mucous and ciliated epithelial cells of the respiratory tract, a chemotactic stimulus leads to directed motility of the mycoplasma to the bases of the cilia.", [["mucous", "ANATOMY", 33, 39], ["epithelial cells", "ANATOMY", 53, 69], ["respiratory tract", "ANATOMY", 77, 94], ["mycoplasma", "ANATOMY", 153, 163], ["cilia", "ANATOMY", 184, 189], ["M pneumoniae", "ORGANISM", 5, 17], ["mucous", "TISSUE", 33, 39], ["ciliated epithelial cells", "CELL", 44, 69], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["cilia", "CELLULAR_COMPONENT", 184, 189], ["mucous and ciliated epithelial cells", "CELL_TYPE", 33, 69], ["M pneumoniae", "SPECIES", 5, 17], ["M pneumoniae", "SPECIES", 5, 17], ["pneumoniae", "PROBLEM", 7, 17], ["the mucous and ciliated epithelial cells of the respiratory tract", "PROBLEM", 29, 94], ["a chemotactic stimulus", "TEST", 96, 118], ["pneumoniae", "OBSERVATION", 7, 17], ["mucous", "ANATOMY", 33, 39], ["ciliated epithelial cells", "OBSERVATION", 44, 69], ["respiratory tract", "ANATOMY", 77, 94], ["chemotactic stimulus", "OBSERVATION", 98, 118], ["mycoplasma", "OBSERVATION", 153, 163], ["bases", "ANATOMY_MODIFIER", 171, 176], ["cilia", "ANATOMY_MODIFIER", 184, 189]]], ["This protects the mycoplasma from the clearance action of the ciliary system.", [["ciliary system", "ANATOMY", 62, 76], ["mycoplasma", "DISEASE", 18, 28], ["ciliary system", "MULTI-TISSUE_STRUCTURE", 62, 76], ["the mycoplasma", "PROBLEM", 14, 28], ["mycoplasma", "OBSERVATION", 18, 28], ["ciliary system", "ANATOMY", 62, 76]]], ["A few hours after this contact, loss of ciliary motility is observed, followed by extensive damage to the host cells.", [["ciliary", "ANATOMY", 40, 47], ["cells", "ANATOMY", 111, 116], ["ciliary", "MULTI-TISSUE_STRUCTURE", 40, 47], ["cells", "CELL", 111, 116], ["host cells", "CELL_TYPE", 106, 116], ["loss of ciliary motility", "PROBLEM", 32, 56], ["extensive damage to the host cells", "PROBLEM", 82, 116], ["few", "OBSERVATION_MODIFIER", 2, 5], ["ciliary motility", "OBSERVATION", 40, 56], ["host cells", "OBSERVATION", 106, 116]]], ["It is likely that ciliary stasis and cell damage result from production of hydrogen peroxide and superoxide by M pneumoniae[14], [15].Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agentsPneumonia is the manifestation of M pneumoniae infection most frequently recognized by clinicians.", [["ciliary", "ANATOMY", 18, 25], ["cell", "ANATOMY", 37, 41], ["ciliary stasis", "DISEASE", 18, 32], ["hydrogen peroxide", "CHEMICAL", 75, 92], ["superoxide", "CHEMICAL", 97, 107], ["Mycoplasma pneumoniae", "DISEASE", 134, 155], ["Pneumonia", "DISEASE", 160, 169], ["Pneumonia", "DISEASE", 204, 213], ["M pneumoniae infection", "DISEASE", 238, 260], ["hydrogen peroxide", "CHEMICAL", 75, 92], ["superoxide", "CHEMICAL", 97, 107], ["cell", "CELL", 37, 41], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 75, 92], ["superoxide", "SIMPLE_CHEMICAL", 97, 107], ["[15]", "SIMPLE_CHEMICAL", 129, 133], ["Mycoplasma pneumoniae", "ORGANISM", 134, 155], ["M pneumoniae", "ORGANISM", 238, 250], ["M pneumoniae", "SPECIES", 111, 123], ["Mycoplasma pneumoniae", "SPECIES", 134, 155], ["M pneumoniae", "SPECIES", 238, 250], ["M pneumoniae", "SPECIES", 111, 123], ["Mycoplasma pneumoniae", "SPECIES", 134, 155], ["M pneumoniae", "SPECIES", 238, 250], ["ciliary stasis", "PROBLEM", 18, 32], ["cell damage", "PROBLEM", 37, 48], ["hydrogen peroxide", "TREATMENT", 75, 92], ["pneumoniae", "PROBLEM", 113, 123], ["Mycoplasma pneumoniae", "PROBLEM", 134, 155], ["Pneumonia", "PROBLEM", 160, 169], ["selected atypical agents", "TREATMENT", 180, 204], ["Pneumonia", "PROBLEM", 204, 213], ["M pneumoniae infection", "PROBLEM", 238, 260], ["likely that", "UNCERTAINTY", 6, 17], ["ciliary stasis", "OBSERVATION", 18, 32], ["cell damage", "OBSERVATION", 37, 48], ["pneumoniae", "OBSERVATION", 145, 155], ["atypical agents", "OBSERVATION", 189, 204], ["pneumoniae", "OBSERVATION_MODIFIER", 240, 250], ["infection", "OBSERVATION", 251, 260]]], ["In a retrospective review of all M pneumoniae pneumonia cases at the Mayo Clinic over a 14-year period, Mansel and colleagues [17] reported on 148 patients.", [["pneumonia", "DISEASE", 46, 55], ["patients", "ORGANISM", 147, 155], ["M pneumoniae", "SPECIES", 33, 45], ["patients", "SPECIES", 147, 155], ["M pneumoniae", "SPECIES", 33, 45], ["all M pneumoniae pneumonia", "PROBLEM", 29, 55], ["pneumoniae", "OBSERVATION_MODIFIER", 35, 45], ["pneumonia", "OBSERVATION", 46, 55]]], ["Cough was the most common symptom, occurring in 97%, followed by fever in 85%.", [["Cough", "DISEASE", 0, 5], ["fever", "DISEASE", 65, 70], ["Cough", "PROBLEM", 0, 5], ["fever", "PROBLEM", 65, 70], ["most common", "OBSERVATION_MODIFIER", 14, 25]]], ["Fifty-two percent of the patients had sore throat, 22% had rhinorrhea, 25% had chest pain, and 17% complained of dyspnea.", [["chest", "ANATOMY", 79, 84], ["sore throat", "DISEASE", 38, 49], ["rhinorrhea", "DISEASE", 59, 69], ["chest pain", "DISEASE", 79, 89], ["dyspnea", "DISEASE", 113, 120], ["patients", "ORGANISM", 25, 33], ["chest", "ORGANISM_SUBDIVISION", 79, 84], ["patients", "SPECIES", 25, 33], ["sore throat", "PROBLEM", 38, 49], ["rhinorrhea", "PROBLEM", 59, 69], ["chest pain", "PROBLEM", 79, 89], ["dyspnea", "PROBLEM", 113, 120], ["sore throat", "ANATOMY", 38, 49], ["chest", "ANATOMY", 79, 84], ["dyspnea", "OBSERVATION", 113, 120]]], ["Other symptoms included nausea, vomiting, diarrhea, anorexia, headache, chills, myalgia, arthralgia, and night sweats.", [["nausea", "DISEASE", 24, 30], ["vomiting", "DISEASE", 32, 40], ["diarrhea", "DISEASE", 42, 50], ["anorexia", "DISEASE", 52, 60], ["headache", "DISEASE", 62, 70], ["chills", "DISEASE", 72, 78], ["myalgia", "DISEASE", 80, 87], ["arthralgia", "DISEASE", 89, 99], ["night sweats", "DISEASE", 105, 117], ["Other symptoms", "PROBLEM", 0, 14], ["nausea", "PROBLEM", 24, 30], ["vomiting", "PROBLEM", 32, 40], ["diarrhea", "PROBLEM", 42, 50], ["anorexia", "PROBLEM", 52, 60], ["headache", "PROBLEM", 62, 70], ["chills", "PROBLEM", 72, 78], ["myalgia", "PROBLEM", 80, 87], ["arthralgia", "PROBLEM", 89, 99], ["night sweats", "PROBLEM", 105, 117], ["anorexia", "OBSERVATION", 52, 60], ["chills", "OBSERVATION", 72, 78], ["myalgia", "OBSERVATION", 80, 87], ["arthralgia", "OBSERVATION", 89, 99]]], ["Seven percent had one or more symptoms of neurologic disease, including diplopia, syncope, confusion, or tinnitus.", [["neurologic", "ANATOMY", 42, 52], ["neurologic disease", "DISEASE", 42, 60], ["diplopia", "DISEASE", 72, 80], ["syncope", "DISEASE", 82, 89], ["confusion", "DISEASE", 91, 100], ["tinnitus", "DISEASE", 105, 113], ["neurologic disease", "PROBLEM", 42, 60], ["diplopia", "PROBLEM", 72, 80], ["syncope", "PROBLEM", 82, 89], ["confusion", "PROBLEM", 91, 100], ["tinnitus", "PROBLEM", 105, 113], ["diplopia", "OBSERVATION", 72, 80]]], ["One patient had severe hemoptysis.", [["hemoptysis", "DISEASE", 23, 33], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["severe hemoptysis", "PROBLEM", 16, 33], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["hemoptysis", "OBSERVATION", 23, 33]]], ["The following findings were noted on physical examination: pharyngeal erythema (47%), pulmonary consolidation (26%), cervical lymphadenopathy (26%), otitis media (20%), bullous myringitis (18%), and skin lesions (6%).Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agentsMortality is uncommon in patients who have M pneumoniae, as illustrated in a study by Marrie and colleagues [18] where 1 of 64 patients requiring admission to hospital for treatment of M pneumoniae pneumonia died.", [["pharyngeal", "ANATOMY", 59, 69], ["pulmonary", "ANATOMY", 86, 95], ["cervical", "ANATOMY", 117, 125], ["bullous", "ANATOMY", 169, 176], ["skin lesions", "ANATOMY", 199, 211], ["pharyngeal erythema", "DISEASE", 59, 78], ["pulmonary consolidation", "DISEASE", 86, 109], ["cervical lymphadenopathy", "DISEASE", 117, 141], ["otitis media", "DISEASE", 149, 161], ["bullous myringitis", "DISEASE", 169, 187], ["skin lesions", "DISEASE", 199, 211], ["Mycoplasma pneumoniae", "DISEASE", 217, 238], ["Pneumonia", "DISEASE", 243, 252], ["pneumonia", "DISEASE", 485, 494], ["pharyngeal", "ORGANISM_SUBDIVISION", 59, 69], ["pulmonary", "ORGAN", 86, 95], ["cervical", "ORGAN", 117, 125], ["skin lesions", "CANCER", 199, 211], ["Mycoplasma pneumoniae", "ORGANISM", 217, 238], ["patients", "ORGANISM", 312, 320], ["M pneumoniae", "ORGANISM", 330, 342], ["patients", "ORGANISM", 414, 422], ["Mycoplasma pneumoniae", "SPECIES", 217, 238], ["patients", "SPECIES", 312, 320], ["M pneumoniae", "SPECIES", 330, 342], ["patients", "SPECIES", 414, 422], ["M pneumoniae", "SPECIES", 472, 484], ["Mycoplasma pneumoniae", "SPECIES", 217, 238], ["M pneumoniae", "SPECIES", 330, 342], ["M pneumoniae", "SPECIES", 472, 484], ["physical examination", "TEST", 37, 57], ["pharyngeal erythema", "PROBLEM", 59, 78], ["pulmonary consolidation", "PROBLEM", 86, 109], ["cervical lymphadenopathy", "PROBLEM", 117, 141], ["otitis media", "PROBLEM", 149, 161], ["bullous myringitis", "PROBLEM", 169, 187], ["skin lesions", "PROBLEM", 199, 211], ["Mycoplasma pneumoniae", "PROBLEM", 217, 238], ["Pneumonia", "PROBLEM", 243, 252], ["M pneumoniae", "PROBLEM", 330, 342], ["treatment", "TREATMENT", 459, 468], ["M pneumoniae pneumonia", "PROBLEM", 472, 494], ["pharyngeal", "ANATOMY", 59, 69], ["erythema", "OBSERVATION", 70, 78], ["pulmonary", "ANATOMY", 86, 95], ["consolidation", "OBSERVATION", 96, 109], ["cervical", "ANATOMY", 117, 125], ["lymphadenopathy", "OBSERVATION", 126, 141], ["otitis", "OBSERVATION", 149, 155], ["bullous", "OBSERVATION_MODIFIER", 169, 176], ["skin", "ANATOMY", 199, 203], ["lesions", "OBSERVATION", 204, 211], ["pneumoniae", "OBSERVATION", 228, 238], ["atypical", "OBSERVATION_MODIFIER", 272, 280], ["pneumoniae", "OBSERVATION", 332, 342], ["pneumoniae", "OBSERVATION_MODIFIER", 474, 484], ["pneumonia", "OBSERVATION", 485, 494]]], ["This patient had terminal Shy-Drager syndrome and died of this disease, not M pneumonia.", [["Shy-Drager syndrome", "DISEASE", 26, 45], ["pneumonia", "DISEASE", 78, 87], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["terminal Shy-Drager syndrome", "PROBLEM", 17, 45], ["this disease", "PROBLEM", 58, 70], ["M pneumonia", "PROBLEM", 76, 87], ["pneumonia", "OBSERVATION", 78, 87]]], ["In Ali's study [19], 1 of 47 patients died\u2014a 38-year-old woman with Down's syndrome.", [["Down's syndrome", "DISEASE", 68, 83], ["patients", "ORGANISM", 29, 37], ["woman", "ORGANISM", 57, 62], ["patients", "SPECIES", 29, 37], ["woman", "SPECIES", 57, 62], ["Ali's study", "TEST", 3, 14], ["Down's syndrome", "PROBLEM", 68, 83]]], ["She was admitted with multilobe pneumonia and hemolytic anemia and died 9 hours after admission.", [["pneumonia", "DISEASE", 32, 41], ["hemolytic anemia", "DISEASE", 46, 62], ["She", "ORGANISM", 0, 3], ["multilobe pneumonia", "PROBLEM", 22, 41], ["hemolytic anemia", "PROBLEM", 46, 62], ["pneumonia", "OBSERVATION", 32, 41], ["hemolytic", "OBSERVATION_MODIFIER", 46, 55], ["anemia", "OBSERVATION", 56, 62]]], ["Lind [20] reported that 20 fatal cases of M pneumoniae pneumonia had been described up to 1983.", [["pneumonia", "DISEASE", 55, 64], ["M pneumoniae", "SPECIES", 42, 54], ["M pneumoniae", "SPECIES", 42, 54], ["M pneumoniae pneumonia", "PROBLEM", 42, 64], ["pneumoniae", "OBSERVATION_MODIFIER", 44, 54], ["pneumonia", "OBSERVATION", 55, 64]]], ["Chan and Welsh [21] performed a review of fulminant M pneumoniae pneumonia from 1966 to 1991.", [["pneumonia", "DISEASE", 65, 74], ["M pneumoniae", "SPECIES", 52, 64], ["M pneumoniae", "SPECIES", 52, 64], ["fulminant M pneumoniae pneumonia", "PROBLEM", 42, 74], ["pneumoniae", "OBSERVATION_MODIFIER", 54, 64], ["pneumonia", "OBSERVATION", 65, 74]]], ["They found 46 such cases and divided them into three categories: nonfatal respiratory failure (26 cases), fatal cases with respiratory failure (13 cases), and fatal cases without respiratory failure (seven cases).Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agentsOne noteworthy feature of M pneumoniae infections is the variety of extrapulmonary infections.", [["respiratory", "ANATOMY", 74, 85], ["respiratory", "ANATOMY", 123, 134], ["respiratory", "ANATOMY", 179, 190], ["extrapulmonary", "ANATOMY", 351, 365], ["respiratory failure", "DISEASE", 74, 93], ["respiratory failure", "DISEASE", 123, 142], ["respiratory failure", "DISEASE", 179, 198], ["Mycoplasma pneumoniae", "DISEASE", 213, 234], ["Pneumonia", "DISEASE", 239, 248], ["M pneumoniae infections", "DISEASE", 309, 332], ["extrapulmonary infections", "DISEASE", 351, 376], ["Mycoplasma pneumoniae", "ORGANISM", 213, 234], ["M pneumoniae", "ORGANISM", 309, 321], ["Mycoplasma pneumoniae", "SPECIES", 213, 234], ["M pneumoniae", "SPECIES", 309, 321], ["Mycoplasma pneumoniae", "SPECIES", 213, 234], ["M pneumoniae", "SPECIES", 309, 321], ["nonfatal respiratory failure", "PROBLEM", 65, 93], ["fatal cases", "PROBLEM", 106, 117], ["respiratory failure", "PROBLEM", 123, 142], ["fatal cases", "PROBLEM", 159, 170], ["respiratory failure", "PROBLEM", 179, 198], ["Mycoplasma pneumoniae", "PROBLEM", 213, 234], ["Pneumonia", "PROBLEM", 239, 248], ["selected atypical agents", "TREATMENT", 259, 283], ["M pneumoniae infections", "PROBLEM", 309, 332], ["extrapulmonary infections", "PROBLEM", 351, 376], ["respiratory failure", "OBSERVATION", 74, 93], ["respiratory failure", "OBSERVATION", 123, 142], ["without", "UNCERTAINTY", 171, 178], ["respiratory failure", "OBSERVATION", 179, 198], ["pneumoniae", "OBSERVATION", 224, 234], ["atypical agents", "OBSERVATION", 268, 283], ["pneumoniae", "OBSERVATION_MODIFIER", 311, 321], ["infections", "OBSERVATION", 322, 332], ["variety", "OBSERVATION_MODIFIER", 340, 347], ["extrapulmonary", "ANATOMY", 351, 365], ["infections", "OBSERVATION", 366, 376]]], ["Almost any organ system can be involved.", [["organ system", "ANATOMY", 11, 23], ["organ", "ORGAN", 11, 16]]], ["In most series, 2% to 7% of patients who have M pneumoniae infection have an extrapulmonary manifestation [20].Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agentsAntimicrobial susceptibility of M pneumoniae can be determined by agar dilution or by the broth dilution method, usually in the form of the metabolism inhibition test.", [["infection", "DISEASE", 59, 68], ["Mycoplasma pneumoniae", "DISEASE", 111, 132], ["Pneumonia", "DISEASE", 137, 146], ["patients", "ORGANISM", 28, 36], ["M pneumoniae", "ORGANISM", 46, 58], ["Mycoplasma pneumoniae", "ORGANISM", 111, 132], ["M pneumoniae", "ORGANISM", 213, 225], ["patients", "SPECIES", 28, 36], ["M pneumoniae", "SPECIES", 46, 58], ["Mycoplasma pneumoniae", "SPECIES", 111, 132], ["M pneumoniae", "SPECIES", 213, 225], ["M pneumoniae", "SPECIES", 46, 58], ["Mycoplasma pneumoniae", "SPECIES", 111, 132], ["M pneumoniae", "SPECIES", 213, 225], ["M pneumoniae infection", "PROBLEM", 46, 68], ["an extrapulmonary manifestation", "PROBLEM", 74, 105], ["Mycoplasma pneumoniae", "PROBLEM", 111, 132], ["Pneumonia", "PROBLEM", 137, 146], ["selected atypical agents", "TREATMENT", 157, 181], ["Antimicrobial susceptibility of M pneumoniae", "PROBLEM", 181, 225], ["the broth dilution method", "TEST", 267, 292], ["the metabolism inhibition test", "TEST", 317, 347], ["pneumoniae", "OBSERVATION_MODIFIER", 48, 58], ["infection", "OBSERVATION", 59, 68], ["extrapulmonary", "ANATOMY", 77, 91], ["pneumoniae", "OBSERVATION", 122, 132], ["atypical agents", "OBSERVATION", 166, 181], ["pneumoniae", "OBSERVATION", 215, 225]]], ["Using these methods, M pneumoniae is susceptible to macrolides, tetracyclines, quinolones, streptomycin, pristinamycin, and ketolides [22].", [["macrolides", "CHEMICAL", 52, 62], ["tetracyclines", "CHEMICAL", 64, 77], ["quinolones", "CHEMICAL", 79, 89], ["streptomycin", "CHEMICAL", 91, 103], ["pristinamycin", "CHEMICAL", 105, 118], ["ketolides", "CHEMICAL", 124, 133], ["macrolides", "CHEMICAL", 52, 62], ["tetracyclines", "CHEMICAL", 64, 77], ["quinolones", "CHEMICAL", 79, 89], ["streptomycin", "CHEMICAL", 91, 103], ["pristinamycin", "CHEMICAL", 105, 118], ["ketolides", "CHEMICAL", 124, 133], ["M pneumoniae", "ORGANISM", 21, 33], ["macrolides", "SIMPLE_CHEMICAL", 52, 62], ["tetracyclines", "SIMPLE_CHEMICAL", 64, 77], ["quinolones", "SIMPLE_CHEMICAL", 79, 89], ["streptomycin", "SIMPLE_CHEMICAL", 91, 103], ["pristinamycin", "SIMPLE_CHEMICAL", 105, 118], ["ketolides [22]", "SIMPLE_CHEMICAL", 124, 138], ["M pneumoniae", "SPECIES", 21, 33], ["M pneumoniae", "SPECIES", 21, 33], ["these methods", "TREATMENT", 6, 19], ["M pneumoniae", "PROBLEM", 21, 33], ["macrolides", "TREATMENT", 52, 62], ["tetracyclines", "TREATMENT", 64, 77], ["quinolones", "TREATMENT", 79, 89], ["streptomycin", "TREATMENT", 91, 103], ["pristinamycin", "TREATMENT", 105, 118], ["ketolides", "TREATMENT", 124, 133], ["pneumoniae", "OBSERVATION", 23, 33]]], ["Erythromycin-resistant strains of M pneumoniae have been isolated from treated patients [22].", [["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "SIMPLE_CHEMICAL", 0, 12], ["M pneumoniae", "ORGANISM", 34, 46], ["patients", "ORGANISM", 79, 87], ["M pneumoniae", "SPECIES", 34, 46], ["patients", "SPECIES", 79, 87], ["M pneumoniae", "SPECIES", 34, 46], ["Erythromycin", "TREATMENT", 0, 12], ["resistant strains", "PROBLEM", 13, 30], ["M pneumoniae", "PROBLEM", 34, 46]]], ["Such resistance is a result of point mutations in 23rRNA gene.Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agentsShames and colleagues [23] evaluated the response to therapy in 317 military trainees with M pneumoniae pneumonia.", [["Mycoplasma pneumoniae", "DISEASE", 62, 83], ["Pneumonia", "DISEASE", 88, 97], ["pneumonia", "DISEASE", 236, 245], ["23rRNA", "GENE_OR_GENE_PRODUCT", 50, 56], ["Mycoplasma pneumoniae", "ORGANISM", 62, 83], ["23rRNA gene", "DNA", 50, 61], ["Mycoplasma pneumoniae", "SPECIES", 62, 83], ["M pneumoniae", "SPECIES", 223, 235], ["Mycoplasma pneumoniae", "SPECIES", 62, 83], ["M pneumoniae", "SPECIES", 223, 235], ["point mutations", "PROBLEM", 31, 46], ["Mycoplasma pneumoniae", "PROBLEM", 62, 83], ["Pneumonia", "PROBLEM", 88, 97], ["therapy", "TREATMENT", 185, 192], ["M pneumoniae pneumonia", "PROBLEM", 223, 245], ["pneumoniae", "OBSERVATION", 73, 83], ["pneumoniae", "OBSERVATION_MODIFIER", 225, 235], ["pneumonia", "OBSERVATION", 236, 245]]], ["They noted that patients treated with demeclocycline (Declomycin) were febrile for 1.8 days compared with 2.4 days for those treated with tetracycline (Achromycin V) or erythromycin stearate (Erythrocin).", [["demeclocycline", "CHEMICAL", 38, 52], ["Declomycin", "CHEMICAL", 54, 64], ["febrile", "DISEASE", 71, 78], ["tetracycline", "CHEMICAL", 138, 150], ["Achromycin V", "CHEMICAL", 152, 164], ["erythromycin stearate", "CHEMICAL", 169, 190], ["Erythrocin", "CHEMICAL", 192, 202], ["demeclocycline", "CHEMICAL", 38, 52], ["Declomycin", "CHEMICAL", 54, 64], ["tetracycline", "CHEMICAL", 138, 150], ["Achromycin V", "CHEMICAL", 152, 164], ["erythromycin stearate", "CHEMICAL", 169, 190], ["Erythrocin", "CHEMICAL", 192, 202], ["patients", "ORGANISM", 16, 24], ["demeclocycline", "SIMPLE_CHEMICAL", 38, 52], ["Declomycin", "SIMPLE_CHEMICAL", 54, 64], ["tetracycline", "SIMPLE_CHEMICAL", 138, 150], ["Achromycin V", "SIMPLE_CHEMICAL", 152, 164], ["erythromycin stearate", "SIMPLE_CHEMICAL", 169, 190], ["Erythrocin", "SIMPLE_CHEMICAL", 192, 202], ["patients", "SPECIES", 16, 24], ["demeclocycline (Declomycin", "TREATMENT", 38, 64], ["febrile", "PROBLEM", 71, 78], ["tetracycline (Achromycin V", "TREATMENT", 138, 164], ["erythromycin stearate", "TREATMENT", 169, 190], ["Erythrocin", "TREATMENT", 192, 202]]], ["Control subjects were febrile for 4.2 days.", [["febrile", "DISEASE", 22, 29], ["febrile", "PROBLEM", 22, 29]]], ["The mean duration of hospitalization was 6.6 days and 7.6 days for demeclocycline and tetracycline, respectively, versus 14 days for control subjects.", [["demeclocycline", "CHEMICAL", 67, 81], ["tetracycline", "CHEMICAL", 86, 98], ["demeclocycline", "CHEMICAL", 67, 81], ["tetracycline", "CHEMICAL", 86, 98], ["demeclocycline", "SIMPLE_CHEMICAL", 67, 81], ["tetracycline", "SIMPLE_CHEMICAL", 86, 98], ["demeclocycline", "TREATMENT", 67, 81], ["tetracycline", "TREATMENT", 86, 98]]], ["Those who were treated with erythromycin stearate were hospitalized a mean of 7.0 days and those treated with erythromycin ethyl succinate (EES) were hospitalized a mean of 9 days.", [["erythromycin stearate", "CHEMICAL", 28, 49], ["erythromycin ethyl succinate", "CHEMICAL", 110, 138], ["EES", "CHEMICAL", 140, 143], ["erythromycin stearate", "CHEMICAL", 28, 49], ["erythromycin ethyl succinate", "CHEMICAL", 110, 138], ["erythromycin", "SIMPLE_CHEMICAL", 28, 40], ["stearate", "SIMPLE_CHEMICAL", 41, 49], ["erythromycin ethyl succinate", "SIMPLE_CHEMICAL", 110, 138], ["erythromycin stearate", "TREATMENT", 28, 49], ["erythromycin ethyl succinate (EES", "TREATMENT", 110, 143]]], ["These investigators also noted that clinical cure did not equate with eradication of M pneumoniae from the respiratory tract.", [["respiratory tract", "ANATOMY", 107, 124], ["M pneumoniae", "ORGANISM", 85, 97], ["respiratory tract", "ORGANISM_SUBDIVISION", 107, 124], ["M pneumoniae", "SPECIES", 85, 97], ["M pneumoniae", "SPECIES", 85, 97], ["M pneumoniae from the respiratory tract", "PROBLEM", 85, 124], ["pneumoniae", "OBSERVATION", 87, 97], ["respiratory tract", "ANATOMY", 107, 124]]], ["At followup, 33% of the control subjects were culture-positive for M pneumoniae, compared with 5% to 20% of the subjects treated with various antibiotics.Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agentsKingston and colleagues [24] treated 59 patients who had M pneumoniae pneumonia with demethylchlortetracycline and 50 patients with placebo.", [["Mycoplasma pneumoniae", "DISEASE", 154, 175], ["Pneumonia", "DISEASE", 180, 189], ["pneumonia", "DISEASE", 294, 303], ["demethylchlortetracycline", "CHEMICAL", 309, 334], ["demethylchlortetracycline", "CHEMICAL", 309, 334], ["subjects", "ORGANISM", 32, 40], ["M pneumoniae", "ORGANISM", 67, 79], ["Mycoplasma pneumoniae", "ORGANISM", 154, 175], ["patients", "ORGANISM", 264, 272], ["demethylchlortetracycline", "SIMPLE_CHEMICAL", 309, 334], ["patients", "ORGANISM", 342, 350], ["M pneumoniae", "SPECIES", 67, 79], ["Mycoplasma pneumoniae", "SPECIES", 154, 175], ["patients", "SPECIES", 264, 272], ["M pneumoniae", "SPECIES", 281, 293], ["patients", "SPECIES", 342, 350], ["M pneumoniae", "SPECIES", 67, 79], ["Mycoplasma pneumoniae", "SPECIES", 154, 175], ["M pneumoniae", "SPECIES", 281, 293], ["culture", "TEST", 46, 53], ["M pneumoniae", "PROBLEM", 67, 79], ["various antibiotics", "TREATMENT", 134, 153], ["Mycoplasma pneumoniae", "PROBLEM", 154, 175], ["Pneumonia", "PROBLEM", 180, 189], ["selected atypical agents", "TREATMENT", 200, 224], ["M pneumoniae pneumonia", "PROBLEM", 281, 303], ["demethylchlortetracycline", "TREATMENT", 309, 334], ["placebo", "TREATMENT", 356, 363], ["pneumoniae", "OBSERVATION", 69, 79], ["pneumoniae", "OBSERVATION", 165, 175], ["atypical agents", "OBSERVATION", 209, 224], ["pneumoniae", "OBSERVATION_MODIFIER", 283, 293], ["pneumonia", "OBSERVATION", 294, 303]]], ["The mean number of days the treated patients had an oral temperature above 99\u00b0F was 3.02 days versus 10.04 days for the placebo-treated group.Mycoplasma pneumoniae ::: Pneumonia caused by selected atypical agents", [["oral", "ANATOMY", 52, 56], ["Mycoplasma pneumoniae", "DISEASE", 142, 163], ["Pneumonia", "DISEASE", 168, 177], ["patients", "ORGANISM", 36, 44], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["Mycoplasma pneumoniae", "ORGANISM", 142, 163], ["patients", "SPECIES", 36, 44], ["Mycoplasma pneumoniae", "SPECIES", 142, 163], ["Mycoplasma pneumoniae", "SPECIES", 142, 163], ["the placebo", "TREATMENT", 116, 127], ["Mycoplasma pneumoniae", "PROBLEM", 142, 163], ["Pneumonia", "PROBLEM", 168, 177], ["selected atypical agents", "TREATMENT", 188, 212], ["pneumoniae", "OBSERVATION", 153, 163], ["atypical agents", "OBSERVATION", 197, 212]]]]}